Dossier na temat Anthony Fauciego/COVID-19

Ta praca została częściowo wsparta przez zbiórkę pieniędzy, w której około 330 osób przekazało fundusze na wsparcie zespołu technologicznego New Earth i Urban Global Health Alliance. Jest ona udostępniona na licencji Creative Commons CC- BY-NC-SA. Wszelkie pochodne wykorzystanie tego dossier musi być upublicznione dla dobra innych. Wszystkie dokumenty, referencje i informacje zawarte w niniejszym dokumencie, mają charakter taki jaki mają w chwili ich opublikowania. Autor nie ponosi odpowiedzialności za błędy w zapisie publicznym lub w odniesieniach do niego. W całym dokumencie, użycie terminów powszechnie przyjętych w literaturze medycznej i naukowej, nie oznacza akceptacji lub odrzucenia dogmatu, który reprezentują.

[Dossier – zbiór dokumentów dotyczących jakiejś sprawy]

SARS-CoV-2 w kontekście patentów sprzed 20 lat – dr David Martin

Wersja po angielsku – The Fauci COVID-19 Dossier

 

Dossier na temat Anthony Fauciego/COVID-19

 

Dossier na temat Anthony Fauciego-COVID-19

Tło:

Przez ostatnie dwie dekady, moja firma – M-CAM – monitorowała możliwe naruszenia Protokołu o zakazie używania gazów duszących, trujących lub innych w czasie wojny; bakteriologicznych metod prowadzenia wojny (Protokół Genewski z 1925 roku) oraz Konwencji o zakazie prowadzenia badań, produkcji i gromadzenia zapasów broni bakteriologicznej i toksycznej oraz ich zniszczeniu (BTWC z 1972 roku). W naszej Globalnej Ocenie Technologii na lata 2003-2004: Zbrojenia Wektorowe [Global Technology Assessment: VectorWeaponization]. W M-CAM zwróciliśmy uwagę na rosnące zaangażowanie Chin, w technologię łańcuchowej reakcji polimerazy (PCR), w odniesieniu do dołączenia do światowej sceny w konstrukcji chimerycznych wektorów wirusowych. Od tego czasu, co tydzień, monitorujemy rozwój badań i wysiłki komercyjne w tej dziedzinie, włączając w to, ale nie ograniczając się, do synergii badawczej tworzącej się pomiędzy amerykańskim Centrum Kontroli i Prewencji Chorób (CDC), Narodowym Instytutem Alergii i Chorób Zakaźnych (NIAID), Uniwersytetem Północnej Karoliny w Chapel Hill (UNC), Uniwersytetem Harvarda, Uniwersytetem Emory, Uniwersytetem Vanderbilta, Uniwersytetem Tsinghua, Uniwersytetem Pensylwanii oraz wieloma innymi instytucjami badawczymi i ich komercyjnymi powiązaniami.

Grant AI23946-08 przyznany przez Narodowy Instytut Zdrowia dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z Narodowym Instytutem Alergii i Chorób Zakaźnych [NIAID] dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenów, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych, skierowanych na te same czynniki. Już 21 maja 2000 roku dr Ralph Baric i Uniwersytet Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów, dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000]. W jednej z kilku prac, powstałych w wyniku prac sponsorowanych przez ten grant, dr R. Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV był oparty na złożonym segmencie DNA.

“Używając panelu przylegających cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy molekularnie sklonowane wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.”- PNAS October 28, 2003 100 (22) 12995-13000; Reversegenetics with a full-lengthinfectiouscDNA of severeacute respiratory syndromecoronavirus https://www.pnas.org/content/100/22/12995

Wiosną, 19 kwietnia 2002 roku, przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent U.S. 7279372 na metodę wytwarzania rekombinowanego koronawirusa. W pierwszym publicznym zapisie stwierdzeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusów w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe wysiłki CDC w zakresie podejmowanych starań uzyskania patentów, gdy 25 kwietnia 2003 r. starało się ono o opatentowanie koronawirusa SARS wyizolowanego od ludzi, który podobno przeniósł się na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] dotyczący wynalazków podlegających opatentowaniu zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent USA 7220852 i ograniczał każdego, kto nie był licencjonowany [upoważniony] przez ich patent, do manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały: znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakteryzację wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica [USA 6593111] (roszczenia 1 i 5) oraz patentowi CDC o numerze 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez zezwolenia lub naruszenia tychże patentów.

Zauważyliśmy, że specjalista w dziedzinie badań nad uzyskiwaniem funkcji [gain-of-function], dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich w postaci dotacji na badania od kilku agencji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów [International Committee on Taxonomy of Viruses (ICTV)] Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG).

Haplogrupy dzielą się na dodatkowe podgrupy - gałęzie (subklad)

Haplogrupy [A] dzielą się na dodatkowe podgrupy (subklad) [A1a i A1b, A2a i A2b].

W tym charakterze, dr Ralph Baric był odpowiedzialny za określanie “nowości” wśród kladów różnych gatunków wirusów, ale także bezpośrednio korzystał z deklarowanych nowości – w formie nowych wniosków na finansowanie badań i związanej z nimi współpracy patentowej i handlowej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi, posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i inne), potężna grupa interesów tworzyła coś, odnośnie czego sugerowalibyśmy, że jest “wzajemnym powiązaniem/zazębianiem się dyrekcji”, zgodnie z amerykańskimi prawami antymonopolowymi.

Podmioty te były również powiązane z Globalną Radą Monitorowania Gotowości [Global Preparedness Monitoring Board [GPMB)] pod WHO, której członkowie odegrali zasadniczą rolę w finansowanym przez Open Philanthropy globalnym ćwiczeniu „przy stole” odnośnie pandemii koronawirusów o nazwie “Wydarzenie 201” w październiku 2019 roku.

To wydarzenie [Event 201], sfinansowane przez głównego inwestora w Sherlock Biosciences oraz Fundację Billa i Melindy Gatesów w mandat Globalnej Rady Monitorowania Gotowości [GPMB] na globalne ćwiczenie w sprawie gotowości na choroby układu oddechowego, które ma być zakończone do września 2020 roku, zaalarmowało nas to, bo pojawiła się wskazówka dotycząca scenariusza przyszłej “epidemii”. Spodziewaliśmy się, że taki scenariusz pojawi się w Wuhan lub Guangdong w Chinach, w północnych Włoszech, w Seattle, w Nowym Jorku lub w kombinacji tych miejsc, ponieważ prace dr Zhengli Shi i dr Barica nad odzwierzęcym przenoszeniem się koronawirusa, zidentyfikowały nakładające się mutacje koronawirusa w populacjach nietoperzy znajdujących się w tych obszarach.

Dossier ten nie jest bynajmniej wyczerpujący. Wskazuje on jednak na liczne naruszenia prawa karnego, które mogą być związane z terroryzmem COVID-19. Wszystkie materiały źródłowe są w nim cytowane. Dodatkowe szczegółowe zestawienie wszystkich osób, instytucji badawczych, fundacji, źródeł finansowania i przedsiębiorstw komercyjnych jest dostępne na życzenie.

 

Spis treści:

35 U.S.C. § 101 – Wynalazki Podlegające Opatentowaniu
18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia
18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich
18 U.S.C. § 1001 – Okłamywanie Kongresu
15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej
15 U.S.C. §8 – Manipulacja i Alokacja Rynku
15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami
35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego
21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne
Podmioty komercyjne

 

 

 

Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101]

 

Z opinii sędziego Clarence’a Thomasa dla większości

Paragraf 101 ustawy o patentach stanowi: „Ktokolwiek wymyśli lub odkryje nowy i użyteczny proces, maszynę, produkcję lub skład materii, lub jakiekolwiek nowe i użyteczne ich ulepszenie, może uzyskać na nie patent, z zastrzeżeniem warunków i wymagań niniejszego rozdziału.”35 U.S.C. § 101.

Od dawna “uważamy, że przepis ten zawiera ważny domyślny wyjątek: prawa natury, zjawiska naturalne i abstrakcyjne idee nie podlegają opatentowaniu”. Mayo, 566 U.S., at , 132 S.Ct., at 1293 (wewnętrzne cytaty i nawiasy pominięte). Są one raczej “podstawowymi narzędziami pracy naukowej i technologicznej”, które leżą poza domeną ochrony patentowej. Tamże 132 S.C., 1293. Jak wyjaśnił Sąd, bez tego wyjątku, istniałoby znaczne niebezpieczeństwo, że przyznanie patentów “uwięziłoby” wykorzystanie takich narzędzi i w ten sposób “zahamowałoby przyszłe innowacje oparte na nich”. Tamże, w 132 S.Ct., na 1301. Byłoby to sprzeczne z samym sensem istnienia patentów, które istnieją po to, by promować twórczość. Diamond v. Chakrabarty, 447 U.S. 303, 309, 100 S.C. 2204, 65 L.Ed.2d 144 (1980) (Produkty natury nie są wytwarzane, a “‘manifestacje… natury [są] wolne dla wszystkich ludzi i nie są zastrzeżone na wyłączność dla kogokolwiek'”).Association for MolecularPathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013)

W swojej większościowej opinii z 2013 roku Sąd Najwyższy USA wyraźnie zaznaczył, że Sąd “od dawna utrzymywał”, że natura nie podlega patentowaniu. Samo wyizolowanie DNA nie stanowi przedmiotu patentu. W swoim patencie CDC przedstawiło fałszywe i wprowadzające w błąd twierdzenia w Biurze Patentów i Znaków Towarowych Stanów Zjednoczonych, stwierdzając, że “nowo wyizolowany ludzki koronawirus został zidentyfikowany jako czynnik wywołujący SARS i nazwany SARS-CoV ” [U.S. Patent 7220852] . Na poparcie tego stwierdzenia nie przedstawiono żadnych danych “przyczynowych”.

Kiedy 25 kwietnia 2003 r. złożyli wniosek patentowy, ich pierwszym roszczeniem (i jedynym, które przetrwało do ostatecznego wydania, mimo sprzeciwu eksperta patentowego w 2006 i 2007 r.) był genom wirusa SARS CoV.

Chociaż patent ten jest wyraźnie nielegalny zgodnie z 35 U.S.C. §101, CDC nie tylko nalegało na jego przyznanie pomimo nieostatecznych i ostatecznych odrzuceń, ale także nadal płaciło opłaty za utrzymanie patentu po tym, jak decyzja Sądu Najwyższego z 2013 r. potwierdziła, że był on sprzeczny z prawem.

Ponadto CDC opatentowało wykrywanie wirusa SARS CoV przy użyciu wielu metod, w tym reakcji łańcuchowej polimerazy z odwrotną transkrypcją (RT-PCR). Dzięki temu patentowi wykluczyli oni kogokolwiek spoza ich licencjonowanych lub spiskujących interesów z legalnego angażowania się w niezależną weryfikację ich twierdzeń, że wyizolowali wirusa, że jest on czynnikiem powodującym SARS, lub że jakakolwiek terapia może być skuteczna przeciwko zgłoszonemu patogenowi.

Należy zauważyć, że wnioski patentowe CDC zostały również odrzucone w odmowach nieostatecznych i ostatecznych z powodu niekwalifikowalności na podstawie 35 U.S.C. § 102, ponieważ zostały publicznie ujawnione przed ich złożeniem. W pierwszym nieostatecznym odrzuceniu USPTO stwierdził, że genom CDC został opublikowany w czterech wpisach akcesyjnych Genbank 14, 18 i 21 kwietnia 2003 r. z identycznością od 96,8% do 99,9% identycznych sekwencji. [Źródło: USPTO Non-FinalRejection File #10822904, September 7, 2006, page 4.]

Dr Fauci wiedział i nie ujawnił dowodów na to, że patent CDC był sprzeczny z prawem, w oparciu o prace, które finansował w latach poprzedzających wybuch SARS.

Po uzyskaniu nielegalnego patentu, złożeniu petycji o unieważnienie decyzji eksperta o jego odrzuceniu, a następnie ostatecznym przyznaniu patentu, CDC okłamało opinię publiczną, twierdząc, że kontroluje patent, aby był on “publicznie dostępny”.

Rzecznik CDC Llelwyn Grant powiedział, że: „Całym celem tego patentu jest uniemożliwienie ludziom kontrolowania technologii. Robi się to po to, aby zapewnić przemysłowi i innym badaczom rozsądny dostęp do próbek.” – Źródło: 6 maj 2003, Race to Patent SARS VirusRenewsDebate]

Tragikomicznym jest fakt, że to publiczne oświadczenie obala prosty fakt, że ich własna publikacja w Genbanku w rzeczywistości uczyniła go domeną publiczną, a tym samym nie nadawała się do opatentowania. Fakt ten, potwierdzony przez inspektorów patentowych, został unieważniony przez CDC w ramach płatnej akwizycji mającej na celu obejście prawa.

Chociaż nie jest to objęte 35 U.S.C. §101, nadużycie prawa patentowego przez dr Anthony Fauciego jest szczegółowo opisany poniżej. Na uwagę zasługuje jednak jego rozmyślne i zwodnicze użycie terminu “szczepionka” w patentach i publicznych wypowiedziach, w celu wypaczenia znaczenia tego terminu dla manipulacji opinią publiczną.

W sprawie Jacobson v. Mass z 1905 roku sąd jasno stwierdził, że aby szczepionka była obowiązkowa, wymagana jest KORZYŚĆ PUBLICZNA. Ani Pfizer, ani Moderna nie udowodniły zakłócenia w transmisji [zaraźliwości] wirusa. W sprawie Jacobson v. Massachusetts, 197 U.S. 11 (1905), sąd stwierdził, że kontekst ich opinii opiera się na następującej zasadzie:

“Ten sąd więcej niż raz uznał to za fundamentalną zasadę, że ‘osoby i własność podlegają wszelkiego rodzaju ograniczeniom i obciążeniom w celu zabezpieczenia ogólnego komfortu, zdrowia i dobrobytu państwa…”.

W testach “rzekomej szczepionki” Moderna i Pfizer wyraźnie przyznali, że ich technologia terapii genowej nie ma żadnego wpływu na infekcję wirusową lub przenoszenie wirusa, a jedynie przekazuje biorcy zdolność do endogennej produkcji białka kolcowego S1 poprzez wprowadzenie syntetycznej sekwencji mRNA. Dlatego podstawa statutu Massachusetts i ustalenia Sądu Najwyższego jest w tym przypadku nieistotna.

Co więcej, Urząd Patentów i Znaków Towarowych Stanów Zjednoczonych [USPTO], podczas procesu REJESTRACJI szczepionki przeciwko HIV, który to wniosek Anthony Fauci złożył, otrzymał następującą odpowiedź na poparcie odrzucenia jego fałszywego “wynalazku”:

Wniosek/numer kontrolny: 09/869,003 Strona 5

Wniosek/numer kontrolny: 09/869,003 Strona 5

Te argumenty są przekonujące w zakresie, w jakim antygenowy peptyd stymuluje odpowiedź immunologiczną, która może wytworzyć przeciwciała wiążące się z określonym peptydem lub białkiem, ale nie są przekonujące w odniesieniu do szczepionki. Odpowiedź immunologiczna wywołana przez szczepionkę musi być czymś więcej niż tylko pewną reakcją immunologiczną, ale musi mieć charakter ochronny. Jak zauważono w poprzedniej skardze do Urzędu, w sztuce [medycznej] termin “szczepionka” oznacza środek, który zapobiega infekcji. Wnioskodawca nie wykazał, że zgłoszona szczepionka spełnia nawet niższy standard określony w specyfikacji, a tym bardziej standardową definicję sztuki, aby być skuteczną w tym zakresie.

Dlatego roszczenia 5, 7 i 9 nie są skuteczne jako szczepionka przeciw HIV-1, a zatem nie mają patentowej użyteczności.

 

18 U.S.C. §2339 C i nast. – Finansowanie Aktów Terroru i Spiskowanie w Celu ich Popełnienia

 

Pośrednio, bezprawnie i umyślnie dostarcza lub gromadzi fundusze z zamiarem ich wykorzystania lub ze świadomością, że fundusze te mają zostać wykorzystane, w całości lub w części, w celu przeprowadzenia:

(A) czynu, który stanowi przestępstwo w ramach traktatu określonego w podsekcji (e)(7), wdrożonego przez Stany Zjednoczone, lub

(B) jakiegokolwiek innego czynu mającego spowodować śmierć lub poważne uszkodzenie ciała osoby cywilnej lub każdej innej osoby nie biorącej czynnego udziału w działaniach wojennych w sytuacji konfliktu zbrojnego, jeżeli celem takiego czynu, ze względu na jego charakter lub kontekst, jest zastraszenie ludności lub zmuszenie rządu lub organizacji międzynarodowej do podjęcia lub zaniechania działania….

Nie później niż 11 kwietnia 2005 r. dr Anthony Fauci publicznie uznał związek SARS z potencjałem bioterrorystycznym. Wykorzystując strach przed bioterroryzmem wywołanym przez wąglik w 2001 roku, publicznie świętował gospodarcze dobrodziejstwo, jakie ludzie od zajmowania się terroryzmem krajowym skierowali na jego budżet. W szczególności stwierdził, że NIAID aktywnie finansuje badania nad mikromacierzą DNA “SARS Chip” do szybkiego wykrywania SARS (coś, co nie zostało udostępnione podczas obecnej “pandemii”) i dwoma kandydatami na szczepionki skoncentrowane na białku kolcowych SARS-CoV.

Emerging Infectious Diseases: a 10-Year Perspective from the National Institute of Allergy and Infectious Diseases
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3320336/

Pod kierownictwem trzech zatrudnionych przez siebie chińskich badaczy – Zhi-yong Yanga, Wing-pui Konga i YueHuanga – Fauci miał do 2004 roku co najmniej jedną szczepionkę DNA w trakcie badań na zwierzętach.

A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7095382/

Zespół ten, wchodzący w skład Centrum Badań nad Szczepionkami przy NIAID, koncentrował się przede wszystkim na opracowywaniu szczepionek przeciwko HIV, ale jego zadaniem było również zidentyfikowanie kandydatów na szczepionkę przeciwko SARS. We współpracy z Sanofi, ScrippsInstitute, Harvardem, MIT i NIH, decyzja dr Fauci o jednostronnym promowaniu szczepionek jako podstawowej interwencji w przypadku kilku wyznaczonych “chorób zakaźnych” uniemożliwiła zastosowanie sprawdzonych terapii u chorych i umierających.

Chloroquine is a potent inhibitor of SARS coronavirus infection and spread
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1232869/

Dr Peter McCullough o blokowaniu metod leczenia Covid-19
Leczenie chorób wirusowych: czy prawdę ukrywano przez dziesięciolecia? – dr Lee D. Merritt

CDC i NIAID pod kierownictwem Anthony’ego Fauci weszły w wymianę handlową między państwami (w tym, ale nie tylko, współpraca z EcoHealth Alliance Inc.) i z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk) poprzez grant z 2014 roku, o oznaczeniu R01AI110964 Narodowego Instytutu Zdrowia [NIH], w celu wykorzystania swoich praw patentowych. Wiadomo było, że badania te dotyczyły białek powierzchniowych koronawirusów, które miały zdolność do bezpośredniego zakażania ludzkich układów oddechowych. Mimo rażącego naruszenia moratorium NIH na badania typu uzyskiwania funkcji [gain of function], NIAID i dr Ralph Baric kontynuowali prace nad chimerycznymi składnikami koronawirusów, specjalnie w celu wzmocnienia patogenności materiału biologicznego.

Do października 2013 roku, w ramach prac finansowanych przez NIAID w Chinach, Instytut Wirusologii w Wuhan opisał białko kolcowe S1 1 koronawirusa. W prace te zaangażowane były NIAID, USAID oraz Peter Daszak, szef EcoHealth Alliance. Praca ta, finansowana w ramach grantu R01AI079231, była kluczowa w izolowaniu i manipulowaniu fragmentami wirusów wybranych z różnych miejsc w całych Chinach, które zawierały wysokie ryzyko poważnej reakcji u ludzi.

Isolation and characterization of a bat SARS-like coronavirus that uses the ACE2 receptor
https://pubmed.ncbi.nlm.nih.gov/24172901/

Do marca 2015 r. wiadomo było, że zarówno wirulencja białka kolcowe S1, jak i receptor ACE2 stanowią znaczne zagrożenie dla zdrowia ludzkiego. NIAID, EcoHealth Alliance i liczni badacze ubolewali nad faktem, że opinia publiczna nie była wystarczająco zaniepokojona koronawirusem, aby odpowiednio finansować ich pożądane badania.

National Academies Press (US); 2016 Feb 12. 6, Developing MCMs for Coronaviruses https://www.ncbi.nlm.nih.gov/books/NBK349040/

Dr Peter Daszak z EcoHealth Alliance zaproponował następującą ocenę sytuacji:

“Daszak powtórzył, że dopóki kryzys związany z chorobami zakaźnymi nie stanie się bardzo realny i nie przekroczy progu sytuacji kryzysowej, jest często w dużym stopniu ignorowany. Aby utrzymać bazę finansową po zakończeniu kryzysu, musimy zwiększyć świadomość opinii publicznej odnośnie konieczności opracowania medycznych środków zapobiegawczych, takich jak powszechny program uniwersalnych szczepień przeciwko koronawirusom. Kluczowym elementem napędzającym ten proces są media, a gospodarka szybko podchwyci ten trend. Musimy wykorzystać ten szum medialny i zaadresować prawdziwe problemy. Inwestorzy się pojawią, gdy tylko wyczują potencjalne zyski z finalizacji tego procesu, stwierdził Daszak.” – Źródło: Rapid Medical Countermeasure Response to Infectious Diseases: Enabling Sustainable Capabilities Through Ongoing Public- and Private-Sector Partnerships: Workshop Summary.

Ekonomia będzie podążać za trendem/szumem.

CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie ograniczając się do pracy z Uniwersytetem Północnej Karoliny w Chapel Hill [UNC]) i z zagranicą (w szczególności, Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowanych przez Shi Zheng-Li) poprzez U19AI109761 (Ralph S. Baric), U19AI107810 (Ralph S. Baric), i dofinansowanie z Narodowej Fundacji Nauk Przyrodniczych w Chinach 81290341 (Zheng-Li Shi) i wsp. 2015-2016. Projekty te miały miejsce w czasie, gdy wykonywane prace były zakazane przez amerykańskie Narodowy Instytut Zdrowia [NIH].

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

Opinia publiczna została wyraźnie poinformowana o niebezpieczeństwach, jakie niosą ze sobą badania finansowane przez NIAID w 2015 i 2016 roku, kiedy materiał z Instytutu Wirusologii w Wuhan był obrabiany w placówce Uniwersytetu Północnej Karoliny [UNC], czyli laboratorium dr Ralpha Barica.

“Jedynym skutkiem tej pracy, jest stworzenie w laboratorium nowego, nienaturalnego zagrożenia” – zgadza się Richard Ebright, biolog molekularny i ekspert ds. obrony biologicznej na Rutgers University w Piscataway, w stanie New Jersey. Zarówno Ebright jak i Wain-Hobson są długoletnimi krytykami badań typu gain-of-function [uzyskiwania funkcji].

W swoim artykule autorzy badania przyznają również, że fundatorzy mogą/powinni się dobrze zastanowić o dopuszczeniu takich eksperymentów w przyszłości. “Panele naukowe mogą uznać, że podobne badania, nad budową wirusów chimerycznych, opartych na krążących szczepach, są zbyt ryzykowne, aby je prowadzić” – piszą, dodając, że potrzebna jest dyskusja na temat tego, “czy tego typu badania nad wirusami chimerycznymi uzasadniają dalsze badania w porównaniu z nieodłącznym ryzykiem”.

Ale dr Baric i inni twierdzą, że badania przyniosły korzyści. Wyniki badań “przesuwają tego wirusa z kandydata na nowo pojawiający się patogen do wyraźnego i obecnego zagrożenia”, mówi dr Peter Daszak, który był współautorem pracy z 2013 roku. Peter Daszak jest prezesem EcoHealth Alliance, międzynarodowej sieci naukowców z siedzibą w Nowym Jorku, która pobiera próbki wirusów od zwierząt i ludzi w miejscach występowania nowych chorób na całym świecie.

Dr Peter Daszak zgadza się, że badania testujące hybrydowe wirusy w ludzkich hodowlach komórkowych i modelach zwierzęcych mają ograniczony zakres, jeśli chodzi o to, co mogą powiedzieć o zagrożeniu stwarzanym przez dzikiego wirusa. Twierdzi on jednak, że mogą one pomóc wskazać, które patogeny powinny być traktowane priorytetowo w dalszych badaniach.” – Nature, 12 listopad 2015, Engineered bat virus stirs debate over risky research https://www.nature.com/articles/nature.2015.18787

Anthony Fauci: „Korzyści ze zgromadzonych danych przeważają nad ryzykiem związanym z pandemią” – dr Chris Martenson
EcoHealth Alliance dr Petera Daszaka ukryło prawie 40 milionów dolarów z Pentagonu i zmilitaryzowało naukę o pandemii – Sam Husseini

Wiedząc, że amerykański Departament Zdrowia i Usług Społecznych [HHS] (poprzez CDC, NIH, NIAID oraz finansowane przez nich laboratoria i partnerów komercyjnych) miał patenty na każdy proponowany element medycznych środków zaradczych i ich finansowanie, dr Fauci, dr Gao (Chińskie CDC) i dr Elias (Fundacja Billa i Melindy Gates) spiskowali, aby popełnić akty terroru na globalnej populacji – w tym obywatelach Stanów Zjednoczonych – kiedy we wrześniu 2019 r. opublikowali następujące informacje w corocznym raporcie na temat globalnej gotowości na sytuacje kryzysowe związane ze zdrowiem:

“Kraje, darczyńcy i instytucje wielostronne muszą być przygotowane na najgorsze.

Szybko rozprzestrzeniająca się pandemia spowodowana śmiertelnym patogenem oddechowym (czy to naturalnie pojawiającym się, czy też przypadkowo lub celowo uwolnionym), stawia dodatkowe wymagania dotyczące gotowości. Darczyńcy i instytucje wielostronne muszą zapewnić odpowiednie inwestycje w rozwój innowacyjnych szczepionek i terapii, zdolności produkcyjnych, leków antywirusowych o szerokim spektrum działania oraz odpowiednich interwencji niefarmakologicznych. Wszystkie kraje muszą opracować system natychmiastowego udostępniania sekwencji genomu każdego nowego czynnika chorobotwórczego do celów zdrowia publicznego, a także środki umożliwiające wymianę ograniczonych medycznych środków zaradczych między krajami.

Wskaźnik(i) postępu do września 2020 roku:

– Darczyńcy i kraje zobowiązują się i określają harmonogramy: finansowania i opracowania uniwersalnej szczepionki przeciwko grypie, leków antywirusowych o szerokim spektrum działania i terapii celowanych. WHO i jej państwa członkowskie opracowują opcje standardowych procedur i harmonogramów udostępniania danych dotyczących sekwencji, próbek i medycznych środków zaradczych dla patogenów innych niż grypa.

– Darczyńcy, kraje i instytucje wielostronne opracowują wieloletni plan i podejście do wzmocnienia zdolności badawczych w zakresie badań i rozwoju, przed i w trakcie epidemii.

– WHO, Fundusz Narodów Zjednoczonych na rzecz Dzieci, Międzynarodowa Federacja Stowarzyszeń Czerwonego Krzyża i Czerwonego Półksiężyca, partnerzy akademiccy i inni partnerzy określają strategie zwiększania możliwości i integracji podejść i badaczy z dziedziny nauk społecznych w całym kontinuum gotowości i reagowania ” – str. 8, Annual report on global preparedness for health emergencies

Jakby na potwierdzenie użyteczności żądania z września 2019 r. o “finansowanie i rozwój” szczepionki oraz fortunnego rzekomego wybuchu SARS CoV-2 w grudniu 2019 r., dr Fauci zaczął napawać się, że jego losy w zakresie dodatkowego finansowania prawdopodobnie zmieniają się na lepsze. W wywiadzie w STAT z 10 lutego 2020 roku, został on zacytowany w następujący sposób:

“”Pojawienie się nowego wirusa zmieni tę liczbę, prawdopodobnie znacznie”, powiedział Fauci. “Nie wiem, jak dużo to będzie. Ale myślę, że to będzie generować bardziej trwałe zainteresowanie koronawirusami, ponieważ jest bardzo jasne, że koronawirusy mogą dokonywać naprawdę interesujących rzeczy.”” – Fluctuating funding and flagging interest hurt coronavirus research, leaving crucial knowledge gaps

 

18 U.S.C. § 2331 §§ 802 – Akty Terroryzmu Krajowego Skutkujące Śmiercią Obywateli Amerykańskich

 

Sekcja 802 amerykańskiej ustawy PATRIOT Act (Pub. L. No. 107-52) rozszerzyła definicję terroryzmu, aby objąć “krajowy,” w przeciwieństwie do międzynarodowego, terroryzm. Osoba angażuje się w terroryzm krajowy, jeśli dokonuje czynu “niebezpiecznego dla życia ludzkiego”, który jest pogwałceniem praw karnych stanu lub Stanów Zjednoczonych, jeśli czyn ten wydaje się być zamierzony, aby: (i) zastraszyć lub wymusić [coś] na ludności cywilnej; (ii) wywrzeć wpływ na politykę rządu poprzez zastraszenie lub wymuszenie;

Dr Anthony Fauci zastraszał i zmuszał ludność cywilną oraz próbował wpłynąć na politykę rządu poprzez zastraszenie i przymus.

Bez żadnego potwierdzenia, dr Anthony Fauci promował symulację komputerową profesora Neila Fergusona, wywodząc z niej twierdzenia, że:

“Świat stoi w obliczu najpoważniejszego kryzysu zdrowia publicznego od pokoleń. Tutaj przedstawiamy konkretne szacunki skali zagrożenia, przed jakim stoją obecnie kraje.”

“Używamy najnowszych szacunków dotkliwości, aby pokazać, że strategie polityczne, których celem jest złagodzenie epidemii, mogą zmniejszyć liczbę zgonów o połowę i ograniczyć szczyt zapotrzebowania na opiekę zdrowotną o dwie trzecie, ale to nie wystarczy, aby zapobiec przeciążeniu systemów opieki zdrowotnej. Aby ograniczyć przenoszenie choroby do niskiego poziomu, konieczne będą zatem bardziej intensywne i społecznie destrukcyjne interwencje. Jest prawdopodobnym, że takie środki – przede wszystkim dystans społeczny na dużą skalę – będą musiały być stosowane przez wiele miesięcy, być może aż do momentu, gdy dostępna będzie szczepionka.” – Imperial College London, 17 marca 2020, COVID-19: Imperial researchers model likely impact of public healthmeasures

Przegląd kodu źródłowego z modelu Fergusona
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Plusy i minusy środków zaradczych przeciw pandemii grypy – dr Thomas Inglesby, prof. Jennifer Nuzzo, prof. Tara O’Toole i prof. Donald Henderson [listopad 2006]
Lockdown jest ponad 10 razy bardziej śmiertelny niż sama pandemia

Informując prezydenta, że aż 2,2 miliona zgonów może być skutkiem patogenu, który nie został jeszcze wyizolowany i którego nie można było zmierzyć z żadną dokładnością, dr Fauci zastraszył i zmusił ludność oraz rząd do lekkomyślnych, niesprawdzonych i szkodliwych działań, powodujących nieodwracalne szkody dla życia i środków do życia.

Ani Imperial College, ani “niezależny” Institute for HealthMetrics and Evaluation [Instytut Mierzenia i Oceny Zdrowia] (finansowany głównie przez Fundację Billa i Melindy Gatesów)nie miały żadnych dowodów na sukces w szacowaniu wcześniejszych obciążeń spowodowanych koronawirusem, ale bez konsultacji czy wzajemnej weryfikacji dr Fauci przyjął ich przerażające szacunki za podstawę interwencji, które są wyraźnie sprzeczne z zaleceniami medycznymi.

– Nałożenie dystansu społecznego było oparte na symulacji komputerowej i modelach środowiskowych, które nie zawierały żadnych dowodów na przenoszenie chorób.

– Narzucenie noszenia masek na twarz było bezpośrednio sprzeczne z dowodami z kontrolowanych badań klinicznych i z pisemną polityką w czasopiśmie Amerykańskiego Stowarzyszenia Medycznego [AMA].

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.”JAMA. 2020;323(15):1517-1518; Medical Masks

– Zarówno w symulacjach Imperial College, jak i IHME, kwarantanny były modelowane dla osób chorych, a nie zdrowych.

Geneza idei zamykania kraju [Lockdown] sięga 2006 roku – Jeffrey A. Tucker [American Institute for Economic Research]
Maseczki nie działają: Przegląd literatury naukowej w kontekście zasadności polityki społecznej wobec COVID-19 – dr Denis Rancourt

Naleganie na szczepionki, przy jednoczesnym blokowaniu awaryjnego stosowania sprawdzonych interwencji farmaceutycznych, mogło przyczynić się do śmierci wielu pacjentów i zdrowych osób.

Wykorzystując władzę NIAID podczas domniemanej pandemii, dr Anthony Fauci aktywnie tłumił sprawdzone medyczne środki zaradcze, stosowane i potwierdzone w postępowaniach naukowych, które oferowały alternatywę dla produktów finansowanych przez jego spiskujące podmioty, którym zapewnił bezpośrednie finansowanie i dla których miał otrzymywać korzyści materialne i niematerialne.

Alan Jones: Biurokraci zaprzeczają, że hydroksychlorochina zmniejsza śmiertelność
Koronawirus: Jak sobie z nim poradzić? – Prof. Didier Raoult [Chlorochina]
Hydroksychlorochina – czy działa na koronawirusa? – Dr Vladimir Zelenko
Wywiad z dr Stellą Immanuel o Hydroksychlorochinie [30 lipiec 2020]
COVID-19 – Dr Richard Bartlett: Strategia oparta na leku Budezonid

 

 

18 U.S.C. § 1001 – Okłamywanie Kongresu

 

(a)O ile niniejsza sekcja nie stanowi inaczej, każdy, kto w jakiejkolwiek sprawie podlegającej jurysdykcji władzy wykonawczej, ustawodawczej lub sądowniczej Rządu Stanów Zjednoczonych, świadomie i umyślnie-

(1) fałszuje, ukrywa lub tuszuje za pomocą jakiejkolwiek sztuczki, schematu lub urządzenia istotny fakt;

(2) składa jakiekolwiek materialnie fałszywe, fikcyjne lub oszukańcze oświadczenie lub reprezentację; lub

(3) sporządza lub wykorzystuje fałszywe pismo lub dokument, wiedząc, że zawiera on fałszywe, fikcyjne lub oszukańcze oświadczenie lub wpis; podlega grzywnie na mocy niniejszego paragrafu, karze pozbawienia wolności na okres nie dłuższy niż 5 lat lub, jeśli przestępstwo wiąże się z międzynarodowym lub krajowym terroryzmem (zgodnie z definicją w sekcji 2331), karze pozbawienia wolności na okres nie dłuższy niż 8 lat, lub obu tym karom. Jeżeli sprawa dotyczy przestępstwa z rozdziału 109A, 109B, 110 lub 117, lub sekcji 1591, wówczas kara pozbawienia wolności nałożona na mocy niniejszej sekcji nie przekracza 8 lat.

 

W dniu 22 października 2020 r. Biuro Odpowiedzialności Rządu Stanów Zjednoczonych (GAO) opublikowało raport zatytułowany:

BIOMEDICAL RESEARCH: NIH Should Publicly Report More Information about the Licensing of Its Intellectual Property.

W dokumencie tym autorzy poinformowali, że Narodowy Instytut Zdrowia (NIH) otrzymał “do 2 miliardów dolarów w tantiemach z tytułu wkładu w 34 leki sprzedane w latach 1991-2019”.

Pobieżny przegląd raportu NIH Office of Technology Transfer dotyczącego aktywnych licencji wydaje się sprzeczny z raportem GAO w odniesieniu do kilku istotnych faktów. W raporcie GAO wyraźnie brakuje ponad 30 patentów związanych z aktywnymi związkami generującymi miliardy dolarów przychodu. Dlaczego GAO i NIH nie mogły dojść do porozumienia w sprawie czegoś tak prostego, jak leki generujące dochód dla NIH?

Od czasu uchwalenia ustawy Bayh Dole Act (Pub. L. 96-517, 12 grudnia 1980 r.), badania finansowane z funduszy federalnych były ekonomiczną bonanzą dla amerykańskich uniwersytetów, agencji federalnych i ich wybranych patronów. W pierwszej dekadzie po wprowadzeniu ustawy Bayh-Dole, fundusze NIH podwoiły się z 3,4 miliarda dolarów do 7,1 miliarda dolarów. Dekadę później- podwoiły się ponownie- osiągając 15,6 miliarda dolarów. W następstwie września 2001 roku, Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID) odnotował bezpośredni wzrost swojego budżetu o ponad 300%, bez uwzględnienia funduszy DARPA, które od 2005 roku wynosiły aż 1,7 miliarda dolarów rocznie. W 2020 roku budżet NIH wynosił ponad 41 miliardów dolarów.

Co się stało z 763 miliardami dolarów z funduszy podatników przeznaczonych na uczynienie Ameryki zdrowszą, odkąd wynalazcy są zachęcani do komercyjnego działania? Kto się wzbogacił?

Odpowiedź, niestety, jest taka, że skrupulatne rozliczenia nie są prowadzone, aby móc odpowiedzieć na te pytania.

Narodowy Instytut Zdrowia [NIH] jest wymienionym z nazwy właścicielem co najmniej 138 patentów od 1980 roku.

Amerykański Departament Zdrowia i Opieki Społecznej [HHS] jest wymienionym z nazwy właścicielem co najmniej 2600 patentów.

Dotacje lub współpraca z NIAID zaowocowały 2655 patentami i wnioskami patentowymi, z których tylko 95 zawiera przypisanie do Departamentu Zdrowia i Usług Społecznych jako właściciela. Większość z tych patentów jest przypisana do uniwersytetów, co sprawia, że ostateczni beneficjenci komercyjni są całkowicie nieprzejrzyści. Jednym z największych posiadaczy jest SIGA Technologies (NASDAQ: SIGA), która, choć publicznie informuje o bliskich związkach z NIAID, nie jest wymieniona w raporcie NIH GAO. Dyrektor generalny SIGA, dr Phillip L. Gomez spędził 9 lat w NIAID, rozwijając program szczepionek przeciwko HIV, SARS, Ebola, Wirusa Zachodniego Nilu i grypy, zanim przeszedł do przedsięwzięć komercyjnych. Chociaż ich technologia wyraźnie wywodzi się z osiągnieć naukowych do których przyczynił się NIAID, firma zgłasza przychody z NIAID, ale nie ma żadnych opłat licencyjnych ani płatności komercyjnych na rzecz NIH lub któregokolwiek z jego programów.

Dyrektor NIAID, dr Anthony Fauci, jest wymieniony jako wynalazca w 8 przyznanych patentach amerykańskich. Żaden z nich nie został zgłoszony w raportach NIAID, NIH lub GAO dotyczących aktywnego licencjonowania, pomimo faktu, że dr Fauci został podobno zmuszony do otrzymania zapłaty za swój “wynalazek” w postaci Interleukiny-2 – płatności, które podobno przekazał nienazwanej organizacji charytatywnej.

Z 21 patentów wymienionych w pomarańczowej księdze amerykańskiej Agencji ds. Żywności i Leków (FDA), wymienionych w raporcie GAO, żaden z patentów dr Anthony’ego Fauci nie jest wymieniony. Co więcej, żaden z patentów NIAID nie jest wymieniony pomimo wyraźnych dowodów na to, że Gilead Sciences i Janssen Pharmaceuticals (oddział Johnson & Johnson) wygenerowały ponad 2 miliardy dolarów rocznie ze sprzedaży, która była bezpośrednim rezultatem osiągnięć naukowych finansowanych przez NIAID. W raporcie GAO brakuje 2 patentów na Velclade, który od kilku lat generuje sprzedaż przekraczającą 2,18 miliarda dolarów rocznie. Żaden z patentów dla Yescarta nie jest wymieniony w raporcie GAO. Żaden z patentów na Lumoxiti nie jest wymieniony w raporcie GAO. Żaden z patentów na lek Kepivance nie został wymieniony w raporcie GAO. Z naruszeniem 37 USC §410.10 i 35 USC §202(a), ponad 13 z 21 patentów w raporcie GAO nie ujawnia interesów rządu, mimo że są one bezpośrednim wynikiem finansowania przez NIH.

Odporność i bezkarność: korupcja w relacjach Państwo-Farmacja – dr PaddyRawlinson
Prawda o firmach farmaceutycznych. Jak nas oszukują i co z tym robić – dr MarciaAngell

Własny dorobek patentowy dr Anthony’ego Fauci:

Patent US 6190656 i 6548055 Wzmocnienie immunologiczne z przerywaną terapią interleukiną-2

Metoda aktywacji układu odpornościowego ssaków obejmuje serię podań IL-2, co odbywa się z przerwami przez dłuższy okres czasu. Każde podanie IL-2 jest wystarczające, aby umożliwić wzrost i szczyt spontanicznej syntezy DNA w komórkach krwi obwodowej lub węzłów chłonnych pacjenta, a każde następne podanie następuje po poprzednim podaniu w serii przez okres czasu, który jest wystarczający, aby umożliwić ekspresję receptora IL-2 w krwi obwodowej lub węzłach chłonnych pacjenta, aby wzrosnąć, osiągnąć szczyt, a następnie zmniejszyć się do 50% wartości szczytowej. Ta przerywana terapia IL-2 może być łączona z inną terapią, która jest ukierunkowana na określony stan chorobowy, taką jak terapia antyretrowirusowa- obejmująca, na przykład, podawanie AZT, ddI lub interferonu alfa. Ponadto, podawanie IL-2 może być stosowane w celu ułatwienia transdukcji in situ limfocytów T w kontekście terapii genowej. W tym podejściu komórki są najpierw aktywowane in vivo przez wspomnianą terapię IL-2, a następnie transdukcja jest dokonywana przez dostarczenie genetycznie zmodyfikowanego wektora retrowirusowego bezpośrednio do pacjenta.

Niniejsze zgłoszenie jest kontynuacją amerykańskiego zgłoszenia patentowego nr ser. 08/487075, złożonego 7 czerwca 1995 r., obecnie zaniechanego, które jest kontynuacją w części amerykańskiego zgłoszenia patentowego nr ser. 08/063315, złożonego 19 maja 1993 r., obecnie wydanego jako patent US 5419900, oraz zgłoszenie patentowe USNr ser. 08/452440, złożone 26 maja 1995 r., obecnie wydane jako patent nr U.S. 5696079, który jest Krajowym Etapem zgłoszonego na podstawie 35 USC 371 zgłoszenia PCT/US94/05397, złożonego 19 maja 1994 r., którego treść jest włączona do niniejszego dokumentu przez przypis.

Zgłoszono 19 maja 1993 r.

Wydano Ostateczne Odrzucenie 20 stycznia 1998 r. odrzucony po odstąpieniu 14 sierpnia 1998 r. i 12 kwietnia 1999 r. ograniczone i zmodyfikowane roszczenia przyznane 8 maja 2000 r.

Ta rodzina patentów była podstawą kłamstwa Fauci’ego dla czasopisma British Medical Journal, w którym fałszywie stwierdził:

“Dr Anthony Fauci powiedział BMJ, że jako pracownik rządowy, był zobowiązany przez prawo do umieszczenia swojego nazwiska na patencie dotyczącym rozwoju interleukiny 2 [IL-2] i był również zobowiązany przez prawo do otrzymania części zapłaty, którą rząd otrzymał za wykorzystanie patentu. Powiedział, że uważa otrzymanie zapłaty za niestosowne (sic) i przekazał całą kwotę na cele charytatywne.”BMJ. 2005 Jan 22; 330(7484): 162.

Nie był “zobowiązany przez prawo” do popełnienia oszustwa wobec urzędu patentowego, a następnie otrzymania za to zapłaty!

 

Patent US 6911527 Peptydy związane z HIV

Wynalazek ten polega na odkryciu nowych specyficznych epitopów i przeciwciał związanych z długotrwałym przeżyciem infekcji HIV-1. Te epitopy i przeciwciała mają zastosowanie w przygotowywaniu szczepionek do zapobiegania infekcji HIV-1 lub do kontrolowania progresji do AIDS.

Zgłoszony 6 maja 1999 r.

Odrzucony jako niepatentowalny 22 stycznia 2003 roku. Wydane z ostatecznym odrzuceniem 15 lipca 2004 r. po złożeniu wniosków o ponowne rozpatrzenie. Zmodyfikowane i ograniczone roszczenia dopuszczone 29 września 2004 roku.

 

Patent US 7368114 Białko fuzyjne, w tym CD4

Odkryto tu nowe rekombinowane polipeptydy, które zawierają polipeptyd CD4 podwiązany na jego końcu C z częścią immunoglobuliny zawierającą region zawiasowy i stałą domenę łańcucha ciężkiego immunoglobuliny ssaków.

Część lub IgG jest połączona na swoim końcu C z polipeptydem zawierającym końcówkę z końcem C łańcucha ciężkiego przeciwciała IgA lub końcówkę z końca C łańcucha ciężkiego przeciwciała IgM. Ujawnione są tu również metody stosowania tych białek fuzyjnych CD4.

Zgłoszono 24 października 2002 r.

Odrzucony jako niepatentowalny 18 sierpnia 2006 roku. Opłacone odwołanie w celu uchylenia ustaleń eksperta 15 lutego 2007 roku. Ponownie odrzucony 11 maja 2007 roku. W dniu 10 października 2007 r. wnioskodawcy jeszcze bardziej zawęzili konstrukcję tego, co wyraźnie nie było patentem, a USPTO przyznało mniej niż połowę roszczeń, o które ubiegano się w pierwotnym zgłoszeniu.

 

Patent US 9896509, 9193790 i 9441041 Zastosowanie antagonistów interakcji pomiędzy HIV GP120 i integryną alfa 4 beta 7

Podano metody leczenia zakażenia HIV. Metody mogą obejmować podawanie podmiotowi z zakażeniem HIV terapeutycznie skutecznej ilości środka, który zakłóca interakcję gp120 i alfa 4 integryny, takiego jak antagonista alfa 4 beta 1 lub integryny alfa 4 beta 7, lecząc w ten sposób zakażenie HIV. W kilku przykładach, antagonistą integryny alfa 4 jest przeciwciało monoklonalne, które wiąże się swoiście z podjednostką integryny alfa 4, beta 1 lub beta7 lub cyklicznym heksapeptydem o sekwencji aminokwasowej CWLDVC. Przedstawiono również metody zmniejszania replikacji lub infekcji HIV. Metody obejmują kontakt komórki ze skuteczną ilością środka, który zakłóca interakcję gp120 i integryny alfa 4, takiego jak antagonista integryny alfa 4 beta 1 lub alfa 4 beta 7. Ponadto, dostarczane są metody określania, czy środek jest użyteczny w leczeniu HIV.

Odrzucony 22 maja 2017 roku jako podwójnie opatentowany. W swojej odpowiedzi wnioskodawcy przyznają się do bezprawnego działania i dążą do uzyskania tylko tych elementów swojego zgłoszenia, które wykraczają poza okres obowiązywania wydanych patentów. W dniu 11 października 2017 r. wydano ograniczone roszczenia.

 

Próbka zagmatwanego przepływu funduszy, który wymyka się publicznemu ujawnieniu.

 

US Patent 8999351 został wydany Tekmira Pharmaceuticals Corporation w Burnaby, Kolumbia Brytyjska, w Kanadzie. W swoim patencie ujawniają oni, że ich badania były wspierane przez grant z Narodowego Instytutu Alergii i Chorób Zakaźnych (Grant HHSN266200600012C). Jak na ironię, ten grant o wartości 23 milionów dolarów został przyznany w 2006 roku firmie Alnylam Pharmaceuticals, Inc, a nie firmie Tekmira.

W 2012 roku firma Alnylam zgodziła się zapłacić firmie Tekmira 65 milionów dolarów w celu rozstrzygnięcia sporów prawnych, w tym roszczenia o odszkodowanie w wysokości 1 miliarda dolarów za “bezlitosne i okrutne” przywłaszczenie tajemnic handlowych firmy Tekmira. Od najwcześniejszego pierwszeństwa zgłoszenia patentowego z 10 listopada 2008 r., nie ma żadnego publicznego zapisu wskazującego na firmę Tekmira jako beneficjenta tego grantu NIAID. Niezależnie od tego, technologia nanocząstek lipidowych opracowana w ramach tego grantu jest technologią wykorzystywaną obecnie w interwencji [szprycy] firmy Moderna na COVID-19. W swoim zgłoszeniu 10-Q firma Alnylam informuje, że posiada licencję na technologię od firmy Arbutus – dawniej Tekmira – która oskarżyła firmę Acuitas o przywłaszczenie tajemnic handlowych i przekazanie licencji na nie firmie Moderna oraz koncernowi Pfizer współpracującego z firmą BioNTech.

Dodatkowe przypisy:
https://www.ott.nih.gov/nih-and-its-role-technology-transfer
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2017/206288Orig1s000TAltr.pdf
https://www.gao.gov/assets/720/710287.pdf
https://grantome.com/search?q=%22National%20Institute%20of%20Allergy%20and%20Infectious%20Diseases%22

 

15 U.S.C. §1-3 – Spiskowanie w Celu Prowadzenia Przestępczej Działalności Gospodarczej

 

Każda umowa, kombinacja w formie powiernictwa lub w inny sposób, lub zmowa, w celu ograniczenia handlu pomiędzy kilkoma Stanami lub z obcymi narodami, jest uznana za nielegalną. Każda osoba, która zawrze jakąkolwiek umowę lub zaangażuje się w jakąkolwiek kombinację lub zmowę uznaną niniejszym za nielegalną, zostanie uznana za winną przestępstwa, a po skazaniu będzie podlegać karze grzywny nieprzekraczającej 100.000.000 dolarów, jeśli jest korporacją, lub, 1.000.000 dolarów jeśli jest inną osobą, lub karze pozbawienia wolności nieprzekraczającej 10 lat, lub obu tym karom, według uznania sądu.

Grant AI23946-08 z Narodowego Instytutu Zdrowia przyznany dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny w Chapel Hill (oficjalnie sklasyfikowany jako powiązany z NIAID dr Anthony’ego Fauci przynajmniej w 2003 roku) rozpoczął prace nad syntetycznym modyfikowaniem Coronaviridae (rodzina koronawirusów) w wyraźnym celu prowadzenia ogólnych badań, wzmacniania patogenności, wykrywania, manipulowania i potencjalnych interwencji terapeutycznych skierowanych na te same czynniki/patogeny. Już 21 maja 2000 roku dr R. Baric z Uniwersytetem Północnej Karoliny [UNC] dążyli do opatentowania krytycznych sekcji rodziny koronawirusów dla własnych korzyści komercyjnych [U.S. Provisional Application No. 60/206,537, filed May 21, 2000].

W jednej z kilku prac powstałych w wyniku prac sponsorowanych przez ten grant, dr Baric opublikował to, co według niego było pełnej długości cDNA wirusa SARS CoV, w którym wyraźnie stwierdzono, że wirus SAR CoV opierał się na kompozycji segmentów DNA.

Używając panelu sąsiadujących cDNA, które obejmują cały genom, złożyliśmy cDNA o pełnej długości szczepu SARS-CoVUrbani i uratowaliśmy sklonowane molekularnie wirusy SARS (klon zakaźny SARS-CoV), które zawierały oczekiwane mutacje markera wstawione do klonów składowych.”PNAS October 28, 2003 100 (22) 12995-13000; Reverse genetics with a full-length infectiousc DNA of severe acute respiratory syndrome coronavirus

Dnia 19 kwietnia 2002 roku – wiosną przed pierwszym wybuchem SARS w Azji – Christopher M. Curtis, Boyd Yount i Ralph Baric złożyli wniosek o patent nr US 7279372 na metodę produkcji rekombinowanego koronawirusa. W pierwszym publicznym zapisie roszczeń, starali się oni opatentować sposób wytwarzania “zakaźnego, defektywnego w replikacji koronawirusa”. Praca ta była wspierana przez grant NIH wspomniany powyżej i GM63228. W skrócie, amerykański Departament Zdrowia i Opieki Społecznej [HHS] był zaangażowany w finansowanie wzmacniania zakaźnej natury koronawirusa w latach 1999-2002, zanim SARS został kiedykolwiek wykryty u ludzi.

Na tym tle zauważyliśmy niezwykłe starania amerykańskiego Centrum Kontroli i Prewencji Chorób [CDC] na opatentowanie koronawirusa SARS wyizolowanego z ludzi, który według doniesień został przeniesiony na ludzi podczas epidemii SARS w Azji w latach 2002-2003. Rozdział 11, paragraf 101 Kodeksu Stanów Zjednoczonych [35 U.S.C. §101] zabrania patentowania przyrody. Ten przepis nie powstrzymał CDC w ich wysiłkach. Ich wniosek, uaktualniony w 2007 roku, ostatecznie został wydany jako patent US 7220852 i ograniczał każdego, kto nie był licencjonowany przez ich patent, od manipulowania SARS CoV, rozwijania testów lub zestawów do pomiaru koronawirusa SARS u ludzi lub pracy z ich opatentowanym wirusem do użytku terapeutycznego. Prace związane z tym wirusem, prowadzone przez wybranych współpracowników, obejmowały znaczne ilości inżynierii chimerycznej, badania typu uzyskiwania funkcji [gain-of-function], charakterystykę wirusa, wykrywanie, leczenie (zarówno szczepionki, jak i interwencje terapeutyczne) oraz badania nad bronią biologiczną.

Krótko mówiąc, dzięki patentowi dr Barica US 6593111 (roszczenia 1 i 5) oraz patentowi CDC US 7220852 (roszczenie 1), żadne badania w Stanach Zjednoczonych nie mogły być prowadzone bez ich zezwolenia lub naruszenia tego patentu.

Zauważyliśmy, że specjalista w dziedzinie badań typu gain-of-function, dr Ralph Baric, był zarówno odbiorcą milionów dolarów amerykańskich dotacji na badania od kilku instytucji federalnych, jak i zasiadał w Międzynarodowym Komitecie Taksonomii Wirusów (ICTV) Światowej Organizacji Zdrowia oraz w Grupie Badawczej Coronaviridae (CSG). W ramach tej funkcji był zarówno odpowiedzialny za określanie “nowości” kladów gatunków wirusów, jak i bezpośrednio korzystał z deklaracji o nowościach w postaci nowych zezwoleń na finansowanie badań oraz związanej z nimi współpracy patentowej i komercyjnej. Razem z CDC, NIAID, WHO, placówkami akademickimi i podmiotami komercyjnymi (w tym Johnson & Johnson; Sanofi i ich kilkoma firmami biotechnologicznymi posiadającymi patenty na koronawirusy; Moderna; Ridgeback; Gilead; Sherlock Biosciences; i, inne), potężna grupa interesów tworzyła to, co sugerowalibyśmy jako “wzajemnympowiązaniem dyrekcji” zgodnie z amerykańskimi prawem antymonopolowym.

1986-1990 NIAID Grant AI 23946 prowadzący do uzyskania patentu US 7279327 “Methods for Producing Recombinant Coronavirus”. Zgłoszony w 2002 r. i wydany w 2007 roku

Praca opublikowana po raz pierwszy na podstawie grantu NIAID to:

An Experimental Model for Dilated Cardiomyopathy after Rabbit Coronavirus Infection

https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC7109931&blobtype=pdf

1990 Pfizer zgłasza patent US 6372224 na szczepionkę przeciwko koronawirusowi opartą o białko S 14 listopada 2000 r. który został porzucony w kwietniu 2010 r., co czyni go domeną publiczną.

Lata 90. Prace koncentrowały się na związku koronawirusów z kardiomiopatią (patrz wyżej)

Wczesne odniesienie do “pojawienia się” koronawirusa jako patogenu układu oddechowego:

High Recombination And Mutation Rates In Mouse Hepatitis Virus Suggest That Coronaviruses May Be Potentiall Y Important Emerging Viruses

https://link.springer.com/content/pdf/10.1007%2F978-1-4615-1899-0_91.pdf

2000Dr Ralph Baric w ramach grantów AI23946 i GM63228 z Narodowego Instytutu Zdrowia [NIH] aktywnie pracuje nad rekombinowanym koronawirusem

2001 Narodowy Instytut Zdrowia, Alergie i Choroby Zakaźne. “Reverse Genetics with a Coronavirus Infectious cDNA Construct”. 4/1/2001-3/31/005 całkowity roczny koszty to 1 milion dolarów. RS Baric, PI

2002 Wybuch epidemii koronawirusa SARS w Azji

2003 25 kwietnia 2003 CDC złożyło patent, który ostatecznie uzyskała, jego numer to US 7220852 (patent na sekwencję RNA) oraz US 7776521 (patent na metodologię badań). Patenty te dają amerykańskiemu Departamentowi Zdrowia i Usług Społecznych [HHS] możliwość kontrolowania komercyjnego wykorzystania koronawirusa SARS.

Dr Anthony Fauci zostaje mianowany członkiem Naukowej Rady Doradczej Global Grand Challenges Fundacji Billa i Melindy Gatesów (pełnił tę funkcję do 2010 roku).

28 kwietnia 2003 r. Sequoia Pharmaceuticals składa wniosek o patent US 7151163(Środki przeciwwirusowe do leczenia, kontroli i zapobiegania zakażeniom koronawirusami). Otrzymało w tym samym roku dwa granty w wysokości 953 tysięcy dolarów od HHS.

21 lipca 2003 r. zespół Ralpha Barica (wykorzystujący granty AI23946 i GM63228) zgłasza patent US 7618802 (Kompozycje koronawirusów z genomem odpornym na rekombinację), który został wydany 17 listopada 2009 roku.

Instytut Onkologii Dana-Farber w listopadzie 2003 zgłasza patent US 7750123 na przeciwciało monoklonalne neutralizujące wirusa SARS CoV. Badania te są wspierane przez kilka grantów NIH, w tym przez granty z Narodowego Instytutu Zdrowia o oznaczeniach A128785, A148436 i A1053822.

2004 6 stycznia 2004 – SARS i bioterroryzm na konferencji Bioterrorism and Emerging Infectious Diseases: antimicrobials, therapeutics and immune modulators.

Na tej konferencji termin “Nowa Normalność” został wprowadzony przez firmę Merck.

Dr FAUCI I dr BARIC zaczynają zarabiać pieniądze!!! Narodowy Instytut Alergii i Chorób Zakaźnych (NIAID). SARS Reverse Genetics. AI059136-01. Koszty całkowite 1,7 miliona dolarów, RS Baric, PI. 10% wysiłku. 4/1/04- 3/31/09. Projekt ma na celu opracowanie pełnej długości zakaźnego cDNA wirusa SARS-CoV, opracowanie cząstek replikonowych SARS-CoV wyrażających heterologiczne geny oraz adaptację SARS-CoV na myszy, co pozwoli na stworzenie mysiego modelu patogennej infekcji SARS-CoV.

Narodowy Instytut Alergii i Chorób Zakaźnych. R01. Remodeling the SARS Coronavirus Genome Regulatory Network. RS Baric, PI 10% nakładu pracy. 7/1/04-6/30/09. 2,1 miliona dolarów.

22 listopada 2004 Uniwersytet w Hong Kongu patentuje białko kolcowe związane z SARS i ubiega się o patent US 7491489 (Syntetyczny peptyd celujący w krytyczne miejsca na białku kolca koronawirusa związanym z SARS odpowiedzialnym za infekcję wirusową i sposób jego zastosowania).

2005 Agencja ds. Zaawansowanych Projektów Badawczych w Obszarze Obronności (DARPA).Biohacking: Biological Warfare Enabling Technologies, czerwiec 2005. Waszyngton, Dystrykt Kolumbia. Wydarzenie sponsorowane przez DARPA/MITRE.

Przegląd osi czasu z https://www.youtube.com/watch?v=rO EeYBQiQU i https://www.davidmartin.world/wp-content/uploads/2020/04/20APRBotWslides.pdf

2008 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 rozpoczyna się od 10.189.682 milionów dolarów dla UNC w Chapel Hill https://taggs.hhs.gov/Detail/AwardDetail?arg_awardNum=U54AI057157&arg_ProgOfficeCode=104

2009 Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano kolejne 5.448.656 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2010 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 8.747.142 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

Liczba wydanych patentów na koronawirus SARS osiągnęła szczyt od czasu wybuchu epidemii w Azji (391 patentów).

6 sierpnia 2010 r., Moderna (przed jej założeniem) składa wniosek o patent US 9447164, który przyciągnął inwestorów (i “wynalazców”) z Flagship Ventures. Patent ten wyrósł z pracy dr Jasona P. Schruma z Harvard Medical School, wspieranego przez National Science Foundation Grant#0434507. Podczas gdy wniosek rości sobie prawo do pierwszeństwa z sierpnia 2010 roku, wniosek nie został sfinalizowany aż do października 2015 roku. W dniu 4 listopada 2015 roku USPTO wydał nieostateczne odrzucenie tego oryginalnego patentu, odrzucając wszystkie roszczenia.

https://www.nsf.gov/awardsearch/showAward?AWD_ID=0434507 z odniesieniem do finansowania w

https://molbio.mgh.harvard.edu/szostakweb/publications/Szostak_pdfs/Schrum_et_al_JACS_2009.pdf

2011 Crucell dołączył do Janssen Pharmaceutical Companies będącego częścią Johnson & Johnson w lutym, zabierając ze sobą całą swoją technologię dotyczącą SARS.

Grant w dziedzinie obrony przed bronią biologicznąU54 AI057157 jest kontynuowany, przekazano 7.344.820 dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2012 MERS wyizolowany w Egipcie

Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.627.657 USD dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID).

2013 Grant w dziedzinie obrony przed bronią biologiczną U54 AI057157 jest kontynuowany, przekazano 7.226.237 milionów dolarów dla UNC w Chapel Hill (niekonkurencyjny grant od NIAID)

2014 23 kwietnia 2014, Moderna zgłasza patent na szczepionkę na bazie kwasu nukleinowego, patenty US9872900 i US10022435

2015 Moderna podpisuje umowę o rozwoju szczepionki z NIAID i realizuje ją z wiodącym na rynku twórcą i wynalazcą mRNA-1273 Guiseppe Ciaramella.

https://www.documentcloud.org/documents/6935295-NIH-Moderna-Confidential-Agreements.html

2016 Narodowy Instytut Zdrowia [NIH] poprzez Scripps Institute i Dartmouth College składają wniosek patentowy WO 2018081318A1 “Prefusion Coronavirus Spike Proteins and their Use [Białka kolcowe koronawirusa sprzed fuzji i ich zastosowanie]” ujawniający technologię mRNA, która pokrywa się (i jest używana w tandemie z) technologią Moderny.

Główny wynalazca Barney Scott Graham był dobrze znany firmie Moderna, jako że jest on osobą w Narodowym Instytucie Zdrowia [NIH], do której Moderna “wysłała e-maila” w celu uzyskania sekwencji dla SARS CoV-2, zgodnie z raportem Moderny tutaj (“W styczniu 2020 roku, gdy odkryto, że infekcja w Wuhan była spowodowana nowym koronawirusem, Bancel szybko wysłał e-maila do dr Barneya Grahama, zastępcy dyrektora Centrum Badań nad Szczepionkami w Narodowym Instytucie Zdrowia, prosząc go o przesłanie sekwencji genetycznej wirusa.” – Źródło: Executives of vaccine developer Moderna cash in, cutcorners, 26 maj 2020)

Ponadto, współwynalazca Jason McLellan pracował z dr Barney’em Grahamem nad patentem na szczepionkę będącą wspólną własnością rządu chińskiego złożonym w Australii w 2013 roku. AU 2014231357A1 – Epitope of RSV fusion protein and antibody identifying same

2017 sierpień – Sanofi kupuje firmę Protein Science Corp posiadającą znaczne zasoby patentów na SARS

2018 czerwiec – firma Sanofi kupuje firmę Ablynx posiadającą znaczne zasoby patentów na SARS

2019 marzec, Sherlock Biosciences licencjonuje technologię Wyss, aby tworzyć przystępną cenowo diagnostykę molekularną – finansowane przez Open Philanthropy – tę samą organizację, która będzie sponsorem finansowym ćwiczeń “przy stole” o nazwie Wydarzeni 201, które ułożyło plan “pandemii” w październiku 2019 roku.

 

15 U.S.C. §8 – Manipulacja i Alokacja Rynku

 

Za sprzeczne z porządkiem publicznym, nielegalne i nieważne uznaje się wszelkie kombinacje, zmowy, powiernictwa, porozumienia lub umowy zawierane przez lub pomiędzy dwiema lub więcej osobami lub korporacjami, z których każda, jako agent lub zleceniodawca, zajmuje się importem jakiegokolwiek artykułu z jakiegokolwiek obcego kraju do Stanów Zjednoczonych, oraz gdy takie kombinacje, zmowy, powiernictwa, porozumienia lub umowy mają na celu ograniczenie legalnego handlu lub wolnej konkurencji w legalnym handlu, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych jakiegokolwiek artykułu lub artykułów importowanych lub przeznaczonych do importu. Porozumienie lub umowa mają na celu ograniczenie handlu zgodnego z prawem lub wolnej konkurencji w handlu zgodnym z prawem, lub zwiększenie ceny rynkowej w jakiejkolwiek części Stanów Zjednoczonych artykułu lub artykułów importowanych lub przeznaczonych do importu do Stanów Zjednoczonych, lub jakiejkolwiek produkcji, do której taki importowany artykuł wchodzi lub ma wejść. Każda osoba, która zajmuje się importem jakichkolwiek towarów z jakiegokolwiek obcego kraju, z naruszeniem przepisów niniejszej sekcji, lub która łączy się lub spiskuje z innymi w celu naruszenia tych przepisów, jest winna wykroczenia i po skazaniu jej w jakimkolwiek sądzie Stanów Zjednoczonych taka osoba zostanie ukarana grzywną w wysokości nie mniejszej niż 100 dolarów i nie przekraczającej 5000 dolarów, a ponadto zostanie ukarana więzieniem, według uznania sądu, na okres nie krótszy niż trzy miesiące i nie przekraczający dwunastu miesięcy.

Poprzez niekonkurencyjne przyznawanie grantów dr Ralphowi Baricowi z Uniwersytetu Północnej Karoliny [UNC]w Chapel Hill, wybór lokalizacji laboratoriów bezpieczeństwa biologicznego poziomu 4 (BSL-4), ustalanie cen Remdesiviru i terapii mRNA firm Moderna i Pfizer, NIAID, CDC i Departament Zdrowia i Opieki Społecznej [HHS] były zaangażowane w przydzielanie funduszy federalnych spiskującym stronom bez niezależnej kontroli.

Od około 12 marca 2020 roku, w celu wzbogacenia własnych interesów ekonomicznych poprzez zapewnienie dodatkowych funduszy zarówno od podmiotów federalnych, jak i fundacji, CDC i dr Fauci z NIAID postanowili zawiesić badania i sklasyfikować COVID-19 wyłącznie na podstawie kapryśnej prezentacji objawów. Zmuszając opinię publiczną do polegania na The COVID Tracking Project – finansowanym przez Fundację Bloomberga, Zuckerberga i Gatesa i prezentowanym przez media (The Atlantic) – a nie agencję zdrowia publicznego – dr Fauci użył oszukańczej technologii testowania (RT-PCR), aby mylić “przypadki COVID” z pozytywnymi testami PCR u żywych, jednocześnie nalegając, aby zgony z powodu COVID były liczone wyłącznie na podstawie objawów. To utrwaliło popyt rynkowy na jego pożądany program szczepień, który był powtarzany przez niego i spiskujące z nim strony na całym świecie aż do chwili obecnej. Nic dziwnego, że było to konieczne z powodu widocznego spadku liczby przypadków, które stanowiły kryteria dr Fauci’ego i innych do pozbawiania obywateli ich praw wynikających z 1. Poprawki Konstytucji.

Myślenie pojęciowe, a myślenie stereotypowe – Andrzej Wronka, Kazimierz Ajdukiewicz
COVID – dlaczego terminologia ma znaczenie? – dr Malcolm Kendrick
Jak dokładne są testy na COVID? – dr Sebastian Rushworth
Testy PCR: Po 35 cyklach odcięcia nie wyhodujesz wirusa – dr Anthony Fauci
Nawet połowa testów na koronowirusa może być fałszywie pozytywna [Chiny]
Nieoczekiwane wykrycie przeciwciał na SARS-CoV-2 w okresie przed pandemicznym we Włoszech. [wrzesień 2019]

15 U.S.C. § 19 – Wzajemne Powiązania Między Dyrekcjami

 

(1) Żadna osoba nie może w tym samym czasie pełnić funkcji dyrektora lub urzędnika w dwóch korporacjach (innych niż banki, stowarzyszenia bankowe i spółki powiernicze), które są-

(A) zaangażowane w całości lub częściowo w handel; oraz

(B) ze względu na swoją działalność i miejsce prowadzenia działalności są konkurentami, tak że wyeliminowanie konkurencji w drodze porozumienia między nimi stanowiłoby naruszenie jakichkolwiek przepisów antymonopolowych; jeżeli każda z tych korporacji posiada kapitał, nadwyżkę i niepodzielne zyski o łącznej wartości przekraczającej 10.000.000 dolarów, skorygowane zgodnie z ustępem (5) niniejszej podsekcji.

Dr Anthony Fauci jest członkiem Rady Przywódczej [Leadership Council] Globalnego Planu Działań na rzecz Szczepionek [Gates Global Vaccine Action Plan] Billa i Malindy Gates.

Dr Fauci, kontrolując wydawanie federalnych funduszy na badania, był i nadal jest członkiem Rady Monitorowania Globalnej Gotowości [Global Preparedness Monitoring Board] Światowej Organizacji Zdrowia. Dołączył do niego w tej radzie skonfliktowany darczyńca z Fundacji Billa i Melindy Gates, dr Chris Elias, oraz dr George F. Gao z Chińskiej Rady Państwowej ichniego Centrum Kontroli i Prewencji Chorób. Ta Rada Monitorowania Globalnej Gotowości [GPMB] przewidywała, że wszystkie państwa członkowskie muszą wziąć udział w globalnej symulacji uwolnienia patogenu układu oddechowego.

Dr Ralph Baric jest jednym z głównych beneficjentów funduszy federalnych USA, prowadzi ośrodek BSL-4 i zasiada w grupie roboczej International Committee on Taxonomy of Virus Corona viridae, której zadaniem jest potwierdzenie obecności lub jego braku patogenu, za co otrzymuje bezpośrednie wynagrodzenie.

Jak wspomniano w części dotyczącej naruszeń 18 U.S.C. § 1001 powyżej, istnieją liczne nieujawnione relacje handlowe pomiędzy naukowcami otrzymującymi finansowanie, ich instytucjami finansującymi oraz interesami handlowymi, w których występują ujawnione i nieujawnione warunki handlowe. Pełna lista wszystkich potencjalnie zaangażowanych stron jest wymieniona w poniższej części zatytułowanej “Podmioty komercyjne”.

Wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny są sprzeczne z prawem, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych kierowany przez Anthony’ego Fauci (dalej odpowiednio “NIAID” i “dr Fauci”) weszły w wymianę handlową między państwami (w tym m.in. współpracując z Ecohealth Alliance Inc. ) oraz z zagranicą (w szczególności z Instytutem Wirusologii w Wuhan oraz Chińską Akademią Nauk) za pośrednictwem grantu R01AI110964 z programu grantów Narodowego Instytutu Zdrowiaz 2014 r. i następnych, w celu wykorzystania swoich praw patentowych.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i Narodowy Instytut Alergii i Chorób Zakaźnych (dalej “NIAID”) weszły w wymianę handlową między stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) oraz z obcymi narodami (w szczególności z Instytutem Wirusologii w Wuhan i Chińską Akademią Nauk reprezentowaną przez dr Shi Zheng-Li) poprzez U19AI109761 (dr Ralph S. Baric), U19AI107810 (Ralph S. Baric) oraz grant Narodowej Fundacji Nauk Przyrodniczych w Chinach o oznaczeniu 81290341 (ShiZheng-Li) i wsp. 2015-2016.

Ponadto wydaje się, że w okresie egzekwowania patentów i po orzeczeniu Sądu Najwyższego potwierdzającym, że patenty na materiał genetyczny były nielegalne, CDC i NIAID weszły w wymianę handlową między Stanami (w tym, ale nie tylko, współpracując z Uniwersytetem Północnej Karoliny w Chapel Hill) i z obcymi narodami w celu prowadzenia chimerycznej konstrukcji nowatorskiego materiału koronawirusowego o specyficznych właściwościach wirulencji przed, w trakcie i po określeniu przez Narodowy Instytut Zdrowia [NIH] w październiku 17, 2014, że praca ta nie była wystarczająco zrozumiała w odniesieniu dostandardów bezpieczeństwa biologicznego tej instytucji.

Wytworzony w laboratorium koronawirus wywołał debatę – Jef Akst [2015]

W tym dochodzeniu zakłada się, że CDC i jej współpracownicy byli:
a) w pełni świadomi prac wykonywanych przy użyciu ich opatentowanej technologii;
b) zawarli wyraźne lub dorozumiane umowy obejmujące licencjonowanie, lub inne wynagrodzenie; i, c) świadomie zaangażowali jeden lub więcej zagranicznych interesów, aby kontynuować eksploatację ich zastrzeżonej technologii, gdy Sąd Najwyższy Stanów Zjednoczonych potwierdził, że takie patenty były nielegalne i gdy Narodowy Instytut Zdrowia [NIH] wydał moratorium na takie badania.

Podobno w styczniu 2018 r. ambasada USA w Chinach wysłała śledczych do Instytutu Wirusologii w Wuhan i stwierdziła, że

“Podczas interakcji z naukowcami w laboratorium Instytucie w Wuhan zauważyli oni, że nowe laboratorium ma poważny niedobór odpowiednio wyszkolonych techników i badaczy potrzebnych do bezpiecznego prowadzenia tegolaboratorium wysokiego poziomu bezpieczeństwa [szczelności biologicznej].” Gazeta Washington Post podała, że informacje te zostały zawarte w depeszy z 19 stycznia 2018 roku. Ponad rok później, w czerwcu 2019 r., CDC przeprowadziło inspekcję w Instytucie Badań Medycznych Chorób Zakaźnych Armii Stanów Zjednoczonych w Fort Detrick (zwanym dalej “USAMRIID”) i nakazało jego zamknięcie po stwierdzeniu, że ich inspekcja znalazła zagrożenia dla bezpieczeństwa biologicznego. Publikacja w czasopiśmie Nature z 2003 r. (423(6936): 103) donosi o współpracy między CDC a USAMRIID w zakresie badań nad koronawirusami, po której nastąpiła późniejsza znacząca współpraca.

„Naukowcy z NIH i armii amerykańskiej połączyli siły w systematycznym programie badań przesiewowych, aby znaleźć kandydatów na leki do zwalczania ciężkiego ostrego zespołu oddechowego (SARS). Współpraca, która już trwa, została ogłoszona na zeszłotygodniowej Międzynarodowej Konferencji na temat Badań Antywirusowych w Savannah w stanie Georgia.” – Nature, 8 maj 2003, US Army join shunt for SARS drug

CDC, ze względu na to, co wydaje się być tym samym rodzajem obaw zidentyfikowanych w Wuhan, zdecydowało się kontynuować współpracę z rządem chińskim, zamykając jednocześnie placówkę armii amerykańskiej.

CDC zgłosiło pierwszy przypadek choroby podobnej do SARS-CoV w Stanach Zjednoczonych w styczniu 2020 r., przy czym Służba Wywiadu Epidemiologicznego CDC zgłosiła 650 przypadków klinicznych i 210 testów. Biorąc pod uwagę, że podejrzany patogen po raz pierwszy pojawił się w oficjalnych raportach 31 grudnia 2019 r., można jedynie stwierdzić, że CDC:
a) posiadało mechanizm i środki do przeprowadzenia testów potwierdzających istnienie “nowego koronawirusa”; lub
b) nie posiadało takiego mechanizmu i fałszywie ogłosiło taki komunikat w styczniu.

Naiwnością jest sugerować, że WHO lub CDC mogły wyprodukować i rozprowadzić testy na “nowy” patogen, kiedy ich własne późniejsze osiągnięcia w zakresie rozwoju i wdrażania testów okazały się niewiarygodne…

Zagrożenie pandemią i wycieki z laboratoriów: Samospełniające się przepowiednie – dr Martin Furmanski
Długa historia przypadkowych ucieczek laboratoryjnych potencjalnie pandemicznych patogenów jest ignorowana w reportażach na temat COVID-19 – Sam Husseini

 

35 U.S.C. §200 – 206 – Ujawnienie Interesu Rządowego/Państwowego

 

35 U.S.C. §202 (c)(6)

Zobowiązanie wykonawcy, w przypadku złożenia wniosku patentowego w Stanach Zjednoczonych przez wykonawcę lub w jego imieniu, lub przez jakiegokolwiek cesjonariusza wykonawcy, do umieszczenia w specyfikacji takiego wniosku i każdego patentu wydanego na jego podstawie, oświadczenia określającego, że wynalazek został dokonany przy wsparciu rządu i że rząd posiada pewne prawa do wynalazku.

Ponad 5000 patentów i wniosków patentowych zawierało odniesienie do koronawirusa SARS sięgające dat pierwszeństwa z 1998 roku. Są one streszczone poniżej.

Liczba patentów związanych z koronawirusem SARS

23 lipca 2020 roku Komisja Patentowa i Odwoławcza Biura Patentów i Znaków Towarowych Stanów Zjednoczonych odrzuciła starania firmy Moderna o unieważnienie patentu US 8058069. Patent ten, będący własnością Arbutus Biopharma Corp (należącej głównie do Roivant Science Ltd), obejmuje nanocząstki lipidowe (LNP) wymagane jako medium do dostarczenia mRNA w szczepionce. Niektóre z podstawowych technologii zostały oparte na pracach wykonanych pierwotnie na Uniwersytecie Kolumbii Brytyjskiej i zostały po raz pierwszy licencjonowane w 1998 roku.

Szczepionki mRNA na COVID-19 – dr James Odell

mRNA-1273 – eksperymentalna szczepionka opracowana przez Modernę na COVID-19 – wykorzystuje technologię nanocząstek lipidowych [LNP], na którą firma Moderna uważała że ma licencje od Acuitas Therapeutics Inc, firmy utworzonej przez byłego dyrektora wcześniejszej firmy Tekmira, należącej do Arbutusa. Ta licencja nie upoważniała firmy Moderna do wykorzystania tej technologii w szczepionce COVID-19.

Firmy M-CAM i Knowledge Ecology International niezależnie potwierdziły, że Moderna naruszyła prawo amerykańskie, nie ujawniając udziału rządu USA w finansowaniu swoich patentów i wniosków patentowych. Chociaż zaniedbanie to ma wpływ na wszystkie z ponad 130 przyznanych amerykańskich patentów firmy Moderna, jest ono szczególnie problematyczne w przypadku amerykańskiego patentu US 10702600 (Beta coronavirus mRNA vaccine), który jest patentem odnoszącym się do, “informacyjnego/matrycowego kwasu rybonukleinowego (mRNA) zawierającego otwartą ramkę odczytu kodującą białko kolca [S] lub podjednostkę białka S betakoronawirusa (BetaCoV), sformułowanego w nanocząstce lipidowej”.

Konkretne roszczenia odnoszące się do kluczowego elementu koronawirusa SARS zostały opatentowane 28 marca 2019 roku – 9 miesięcy przed wybuchem epidemii SARS CoV-2! Zarówno patent, jak i finansowanie DARPA dla tej technologii zostały ujawnione w publikacji naukowej (New England Journal of Medicine), ale fundusze rządowe nie zostały wspomniane w patencie.

W 2013 r. w ramach programu Autonomiczna Diagnostyka Umożliwiająca Profilaktykę i Terapię [Autonomous Diagnostics to Enable Prevention and Therapeutics – ADEPT] przyznano grant firmie Moderna Therapeutics na opracowanie nowego typu szczepionki opartej na informacyjnym RNA [mRNA]. Pierwotny grant DARPA nosił numer W911NF-13-1-0417. Firma wykorzystała tę technologię do opracowania swojej szczepionki na COVID-19, która w momencie opublikowania tego dossier przechodziła I fazę badań klinicznych we współpracy z NIH.29

Zgodnie z przepisami Federal Acquisition Regulation (FAR), kontrahenci rządu federalnego muszą w ramach kontraktu przedstawić informacje dotyczące kwestii naruszenia własności intelektualnej. Zgodnie z FAR §27.201-1(c) i (d) rząd wymaga zarówno zawiadomienia o naruszeniu lub potencjalnym naruszeniu, jak i zachowania odpowiedzialności ekonomicznej za naruszenie patentu. Konkretnie, w FAR §52.227.3 (a),

“Wykonawca zabezpieczy rząd i jego urzędników, agentów i pracowników przed odpowiedzialnością, w tym kosztami, za naruszenie jakiegokolwiek patentu Stanów Zjednoczonych…”. Oprócz patentów cytowanych przez USPTO podczas badań, które doprowadziły do patentu US 10702600, M-CAM zidentyfikowało czternaście innych wydanych patentów poprzedzających patent US 10702600, które zostały wykorzystane przez egzaminatorów patentowych do ograniczenia patentów wynikających z tych samych finansowanych badań, w tym patentów poszukiwanych przez CureVac.

Krótko mówiąc, podczas gdy Moderna cieszy się setkami milionów dolarów finansowania i wsparcia ze strony Anthony’ego Fauci i jego NIAID, od początku swego istnienia była zaangażowana w nielegalną działalność patentową i okazywała pogardę dla amerykańskiego prawa patentowego. Co gorsza, rząd Stanów Zjednoczonych udzielił firmie Moderna wsparcia finansowego w obliczu nieujawnionego ryzyka naruszenia prawa, potencjalnie przyczyniając się do tego samego naruszenia, za które otrzymali odszkodowanie.

 

21 C.F.R. § 50.24 et seq., Nielegalne Badania Kliniczne

 

Prowadzenie badań medycznych (nawet w nagłych przypadkach) jest niezgodne z prawem bez podjęcia szeregu kroków w celu:

  1. Zorganizowania badań przez uprawnioną i instytucjonalną komisją rewizyjną;
  2. Zapewnienia świadomej zgody wszystkim uczestnikom, w tym oświadczenia o ryzyku i korzyściach; oraz,
  3. Zaangażowania się w konsultacje ze społecznością, w której badanie ma być przeprowadzone.

 

Dr Anthony Fauci wymusił na zdrowej populacji Stanów Zjednoczonych bezprawne badanie kliniczne, w którym amerykański Departament Zdrowia i Usług Społecznych [HHS] ekstrapoluje dane epidemiologiczne. Nie uzyskano ani nie zabezpieczono świadomej zgody na żaden z “medycznych środków zaradczych” narzuconych populacji i nie powołano żadnej niezależnej komisji rewizyjnej – zgodnie z definicją zawartą w ustawie.

Do kwietnia 2020 roku, oficjalne zalecenie Journal of the American Medical Association było jednoznaczne.

“Maski na twarz nie powinny być noszone przez zdrowe osoby w celu ochrony przed nabyciem infekcji dróg oddechowych, ponieważ nie ma dowodów sugerujących, że maski na twarz noszone przez zdrowe osoby są skuteczne w zapobieganiu chorobie.”JAMA. 2020;323(15):1517-1518; MedicalMasks

Część tego braku dowodów w rzeczywistości wykazała, że płócienne maski na twarz w rzeczywistości zwiększyły liczbę zachorowań związanych z grypą.

Maski z tkanin: niebezpieczne dla twojego zdrowia? – prof. Raina MacIntyre [2015]

Wbrew ustaleniom naukowym, stany, hrabstwa i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas sytuacji zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że maski na twarz ograniczają rozprzestrzenianie się wirusa SARS CoV-2. Jak dotąd, żadne z badań nie potwierdziło, że maska zapobiega przenoszeniu lub zakażeniu się SARS CoV-2.

Wydychany aerozol i maski na twarz

Wszystkie strony nakazujące stosowanie masek na twarz nie tylko świadomie ignorują ugruntowaną wiedzę z badań empirycznych, ale angażują się w coś, co jest równoznaczne z badaniem klinicznym całej populacji. Do takiego wniosku prowadzi fakt, że stosowanie masek na twarz i zapadalność na COVID-19 są omawiane w artykułach medycznych [naukowych] promowanych przez Amerykańskie Centrum Kontroli i Prewencji Chorób i inne instytucje.

2 metry czy 20 metrów, dystans nie ma większego znaczenia dla Covid-19 – prof. Martin Bazant i prof. John Bush z MIT

Dystans społeczny do 2 metrów był promowany jako środek zapobiegający przenoszeniu się wirusów grypy z osoby na osobę. Chociaż w jednym z badań wysunięto hipotezę, że do zakażenia może dojść w odległości do około 2 metrów, w badaniu tym wyraźnie stwierdzono, że nie testowano przenoszenia się wirusa między osobami, a żywotność wirusa w odległości 2 metrów nie była nawet przedmiotem badania. Nie powstrzymało to jednak przeinaczenia wyników badania, które wykorzystano jako podstawę dla niezweryfikowanego medycznego środka zaradczego, jakim jest dystans społeczny. Do tej pory żadne badanie nie wykazało skuteczności dystansu społecznego w modyfikowaniu przenoszenia wirusa SARS CoV-2. Urzędnicy zdrowia publicznego powołują się na publikację J InfectDis. 2013 Apr;207(7):1037-46:

„Wyniki: Piętnaście badań, w tym 12 modelujących i trzy epidemiologiczne, spełniło kryteria kwalifikacji. Badania epidemiologiczne wykazały, że dystans społeczny był związany z redukcją zachorowań na choroby grypopodobne i serokonwersji na grypę A (H1N1) z 2009 roku. Jednak ogólne ryzyko błędu systematycznego w badaniach epidemiologicznych było poważne. W badaniach modelujących oszacowano, że same środki dystansu społecznego w miejscu pracy spowodowały medianę obniżenia o 23% skumulowanego wskaźnika zachorowań na grypę w populacji ogólnej. Opóźniły one również i zmniejszyły szczytową częstotliwość ataków grypy. Redukcja skumulowanego wskaźnika ataków była bardziej wyraźna, gdy dystans społeczny w miejscu pracy był połączony z innymi interwencjami niefarmakologicznymi lub farmaceutycznymi. Oceniono jednak, że skuteczność zmniejszała się wraz z wyższymi wartościami podstawowej liczby reprodukcyjnej, opóźnieniem uruchomienia dystansu społecznego w miejscu pracy lub mniejszą zgodnością.

Wnioski: Badania modelowe przemawiają za stosowaniem dystansu społecznego w miejscach pracy niezwiązanych z opieką zdrowotną, ale brakuje dobrze zaprojektowanych badań epidemiologicznych.” BMC Public Health. 2018; 18: 518; Effectiveness of workplace social distancing measures in reducing influenza transmission: a systematic review

Wbrew ustaleniom naukowym, państwa, powiaty i przedsiębiorstwa naruszyły wymogi prawne dotyczące ogłaszania medycznych środków zaradczych podczas zagrożenia zdrowia publicznego, wyrażając “przekonanie”, że dystans społeczny zdrowej populacji ogranicza rozprzestrzenianie się SARS CoV-2. Jak dotąd, ani jedno badanie nie potwierdziło, że dystansowanie społeczne jakiejkolwiek populacji zapobiegło rozprzestrzenianiu się lub zakażeniu SARS CoV-2.

Zgodnie z ustawą o Federalnej Komisji Handlu [FTC Act], Rozdział 15, paragraf 41 Kodeksu Stanów Zjednoczonych [15 U.S.C. § 41] i następne, niezgodne z prawem jest reklamowanie, że produkt lub usługa może zapobiegać, leczyć lub uzdrawiać choroby ludzkie, chyba że posiada się kompetentne i wiarygodne dowody naukowe, w tym, w stosownych przypadkach, rzetelne kontrolowane badania kliniczne z udziałem ludzi, potwierdzające, że twierdzenia te są prawdziwe w chwili ich wygłaszania. W związku z tym, każda strona promująca stosowanie maseczek na twarz, narusza Ustawę o Federalnej Komisji Handlu.

Wszystkie te przepisy zostały złamane. Wszystkie właściwe władze w Stanach Zjednoczonych muszą zaprzestać stosowania masek na twarz do czasu skorygowania powyższych spraw.

 

Podmioty komercyjne

 

Dla wielu osób koronawirus SARS jest nowym tematem. Od 1999 roku możliwość manipulacji i wykorzystania koronawirusów do różnych celów przyciągnęło uwagę wielu osób, instytucji i organizacji komercyjnych, zarówno w sektorze publicznym, prywatnym jak i non-profit. Poniżej znajduje się lista ponad 5100 patentów i wniosków patentowych, zgłoszonych w wyraźnym celu kontrolowania jakiegoś aspektu koronawirusa SARS.

 

 

 

 

 

PATENTTytułWłaścicielPriorytetData złożeniaData otrzymania
US9995706Amperometric gas sensorSteris Corporation25-

Jun-

12

30-

Sep

-14

12-

Jun-

18

US9995705Amperometric gas sensorSteris Corporation25-

Jun-

12

30-

Sep

-14

12-

Jun-

18

US9994558Multicyclic compounds and methods of using sameKaryopharm Therapeutics Inc.20-

Sep-

13

19-

Sep

-14

12-

Jun-

18

US9994550Heterocyclic modulators of lipid synthesis for use against cancer and viral infections3-V Biosciences, Inc.7-

Jan-

14

7-

Jan

-15

12-

Jun-

18

US9993543Immunogenic compositions comprising silicified virus and methods of usePortland State University31-

Jan-

13

31-

Jan

-14

12-

Jun-

18

US9982257Chiral controlWAVE LIFE SCIENCES LTD.13-

Jul-12

12-

Jul-

13

29-

May

-18

US9982241Recombinant HCMV and RHCMV vectors and uses thereofOregon Health & Science University14-

May-

10

1-

Oct

-15

29-

May

-18

US9982025Monomeric griffithsin tandemersThe United States of America, as represented by the Secretary, Department of Health and Human Services5-

Jun-

13

5-

Jun

-14

29-

May

-18

US9981036Compositions, comprising improved Il-12 genetic constructs and vaccines, immunotherapeutics and methods of using the sameTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA12-

Dec-

11

26-

Feb

-16

29-

May

-18

US9975885Broad-spectrum non-covalent coronavirus protease inhibitorsPURDUE RESEARCH FOUNDATION28-

Apr-

16

28-

Apr

-17

22-

May

-18

US9974850Immunogenic compositions and uses thereofBOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM25-

Mar-

15

25-

Mar

-16

22-

May

-18

US9974848Tetanus toxoid and CCL3 improve DC vaccinesDuke University14-

Nov-

13

14-

Nov

-14

22-

May

-18

US9974845Combination of vaccination and inhibition of the PD-1 pathwayCureVac AG22-

Feb-

13

21-

Feb

-14

22-

May

-18

US9970061Bioagent detection oligonucleotidesIBIS BIOSCIENCES, INC.27-

Dec-

11

27-

Dec

-12

15-

May

-18

US9969793Compositions and methods for the treatment of immunodeficiencyADMA Biologics, Inc.28-

Oct-

14

13-

Nov

-17

15-

May

-18

US9963718LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumorsVIRATHERAPEUTICS GMBH8-

Oct-

08

7-

Apr

-17

8-

May

-18

US9963611Composition for use in decreasing the transmission of human pathogensInnonix Technologies, Incorporated29-

May-

09

21-

May

-10

8-

May

-18

US9963427Dithiol mucolytic agentsPARION SCIENCES, INC.23-

Aug-

13

11-

Mar

-16

8-

May

-18

US9962439Injectable vaccine compositionNITTO DENKO CORPORATION3-

Oct-

13

2-

Oct

-14

8-

May

-18

US9957302Treating cancer with viral nucleic acidMayo Foundation for Medical Education and Research20-

Feb-

07

6-

Jul-

15

1-

May

-18

US9957300Virus-like particles, methods of preparation, and immunogenic compositionsEmory University17-

May-

02

4-

May

-15

1-

May

-18

US9957238Arylalkyl-and aryloxyalkyl-substituted epithelial sodium channel blocking compoundsParion Sciences, Inc.13-

Dec-

13

1-

Mar

-17

1-

May

-18

US9951317Highly efficient influenza matrix (M1) proteinsNOVAVAX, INC.11-

Jul-03

6-

Oct

-16

24-

Apr-

18

 

US9951124Antibody producing non-human mammalsMERUS N.V.27-

Jun-

08

25-

Jan

-13

24-

Apr-

18

US9951122Antibodies against influenza virus and methods of use thereofBURNHAM INSTITUTE FOR MEDICAL RESEARCH6-

Dec-

07

12-

Aug

-13

24-

Apr-

18

US9950062Compounds and compositions as TLR activity modulatorsGLAXOSMITHKLINE BIOLOGICALS SA2-

Sep-

09

1-

Sep

-10

24-

Apr-

18

US9945856Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnosticsAMSTERDAM INSTITUTE OF VIRAL GENOMICS B.V.18-

Aug-

03

13-

Aug

-14

17-

Apr-

18

US9945780Use of a fluorescent material to detect failure or deteriorated performance of a fluorometerGEN-PROBE INCORPORATED14-

Jun-

12

7-

Jun

-13

17-

Apr-

18

US9944928Construction of pool of interfering nucleic acids covering entire RNA target sequence and related compositionsYork Yuan Yuan Zhu23-

Jul-07

2-

Jul-

15

17-

Apr-

18

US9944695Antibody producing non-human mammalsMenus N.V.27-

Jun-

08

30-

Apr

-14

17-

Apr-

18

US9944686Treatment of tumors with recombinant interferon alphaSUPERLAB FAR EAST LIMITED28-

Feb-

01

5-

Sep

-13

17-

Apr-

18

US9944649Compounds and compositions as toll-like receptor 7 agonistsNovartis Ag1-

May-

14

29-

Apr

-15

17-

Apr-

18

US9943614Cationic steroid antimicrobial diagnostic, detection, screening and imaging methodsBRIGHAM YOUNG UNIVERSITY17-

Jun-

08

16-

Jun

-09

17-

Apr-

18

US9938300Isothiazolopyrimidinones, pyrazolopyrimidinones, and pyrrolopyrimidinones as ubiquitin-specific protease 7 inhibitorsForma Therapeutics, Inc.5-

Feb-

15

4-

Feb

-16

10-

Apr-

18

US9938275Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines3M Innovative Properties Company18-

Jun-

04

23-

Jan

-17

10-

Apr-

18

US9938258Substituted 2,3-dihydrobenzofuranyl compounds and uses thereofKaryopharm Therapeutics Inc.29-

Nov-

12

27-

Nov

-13

10-

Apr-

18

US9932351Thienopyrimidinones as ubiquitin-specific protease 7 inhibitorsForma Therapeutics, Inc.5-

Feb-

15

4-

Feb

-16

3-

Apr-

18

US9932323Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinonesRutgers, The State University of New Jersey11-

Sep-

12

13-

Jan

-17

3-

Apr-

18

US9931316Antiviral activity from medicinal mushrooms and their active constituentsNot Available31-

Mar-

15

14-

Sep

-15

3-

Apr-

18

US9926340NAD analogs and methods of using said NAD analogs in determining ribosylation of proteins with PARP mutantsBiolog Life Science Institute Forshungslabor und Biochemica-Vertrieb GmbH8-

Apr-

15

1-

Apr

-16

27-

Mar

-18

US9925215Anionically modified polyallylamine derivative, use of anionically modified polyallylamine derivative as medicine, particularly for propylaxis and treatment of infections of respiratory tract caused by human metapneumovirus (hMPV), human rhinoviruses (HRV), and infection by influenza virus type A (IAV) and pharmaceutical composition comprising the anionically modified polyallylamine derivativeUNIWERSYTET JAGIELLONSKI29-

Jul-14

25-

Oct

-17

27-

Mar

-18

US9920314Compositions for and methods of identifying antigensPresident and Fellows of Harvard College21-

Feb-

06

6-

May

-15

20-

Mar

-18

US9920128Synthetic antiserum for rapid-turnaround therapiesThe Johns Hopkins University28-

Jan-

15

20-

Jan

-16

20-

Mar

-18

US9919034Methods of treating and prophylactically protecting mammalian patients infected by viruses classified in Baltimore group VTAMIR BIOTECHNOLOGY, INC.28-

Mar-

14

10-

Jun

-15

20-

Mar

-18

US9915613Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detectorGEN-PROBE INCORPORATED24-

Feb-

11

21-

Mar

-14

13-

Mar

-18

US9914976Methods and compositions for prostate cancer metastasisFLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FA25-

Mar-

11

27-

May

-16

13-

Mar

-18

US9913801Treatment of evolving bacterial resistance diseases including Klebsiella pneumoniae with liposomally formulated glutathioneYOUR ENERGY SYSTEMS, LLC15-

Feb-

13

15-

Mar

-13

13-

Mar

-18

US9909176Efficient deep sequencing and rapid genomic speciation of RNA viruses (vRNAseq)The Johns Hopkins University8-

Sep-

14

1-

Sep

-15

6-

Mar

-18

US9908946Generation of binding moleculesMerus N.V.26-

Sep-

11

16-

Sep

-15

6-

Mar

-18

US9908675Powdered pouch and method of making sameMONOSOL, LLC16-

Apr-

12

19-

Jul-

16

6-

Mar

-18

 

US9907796Methods of treating tumoral diseases, or bacterial or viral infectionsINHIBIKASE THERAPEUTICS, INC.4-

Oct-

12

15-

Sep

-16

6-

Mar

-18

US9895692Sample-to-answer microfluidic cartridgeMicronics, Inc.29-

Jan-

10

5-

Aug

-15

20-

Feb

-18

US9895411Analogs of C5a and methods of using sameBOARD OF REGENTS OF THE UNIVERSITY OF NEBRASKA29-

Jun-

10

29-

Jun

-11

20-

Feb

-18

US9895341Inflammation and immunity treatmentsOcean Spray Cranberries, Inc.1-

Apr-

11

30-

Mar

-12

20-

Feb

-18

US9894888Transgenic immunodeficient mouse expressing human SIRP-alphaINSTITUT PASTEUR26-

Mar-

12

26-

Mar

-13

20-

Feb

-18

US9890419Nanoreporters and methods of manufacturing and use thereofNanoString Technologies, Inc.23-

Dec-

05

20-

May

-16

13-

Feb

-18

US9890408Multiple displacement amplificationIBIS BIOSCIENCES, INC.15-

Oct-

09

15-

Oct

-10

13-

Feb

-18

US9890362Compositions, methods and uses for inducing viral growthTakeda Vaccines, Inc.5-

Dec-

08

19-

Sep

-14

13-

Feb

-18

US9890361 Methods for increasing the infectivity of viruses utilizing alkyne- modified fatty acids LIFE TECHNOLOGIES CORPORATION

26-Jan-12
25-Jan-13
13-Feb-18

US9890206 H1N1 flu virus neutralizing antibodies Medigen Biotechnology Corporation
20-Aug-15
20-Aug-15
13-Feb-18

US9890169 Triazolinone compounds as HNE inhibitors CHIESI FARMACEUTICI S.P.A.
14-Dec-15
12-Dec-16
13-Feb-18
US9890124 Benzazepine sulfonamide compounds Hoffmann-La Roche Inc.
15-Dec-15
14-Jun-17
13-Feb-18
US9889194 Immunogenic composition for MERS coronavirus infection New York Blood Center, Inc.
1-Mar-13
28-Feb-14
13-Feb-18
US9885092 Materials and methods for detection of HPV nucleic acids QIAGEN GAITHERSBURG INC.
24-Feb-11
23-Feb-12

6-Feb-18
US9885082 Embodiments of a probe and method for targeting nucleic acids University of Idaho
19-Jul-11
19-Jul-12
6-Feb-18
US9885037 Chiral control WAVE LIFE SCIENCES LTD.
13-Jul-12
12-Jul-13
6-Feb-18
US9884895 Methods and compositions for chimeric coronavirus spike proteins The University of North Carolina at Chapel Hill
20-Mar-14
20-Mar-15
6-Feb-18
US9884876 Anti-viral compounds, pharmaceutical compositions, and methods of use thereof Kineta, Inc.
9-May-14
8-May-15
6-Feb-18
US9884129 Release of agents from cells The Brigham and Women’s Hospital, Inc.
15-Oct-09
5-Jan-15
6-Feb-18
US9884032 Esters of short chains fatty acids for use in the treatment of immunogenic disorders PROPONENT BIOTECH GMBH
3-Oct-12
3-Mar-16
6-Feb-18

US9884026 Modular particles for immunotherapy YALE UNIVERSITY

1-Nov-13
31-Oct-14
6-Feb-18
US9880151 Method of determining, identifying or isolating cell-penetrating peptides Phylogica Limited
23-May-11
23-May-12
30-Jan-18

US9879026 Substituted spirocycles Boehringer Ingelheim International GmbH
12-Sep-14
29-Nov-16
30-Jan-18
US9879003 Host targeted inhibitors of dengue virus and other viruses Dana-Farber Cancer Institute, Inc.
11-Apr-12
15-Mar-13
30-Jan-18
US9878988 Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseases PARION SCIENCES, INC.
29-May-12
5-Jan-16
30-Jan-18
US9873678 Chemical compounds AstraZeneca AB
18-Mar-14
17-Mar-15
23-Jan-18
US9873674 C-Rel inhibitors and uses thereof CORNELL UNIVERSITY

21-Sep-12
19-Sep-13
23-Jan-18
US9872900 Nucleic acid vaccines ModernaTX, Inc.
23-Apr-14
5-Apr-16
23-Jan-18
US9872898 Compositions and methods for treating and preventing porcine reproductive and respiratory syndrome Ohio State Innovation Founation
24-Apr-12
3-Oct-16
23-Jan-18
US9872895 TLR5 ligands, therapeutic methods, and compositions related thereto Emory University
24-Sep-10
20-Sep-11
23-Jan-18

 

US9868952Compositions and methods for âCœresistance-proofâC SiRNA therapeutics for influenzaSirnaomics, Inc.8-Jul-

12

7-

Jul-

13

16-

Jan-

18

US9868740Pyrimidinone compounds which are HNE inhibitorsCHIESI FARMACEUTICI S.p.A.12-

Jun-

14

12-

Jun

-14

16-

Jan-

18

US9868736Deubiquitinase inhibitors and methods for use of the sameTHE REGENTS OF THE UNIVERSITY OF MICHIGAN10-

Oct-

13

10-

Oct

-14

16-

Jan-

18

US9867882Carbohydrate conjugates as delivery agents for oligonucleotidesAlnylam Pharmaceuticals, Inc.4-

Dec-

07

25-

Aug

-15

16-

Jan-

18

US9867877Methods for preparing squaleneNOVARTIS AG12-

May-

10

22-

Nov

-16

16-

Jan-

18

US9862706CompoundsCHIESI FARMACEUTICI S.p.A.31-

May-

16

26-

May

-17

9-

Jan-

18

US9861614Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.9-

May-

12

23-

Jun

-15

9-

Jan-

18

US9856254Alkoxy substituted imidazoquinolines3M Innovative Properties Company3-

Oct-

03

13-

Jun

-16

2-

Jan-

18

US9856241Substituted benzofuranyl and benzoxazolyl compounds and uses thereofKaryopharm Therapeutics Inc.3-Jul-

13

3-

Jul-

14

2-

Jan-

18

US9856228Peptidyl nitril compounds as dipeptidyl peptidase I inhibitorsPROZYMEX A/S9-

Sep-

13

8-

Sep

-14

2-

Jan-

18

US9856224Stable sodium channel blockersPARION SCIENCES, INC.30-

Jun-

14

30-

Jan

-17

2-

Jan-

18

US9855287Anti-viral azide containing compoundsLIFE TECHNOLOGIES CORPORATION28-

Jul-10

20-

Aug

-15

2-

Jan-

18

US9855284Pharmaceutical compositions and methodsPop Test Oncology LLC3-

Aug-

15

6-

Dec

-16

2-

Jan-

18

US9849143Broad spectrum antiviral and methods of useThe Burlington HC Research Group, Inc.17-

Apr-

06

16-

Feb

-17

26-

Dec

-17

US9845342Fusion proteins, recombinant bacteria, and methods for using recombinant bacteriaSpogen Biotech Inc.17-

Sep-

14

17-

Sep

-15

19-

Dec

-17

US9840731Preservation of biological materials in non-aqueous fluid mediaGentegra, LLC14-

Mar-

13

14-

Mar

-14

12-

Dec

-17

US9840719Variant AAV and compositions, methods and uses for gene transfer to cells, organs and tissuesThe Children’s Hospital of Philadelphia22-

Jul-13

22-

Jul-

14

12-

Dec

-17

US9840491Quinazolinones and azaquinazolinones as ubiquitin-specific protease 7 inhibitorsFORMA Therapeutics, Inc.5-

Feb-

15

4-

Feb

-16

12-

Dec

-17

US9839687Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding moleculeSUZHOU M-CONJ BIOTECH CO., LTD.15-

Jul-15

15-

Jul-

15

12-

Dec

-17

US9834812Probe kit for detecting a single strand target nucleotide sequenceFondazione Istituto Italiano Di Tecnologia27-

Dec-

12

27-

Dec

-13

5-

Dec

-17

US9834791CRISPR-related methods and compositions with governing gRNASEditas Medicine, Inc.7-

Nov-

13

7-

Nov

-14

5-

Dec

-17

US9834757Hand, foot, and mouth vaccines and methods of manufacture and use thereofTakeda Vaccines, Inc.7-

Nov-

14

6-

Nov

-15

5-

Dec

-17

US9834595Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseasesAblynx N.V.5-

Jun-

08

29-

Oct

-15

5-

Dec

-17

US9833504Virus-like particles and process for preparing sameFolia Biotech Inc.13-

May-

11

1-

May

-12

5-

Dec

-17

US9833492Combinations of a caspase inhibitor and an antiviral agentCentre National de la Recherche Scientifique2-

Nov-

07

15-

May

-15

5-

Dec

-17

US9832998Antiviral compositionsLong Island University30-

May-

07

19-

Mar

-15

5-

Dec

-17

US9828382Pyrimidinone compounds as human neutrophil elastase inhibitorsChiesi Farmaceutici S.p.A.18-

Dec-

12

10-

May

-16

28-

Nov

-17

US9828379Pyrrolo-pyrrole carbamate and related organic compounds, pharmaceutical compositions, and medical uses thereofABIDE THERAPEUTICS, INC.3-Jul-

13

1-

Jul-

14

28-

Nov

-17

US9828370Compositions and methods for inhibiting kinasesINHIBIKASE THERAPEUTICS, INC.23-

Apr-

15

22-

Apr

-16

28-

Nov

-17

US9828346N-myristoyl transferase inhibitorsUniversity of Dundee2-

Sep-

08

31-

Aug

-15

28-

Nov

-17

 

US9828342Isatin derivatives, pharmaceutical compositions thereof, and methods of use thereofCITY OF HOPE24-

Feb-

12

25-

Feb

-13

28-

Nov

-17

US9827190Intradermal delivery of immunological compositions comprising toll­like receptor 7 agonistsGLAXOSMITHKLINE BIOLOGICALS SA1-

Feb-

13

30-

Jan

-14

28-

Nov

-17

US9822339Means and methods for influencing the stability of antibody producing cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM9-

Dec-

05

26-

Aug

-15

21-

Nov

-17

US9822173Heterodimeric immunoglobulinsAMGEN INC.21-

Nov-

12

21-

Nov

-13

21-

Nov

-17

US9822165Hydrocarbon stapled stabilized alpha-helices of the HIV-1 GP41 membrane proximal external regionDANA-FARBER CANCER INSTITUTE, INC.18-

Jun-

09

18-

Jun

-10

21-

Nov

-17

US9822155Method of preventively treating a subject at the risk of developing infections of a respiratory virusXiangxue Group (Hong Kong) Company Limited9-

May-

13

23-

Aug

-16

21-

Nov

-17

US9822127GAK modulators as antiviralsThe Board of Trustees of the Leland Stanford Junior University23-

Jul-14

23-

Jul-

15

21-

Nov

-17

US9822065Benzazepine dicarboxamide compoundsHoffmann-La Roche Inc.6-

Mar-

15

14-

Feb

-17

21-

Nov

-17

US9821052Reverse genetics systemsSeqirus UK Limited31-

Jul-09

30-

Jul-

10

21-

Nov

-17

US9821051Reducing hospitalization in elderly influenza vaccine recipientsSeqirus UK Limited28-

Oct-

10

21-

Oct

-11

21-

Nov

-17

US9816078Compositions for increasing polypeptide stability and activity, and related methodsSOLIS BIODYNE OAre19-

Nov-

09

11-

Mar

-16

14-

Nov

-17

US9815886Compositions and methods for the treatment of immunodeficiencyADMA BIOLOGICS, INC.28-

Oct-

14

8-

Jan

-15

14-

Nov

-17

US9815805Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitorsASTRAZENECA AB24-

Jan-

14

8-

Nov

-16

14-

Nov

-17

US9814777Targeting lipidsArbutus Biopharma Corporation4-

Dec-

07

22-

Oct

-13

14-

Nov

-17

US9810683Use of live cell inteferometry with reflective floor of observation chamber to determine changes in mass of mammalian cellsThe Regents of the University of California6-

May-

09

25-

Nov

-13

7-

Nov

-17

US9809845Methods and reagents for amplifying nucleic acidsThe United States of America, as represented by the Secretary, Department of Health and Human Services6-

Aug-

12

6-

Aug

-12

7-

Nov

-17

US9809796Animal protein-free media for cultivation of cellsBaxalta GmbH29-

Oct-

04

18-

May

-17

7-

Nov

-17

US9809632Universal protein tag for double stranded nucleic acid deliveryUniversity of Washington Through its Center for Commercialization23-

Oct-

13

22-

Oct

-14

7-

Nov

-17

US9809591Heterocyclic modulators of lipid synthesis3-V Biosciences, Inc.8-

Mar-

11

5-

Oct

-15

7-

Nov

-17

US9808490Induced hepatocytes and uses thereofACCELERATED BIOSCIENCES CORP.26-

Nov-

14

25-

Nov

-15

7-

Nov

-17

US9803236Microarray-based assay integrated with particles for analyzing molecular interactionsCapitalBio Corporation6-

Aug-

10

6-

Aug

-10

31-

Oct-

17

US9803197Particle-nucleic acid conjugates and therapeutic uses related theretoEmory University25-

Jun-

12

27-

Feb

-13

31-

Oct-

17

US9802937Substituted pyrazolo{4,3-D}pyrimidines as kinase inhibitorsORIGENIS GMBH21-

Apr-

11

23-

Apr

-12

31-

Oct-

17

US9802919CompoundsCHIESI FARMACEUTICI S.p.A.31-

May-

16

26-

May

-17

31-

Oct-

17

US9801948Antimicrobial compositions and methods of use thereofYale University21-

Sep-

11

21-

Sep

-12

31-

Oct-

17

US9801947Methods and compositions for enhancing immune response3M INNOVATIVE PROPERTIES COMPANY10-

Apr-

03

6-

Oct

-14

31-

Oct-

17

US9801935Soluble needle arrays for delivery of influenza vaccinesSEQIRUS UK LIMITED20-

Aug-

10

11-

Oct

-16

31-

Oct-

17

US9801897Delivery of RNA to trigger multiple immune pathwaysGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

10

6-

Jul-

11

31-

Oct-

17

US9797000Non-target amplification method for detection of RNA splice-forms in a sampleQIAGEN GAITHERSBURG INC.1-

May-

09

30-

Apr

-10

24-

Oct-

17

US9796979Oligonucleotide modulators of the toll-like receptor pathwayQuark Pharmaceuticals Inc.3-

Mar-

11

28-

Jul-

16

24-

Oct-

17

 

US9796735Boron-containing small moleculesAnacor Pharmaceuticals, Inc.20-

Jun-

07

7-

Nov

-14

24-

Oct-

17

US9795669Lipidated immune response modifier compound compositions, formulations, and methods3M INNOVATIVE PROPERTIES COMPANY17-

Aug-

10

15-

Dec

-15

24-

Oct-

17

US9795668Delivery of self-replicating RNA using biodegradable polymer particlesGlaxoSmithKline Biologicals S.A.6-Jul-

10

23-

Nov

-15

24-

Oct-

17

US9795666High-yield transgenic mammalian expression system for generating virus-like particlesAcademia Sinica5-

Sep-

06

11-

Feb

-15

24-

Oct-

17

US9791437Multianalyte assayNexus Dx, Inc.30-

Apr-

07

15-

Jun

-15

17-

Oct-

17

US9789180D-amino acid derivative-modified peptidoglycan and methods of use thereofThe Regents of the University of California30-

Nov-

12

31-

Mar

-16

17-

Oct-

17

US9786050Stain-free histopathology by chemical imagingThe Board of Trustees of the University of Illinois15-

Mar-

13

14-

Mar

-14

10-

Oct-

17

US9783595Neutralizing GP41 antibodies and their useThe United States of America, as represented by the Secretary, Department of Health and Human Services7-

Nov-

11

2-

Aug

-16

10-

Oct-

17

US9782470Method of obtaining thermostable dried vaccine formulationsMerck Sharp & Dohme Corp.16-

Oct-

13

13-

Oct

-14

10-

Oct-

17

US9782434Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solutionSonoma Pharmaceuticals, Inc.20-

Jan-

06

7-

Jul-

15

10-

Oct-

17

US9770504Generating peptoid vaccinesThe Board of Regents of the University of Texas System3-

May-

13

2-

May

-14

26-

Sep

-17

US9770463Delivery of RNA to different cell typesGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

10

7-

Jun

-11

26-

Sep

-17

US9765395System and method for DNA sequencing and blood chemistry analysisNanomedical Diagnostics, Inc.28-

Apr-

14

10-

Apr

-15

19-

Sep

-17

US9765133Antibody producing non-human mammalsMerus N.V.27-

Jun-

08

29-

Apr

-14

19-

Sep

-17

US9765071Substituted imidazo ring systems and methods3M INNOVATIVE PROPERTIES COMPANY25-

Nov-

03

14-

Mar

-16

19-

Sep

-17

US9764027Outer membrane vesiclesGLAXOSMITHKLINE BIOLOGICALS SA18-

Sep-

12

18-

Sep

-13

19-

Sep

-17

US9759723B-cell antigen presenting cell assayUniversity of Pittsburgha€”Of the Commonwealth System of Higher Education8-

Apr-

10

21-

Mar

-16

12-

Sep

-17

US9758840Parasite detection via endosymbiont detectionIBIS BIOSCIENCES, INC.14-

Mar-

10

11-

Mar

-11

12-

Sep

-17

US9758820Organism identification panelBioFire Diagnostics, LLC2-

Apr-

07

1-

Apr

-08

12-

Sep

-17

US9758775TAL effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

14-

Apr

-14

12-

Sep

-17

US9758568Oligopeptide-free cell culture mediaBaxalta GmbH4-

Jan-

06

16-

Nov

-15

12-

Sep

-17

US9758553Yeast strain for the production of proteins with terminal alpha-1,3- linked galactoseMERCK SHARP & DOHME CORP.30-

May-

08

2-

Jul-

14

12-

Sep

-17

US9757478Mutant protease biosensors with enhanced detection characteristicsPromega Corporation11-

May-

10

7-

Jan

-16

12-

Sep

-17

US9757470Peptides for assisting delivery across the blood brain barrierChildren’s Medical Center Corporation22-

May-

06

30-

Apr

-14

12-

Sep

-17

US9757446Influenza virus vectors and uses thereforFLUGEN, INC.17-

Mar-

14

13-

Mar

-15

12-

Sep

-17

US9757407T reatment of viral infections by modulation of host cell metabolic pathwaysThe Trustees of Princeton University1-

Jun-

07

21-

Dec

-15

12-

Sep

-17

US9751945Sortase-modified VHH domains and uses thereofWhitehead Institute for Biomedical Research13-

Apr-

12

15-

Apr

-13

5-

Sep

-17

US9750798Bunyaviruses with segmented glycoprotein precursor genes and methods for generating these virusesSTICHTING WAGENINGEN RESEARCH21-

May-

13

21-

May

-14

5-

Sep

-17

US9750797Sustained release vaccine compositionVIRBAC CORPORATION16-

Jun-

04

16-

Jun

-05

5-

Sep

-17

US9750690Circulation of components during microfluidization and/or homogenization of emulsionsNOVARTIS AG3-

Dec-

09

5-

Sep

-14

5-

Sep

-17

 

US9746985System and method for detecting, collecting, analyzing, and communicating event-related informationGeorgetown University25-

Feb-

08

20-

Apr

-11

29-

Aug

-17

US9746459Antigen presenting cell assayUniversity of Pittsburgha€”Of the Commonwealth System of Higher Education8-

Apr-

10

11-

Oct

-13

29-

Aug

-17

US97453062-((4-amino-3-(3-fluoro-5-hydroxyphenyl)-1H-pyrazolo[3,4- D]pyrimidin-1-yl)methyl)-3-(2-(trifluoromethyl)benzyl) quinazolin- 4(3H)-one derivatives and their use as phosphoinositide 3-kinase inhibitorsRespivert Li mited15-

Mar-

13

14-

Mar

-14

29-

Aug

-17

US9744231Quality control methods for oil-in-water emulsions containing squaleneNOVARTIS AG8-

Nov-

06

27-

Aug

-13

29-

Aug

-17

US9744229Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the sameTHE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA4-

Apr-

08

28-

Apr

-14

29-

Aug

-17

US9744183Nucleic acid prodrugs and methods of use thereofWAVE LIFE SCIENCES LTD.6-Jul-

09

6-

Jul-

10

29-

Aug

-17

US9738894Short interfering RNA (siRNA) analoguesRoche Innovation Center Copenhagen A/S21-

Mar-

03

28-

Mar

-16

22-

Aug

-17

US9738624Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.21-

Jun-

13

20-

Jun

-14

22-

Aug

-17

US9737618Adeno-associated virus (AAV) glades, sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania30-

Sep-

03

20-

Jul-

15

22-

Aug

-17

US9737593Carbon nanotube compositions and methods of use thereofYale University19-

Mar-

08

15-

Mar

-13

22-

Aug

-17

US9730997Alphavirus vectors for respiratory pathogen vaccinesNovartis Vaccines and Diagnostics, Inc.21-

May-

04

20-

Aug

-14

15-

Aug

-17

US9730912Pharmaceutical compoundsASTEX THERAPEUTICS LIMITED12-

Oct-

06

12-

Oct

-07

15-

Aug

-17

US9727810Spatially addressable molecular barcodingCellular Research, Inc.27-

Feb-

15

26-

Feb

-16

8-

Aug

-17

US9726607Systems and methods for detecting multiple optical signalsGEN-PROBE INCORPORATED10-

Mar-

05

3-

Mar

-14

8-

Aug

-17

US9725770Methods and compositions for identification of source of microbial contamination in a sampleThe Regents of the University of California6-

Mar-

12

6-

Mar

-13

8-

Aug

-17

US9725487Compositions and methods for measles virus inhibitionAutoimmune Technologies, LLC4-

Nov-

03

13-

May

-15

8-

Aug

-17

US9719106Tissue preferential codon modified expression cassettes, vectors containing same, and uses thereofThe Trustees of the University of Pennsylvania29-

Apr-

13

29-

Apr

-14

1-

Aug

-17

US9719083Bioagent detection methodsIBIS BIOSCIENCES, INC.8-

Mar-

09

8-

Mar

-10

1-

Aug

-17

US9718774Indole carboxamide derivatives as P2X7 receptor antagonistIDORSIA PHARMACEUTICALS LTD12-

Dec-

12

11-

Dec

-13

1-

Aug

-17

US9717755Method of treating inflammationCytosorbents Corporation1-

Apr-

10

1-

Apr

-11

1-

Aug

-17

US9717749Production of stable non-polyadenylated RNAsMassachusetts Institute of Technology16-

Oct-

12

16-

Oct

-13

1-

Aug

-17

US9717732Drug combinationVERONA PHARMA PLC15-

Mar-

13

17-

Mar

-14

1-

Aug

-17

US9714411Animal protein-free media for cultivation of cellsBaxalta GmbH29-

Oct-

04

30-

Nov

-15

25-

Jul-

17

US9714283Compositions and methods for the treatment of immunodeficiencyADMA BIOLOGICS, INC.28-

Oct-

14

2-

Jul-

15

25-

Jul-

17

US9714226Hydrazide containing nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.29-

Jul-11

13-

Nov

-15

25-

Jul-

17

US9713641Anti-TIGIT antigen-binding proteins and methods of use thereofPotenza Therapeutics, Inc.13-

Feb-

17

13-

Feb

-17

25-

Jul-

17

US9713606Methods for treating pulmonary emphysema using substituted 2- Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)- amides inhibitors of cathepsin CBoehringer Ingelheim International GmbH14-

Mar-

13

1-

Dec

-15

25-

Jul-

17

US9708375Inhibitory polypeptides specific to WNT inhibitorsAmgen Inc.15-

Mar-

13

14-

Mar

-14

18-

Jul-

17

US9707278Methods of modulating immune responses by modifying Akt3 bioactivityAugusta University Research Institute, Inc.17-

Apr-

14

17-

Apr

-15

18-

Jul-

17

 

US9701736Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infectionNew York Blood Center, Inc.20-

Oct-

10

9-

Oct

-14

11-

Jul-

17

US9701638Therapeutic hydroxyquinolonesRutgers, The State University of New Jersey9-

Nov-

12

8-

Nov

-13

11-

Jul-

17

US9700616Arranging interaction and back pressure chambers for microfluidizationNOVARTIS AG3-

Dec-

09

22-

Mar

-16

11-

Jul-

17

US9700614Intranasal vaccination dosage regimenEurocine Vaccines AB17-

Dec-

12

17-

Dec

-13

11-

Jul-

17

US9700558Drug combination of PDE3/PDE4 inhibitor and muscarinic receptor antagonistVERONA PHARMA PLC15-

Mar-

13

17-

Mar

-14

11-

Jul-

17

US9696247Sample fixation and stabilizationRNASSIST LTD.1-

Mar-

13

28-

Feb

-14

4-

Jul-

17

US9695445Method for production of reprogrammed cell using chromosomally unintegrated virus vectorID Pharma Co., Ltd.16-

Jul-08

29-

Jul-

15

4-

Jul-

17

US9695135Therapeutic catecholsRutgers, The State University of New Jersey12-

May-

14

11-

May

-15

4-

Jul-

17

US96951343,5-diamino-6-chloro-N-(n-(4-phenylbutyl)carbamimidoyl)pyrazine- 2-carboxamide compoundsParion Sciences, Inc.17-

Dec-

12

8-

Jan

-15

4-

Jul-

17

US9689018Mixed cell diagnostic systems for detection of respiratory, herpes and enteric virusesDiagnostic Hybrids, Inc.24-

Apr-

98

4-

Aug

-14

27-

Jun-

17

US9688982Methods and compositions for the treatment of cancer or other diseasesCITY OF HOPE26-

Jan-

07

11-

Oct

-13

27-

Jun-

17

US9687536Methods and compositions for intranasal deliverySHIN NIPPON BIOMEDICAL LABORATORIES, LTD.15-

Apr-

10

15-

Apr

-11

27-

Jun-

17

US9683256Biological specimen collection and transport systemLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

15-

Dec

-15

20-

Jun-

17

US9683017Inhibitory peptides of viral infectionUNIVERSITY TENNESSEE RESEARCH FOUNDATION17-

Jul-14

16-

Jul-

15

20-

Jun-

17

US9682133Disrupted adenovirus-based vaccine against drugs of abuseCORNELL UNIVERSITY17-

Mar-

10

17-

Mar

-11

20-

Jun-

17

US9677089Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

30-

Mar

-16

13-

Jun-

17

US9676867Chimeric T cell receptor comprising carbonic anhydrase IX (G250) antibodyDana-Farber Cancer Institute Inc.2-

Dec-

05

8-

May

-13

13-

Jun-

17

US9676857Soluble engineered monomeric FcThe United States of America, as represented by the Secretary, Department of Health and Human Services16-

Mar-

12

14-

Mar

-13

13-

Jun-

17

US9676727Myxovirus therapeutics, compounds, and uses related theretoChildren’s Healthcare of Atlanta, Inc.24-

Oct-

11

7-

Jul-

16

13-

Jun-

17

US9675550Methods for inducing an immune response via buccal and/or sublingual administration of a vaccineBOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM26-

Jul-10

25-

Jan

-13

13-

Jun-

17

US9670507Directed evolution and in vivo panning of virus vectorsThe University of North Carolina at Chapel HillCO 1 128-

Jun

-16

6-

Jun-

17

US9670166Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH6-

Feb-

13

5-

Aug

-16

6-

Jun-

17

US9669092Antagonism of the VIP signaling pathwayEmory University2-

Feb-

11

31-

Jan

-12

6-

Jun-

17

US9669089Nucleic acid comprising or coding for a histone stem-loop and a poly(A) sequence or a polyadenylation signal for increasing the expression of an encoded pathogenic antigenCureVac AG15-

Feb-

12

15-

Feb

-13

6-

Jun-

17

US9669088Vaccination with multiple clades of H5 influenza A virusSeqirus UK Limited26-

Nov-

07

25-

Nov

-08

6-

Jun-

17

US9661856Synergy of plant antimicrobials with silverThe Arizona Board of Regents on Behalf of The University of Arizona24-

Aug-

12

26-

Aug

-13

30-

May

-17

US9657278Methods to produce bunyavirus replicon particlesStichting Dienst Landbouwkundig Onderzoek20-

Sep-

10

10-

Jul-

15

23-

May

-17

US9657076GM-CSF and IL-4 conjugates, compositions, and methods related theretoChildren’s Healthcare of Atlanta, Inc.23-

Oct-

12

23-

Oct

-13

23-

May

-17

US9657048Enantiomers of the 1a€2,6a€2-isomer of neplanocin AAuburn University4-

Aug-

14

4-

Aug

-15

23-

May

-17

 

US9657015Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH31-

Jul-14

27-

Jul-

15

23-

May

-17

US9655896Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activityPARION SCIENCES, INC.27-

Jun-

11

12-

Jan

-15

23-

May

-17

US9655845Oil-in-water emulsions that contain nucleic acidsGlaxoSmithKline Biologicals, S.A.6-Jul-

11

6-

Jul-

12

23-

May

-17

US9655367Disinfecting composition and wipes with reduced contact timeLONZA, INC.6-

Nov-

13

4-

Nov

-14

23-

May

-17

US9651543Malaria antigen screening methodThe United States of America as Represented by the Secretary of the Navy31-

Aug-

05

19-

Apr

-13

16-

May

-17

US9650685Selective detection of human rhinovirusThe United States of America, as represented by the Secretary, Department of Health and Human Services5-

Dec-

08

15-

Dec

-14

16-

May

-17

US9650649LCMV-GP-VSV-pseudotyped vectors and tumor-infiltrating virus- producing cells for the therapy of tumorsVIRATHERAPEUTICS GMBH8-

Oct-

08

8-

Oct

-09

16-

May

-17

US9649324Use of tylvalosin as antiviral agentCAMBRIDGE UNIVERSITY TECHNICAL SERVICES13-

Jul-06

8-

Jun

-15

16-

May

-17

US9649309Therapeutic uses of selected pyrimidine compounds with anti-Mer tyrosine kinase activityThe University of North Carolina at Chapel Hill11-

Apr-

14

3-

Apr

-15

16-

May

-17

US9644180Synthetic membrane-receiver complexesRUBIUS THERAPEUTICS, INC.18-

Nov-

13

12-

Jun

-15

9-

May

-17

US9642876Method of preventing or treating sinusitis with oxidative reductive potential water solutionSONOMA PHARMACEUTICALS, INC.30-

Dec-

03

27-

Oct

-15

9-

May

-17

US9642873Combinations of TGFÎ2 and COX-2 inhibitors and methods for their therapeutic applicationSirnaomics, Inc.4-

May-

10

4-

May

-11

9-

May

-17

US9637524Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vectorThe Regents of the University of California27-

Feb-

09

5-

Nov

-14

2-

May

-17

US9637491Pyrazolo[4,3-D]pyrimidines as kinase inhibitorsORIGENIS GMBH19-

Oct-

12

18-

Oct

-13

2-

May

-17

US9636410Cationic oil-in-water emulsionsGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

11

6-

Jul-

12

2-

May

-17

US9636397Adjuvant compositions and related methodsVaxliant, LLC24-

Mar-

15

24-

Mar

-16

2-

May

-17

US9636370AAV vectors targeted to oligodendrocytesThe University of North Carolina at Chapel Hill28-

Sep-

12

27-

Sep

-13

2-

May

-17

US9629907Compositions for and methods of inducing mucosal immune responsesThe Trustees of the University of Pennsylvania19-

Nov-

04

28-

Oct

-11

25-

Apr-

17

US9624173Heterocyclic modulators of lipid synthesis3-V Biosciences, Inc.8-

Mar-

11

19-

Mar

-15

18-

Apr-

17

US9623040Immunomodulation by controlling expression levels of microRNAs in dendritic cellsThe Board of Trustees of the Leland Stanford Junior University14-

Jul-14

10-

Jul-

15

18-

Apr-

17

US9618508Flow cytometry analysis of materials adsorbed to metal saltsGlaxoSmithKline Biologicals SA14-

Dec-

10

14-

Dec

-11

11-

Apr-

17

US9618476System and method for electronic biological sample analysisNANOMEDICAL DIAGNOSTICS, INC.28-

Apr-

14

28-

Apr

-14

11-

Apr-

17

US9618429Polymer stabilization of chromogen solutionsVentana Medical Systems, Inc.23-

Jan-

12

18-

Jan

-13

11-

Apr-

17

US9611481Chimeric polynucleotides and polypeptides enabling the secretion of a polypeptide of interest in combination with exosomes and uses thereofUNIVERSITE DE MONTPELLIER24-

Sep-

09

23-

Sep

-10

4-

Apr-

17

US9611474Double-stranded oligonucleotide molecules to DDIT4 and methods of use thereofQUARK PHARMACEUTICALS, INC.12-

Sep-

12

12-

Sep

-13

4-

Apr-

17

US9605276Replication defective adenovirus vector in vaccinationEtubics Corporation24-

Aug-

12

15-

Mar

-13

28-

Mar

-17

US9603864Substituted nucleosides, nucleotides and analogs thereofAlios BioPharma, Inc.24-

Jun-

14

22-

Jun

-15

28-

Mar

-17

US9603850MerTK-specific pyrazolopyrimidine compoundsThe University of North Carolina at Chapel Hill11-

Apr-

14

3-

Apr

-15

28-

Mar

-17

US9599606ADP-ribose detection reagentsThe Board of Regents of the University of Texas System10-

Jun-

14

9-

Jun

-15

21-

Mar

-17

US9598459Pharmaceutical compositions and methodsPop Test Oncology LLC3-

Aug-

15

28-

Jul-

16

21-

Mar

-17

 

US9597333Benzazepine dicarboxamide compoundsHoffmann-La Roche Inc.6-

Mar-

15

28-

Sep

-16

21-

Mar

-17

US9593334Use of the chromosome 19 microRNA cluster (C19MC) for treating viral disease and promoting authophagyUniversity of Pittsburgh—Of the Commonwealth System of Higher Education7-

Mar-

12

6-

Mar

-13

14-

Mar

-17

US9593331Double-stranded nucleic acid molecule for gene expression controlOsaka City University2-

Nov-

11

1-

Nov

-12

14-

Mar

-17

US9593084Chloro-pyrazine carboxamide derivatives with epithelial sodium channel blocking activityParion Sciences, Inc.17-

Dec-

12

13-

Dec

-13

14-

Mar

-17

US9592284Immunization regimen with E4-deleted adenovirus prime and E1- deleted adenovirus boostThe Trustees of the University of Pennsylvania28-

Apr-

04

27-

Apr

-05

14-

Mar

-17

US9592277Compositions with modified nucleases targeted to viral nucleic acids and methods of use for prevention and treatment of viral diseasesAvirid, Inc.14-

Apr-

04

14-

Apr

-05

14-

Mar

-17

US9588069Methods for performing thermal melt analysisGEN-PROBE INCORPORATED31-

Jul-12

31-

Jul-

13

7-

Mar

-17

US9587250Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforTrustees of the University of Pennsylvania17-

Dec-

01

16-

Jan

-15

7-

Mar

-17

US9586998Methods of propagating monkey adenoviral vectorsGenVec, Inc.9-

Nov-

09

4-

Aug

-15

7-

Mar

-17

US9586911Arylalkyl- and aryloxyalkyl-substituted epthelial sodium channel blocking compoundsParion Sciences, Inc.13-

Dec-

13

19-

Dec

-14

7-

Mar

-17

US95869103,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-

pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra

zine-2-carboxamide

Parion Sciences, Inc.27-

Jun-

11

18-

Dec

-13

7-

Mar

-17

US9585968Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom3M Innovative Properties Company3-

Jun-

11

14-

Aug

-15

7-

Mar

-17

US9585953Immunogenic compositions in particulate form and methods for producing the sameMUCOSIS B.V.22-

Mar-

11

22-

Mar

-12

7-

Mar

-17

US9585874Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.9-

May-

12

6-

Jan

-16

7-

Mar

-17

US9585849Broad spectrum antiviral and methods of useThe Burlington HC Research Group, Inc.17-

Apr-

06

17-

Apr

-07

7-

Mar

-17

US9580474Polyionic papilloma virus-like particle (VLP) vaccinesTHE JOHNS HOPKINS UNIVERSITY8-

Sep-

10

8-

Sep

-11

28-

Feb

-17

US9580468Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cellsCENTRE DE INVESTIGACION BIOMEDICA EN RED BIOINGENIERA BIOMATERIALS Y NANOMEDICINA (CIBER BBN)13-

Jan-

11

13-

Jan

-12

28-

Feb

-17

US9580429Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapyAstraZeneca AB6-

Dec-

04

15-

Sep

-14

28-

Feb

-17

US9574189Enzymatic encoding methods for efficient synthesis of large librariesNuevolution A/S1-

Dec-

05

1-

Dec

-06

21-

Feb

-17

US9574181Influenza virus reassortment methodSeqirus UK Limited21-

May-

10

24-

Oct

-14

21-

Feb

-17

US9573955CompoundsChiese Farmaceutici S.p.A.16-

Dec-

13

16-

Dec

-14

21-

Feb

-17

US9573938Therapeutic hydroxypyridinones, hydroxypyrimidinones and hydroxypyridazinonesRutgers, The State University of New Jersey11-

Sep-

12

11-

Sep

-13

21-

Feb

-17

US9572899Compositions for enhancing transport of molecules into cellsAVI BIOPHARMA, INC.29-

Apr-

03

5-

Nov

-08

21-

Feb

-17

US9572864Compositions and uses of lectinsEmory University12-

Feb-

10

11-

Dec

-15

21-

Feb

-17

US9572823Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

5-

Apr

-16

21-

Feb

-17

US9567336Conjugated TLR7 and/or TLR8 and TLR2 agonistsINVIVOGEN19-

Nov-

12

15-

Mar

-13

14-

Feb

-17

US9566326Adjuvanted influenza vaccines for pediatric useSeqirus UK Limited22-

Feb-

08

21-

Jun

-13

14-

Feb

-17

US9566291Nutritional composition comprising indigestible oligosaccharidesN.V. Nutricia24-

Aug-

04

24-

Aug

-05

14-

Feb

-17

US9566290Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

20-

Apr

-16

14-

Feb

-17

 

US9566289Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

17-

Feb

-16

14-

Feb

-17

US9565857Antimicrobial solutionsBoard of Regents, The University of Texas System10-

Sep-

10

9-

Sep

-11

14-

Feb

-17

US9562110Bispecific antibodyWuhan YZY Biopharma Co., Ltd.21-

Nov-

12

21-

Nov

-12

7-

Feb

-17

US9561263Treatment of inflammatory illnesses with ACE2Apeiron Biologics AG18-

Dec-

07

18-

Dec

-08

7-

Feb

-17

US9556237Antiviral rift valley fever virus peptides and methods of useThe United States of America, as represented by the Secretary of the Army, on behalf of the U.S. Army Medical Research Institute of Infectious Diseases6-

Dec-

12

4-

Jun

-15

31-

Jan-

17

US9556229Modification of peptides using a bis(thioether)arylbridge approachThe Regents of the University of California18-

May-

12

17-

May

-13

31-

Jan-

17

US9556184Phosphoinositide 3-kinase inhibitorsRespivert, Ltd.15-

Mar-

13

4-

Dec

-15

31-

Jan-

17

US9556117Indole carboxamide derivatives as P2X7 receptor antagonistsACTELION PHARMACEUTICALS LTD.18-

Dec-

12

17-

Dec

-13

31-

Jan-

17

US9555031Therapeutic uses of selected pyrrolopyrimidine compounds with anti-mer tyrosine kinase activityThe University of North Carolina at Chapel Hill11-

Apr-

14

3-

Apr

-15

31-

Jan-

17

US9555030Therapeutic uses of selected pyrazolopyrimidine compounds with anti-Mer tyrosine kinase activityThe University of North Carolina at Chapel Hill11-

Apr-

14

3-

Apr

-15

31-

Jan-

17

US9550773Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines3M Innovative Properties Company18-

Jun-

04

13-

Apr

-15

24-

Jan-

17

US9550757Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.5-

Mar-

10

28-

Jun

-13

24-

Jan-

17

US9549949Antiviral agentNBC MESHTEC, INC.3-

Sep-

08

31-

Aug

-09

24-

Jan-

17

US9549938Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

11-

Mar

-16

24-

Jan-

17

US9546371Chimeric polynucleotides and polypeptides enabling secretion of a polypeptide of interest in association with exosomes and use thereof for the production of immunogenic compositionsCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE18-

Mar-

08

18-

Mar

-09

17-

Jan-

17

US9546184Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines3M INNOVATIVE PROPERTIES COMPANY13-

Aug-

08

8-

Jun

-15

17-

Jan-

17

US9546150Substituted quinazolin-4-ones for inhibiting ubiquitin specific protease 7HYBRIGENICS SA2-

Sep-

11

29-

Aug

-12

17-

Jan-

17

US9545440Methods for preparing squaleneNOVARTIS AG12-

May-

10

23-

Oct

-15

17-

Jan-

17

US9540373Substituted spirocyclesBoehringer Ingelheim International GmbH12-

Sep-

14

10-

Sep

-15

10-

Jan-

17

US9539321HMGBl-derived peptides enhance immune response to antigensThe Regents of the University of California27-

Jul-10

9-

Mar

-15

10-

Jan-

17

US9539217Nanoparticle compositionsAllertein Therapeutics, LLC3-

Apr-

13

3-

Apr

-14

10-

Jan-

17

US9533978Pyrimidine derivatives and their use in the treatment of cancer and further diseasesSumitomo Dainippon Pharma Co., Ltd21-

May-

09

26-

Aug

-14

3-

Jan-

17

US9533037Methods for designing and preparing vaccines comprising directed sequence polymer compositions via the directed expansion of epitopesDeclion Holdings LLC16-

Oct-

07

16-

Oct

-08

3-

Jan-

17

US9529974System and method for detecting, collecting, analyzing, and communicating event-related informationGeorgetown University25-

Feb-

08

27-

Jul-

11

27-

Dec

-16

US9527903Engineered antibody constant domain moleculesThe United States of America, as represent by the Secretary, Department of Health and Human Services31-

Jan-

08

1-

Oct

-13

27-

Dec

-16

US9526803Diagnostic chewing gum for pathogensJulius-Maximilians-Universitaet Wuerzburg8-

Mar-

12

8-

Mar

-13

27-

Dec

-16

US9526700Composition for inactivating an enveloped virusVIROBLOCK SA19-

May-

06

17-

Nov

-14

27-

Dec

-16

US9522962Peptides, conjugates and method for increasing immunogenicity of a vaccineAcademisch Ziekenhuis Leiden h.o.d.n. LUMC15-

Mar-

10

15-

Mar

-11

20-

Dec

-16

US9522894Certain (2S)-N-[(1S)-1-cyano-2-phenylethyl]-1,4-oxazepane-2- carboxamides as dipeptidyl peptidase 1 inhibitorsAstraZeneca AB24-

Jan-

14

21-

Jan

-15

20-

Dec

-16

 

US9522171EV576 for use in the treatment of viral infections of the respiratory tra ctVolution Immuno Pharmaceuticals SA8-

Jan-

10

2-

Jan

-15

20-

Dec

-16

US9518093Topical formulation of arginine-rich cyclic antimicrobial peptidesNOVABIOTICS LIMITED24-

Feb-

06

9-

Nov

-15

13-

Dec

-16

US9518083Gadd45beta targeting agentsImperial Innovations Limited22-

Oct-

09

10-

Feb

-15

13-

Dec

-16

US9517263Benzonaphthyridine-containing vaccinesGlaxoSmithKline Biologicals SA10-

Jun-

09

10-

Jun

-10

13-

Dec

-16

US9517205Soluble needle arrays for delivery of influenza vaccinesSeqirus UK Limited20-

Aug-

10

19-

Aug

-11

13-

Dec

-16

US9512471Methods and kits for detecting human papillomavirusDIACARTA Inc30-

Jun-

10

30-

Jun

-10

6-

Dec

-16

US9512443Recombinant expression of multiprotein complexes using polygenesETH ZURICH8-

Nov-

05

6-

Nov

-06

6-

Dec

-16

US9512181Fusion proteins of ciliate granule lattice proteins, granular protein particles thereof, and uses thereforTetragenetics, Inc.27-

May-

11

29-

May

-12

6-

Dec

-16

US9511070Heterocyclyl carboxamides for treating viral diseasesNovaDrug, LLC31-

Aug-

12

30-

Aug

-13

6-

Dec

-16

US9506063SiRNA compositions and methods for treatment of HPV and other infectionsSirnaomics, Inc.29-

Jul-10

29-

Jan

-13

29-

Nov

-16

US9504747Lipids and lipid compositions for the delivery of active agentsNovartis AG8-

Mar-

13

7-

Mar

-14

29-

Nov

-16

US9504673Agent for the prophylaxis and treatment of highly pathogenic infectious diseasesLTD “Valenta-Intellektâ€21-

May-

09

10-

May

-10

29-

Nov

-16

US9504255Physical antimicrobial methodNMS TECHNOLOGIES CO., LTD.1-

Aug-

12

16-

Jul-

13

29-

Nov

-16

US9499799Cells and methodology to generate non-segmented negative-strand RNA virusesCentre National De La Recherche Scientifique22-

Dec-

06

15-

Oct

-13

22-

Nov

-16

US9499535Kinase inhibitorsORIGENIS GMBH21-

Apr-

11

23-

Apr

-12

22-

Nov

-16

US9499489Myxovirus therapeutics, compounds, and uses related theretoChildren’s Healthcare of Atlanta, Inc.24-

Oct-

11

24-

Oct

-12

22-

Nov

-16

US9498548Method of using oxidative reductive potential water solution in dental applicationsOculus Innovative Sciences, Inc.2-

May-

05

2-

May

-06

22-

Nov

-16

US9498544Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agentsTissue Regeneration Therapeutics Inc.21-

Apr-

08

13-

Mar

-15

22-

Nov

-16

US9498527Vaccine compositionNITTO DENKO CORPORATION4-

Apr-

12

3-

Apr

-13

22-

Nov

-16

US9494571Methods of testing for intracellular pathogensNovartis AG8-

Mar-

10

7-

Mar

-11

15-

Nov

-16

US9493788Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

16-

Jan

-15

15-

Nov

-16

US9493572GITR antibodies and methods of inducing or enhancing an immune responseGITR, Inc.25-

Mar-

05

23-

Mar

-15

15-

Nov

-16

US9493518Compositions and methods for treating clostridium difficile- associated diseasesNational Health Research Institutes14-

Mar-

13

13-

Mar

-14

15-

Nov

-16

US9492528Influenza virus-like particles (VLPS) comprising hemagglutininMEDICAGO INC.13-

Jul-07

2-

Jul-

09

15-

Nov

-16

US9492413Use of salt of an acetylsalicylic acid for the treatment of viral infectionsVentaleon GMBH14-

Jan-

08

14-

Jan

-09

15-

Nov

-16

US9489495System and method for detecting, collecting, analyzing, and communicating event-related informationGEORGETOWN UNIVERSITY25-

Feb-

08

28-

Aug

-08

8-

Nov

-16

US9487838Oligonucleotide probe for the detection of adenovirusQIAGEN HAMBURG GMBH28-

Dec-

10

28-

Dec

-10

8-

Nov

-16

US9487837Exosome-mediated diagnosis of hepatitis virus infections and diseasesMOREHOUSE SCHOOL OF MEDICINE6-

Oct-

08

21-

Jan

-14

8-

Nov

-16

US9487778Oligonucleotide modulators of the toll-like receptor pathwayQUARK PHARMACEUTICALS, INC.3-

Mar-

11

1-

Mar

-12

8-

Nov

-16

US9487749Use of methylsulfonylmethane (MSM) to modulate microbial activityBiogenic Innovations, LLC30-

Oct-

09

12-

Aug

-14

8-

Nov

-16

 

US9487528CompoundsChiesi Farmaceutici S.p.A.9-

Jun-

14

5-

Jun

-15

8-

Nov

-16

US9486479Antimicrobial solutions containing dichloride monoxide and methods of making and using the sameOculus Innovative Sciences, Inc.13-

Mar-

07

21-

Jul-

14

8-

Nov

-16

US9481912Compositions and methods for detecting and identifying nucleic acid sequences in biological samplesLonghorn Vaccines and Diagnostics, LLC12-

Sep-

06

8-

Oct

-13

1-

Nov

-16

US9481724hDC-sign binding peptidesSloan-Kettering Institute for Cancer Research19-

Dec-

11

10-

Dec

-12

1-

Nov

-16

US9481630Ingenane-type diterpene compound, and pharmaceutical composition for treating or preventing viral infectious diseases containing sameKOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY19-

Oct-

11

28-

Sep

-12

1-

Nov

-16

US9476090Signal propagation biomolecules, devices and methodsSTC.UNM21-

May-

13

21-

May

-14

25-

Oct-

16

US9476032Attenuated viruses useful for vaccinesThe Research Foundation for The State University of New York30-

Mar-

07

31-

Mar

-08

25-

Oct-

16

US9475872Nucleic acid molecules encoding moonoclonal antibodies speceific for IL17FImmunoQure AG28-

Dec-

11

2-

Jan

-13

25-

Oct-

16

US9475862Neutralizing GP41 antibodies and their useThe United States of America, as represented by the Secretary, Department of Health and Human Services7-

Nov-

11

7-

Nov

-12

25-

Oct-

16

US9475832Phosphonates with reduced toxicity for treatment of viral infectionsThe Regents of the University of California14-

Apr-

10

29-

Sep

-14

25-

Oct-

16

US9475804Heterobifunctional linkers with polyethylene glycol segments and immune response modifier conjugates made therefrom3M Innovative Properties Company3-

Jun-

11

1-

Jun

-12

25-

Oct-

16

US9475779Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH31-

Jul-14

27-

Jul-

15

25-

Oct-

16

US9475775Benzazepine dicarboxamide compoundsHoffmann-La Roche Inc.6-

Mar-

15

4-

Mar

-16

25-

Oct-

16

US9474844Methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer theretoHemalux LLC22-

Oct-

14

29-

Dec

-15

25-

Oct-

16

US9474759Broad-spectrum antivirals against 3C or 3C-like proteases of picornavirus-like supercluster: picornaviruses, caliciviruses and coronavirusesKansas State University Research Foundation27-

Sep-

11

27-

Sep

-12

25-

Oct-

16

US9469876Circulating biomarkers for metastatic prostate cancerCaris Life Sciences Switzerland Holdings GmbH6-

Apr-

10

6-

Apr

-11

18-

Oct-

16

US9464276Highly efficient influenza matrix (M1) proteinsNovavax, Inc.11-

Jul-03

23-

Feb

-15

11-

Oct-

16

US9464123Peptides having activity of inhibiting infections of respiratory viruses and use of the sameXIANGXUE GROUP (HONG KONG) COMPANY LIMITED9-

May-

13

21-

Feb

-14

11-

Oct-

16

US9463240Arranging interaction and back pressure chambers for microfluidizationNOVARTIS AG3-

Dec-

09

11-

Jul-

14

11-

Oct-

16

US9459247Quantitative measurement of nano/micro particle endocytosis with cell mass spectrometryAcademia Sinica29-

Mar-

10

29-

Mar

-11

4-

Oct-

16

US9459233Amperometric gas sensorSteris Corporation25-

Jun-

12

26-

Feb

-13

4-

Oct-

16

US9458492Methods and cells for identifying RIG-I pathway regulatorsKineta, Inc.25-

Feb-

11

23-

Feb

-12

4-

Oct-

16

US9458470Recombinant influenza virus-like particles (VLPs) produced in transgenic plants expressing hemagglutininMEDICAGO INC.21-

Jan-

08

23-

Jan

-13

4-

Oct-

16

US9458184Compositions of TLR7 and/or TLR8 agonists conjugated to lipidsINVIVOGEN15-

Jun-

12

15-

Mar

-13

4-

Oct-

16

US9458113Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH31-

Jul-14

27-

Jul-

15

4-

Oct-

16

US9457074Compositions and methods for treating and preventing porcine reproductive and respiratory syndromeOhio State Innovation Foundation24-

Apr-

12

23-

Feb

-15

4-

Oct-

16

US9453043Nucleic acid chemical modificationsALNYLAM PHARMACEUTICALS, INC.2-

Mar-

09

22-

Jan

-15

27-

Sep

-16

US9452973Modulators of the relaxin receptor 1THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES4-

May-

12

15-

Mar

-13

27-

Sep

-16

US9452210Influenza virus-like particles (VLPS) comprising hemagglutinin produced within a plantMEDICAGO INC.13-

Jul-07

4-

Jan

-13

27-

Sep

-16

 

US9447462Methods for concurrent identification and quantification of an unknown bioagentIBIS BIOSCIENCES, INC.18-

Feb-

04

27-

Jan

-14

20-

Sep

-16

US9447132Highly active nucleoside derivative for the treatment of HCVAchillion Pharmaceuticals, Inc.12-

Apr-

13

14-

Apr

-14

20-

Sep

-16

US94470974-amino-imidazoquinoline compoundsHoffmann-La Roche Inc.22-

Apr-

14

7-

Apr

-16

20-

Sep

-16

US9446062Methods of treating ischemia-reperfusion injury with siRNAsQuark Pharmaceuticals, Inc.25-

Oct-

06

8-

Jan

-15

20-

Sep

-16

US9442107Antibody-nanoparticle conjugates and methods for making and using such conjugatesVentana Medical Systems, Inc.27-

Apr-

10

21-

Apr

-15

13-

Sep

-16

US9441247TC-83-derived alphavirus vectors, particles and methodsALPHAVAX, INC.18-

May-

04

6-

Jul-

15

13-

Sep

-16

US9440960Substituted oxetanes and their use as inhibitors of cathepsin CBoehringer Ingelheim International GmbH1-

Aug-

14

31-

Jul-

15

13-

Sep

-16

US9440930Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH31-

Jul-14

27-

Jul-

15

13-

Sep

-16

US9435795Enhanced deposition of chromogens utilizing pyrimidine analogsVentana Medical Systems, Inc.30-

Dec-

10

6-

Oct

-14

6-

Sep

-16

US9435000Primate T-lymphotropic virusesJohns Hopkins University21-

Feb-

05

20-

Sep

-13

6-

Sep

-16

US9434997Methods, compounds and systems for detecting a microorganism in a sampleLawrence Livermore National Security, LLC24-

Aug-

07

21-

Aug

-08

6-

Sep

-16

US9434769Peptide compositions and methods for inhibiting herpesvirus infectionThe Administrators of the Tulane Educational Fund30-

Oct-

09

9-

Jul-

14

6-

Sep

-16

US9433672Compositions and methods for activating innate and allergic immunityID Biomedical Corporation of Quebec26-

Apr-

12

28-

Apr

-14

6-

Sep

-16

US9430610Re-sequencing pathogen microarrayThe United States of America, as represented by the Secretary of the Navy2-Jul-

04

10-

Apr

-08

30-

Aug

-16

US9428739Norovirus and Sapovirus antigensNOVARTIS VACCINES AND DIAGNOSTICS, INC.24-

Mar-

01

27-

Nov

-12

30-

Aug

-16

US9428574Polypeptides and uses thereof for treatment of autoimmune disorders and infectionCOMPUGEN LTD.30-

Jun-

11

1-

Jul-

12

30-

Aug

-16

US9428571Antibodies and processes for preparing the sameTAIGA BIOTECHNOLOGIES, INC.16-

May-

08

18-

Mar

-15

30-

Aug

-16

US9428490Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.29-

Jul-11

26-

Jul-

12

30-

Aug

-16

US9428439Hydrobenzamide derivatives as inhibitors of Hsp90ASTEX THERAPEUTICS LTD.12-

Oct-

06

7-

Jan

-14

30-

Aug

-16

US9426989Organic peroxide compounds for microorganism inactivationNOVARTIS AG6-

May-

10

6-

May

-11

30-

Aug

-16

US9422367Antigenic GM-CSF peptides and antibodies to GM-CSFMorphotek, Inc.7-

Feb-

06

26-

Nov

-13

23-

Aug

-16

US9421254Immunostimulatory combinations of TLR ligands and methods of useThe United States of America, as represented by the Secretary, Department of Health and Human Services24-

Sep-

07

24-

Sep

-08

23-

Aug

-16

US9416416Biological specimen collection/transport compositions and methodsLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

16-

Dec

-11

16-

Aug

-16

US9416409Capture primers and capture sequence linked solid supports for molecular diagnostic testsIBIS BIOSCIENCES, INC.31-

Jul-09

30-

Jul-

10

16-

Aug

-16

US9416396Covalently linked thermostable kinase for decontamination process validationThe Secretary of State for Health20-

Feb-

08

18-

Feb

-09

16-

Aug

-16

US9415392Slip chip device and methodsThe University of Chicago24-

Mar-

09

23-

Mar

-10

16-

Aug

-16

US9415087Compositions and methods for treating coronavirus infectionLudwig-Maximilians-Universitaet Muenchen11-

Mar-

14

8-

May

-15

16-

Aug

-16

US9415033Esters of short chains fatty acids for use in the treatment of immunogenic disordersPROPONENT BIOTECH GMBH3-

Oct-

12

3-

Oct

-13

16-

Aug

-16

US9409987Polypeptides and polynucleotides, and uses thereof for treatment of immune related disorders and cancerCOMPUGEN LTD15-

Apr-

11

16-

Apr

-12

9-

Aug

-16

US9409917Heterocyclic amide derivatives as P2X7 receptor antagonistsACTELION PHARMACEUTICALS LTD.20-

Jan-

12

18-

Jan

-13

9-

Aug

-16

 

US9409870CompoundsCHIESI FARMACEUTICI S.p.A.15-

Dec-

14

27-

Nov

-15

9-

Aug

-16

US9408908Combination adjuvant formulationNot Available16-

Oct-

08

15-

Feb

-13

9-

Aug

-16

US9408907Homogenous suspension of immunopotentiating compounds and uses thereofGlaxoSmithKline Biologicals SA15-

Dec-

09

15-

Dec

-10

9-

Aug

-16

US9404160Methods for the detection of microorganismsBecton, Dickinson and Company22-

Dec-

09

21-

Dec

-10

2-

Aug

-16

US9403868Crystalline tripeptide epoxy ketone protease inhibitorsOnyx Therapeutics, Inc.20-

Mar-

09

5-

Mar

-15

2-

Aug

-16

US9402921Directed evolution and in vitro panning of virus vectorsThe University of North Carolina at Chapel Hill30-

Apr-

08

22-

Oct

-14

2-

Aug

-16

US9402878Depsipeptide and uses thereofNovoBiotic Pharmaceuticals, LLC3-

Dec-

12

1-

Jul-

15

2-

Aug

-16

US9402812Methods for the preparation of liposomesIndu Javeri23-

Sep-

09

23-

Sep

-10

2-

Aug

-16

US9394092Powdered pouch and method of making sameMONOSOL, LLC16-

Apr-

12

14-

Mar

-13

19-

Jul-

16

US9393564Bioagent detection systems, devices, and methodsIBIS BIOSCIENCES, INC.30-

Mar-

09

30-

Mar

-10

19-

Jul-

16

US9393295Nanoparticles for use in pharmaceutical compositionsNovartis AG28-

Apr-

08

28-

Apr

-09

19-

Jul-

16

US9393215Nanoparticles for use in immunogenic compositionsNovartis AG2-

Dec-

05

1-

Dec

-06

19-

Jul-

16

US9388429Method for propagating adenoviral vectors encoding inhibitory gene productsGenVec, Inc.10-

Nov-

05

28-

May

-14

12-

Jul-

16

US9388234Systems and methods for identifying Replikin Scaffolds and uses of said Replikin ScaffoldsNot Available6-

Jun-

03

19-

Jun

-13

12-

Jul-

16

US9388198Heterocyclic amide derivatives as P2X7 receptor antagonistsACTELION PHARMACEUTICALS LTD.21-

Jan-

14

21-

Jan

-14

12-

Jul-

16

US9388197Heterocyclic amide derivatives as P2X7 receptor antagonistsACTELION PHARMACEUTICALS LTD.22-

Jan-

13

21-

Jan

-14

12-

Jul-

16

US9387242Chimeric viruses presenting non-native surface proteins and uses thereofIcahn School of Medicine at Mount Sinai2-

Dec-

05

1-

Dec

-06

12-

Jul-

16

US9382590Methods and compositions for prostate cancer metastasisFLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)25-

Mar-

11

20-

May

-15

5-

Jul-

16

US9382545CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activityCOLEY PHARMACEUTICAL GMBH27-

Sep-

06

4-

Oct

-13

5-

Jul-

16

US9382288Derivatives of steroid benzylamines, having an antiparasitic antibacterial, antimycotic and/or antiviral actionJustus-Liebig-Universitat Giessen6-

Oct-

10

6-

Oct

-11

5-

Jul-

16

US9381244VISTA modulators for diagnosis and treatment of cancerKING’S COLLEGE LONDON7-

Sep-

12

9-

Sep

-13

5-

Jul-

16

US9381239VLPS derived from cells that do not express a viral matrix or core proteinNovavax, Inc.25-

May-

07

14-

Apr

-14

5-

Jul-

16

US9381226Methods and compositions related to inhibition of viral entryUNIVERSITY OF UTAH RESEARCH FOUNDATION8-

Feb-

07

8-

Feb

-08

5-

Jul-

16

US9381220Sceletium extract and uses thereofH. L. Hall & Sons Limited20-

Mar-

09

15-

Jul-

14

5-

Jul-

16

US9380785Antiviral resin memberNBC MESHTEC, INC.6-Jul-

11

6-

Jul-

12

5-

Jul-

16

US9376486Human monoclonal antibody with specificity for Dengue virus serotype 1 E protein and uses thereofDSO National Laboratories14-

Dec-

10

14-

Dec

-11

28-

Jun-

16

US9376398Carboxylic acid compoundsAstrazeneca Aktiebolag18-

May-

12

17-

May

-13

28-

Jun-

16

US9375465Conjugates of GM-CSF and IL-7, compositions and methods related theretoChildren’s Healthcare of Atlanta, Inc.14-

Nov-

11

13-

Nov

-12

28-

Jun-

16

US9372156System for processing contents of a receptacle to detect an optical signal emitted by the contentsGEN-PROBE INCORPORATED10-

Mar-

05

22-

Feb

-11

21-

Jun-

16

US9371563Nanoreporters and methods of manufacturing and use thereofNanoString Technologies, Inc.23-

Dec-

05

11-

Mar

-13

21-

Jun-

16

 

US9370582Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS, INC.4-

Dec-

07

11-

Jul-

14

21-

Jun-

16

US9370581Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS, INC.4-

Dec-

07

11-

Jul-

14

21-

Jun-

16

US9370570Polychlorinated biphenyls and squalene-containing adjuvantsNovartis AG28-

Dec-

07

10-

Dec

-13

21-

Jun-

16

US9370531Method of providing patient specific immune response in amyloidoses and protein aggregation disordersNew York University31-

Aug-

07

1-

Sep

-08

21-

Jun-

16

US9365577Pyrimidinone compounds as human neutrophil elastase inhibitorsChiesi Farmaceutici S.p.A.18-

Dec-

12

17-

Dec

-13

14-

Jun-

16

US9365567Alkoxy substituted imidazoquinolines3M Innovative Properties Company3-

Oct-

03

30-

Sep

-14

14-

Jun-

16

US9365523Imidazolyl amide compounds and uses related theretoChildren’s Healthcare of Atlanta, Inc.31-

Mar-

11

28-

Mar

-12

14-

Jun-

16

US9365506Compounds and compositions as TLR2 agonistsNOVARTIS AG23-

Mar-

10

9-

Jul-

14

14-

Jun-

16

US9364511Antiviral preparations obtained from a natural cinnamon extractRAMOT AT TEL-AVIV UNIVERSITY LTD.24-

Dec-

03

22-

Jun

-06

14-

Jun-

16

US9359360TLR agonistsThe Regents of The University of California22-

Aug-

05

20-

Nov

-12

7-

Jun-

16

US9358280Decreasing potential iatrogenic risks associated with influenza vaccinesNovartis AG9-

Sep-

04

11-

Jan

-13

7-

Jun-

16

US9353133Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

7-

Mar

-14

31-

May

-16

US9352048Carbohydrate conjugates as delivery agents for oligonucleotidesALNYLAM PHARMACEUTICALS, INC.4-

Dec-

07

22-

Jul-

14

31-

May

-16

US9347055Method and kit for preparation of sample for use in nucleic acid amplificationEIKEN KAGAKU KABUSHIKI KAISHA5-

Nov-

07

5-

Nov

-08

24-

May

-16

US9346866Inhibition of tace activity with cyclic peptidesThe Regents of the University of California2-

Jun-

11

19-

Sep

-14

24-

May

-16

US9346794Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH23-

Aug-

12

29-

Dec

-15

24-

May

-16

US9346769Tetrazolones as inhibitors of fatty acid synthaseInfinity Pharmaceuticals, Inc.5-

May-

10

23-

Aug

-13

24-

May

-16

US9346753Dithiol mucolytic agentsPARION SCIENCES, INC.23-

Aug-

13

13-

Aug

-14

24-

May

-16

US9345760IPNV-ISAV bivalent vaccine using a virus-like particle-based platform and methods of using the sameAdvanced Bionutrition Corporation9-

Sep-

11

7-

Sep

-12

24-

May

-16

US9340507Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH23-

Aug-

12

2-

Sep

-15

17-

May

-16

US9339561Mutant protease biosensors with enhanced detection characteristicsPROMEGA CORPORATION11-

May-

10

5-

May

-14

17-

May

-16

US9339525Inhibition of biofilm organismsNovabiotics Limited31-

Mar-

09

31-

Mar

-10

17-

May

-16

US93342684-amino-imidazoquinoline compoundsHOFFMAN-LA ROCHE INC.22-

Apr-

14

22-

Apr

-15

10-

May

-16

US9328110Substituted imidazo ring systems and methods3M INNOVATIVE PROPERTIES COMPANY25-

Nov-

03

11-

Mar

-14

3-

May

-16

US9328093Selective inhibitors of ubiquitin specific protease 7, the pharmaceutical compositions thereof and their therapeutic applicationsHYBRIGENICS SA15-

Jan-

10

17-

Sep

-14

3-

May

-16

US9326972Use of phenylmethimazoles, methimazole derivatives, and tautomeric cyclic thiones for the treatment of autoimmune/inflammatory diseases associated with toll-like receptor overexpressionOhio University16-

Mar-

04

9-

Feb

-12

3-

May

-16

US9322827B-cell antigen presenting cell assayUniversity of Pittsburgh – Of the Commonwealth System of Higher Education8-

Apr-

10

8-

Apr

-11

26-

Apr-

16

US9321999Compositions for increasing polypeptide stability and activity, and related methodsSOLIS BIODYNE OAre19-

Nov-

09

19-

Nov

-10

26-

Apr-

16

US9321847Activatable toxin complexes comprising a cleavable inhibitory peptideRAMOT at Tel Aviv University Ltd.20-

Sep-

10

22-

Aug

-11

26-

Apr-

16

 

US9321831RSV-specific binding molecules and means for producing themMedImmune Limited1-

Jun-

07

13-

Sep

-13

26-

Apr-

16

US9320784Peptides shared among lethal cancers and therapeutic compositions comprising said peptidesNot Available7-

Aug-

09

19-

Jul-

12

26-

Apr-

16

US9320748Immunologically useful arginine saltsNovartis AG7-

Mar-

12

7-

Mar

-13

26-

Apr-

16

US9315530Adsorption of immunopotentiators to insoluble metal saltsNovartis AG1-

Sep-

10

1-

Sep

-11

19-

Apr-

16

US9310375Luminophore-labeled molecules coupled with particles for microarray-based assaysCapitalBio Corporation27-

Oct-

10

27-

Oct

-10

12-

Apr-

16

US9310088Device and method for reducing spread of microorganisms and airborne health hazardous matter and/or for protection from microorganisms and airborne health hazardous matterTechnical University of Denmark17-

Jul-09

14-

Jul-

10

12-

Apr-

16

US9309325Antibodies and methods of use thereofThe Regents of the University of California7-

May-

09

4-

May

-10

12-

Apr-

16

US9303068D-amino acid derivative-modified peptidoglycan and methods of use thereofThe Regents of the University of California30-

Nov-

12

27-

Nov

-13

5-

Apr-

16

US9303000Olefin containing nuclear transport modulators and uses thereofKARYOPHARM THERAPEUTICS INC.17-

Jan-

11

16-

Jan

-12

5-

Apr-

16

US9297010Short interfering RNA (siRNA) analoguesRoche Innovation Center Copenhagen A/S21-

Mar-

03

11-

Feb

-14

29-

Mar

-16

US9295732Conjugated TLR7 and/or TLR8 and TLR2 polycationic agonistsINVIVOGEN22-

Feb-

13

22-

Feb

-13

29-

Mar

-16

US9295708Modified release formulations for oprozomibOnyx Therapeutics, Inc.24-

Oct-

12

24-

Oct

-13

29-

Mar

-16

US9295646Cationic oil-in-water emulsionsNovartis AG6-Jul-

10

18-

Sep

-11

29-

Mar

-16

US9291628Direct clone analysis and selection technologyDublin City University13-

Jul-10

13-

Jul-

11

22-

Mar

-16

US9291597Detecting targets using mass tags and mass spectrometryVENTANA MEDICAL SYSTEMS, INC.2-Jul-

10

1-

Jul-

11

22-

Mar

-16

US9290794Mutant protease biosensors with enhanced detection characteristicsPROMEGA CORPORATION11-

May-

10

12-

Nov

-12

22-

Mar

-16

US9290786Monoclonal antibody production by EBV transformation of B cellsInstitute for Research in Biomedicine26-

Feb-

03

25-

Apr

-13

22-

Mar

-16

US9290760Modified iRNA agentsALNYLAM PHARMACEUTICALS, INC.15-

Sep-

10

14-

Sep

-11

22-

Mar

-16

US9290745Luciferase biosensorPROMEGA CORPORATION10-

Oct-

03

14-

Feb

-14

22-

Mar

-16

US9290545Compositions and methods for the treatment of viral infectionsDana-Farber Cancer Institute, Inc.23-

Jan-

08

23-

Jul-

10

22-

Mar

-16

US9290459Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH6-

Feb-

13

9-

Nov

-15

22-

Mar

-16

US9290457Substituted dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH31-

Jul-14

27-

Jul-

15

22-

Mar

-16

US9289487II-key/antigenic epitope hybrid peptide vaccinesAntigen Express, Inc.14-

Sep-

99

11-

Jan

-05

22-

Mar

-16

US9284560Application of highly conserved domain sequences from viral genome as template to design therapeutic sliRNAsBiocross Institute of Molecular Medicine (Nantong) Co., Ltd.19-

Sep-

11

19-

Sep

-11

15-

Mar

-16

US9278128Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the sameThe Trustees of the University of Pennsylvania14-

Sep-

09

6-

Jan

-14

8-

Mar

-16

US9278126Influenza vaccines with reduced amounts of squaleneSeqirus UK Limited10-

Feb-

09

10-

Feb

-10

8-

Mar

-16

US9272024Compositions, comprising improved IL-12 genetic constructs and vaccines, immunotherapeutics and methods of using the sameThe Trustees of the University of Pennsylvania12-

Dec-

11

11-

Dec

-12

1-

Mar

-16

US9271494Shelf stable, reduced corrosion, ready to use peroxycarboxylic acid antimicrobial compositionsEcolab USA, Inc.30-

Aug-

07

30-

Aug

-07

1-

Mar

-16

US9266844Suppression of SARS replication by SARS helicase inhibitorsThe Curators of the University of Missouri15-

Jun-

12

17-

Jun

-13

23-

Feb

-16

 

US9266843Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.9-

May-

12

9-

May

-13

23-

Feb

-16

US9265876Systems and methods for pathogen inactivation in blood using UV irradiation while minimizing heat transfer theretoHemalux Technologies LLC22-

Oct-

14

22-

Oct

-14

23-

Feb

-16

US9260398Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseasesPARION SCIENCES, INC.29-

May-

12

9-

Dec

-14

16-

Feb

-16

US9255144Anti-IL-18 antibodies and their usesMedImmune Limited20-

Dec-

10

20-

Dec

-11

9-

Feb

-16

US9255140Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulusNEW YORK BLOOD CENTER, INC.15-

Jun-

04

23-

Mar

-09

9-

Feb

-16

US9254315Systems and methods for identifying replikin scaffolds and uses of said replikin scaffoldsNot Available28-

Apr-

04

3-

Feb

-10

9-

Feb

-16

US9254265Small liposomes for delivery of immunogen encoding RNANOVARTIS AG31-

Aug-

10

31-

Aug

-11

9-

Feb

-16

US9249427Recombinant HCMV and RHCMV vectors and uses thereofOregon Health & Science University14-

May-

10

14-

Nov

-12

2-

Feb

-16

US9249195Reovirus vaccines and methods of use thereforVanderbilt University7-

Apr-

10

4-

Apr

-11

2-

Feb

-16

US9248201Mutant protease biosensors with enhanced detection characteristicsPROMEGA CORPORATION11-

May-

10

5-

May

-14

2-

Feb

-16

US9248178Different serotypes of vesicular stomatitis virus as expression vectors for immunization regimensNot Available8-

Jun-

09

8-

Jun

-10

2-

Feb

-16

US9242980Lipidated immune response modifier compound compositions, formulations, and methods3M Innovative Properties Company17-

Aug-

10

16-

Aug

-11

26-

Jan-

16

US9238809Compositions, methods, and kits for isolating and analyzing nucleic acids using an anion exchange materialQIAGEN GAITHERSBURG, INC.24-

Sep-

09

5-

Aug

-10

19-

Jan-

16

US9234175Creating bioengineered lymph nodesH. Lee Moffitt Cancer Center and Research Institute, Inc.17-

Nov-

09

16-

Nov

-10

12-

Jan-

16

US9233148Replikin-based compounds for prevention and treatment of influenza and methods of differentiating infectivity and lethality in influenzaNot Available9-

Jan-

09

16-

Oct

-09

12-

Jan-

16

US9227977Phosphoinositide 3-kinase inhibitorsRespivert Ltd.15-

Mar-

13

14-

Mar

-14

5-

Jan-

16

US9222075Animal protein-free media for cultivation of cellsBaxalta GmbH29-

Oct-

04

2-

May

-14

29-

Dec

-15

US9221832Heterocyclic amide derivatives as P2X7 receptor antagonistsACTELION PHARMACEUTICALS LTD.22-

Jul-11

20-

Jul-

12

29-

Dec

-15

US9221807Substituted pyridones and pyrazinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH21-

Feb-

14

12-

Feb

-15

29-

Dec

-15

US9220768Decreasing potential iatrogenic risks associated with influenza vaccinesNovartis AG9-

Sep-

04

14-

Oct

-11

29-

Dec

-15

US9217745Arrayed detector system for measurement of influenza immune responseUniversity of Rochester2-

May-

08

11-

Jul-

13

22-

Dec

-15

US9217157Recombinant influenza viruses and uses thereofIcahn School of Medicine at Mount Sinai27-

Jul-09

27-

Jul-

10

22-

Dec

-15

US9216192Toll-like receptor agonist formulations and their useVentiRx Pharmaceuticals, Inc.1-

Aug-

08

16-

Jul-

12

22-

Dec

-15

US9213027Lipoparticles comprising proteins, methods of making, and using the sameIntegral Molecular, Inc.30-

Jul-03

1-

Nov

-13

15-

Dec

-15

US9212399Biological specimen collection and transport system and method of useLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

7-

Jan

-14

15-

Dec

-15

US9212205Nucleic acid binding compounds and methods of useUniversity of Rochester26-

Jul-07

28-

Jul-

08

15-

Dec

-15

US9206396Methods and devices for quantitative viral assaysWisconsin Alumni Research Foundation16-

Nov-

05

16-

Nov

-06

8-

Dec

-15

US9206158Hydrazide containing nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.29-

Jul-11

10-

Jun

-15

8-

Dec

-15

US9200329Rapid epidemiologic typing of bacteriaBioFire Diagnostics, LLC19-

May-

08

18-

May

-09

1-

Dec

-15

 

US9200287Phosphate-modified oligonucleotide analogs with enhanced immunostimulatory activityAdiuTide Pharmaceuticals GmbH18-

May-

07

15-

May

-08

1-

Dec

-15

US9200280Methods and compositions for the treatment of cancer or other diseasesCITY OF HOPE26-

Jan-

07

9-

Jun

-14

1-

Dec

-15

US9200279Methods and compositions for the treatment of cancer or other diseasesCITY OF HOPE26-

Jan-

07

14-

Jan

-14

1-

Dec

-15

US9200074Antibodies to IL-1 R1 and methods of making themMEDIMMUNE LIMITED7-

Nov-

08

16-

Apr

-14

1-

Dec

-15

US9199981Compounds and compositions as C-kit kinase inhibitorsNOVARTIS AG1-

Sep-

11

27-

Aug

-12

1-

Dec

-15

US9199897Methods for preparing squaleneNOVARTIS AG12-

May-

10

12-

May

-11

1-

Dec

-15

US9198927Targeting opposite strand replication intermediates of single­stranded viruses by RNAIALNYLAM PHARMACEUTICALS, INC.24-

Sep-

04

1-

Mar

-10

1-

Dec

-15

US9193780Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseasesAblynx N.V.5-

Jun-

08

5-

Jun

-09

24-

Nov

-15

US9192661Delivery of self-replicating RNA using biodegradable polymer particlesNovartis AG6-Jul-

10

7-

Jun

-11

24-

Nov

-15

US9187748Compositions and methods for silencing ebola virus gene expressionNot Available20-

Jul-09

28-

Mar

-14

17-

Nov

-15

US9187426Organic compoundsNovartis AG27-

Jun-

08

25-

Jun

-09

17-

Nov

-15

US9186419Directed evolution and in vitro panning of virus vectorsThe University of North Carolina at Chapel Hill30-

Apr-

08

17-

Jan

-14

17-

Nov

-15

US9186399Immune stimulatory oligonucleotide analogs containing modified sugar moietiesAdiutTide Pharmaceuticals GmbH9-

Oct-

07

29-

Sep

-08

17-

Nov

-15

US9181303Treatment of bacterial infections with cyclic antimicrobial peptidesNovaBiotics Limited22-

Dec-

05

20-

Jun

-14

10-

Nov

-15

US9181290Inhibition of biofilm formation by 1,2,3,4,6-penta-O-galloyl-D- glucopyranoseCHANG GUNG UNIVERSITY17-

Jun-

11

19-

Sep

-11

10-

Nov

-15

US9175047Peptidomimetic macrocyclesAileron Therapeutics, Inc.14-

Jan-

09

14-

Jan

-10

3-

Nov

-15

US9174925Phorbol type diterpene compound, pharmaceutical composition for treatment or prevention of viral infectious diseases including sameKOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY26-

Oct-

11

28-

Sep

-12

3-

Nov

-15

US9169318Neutralizing molecules to viral antigensSea Lane Biotechnologies, Inc.28-

Mar-

08

18-

Jul-

11

27-

Oct-

15

US9168318Oxidative reductive potential water solution and methods of using the sameOculus Innovative Sciences, Inc.30-

Dec-

03

11-

Aug

-04

27-

Oct-

15

US9168299Methods for treating juvenile arthritis with ant-bile salt-stimulated lipase (BSSL) antibodiesLIPUM AB8-

Apr-

09

30-

Oct

-13

27-

Oct-

15

US9168269Inhibitors of long and very long chain fatty acid metabolism as broad spectrum anti-viralsTHE TRUSTEES OF PRINCETON UNIVERSITY18-

Feb-

10

18-

Feb

-11

27-

Oct-

15

US9163222Mutations in OAS1 genesKineta Two, LLC4-

May-

05

14-

Nov

-12

20-

Oct-

15

US9163065Depsipeptide and uses thereofNovoBiotic Pharmaceuticals, LLC3-

Dec-

12

3-

Dec

-13

20-

Oct-

15

US9161976Immunotherapy comprising TLR9 ligand and CD40 ligandTrustees of Dartmouth College30-

Dec-

02

22-

Oct

-12

20-

Oct-

15

US9156811N-myristoyl transferase inhibitorsUniveristy of Dundee2-

Sep-

08

29-

Aug

-09

13-

Oct-

15

US9155309Virus inactivating sheetNBC MESHTEC, INC.2-

Oct-

09

4-

Oct

-10

13-

Oct-

15

US9149473Targeted whole genome amplification method for identification of pathogensIBIS BIOSCIENCES, INC.14-

Sep-

06

14-

Sep

-07

6-

Oct-

15

US9149445Inhibition of glycerol-3-phosphate acyltransferase (GPAT) and associated enzymes for treatment of viral infectionsTHE TRUSTEES OF PRINCETON UNIVERSITY27-

Jul-09

27-

Jul-

10

6-

Oct-

15

US9145588Generation of binding moleculesMERUS BIOPHARMACEUTICALS B.V.26-

Sep-

11

26-

Sep

-12

29-

Sep

-15

 

US9145585Method for using permuted nucleic acid probesVentana Medical Systems, Inc.1-

Sep-

06

5-

Aug

-14

29-

Sep

-15

US9145410Pyrazolopyridines and analogs thereof3M Innovative Properties Company3-

Oct-

03

26-

Jan

-12

29-

Sep

-15

US9144575Anti-viral azide containing compoundsLIFE TECHNOLOGIES CORPORATION28-

Jul-10

28-

Jul-

11

29-

Sep

-15

US9139833Modified small interfering RNA molecules and methods of useArrowhead Research Corporation26-

Jul-02

12-

Mar

-13

22-

Sep

-15

US9139647Diagnosis and treatment of cancer using anti-TM4SF20 antibodyFORERUNNER PHARMA RESEARCH CO., LTD.25-

Dec-

08

25-

Dec

-09

22-

Sep

-15

US9139620Feline morbillivirus and uses thereofTHE GOVERNMENT OF THE HONG KONG SPECIAL ADMINISTRATIVE REGION OF THE PEOPLE’S REPUBLIC OF CHINA20-

Jan-

12

22-

Jan

-13

22-

Sep

-15

US9138472CD40L vaccines, compositions, and methods related theretoEMORY UNIVERSITY28-

Sep-

10

28-

Sep

-11

22-

Sep

-15

US9134247Method and apparatus for two-step surface-enhanced raman spectroscopyREAL-TIME ANALYZERS, INC.16-

Dec-

11

16-

Dec

-11

15-

Sep

-15

US9133248Methods of propagating monkey adenoviral vectorsGenVec, Inc.9-

Nov-

09

9-

Nov

-10

15-

Sep

-15

US9132423Sample-to-answer microfluidic cartridgeMicronics, Inc.29-

Jan-

10

28-

Jan

-11

15-

Sep

-15

US9132175Bacillus based delivery system and methods of useThe Curators of the University of Missouri18-

Apr-

11

18-

Apr

-11

15-

Sep

-15

US9128101Biomarkers for theranosticsCaris Life Sciences Switzerland Holdings GmbH1-

Mar-

10

1-

Mar

-11

8-

Sep

-15

US9127256Method for production of reprogrammed cell using chromosomally unintegrated virus vectorDNAVEC CORPORATION16-

Jul-08

16-

Jul-

09

8-

Sep

-15

US9127251Means and methods for influencing the stability of antibody producing cellsACADEMISCH MEDISCH CENTRUM BIJ DE UNIVERSITEIT VAN AMSTERDAM9-

Dec-

05

8-

Dec

-06

8-

Sep

-15

US9127028Substrates for chromogenic detection and methods of use in detection assays and kitsVentana Medical Systems, Inc.16-

Aug-

10

12-

Aug

-11

8-

Sep

-15

US9125952Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopesIndustry Academic Cooperation Foundation, Hallym University17-

Jul-09

13-

Aug

-14

8-

Sep

-15

US9115093Substituted bicyclic dihydropyrimidinones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH4-

Mar-

13

20-

Feb

-14

25-

Aug

-15

US9115065Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with ArenavirusesKineta, Inc.6-

Dec-

04

26-

Feb

-13

25-

Aug

-15

US9109199Methods to produce bunyavirus replicon particlesSTICHTING DIENST LANDBOUWKUNDIG ONDERZOEK20-

Sep-

10

20-

Sep

-11

18-

Aug

-15

US9107970Method and a filter for capturing airborne agentsNot Available15-

Jul-08

13-

Jul-

09

18-

Aug

-15

US9107958Hydrazino 1H-imidazoquinolin-4-amines and conjugates made therefrom3M Innovative Properties Company3-

Jun-

11

1-

Jun

-12

18-

Aug

-15

US9107906Compositions and methods for the treatment of immunodeficiencyADMA BIOLOGICS, INC.28-

Oct-

14

8-

Jan

-15

18-

Aug

-15

US9107904Immunostimulatory compositions and methods of use thereofMassachusetts Institute of Technology5-

Apr-

12

15-

Mar

-13

18-

Aug

-15

US91029382â€2 and 5â€2 modified monomers and oligonucleotidesALNYLAM PHARMACEUTICALS, INC.31-

Mar-

11

31-

Mar

-11

11-

Aug

-15

US9102911High density self-contained biological analysisBioFire Diagnostics, LLC15-

May-

09

28-

Jan

-13

11-

Aug

-15

US9102741GAS57 mutant antigens and GAS57 antibodiesNovartis AG12-

Sep-

07

13-

Oct

-14

11-

Aug

-15

US9102740Cna-B domain antigens in vaccines against gram positive bacteriaNOVARTIS AG12-

Jan-

09

7-

Jun

-13

11-

Aug

-15

US9102633Arylalkyl- and aryloxyalkyl-substituted epithelial sodium channel blocking compoundsParion Sciences, Inc.13-

Dec-

13

13-

Dec

-13

11-

Aug

-15

US9102624Substituted 4-pyridones and their use as inhibitors of neutrophil elastase activityBoehringer Ingelheim International GmbH23-

Aug-

12

20-

Aug

-13

11-

Aug

-15

 

US9101597Immunoprotective primary mesenchymal stem cells and methodsAutoimmune Technologies, LLC14-

Mar-

13

14-

Mar

-13

11-

Aug

-15

US9101582Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogenThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention31-

Jul-08

27-

Mar

-13

11-

Aug

-15

US9096585Antiviral compounds and uses thereofIcahn School of Medicine at Mount Sinai28-

May-

10

31-

May

-11

4-

Aug

-15

US9096543Nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.9-

May-

12

9-

May

-13

4-

Aug

-15

US9090897Production of IFN-lambda by conventional dendritic cellsBavarian Nordic A/S18-

Dec-

09

17-

Dec

-10

28-

Jul-

15

US9085641Peptides regulating the surface expression of the T cell receptorMax-Delbruck-Centrum Fur Molekulare Medizin23-

Jun-

06

23-

Jun

-07

21-

Jul-

15

US9084808Modified small interfering RNA molecules and methods of useArrowhead Research Corporation1-

Oct-

04

9-

May

-14

21-

Jul-

15

US9084758Antiviral compositions comprising ethanol extract of Tetracera scandens and use thereofThe Catholic University of Korea Industry-Academic Cooperation Foundation24-

Jul-12

25-

Aug

-14

21-

Jul-

15

US9080209Non-mass determined base compositions for nucleic acid detectionIBIS BIOSCIENCES, INC.6-

Aug-

09

6-

Aug

-10

14-

Jul-

15

US9080204Compositions and methods for rapid, real-time detection of influenza a virus (H1N1) Swine 2009Longhorn Vaccines and Diagnostics, LLC12-

Sep-

06

30-

Dec

-11

14-

Jul-

15

US9079965Bispecific antibodyWuhan YZY Biopharma Co., LTD.21-

Nov-

12

13-

Mar

-14

14-

Jul-

15

US9079943TC-83-derived alphavirus vectors, particles and methodsALPHAVAX, INC.18-

May-

04

28-

Mar

-14

14-

Jul-

15

US9079865Hydrazide containing nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.29-

Jul-11

29-

Jul-

12

14-

Jul-

15

US9078885Respiratory disease treatmentPulmagen Therapeutics (Inflammation) Limited7-

Aug-

08

7-

Apr

-14

14-

Jul-

15

US9078868Therapeutic agent for accelerating recovery of animal under medical treatmentDAIICHI SANKYO COMPANY, LIMITED15-

Jan-

10

14-

Jan

-11

14-

Jul-

15

US9073869Method of using substituted 2-Aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin CBoehringer Ingelheim International GmbH14-

Mar-

13

11-

Sep

-14

7-

Jul-

15

US9072738Chemically and metabolically stable dipeptide possessing potent sodium channel blocker activityPARION SCIENCES, INC.27-

Jun-

11

27-

Jun

-12

7-

Jul-

15

US9072726Methods of treating or preventing inflammation and hypersensitivity with oxidative reductive potential water solutionOculus Innovative Sciences, Inc.20-

Jan-

06

21-

Dec

-09

7-

Jul-

15

US9072702Reverse genetics using non-endogenous pol I promotersNovartis AG21-

May-

09

21-

May

-10

7-

Jul-

15

US9067873Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenavirusesKineta Four, LLC6-

Dec-

04

19-

Dec

-13

30-

Jun-

15

US9066964Use of tylvalosin as antiviral agentCambridge University Technical Services13-

Jul-06

13-

Jul-

07

30-

Jun-

15

US9063150Method for detection of antigen-specific antibodies in biological samplesThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control Prevention2-

Sep-

08

25-

Aug

-09

23-

Jun-

15

US9061001Combination adjuvant formulationDalhousie University16-

Oct-

08

15-

Oct

-09

23-

Jun-

15

US9056900Compositions and methods for coronavirus inhibitionAutoimmune Technologies, LLC.4-

Nov-

03

8-

Aug

-13

16-

Jun-

15

US9056898Attenuated RNA virus and applications thereofWashington University20-

Sep-

07

22-

Sep

-08

16-

Jun-

15

US9056071Compounds and methods for preventing or treating a viral infectionCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (C.N.R.S.)2-

Nov-

07

19-

Jun

-13

16-

Jun-

15

US9051619Methods and compositions for prostate cancer metastasisFLORIDA AGRICULTURAL AND MECHANICAL UNIVERSITY (FAMU)25-

Mar-

11

23-

Mar

-12

9-

Jun-

15

US9051564Compositions for and methods of identifying antigensPresident and Fellows of Harvard College21-

Feb-

06

21-

Feb

-07

9-

Jun-

15

US9051353Crystalline tripeptide epoxy ketone protease inhibitorsOnyx Therapeutics, Inc.20-

Mar-

09

24-

Sep

-13

9-

Jun-

15

 

US9050376Conjugates of synthetic TLR agonists and uses thereforThe Regents of the University of California7-

Feb-

07

19-

Jun

-14

9-

Jun-

15

US9046523Rapid bioluminescence detection systemTHE SECRETARY OF STATE FOR HEALTH7-

Jan-

09

2-

Aug

-13

2-

Jun-

15

US9045855Anti-viral memberNBC Meshtec, Inc.26-

Dec-

08

28-

Dec

-09

2-

Jun-

15

US9045727Virus-like particles, methods of preparation, and immunogenic compositionsEMORY UNIVERSITY17-

May-

02

4-

Apr

-06

2-

Jun-

15

US9045472Imidazoquinoline compoundsASTRAZENECA AB16-

Dec-

10

16-

Dec

-11

2-

Jun-

15

US9045470Compounds and compositions as TLR activity modulatorsIRM LLC2-

Sep-

09

1-

Sep

-10

2-

Jun-

15

US9044420Immunogenic compositions and methods of using the compositions for inducing humoral and cellular immune responsesIMMUNE DESIGN CORP.8-

Apr-

11

6-

Apr

-12

2-

Jun-

15

US9040310Antibody-nanoparticle conjugates and methods for making and using such conjugatesVentana Medical Systems, Inc.27-

Apr-

10

27-

Apr

-11

26-

May

-15

US9034646Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereofZHENG YANG BIOMEDICAL TECHNOLOGY CO., LTD.25-

May-

10

26-

Nov

-12

19-

May

-15

US9034313Nucleic acid molecules encoding rantes, and compositions comprising and methods of using the sameInovio Pharmaceuticals, Inc.8-

Feb-

10

8-

Feb

-11

19-

May

-15

US9029413T reatment of viral infections by modulation of host cell metabolic pathwaysThe Trustees of Princeton University1-

Jun-

07

3-

Apr

-12

12-

May

-15

US90293823,5-diamino-6-chloro-N-(N-(4-phenylbutyl)carbamimidoyl) pyrazine-2-carboxamide compoundsParion Sciences, Inc.17-

Dec-

12

13-

Dec

-13

12-

May

-15

US9029315Soluble PD-1 variants, fusion constructs, and uses thereofThe University of Hong Kong11-

Nov-

10

11-

Nov

-11

12-

May

-15

US9028841Synergistic bacterial compositions and methods of production and use thereofSeres Health, Inc.23-

Nov-

12

20-

Mar

-14

12-

May

-15

US9028837Methods and compositions for poxvirus A35R proteinEast Carolina University7-

Jun-

12

20-

Dec

-12

12-

May

-15

US9028823Methods of inducing or enhancing an immune response in a subject by administering agonistic GITR binding antibodiesGITR, Inc.25-

Mar-

05

1-

Mar

-13

12-

May

-15

US9024001Alphavirus replicon packaging constructsNovartis Vaccines and Diagnostics, Inc.25-

May-

04

20-

May

-05

5-

May

-15

US9023855CompoundsChiesi Farmaceutici S.p.A.14-

Sep-

11

11-

Feb

-14

5-

May

-15

US9023839Compounds and compositions as c-kit kinase inhibitorsIRM LLC1-

Sep-

11

22-

Apr

-14

5-

May

-15

US9017699Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulusNew York Blood Center, Inc.15-

Jun-

04

18-

Feb

-10

28-

Apr-

15

US9017696Adenovirus vectorsIsis Innovation Limited10-

Apr-

07

10-

Apr

-08

28-

Apr-

15

US9012622Compositions and methods using siRNA molecules and siRNA cocktails for the treatment of breast cancerNot Available31-

Dec-

08

31-

Dec

-09

21-

Apr-

15

US9011767Transportable vacuum assisted decontamination unit and decontamination processSTERIS Inc.1-

Apr-

13

31-

Mar

-14

21-

Apr-

15

US9006264Substituted imidazoquinolines, imidazopyridines, and i midazonaphthyridines3M Innovative Properties Company18-

Jun-

04

9-

Sep

-13

14-

Apr-

15

US9006194Compositions and methods for diminishing viral infection and inflammation associated with viral infectionDrexel University19-

Dec-

08

17-

Dec

-09

14-

Apr-

15

US9005974Means and methods for influencing the stability of cellsAcademish Medisch Centrum Bij de Universiteit van Amsterdam9-

Dec-

05

9-

Dec

-05

14-

Apr-

15

US9005665Compositions and methods for treating and preventing porcine reproductive and respiratory syndromeOhio State Innovation Foundation24-

Apr-

12

24-

Apr

-13

14-

Apr-

15

US9005599Genetically modified human umbilical cord perivascular cells for prophylaxis against or treatment of biological or chemical agentsTissue Regeneration Therapeutics Inc.21-

Apr-

08

20-

Apr

-09

14-

Apr-

15

US8999996Hydrazide containing nuclear transport modulators and uses thereofKaryopharm Therapeutics Inc.29-

Jul-11

19-

Mar

-14

7-

Apr-

15

 

US8999975Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin CBoehringer Ingelheim International GmbH19-

Sep-

11

14-

Sep

-12

7-

Apr-

15

US8999678Method of increasing the function of an AAV vectorThe Trustees of the University of Pennsylvania7-

Apr-

05

7-

Apr

-06

7-

Apr-

15

US8999349HMGBl-derived peptides enhance immune response to antigensThe Regents of the University of California27-

Jul-10

27-

Jul-

11

7-

Apr-

15

US8999316Antiviral compoundsLong Island University30-

May-

07

30-

May

-08

7-

Apr-

15

US8993717Gadd45beta targeting agentsImperial Innovations Limited22-

Oct-

09

22-

Oct

-10

31-

Mar

-15

US8993581Methods for treating viral disordersTrustees of Boston University24-

Sep-

09

11-

Jun

-13

31-

Mar

-15

US8993295Methods, compositions, and kits for the selective activation of protoxins through combinatorial targetingThe General Hospital Corporation20-

Jul-06

20-

Jul-

07

31-

Mar

-15

US8992939Highly efficient influenza matrix (M1) proteinsNovavax, Inc.11-

Jul-03

24-

Oct

-11

31-

Mar

-15

US8987249Substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of Cathepsin CBoehringer Ingelheim International GmbH14-

Mar-

13

12-

Mar

-14

24-

Mar

-15

US8987191Bioactive peptides and methods of using sameCompugen Ltd.12-

Jul-07

21-

Jun

-13

24-

Mar

-15

US8986933Selective detection of human rhinovirusThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control5-

Dec-

08

5-

Dec

-08

24-

Mar

-15

US8986926Compositions comprising oriented, immobilized macromolecules and methods for their preparationNanoString Technologies, Inc.23-

Dec-

05

22-

Dec

-06

24-

Mar

-15

US8986702Antibodies and processes for preparing the sameTaiga Biotechnologies, Inc.16-

May-

08

18-

May

-09

24-

Mar

-15

US8980898Dendrimer like amino amides possessing sodium channel blocker activity for the treatment of dry eye and other mucosal diseasesParion Sciences, Inc.29-

May-

12

29-

May

-13

17-

Mar

-15

US8980338Sceletium extract and uses thereofH.L. Hall & Sons Limited20-

Mar-

09

16-

Mar

-10

17-

Mar

-15

US8980281High-yield transgenic mammalian expression system for generating virus-like particlesAcademia Sinica5-

Sep-

06

12-

Feb

-10

17-

Mar

-15

US8975389Nucleic acid chemical modificationsAlnylam Pharmaceuticals, Inc.2-

Mar-

09

2-

Mar

-10

10-

Mar

-15

US89693629-substituted 8-oxoadenine compoundAstraZeneca Aktiebolag26-

Mar-

04

21-

Oct

-13

3-

Mar

-15

US8969350Pharmaceutical product comprising a p38 kinase inhibitor and a second active ingredientAstrazeneca AB18-

Dec-

08

17-

Dec

-09

3-

Mar

-15

US8962580Chemical modifications of monomers and oligonucleotides with cycloadditionAlnylam Pharmaceuticals, Inc.23-

Sep-

08

23-

Sep

-09

24-

Feb

-15

US8962332Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

13-

Sep

-13

24-

Feb

-15

US8962330Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

31-

Oct

-07

24-

Feb

-15

US8961983Mucosal vaccine using cationic nanogelNational University Corporation Tokyo Medical and Dental University31-

Oct-

08

5-

Sep

-14

24-

Feb

-15

US8961477Delivery of immune response modifier compounds3M Innovative Properties Company25-

Aug-

03

25-

Aug

-04

24-

Feb

-15

US8956863Agents from cellsThe Brigham and Women’s Hospital, Inc.15-

Oct-

09

15-

Oct

-10

17-

Feb

-15

US8956616Constructs binding to phosphatidylserine and their use in disease treatmentBoard of Regents, The University of Texas System24-

Jan-

05

24-

Jan

-06

17-

Feb

-15

US8951768Mutations in OAS1 genesKineta Two, LLC4-

May-

05

11-

Jul-

11

10-

Feb

-15

US8951528Immune response modifier conjugates3M Innovative Properties Company22-

Feb-

06

21-

Feb

-07

10-

Feb

-15

US8945943Personal glucose meters for detection and quantification of a broad range of analytesThe Board of Trustees of the University of Illinois26-

May-

10

26-

May

-11

3-

Feb

-15

US8945904Influenza virus reassortmentNovartis AG21-

May-

10

20-

May

-11

3-

Feb

-15

 

US8945610Condensation products based on bicyclic or polycyclic aromatics or heteroaromaticsBASF SE14-

Nov-

07

11-

Nov

-08

3-

Feb

-15

US8940864Stabilized therapeutic small helical antiviral peptidesNew York Blood Center, Inc.5-

Oct-

06

2-

Oct

-07

27-

Jan-

15

US8940501Methods for ligation and uses thereofWhitehead Institute for Biomedical Research30-

Jan-

09

1-

Feb

-10

27-

Jan-

15

US8937154Stabilized therapeutic small helical antiviral peptidesNew York Blood Center, Inc.5-

Oct-

06

2-

Feb

-12

20-

Jan-

15

US8933210Label-free functional nucleic acid sensors for detecting target agentsThe Board of Trustees of the University of Illinois6-

Oct-

10

6-

Oct

-11

13-

Jan-

15

US8933019Antiviral cell-penetrating peptidesNew York Blood Center, Inc.6-

May-

08

31-

Oct

-12

13-

Jan-

15

US8916552Pharmaceutical combinationsAstex Therapeutics Limited12-

Oct-

06

12-

Oct

-07

23-

Dec

-14

US8916340Method for identifying and validating dominant T helper cell epitopes using an HLA-DM-assisted class II binding assayThe John Hopkins University6-

Jan-

06

8-

Jan

-07

23-

Dec

-14

US8906872Antisense antiviral compound and method for treating ssRNA viral infectionSarepta Therapeutics, Inc.16-

Sep-

04

22-

Dec

-11

9-

Dec

-14

US8906863Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vectorThe Regents of the University of California27-

Feb-

09

1-

Sep

-11

9-

Dec

-14

US8906862Multiple antigen delivery system using hepatitis E virus-like particleNational Institute of Infectious Disease27-

Feb-

09

29-

Aug

-11

9-

Dec

-14

US8901071Compounds and their useNovabiotics Limited31-

Mar-

10

30-

Mar

-11

2-

Dec

-14

US8900585Influenza hemagglutinin-specific monoclonal antibodies for preventing and treating influenza virus infectionNew York Blood Center, Inc.20-

Oct-

10

20-

Oct

-11

2-

Dec

-14

US8895629Circulation of components during homogenization of emulsionsNovartis AG3-

Dec-

09

3-

Dec

-10

25-

Nov

-14

US8895577Compounds and compositions as TLR activity modulatorsNot Available3-

Mar-

08

22-

Apr

-13

25-

Nov

-14

US8895570Purine derivativesAstraZeneca AB17-

Dec-

10

14-

Dec

-11

25-

Nov

-14

US8895534Boron containing small moleculesAnacor Pharmaceuticals, Inc.20-

Jun-

07

30-

Jul-

10

25-

Nov

-14

US8895295High density self-contained biological analysisBiofire Diagnostics, LLC15-

Nov-

06

14-

Nov

-07

25-

Nov

-14

US8889708Substituted bicyclic 1-carboxylic-acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin CBoehringer Ingelheim International GmbH14-

Mar-

13

12-

Mar

-14

18-

Nov

-14

US8889692Pyrazinone derivatives, pharmaceutically acceptance salts thereof and their usesAstraZeneca AB27-

Jun-

07

14-

Sep

-12

18-

Nov

-14

US8889656Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

30-

Apr

-13

18-

Nov

-14

US8889398Composition for inactivating an enveloped virusViroblock SA19-

May-

06

18-

May

-07

18-

Nov

-14

US8889181Immunostimulatory compositions comprising liposome-encapsulated oligonucleotides and epitopesIndustry Academic Cooperation Foundation, Hallym University17-

Jul-09

16-

Jun

-10

18-

Nov

-14

US8889118Anticancer agent containing dendritic cell having RNA virus transferred thereintoDNA VEC Research Inc.24-

Jun-

04

28-

Apr

-05

18-

Nov

-14

US8889117Modular nanoparticles for adaptable vaccinesYale University15-

Feb-

07

15-

Feb

-08

18-

Nov

-14

US8884020Indole compoundsIronwood Pharmaceuticals, Inc.7-

Aug-

06

7-

Aug

-07

11-

Nov

-14

US8883790Pharmaceutical combinationsAstex Therapeutics Limited12-

Oct-

06

12-

Oct

-07

11-

Nov

-14

US8883500Method of preparing adenosine-resistant anti-tumor T lymphocytes for adoptive immunotherapyNortheastern University5-

Dec-

08

7-

Dec

-09

11-

Nov

-14

US8883481Reverse genetics methods for virus rescueNovartis AG20-

Oct-

09

20-

Oct

-10

11-

Nov

-14

US8883477Oligoadenylate synthetase (OAS)Kineta Two, LLC23-

Nov-

05

14-

Jun

-13

11-

Nov

-14

 

US8882484Methods and compositions for production of recombinant protein in HBX-expressing mammalian cellsBayer Healthcare LLC28-

May-

08

27-

May

-09

11-

Nov

-14

US8881040System and method for detecting, collecting, analyzing, and communicating event-related informationGeorgetown University28-

Aug-

08

2-

Dec

-09

4-

Nov

-14

US8877775Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl- cyano-methyl)-amides inhibitors of cathepsin CBoehringer Ingelheim International GmbH14-

Mar-

13

12-

Mar

-14

4-

Nov

-14

US8877187Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseasesAvianax, LLC25-

Jul-05

23-

Nov

-10

4-

Nov

-14

US8877060Methods for removing pathogens from a platelet preparationBiovec Transfusion, LLC23-

Nov-

10

31-

Oct

-11

4-

Nov

-14

US8871816Methods for producing vaccine adjuvantsNovartis AG3-

Dec-

09

3-

Dec

-10

28-

Oct-

14

US8871790Heterocyclic modulators of lipid synthesis3-V Biosciences, Inc.8-

Mar-

11

8-

Mar

-12

28-

Oct-

14

US8871783Substituted 2-aza-bicyclo[2.2.1]heptane-3-carboxylic acid (cyano- methyl)-amides inhibitors of cathepsin CBoehringer Ingelheim International GmBh14-

Mar-

13

12-

Mar

-14

28-

Oct-

14

US8871782Alkoxy substituted imidazoquinolines3M Innovative Properties Company3-

Oct-

03

1-

Oct

-04

28-

Oct-

14

US8871503ConstructIsis Innovation Limited28-

Mar-

06

28-

Mar

-07

28-

Oct-

14

US8871487Compositions, methods and uses for inducing viral growthTakeda Vaccines, Inc.5-

Dec-

08

4-

Dec

-09

28-

Oct-

14

US8871442Enhanced deposition of chromogensVentana Medical Systems, Inc.30-

Dec-

10

28-

Dec

-11

28-

Oct-

14

US8865865N-terminally modified tetrapeptide derivatives having a C-terminal arginine mimeticPhilipps-Universitat Marburg29-

Oct-

08

29-

Oct

-09

21-

Oct-

14

US8865166Antibodies to IL-17A and uses thereofMedImmune Limited23-

Jun-

06

22-

Jun

-07

21-

Oct-

14

US8859568Pyrrolo[3,2-D]pyrimidin-4-one derivatives and their use in therapyAstrazeneca AB6-

Dec-

04

3-

Nov

-10

14-

Oct-

14

US8859251Oligoadenylate synthetase (OAS)Kineta Two, LLC23-

Nov-

05

1-

Jul-

13

14-

Oct-

14

US8858958Adjuvant comprising aluminum, oligonucleotide and polycationNovartis AG27-

Aug-

09

27-

Aug

-10

14-

Oct-

14

US8858957GAS57 mutant antigens and GAS57 antibodiesNovartis AG12-

Sep-

07

14-

Mar

-13

14-

Oct-

14

US8854617Compounds and markers for surface-enhanced Raman scatteringJulius-Maximilians-Universitat Wurzburg24-

Sep-

07

24-

Sep

-08

7-

Oct-

14

US8853382Expression of antibody or a fragment thereof in lactobacillusHera Pharmaceuticals, Inc.5-

Aug-

10

4-

Aug

-11

7-

Oct-

14

US8846710Method of preferentially inducing the biosynthesis of interferon3M Innovative Properties Company23-

Feb-

05

22-

Feb

-06

30-

Sep

-14

US8846697Purine analogsThe Regents of the University of California31-

May-

06

23-

Apr

-07

30-

Sep

-14

US8846643Phosphonates with reduced toxicity for treatment of viral infectionsThe Regents of the University of California14-

Apr-

10

11-

Oct

-12

30-

Sep

-14

US8846051Modulation of replicative fitness by deoptimization of synonymous codonsThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention8-

Oct-

04

7-

Oct

-05

30-

Sep

-14

US8841100Use of methylsulfonylmethane (MSM) to modulate microbial activityBiogenic Innovations, LLC30-

Oct-

09

16-

Feb

-11

23-

Sep

-14

US8840899Use of mTOR inhibitors to enhance T cell immune responsesEmory University5-

Aug-

08

5-

Aug

-09

23-

Sep

-14

US8840890Rapid expression cloning of human monoclonal antibodies from memory B cellsUniversity of Maryland, Baltimore12-

Nov-

08

12-

Nov

-09

23-

Sep

-14

US8840873Method of treating second and third degree burns using oxidative reductive potential water solutionOculus Innovative Sciences, Inc.23-

Mar-

05

23-

Mar

-06

23-

Sep

-14

US8840774Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrodeBoard of Regents of the University of Texas System3-

Jun-

05

28-

Oct

-13

23-

Sep

-14

US8835107Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnosticsAmsterdam Institute of Viral Genomics B.V.18-

Aug-

03

26-

Jul-

10

16-

Sep

-14

 

US8834445Methods of treating or preventing peritonitis with oxidative reductive potential water solutionOculus Innovative Sciences, Inc.20-

Jan-

06

30-

Mar

-12

16-

Sep

-14

US8828962SiRNA compositions and methods for potently inhibiting viral infectionXiangxue Group (Hong Kong) Company Limited11-

Dec-

08

12-

Dec

-11

9-

Sep

-14

US8828956Carbohydrate conjugates as delivery agents for oligonucleotidesAlnylam Pharmaceuticals, Inc.4-

Dec-

07

4-

Dec

-12

9-

Sep

-14

US8828940Method of treating an ischemia-reperfusion injury-related disorder by administering GPCR ligandsCompugen Ltd.18-

Sep-

06

14-

Dec

-10

9-

Sep

-14

US8828929Cytotoxic T cell epitope peptide for SARS coronavirus, and use thereofJapan as Represented by Director-General of National Institute of Infectious Diseases28-

Nov-

08

27-

Nov

-09

9-

Sep

-14

US8828673Mixed cell diagnostic systems for detection of respiratory, herpes and enteric virusesDiagnostic Hybrids Inc24-

Apr-

98

1-

Mar

-12

9-

Sep

-14

US8828659Method for producing nucleic acid probesVentana Medical Systems, Inc.1-

Sep-

06

11-

Mar

-13

9-

Sep

-14

US8828407Chimaeric proteinThe Pirbright Institute7-Jul-

09

5-

Jul-

10

9-

Sep

-14

US8828406Influenza viruses and uses thereofIcahn School of Medicine at Mount Sinai30-

Jul-09

29-

Jul-

10

9-

Sep

-14

US8822512Crystalline tripeptide epoxy ketone protease inhibitorsOnyx Therapeutics, Inc.20-

Mar-

09

20-

Sep

-11

2-

Sep

-14

US8822409Compositions and uses thereof for the treatment of acute respiratory distress syndrome (ARDS) and clinical disorders associated with therewithPhylogica Limited20-

Jun-

07

20-

Jun

-08

2-

Sep

-14

US8821897Viral adjuvantsThe University of North Carolina at Chapel Hill9-Jul-

04

24-

Nov

-10

2-

Sep

-14

US8816089Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activityMasatoshi Hagiwara26-

Dec-

03

19-

Nov

-12

26-

Aug

-14

US8816053Methods for treating viral infection using IL-28 and IL-29 cysteine mutantsZymoGenetics, Inc.2-

Apr-

04

7-

Sep

-12

26-

Aug

-14

US8815837Respiratory disease treatmentPulmagen Therapeutics (Inflammation) Limited7-

Aug-

08

29-

Jun

-12

26-

Aug

-14

US8815831Treatment of Acinetobacter with alginate oligomers and antibioticsAlgipharma AS3-

Jun-

09

3-

Jun

-10

26-

Aug

-14

US8815611Surface for label independent detection and method thereofCorning Incorporated10-

Apr-

08

3-

Apr

-09

26-

Aug

-14

US8815249Ii-key/antigenic epitope hybrid peptide vaccinesAntigen Express, Inc.4-

Sep-

99

26-

Jul-

10

26-

Aug

-14

US8815244Method for production of antibody using ostrichJapan Science and Technology Agency29-

Aug-

05

16-

Aug

-11

26-

Aug

-14

US8809377Deubiquitinase inhibitors and methods for use of the sameThe Regents of the University of Michigan24-

Sep-

10

23-

Sep

-11

19-

Aug

-14

US8808703Compounds (cystein based lipopeptides) and compositions as TLR2 agonists used for treating infections, inflammations, respiratory diseases etcNot Available23-

Mar-

10

23-

Mar

-11

19-

Aug

-14

US8808686Adjuvant-sparing multi-dose influenza vaccination regimenNovartis AG15-

Jun-

06

19-

Sep

-11

19-

Aug

-14

US8802853Arylalkenyl and arylalkynyl substituted imidazoquinolines3M Innovative Properties Company29-

Dec-

03

17-

Dec

-04

12-

Aug

-14

US8802647Materials and methods for prevention and treatment of RNA viral diseasesUniversity of South Florida30-

Apr-

02

17-

Sep

-12

12-

Aug

-14

US8802106Peptide compositions and methods for inhibiting herpesvirus infectionThe Administrators of the Tulane Educational Fund30-

Oct-

09

29-

Oct

-10

12-

Aug

-14

US8796423Anti-TSG101 antibodies and their uses for treatment of viral infectionsEli Lilly and Company15-

Nov-

06

18-

Apr

-08

5-

Aug

-14

US8790655Conjugates of synthetic TLR agonists and uses thereforThe Regents of The University of California7-

Feb-

07

8-

Jan

-13

29-

Jul-

14

US8785408Compositions and methods for reducing or protecting against delayed graft function (DGF)Quark Pharmaceuticals, Inc.27-

Jun-

07

26-

Jun

-08

22-

Jul-

14

US8785375Cyclic antimicrobial peptides for treating bacterial infectionsNovabiotics Ltd.22-

Dec-

05

22-

Aug

-12

22-

Jul-

14

 

US8784900Antimicrobial solutions containing dichlorine monoxide and methods of making and using the sameOculus Innovative Sciences, Inc.13-

Mar-

07

13-

Mar

-08

22-

Jul-

14

US8779132Pharmaceutical compoundsAstex Therapeutics Limited12-

Oct-

06

12-

Oct

-07

15-

Jul-

14

US8778963Hydroxylamine and oxime substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines3M Innovative Properties Company25-

Nov-

03

24-

Nov

-04

15-

Jul-

14

US8778846Composition, device and associated methodGeneral Electric Company4-

Dec-

06

1-

Mar

-07

15-

Jul-

14

US8778845Composition, device and associated methodGenral Electric Company15-

Dec-

05

1-

Mar

-07

15-

Jul-

14

US8778358Immunogenic compositions for gram positive bacteria such as Streptococcus agalactiaeNovartis Vaccines and Diagnostics, Inc.29-

Jul-04

18-

Oct

-10

15-

Jul-

14

US8778275Methods for producing vaccine adjuvantsNovartis AG3-

Dec-

09

3-

Dec

-10

15-

Jul-

14

US8772471Targeted delivery of siRNAImmune Disease Institute26-

Jan-

07

25-

Jan

-08

8-

Jul-

14

US8765939Pyrimidline derivatives having immune modulating properties that act via TLR7 for the treatment of viral or allergic diseases and cancersAstraZeneca AB22-

Nov-

07

16-

Aug

-12

1-

Jul-

14

US8765704Modified small interfering RNA molecules and methods of useNovartis AG28-

Feb-

08

14-

Dec

-11

1-

Jul-

14

US8765643Composition, device and associated methodGeneral Electric Company4-

Dec-

06

1-

Mar

-07

1-

Jul-

14

US8765146Adenoviral vector-based malaria vaccinesGenVec, Inc.31-

Aug-

05

31-

Aug

-06

1-

Jul-

14

US8765138Antiviral and antibacterial activity from medicinal mushroomsNot Available6-

Jan-

04

24-

Sep

-08

1-

Jul-

14

US8765133Method of producing anti-CD166 antibody in ostrichJapan Science and Technology Agency29-

Aug-

05

16-

Aug

-11

1-

Jul-

14

US8759307Oligonucleotide compound and method for treating nidovirus infectionsSarepta Therapeutics, Inc.24-

Dec-

03

25-

Apr

-08

24-

Jun-

14

US8758763Archaeal polar lipid aggregates for administration to animalsNational Research Council of Canada15-

Dec-

06

23-

Jan

-13

24-

Jun-

14

US8758680Method and device for cleaning airNot Available29-

Sep-

10

27-

Sep

-11

24-

Jun-

14

US8754071Compounds and compositions as c-kit kinase inhibitorsNot Available1-

Sep-

11

19-

Sep

-13

17-

Jun-

14

US8754015Modified phage for displaying post-translationally modified proteins and uses thereofUniversity of Rochester21-

Nov-

06

20-

Nov

-07

17-

Jun-

14

US8748567Method for delivery across the blood brain barrierChildren’s Medical Center Corporation22-

May-

06

22-

May

-07

10-

Jun-

14

US8748464Use of SIRT1 activators or inhibitors to modulate an immune responseThe J. David Gladstone Institutes7-

Feb-

08

16-

Jul-

10

10-

Jun-

14

US8748405Methods and compositions for the treatment of cancer or other diseasesCity of Hope26-

Jan-

07

9-

Sep

-11

10-

Jun-

14

US8748156Animal protein-free media for cultivation of cellsBaxter Healthcare SA29-

Oct-

04

16-

Apr

-13

10-

Jun-

14

US8741813Composition, device and associated methodGeneral Electric Company15-

Dec-

05

28-

Feb

-07

3-

Jun-

14

US8741653Single recombination system and methods of useEmergent Product Development GmbH22-

Dec-

08

16-

Dec

-09

3-

Jun-

14

US8741604Nucleic acid molecule encoding a specific IL-1R1 antibodyMedimmune Limited7-

Nov-

08

14-

Sep

-12

3-

Jun-

14

US8741564Quantitative nuclease protection assay (QNPA) and sequencing (QNPS) improvementsHTG Molecular Diagnostics, Inc.4-

May-

11

26-

Apr

-12

3-

Jun-

14

US8741311Methods and compositions for immunization against virusAcademia Sinica27-

Mar-

09

26-

Mar

-10

3-

Jun-

14

US8735567Multi-targeted RNAi therapeutics for scarless wound healing of skinNot Available6-

Nov-

07

6-

Nov

-08

27-

May

-14

US8735559Mutant protease biosensors with enhanced detection characteristicsPromega Corporation11-

May-

10

11-

May

-11

27-

May

-14

 

US8735421Imidazoquinolinyl sulfonamides3M Innovative Properties Company30-

Dec-

03

23-

Dec

-04

27-

May

-14

US8735410Quinazoline derivatives as tyrosine kinase inhibitorsAstraZeneca AB26-

Feb-

05

24-

Feb

-06

27-

May

-14

US8735348Casein derived peptides and uses thereofPeptera Ltd.1-

Mar-

00

5-

Sep

-12

27-

May

-14

US8734823Device including altered microorganisms, and methods and systems of useThe Invention Science Fund I, LLC14-

Dec-

05

28-

May

-10

27-

May

-14

US8728793Amphipathic alpha-helical peptide compositions as antiviral agentsThe Board of Trustees of the Leland Stanford Junior University19-

Jul-07

14-

Jul-

08

20-

May

-14

US8722917Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

23-

Jan

-12

13-

May

-14

US8722741Biphenyloxyacetic acid derivatives for the treatment of respiratory diseaseAstraZeneca AB24-

Aug-

04

6-

Dec

-11

13-

May

-14

US8722725Caffeoylquinic acid derivatives containing nitrogen, and preparation method, pharmaceutical composition and usage thereofZhejiang Medicine Co., Ltd. Xinchang Pharmaceutical Factory23-

Mar-

07

21-

Mar

-08

13-

May

-14

US8718948Systems and methods for distinguishing optical signals of different modulation frequencies in an optical signal detectorGen-Probe Incorporated24-

Feb-

11

24-

Feb

-12

6-

May

-14

US8716464Compositions and methods for silencing Ebola virus gene expressionNot Available20-

Jul-09

20-

Jul-

10

6-

May

-14

US8716461Human parvovirusBlood Systems, Inc.24-

May-

04

24-

May

-05

6-

May

-14

US8710224Heterocyclic compounds as CCR2B antagonistsAstraZeneca AB24-

Dec-

04

13-

Sep

-13

29-

Apr-

14

US8709730Methods of preventing and treating viral infections by inhibiting the deISGylation activity of OTU domain-containing viral proteinsIcahn School of Medicine at Mount Sinai5-

Apr-

07

7-

Apr

-08

29-

Apr-

14

US8709496Use of deuterium oxide for the treatment of virus-based diseases of the respiratory tractD2 Bioscience Group Ltd.6-

Jan-

10

23-

May

-12

29-

Apr-

14

US8709447Compositions and methods for activating innate and allergic immunityID Biomedical Corporation of Quebec22-

Oct-

03

26-

Apr

-12

29-

Apr-

14

US8709441TC-83-derived alphavirus vectors, particles and methodsAlphavax, Inc.18-

May-

04

6-

Jul-

10

29-

Apr-

14

US8704169Direct impact ionization (DII) mass spectrometryThe United States of America, as represented by the Secretary, Department of Health and Human Services11-

Oct-

11

11-

Oct

-11

22-

Apr-

14

US8703748Cleaning composition for treating tissue for transplantation derived from human/animalCG BIO Co., Ltd.11-

Feb-

09

10-

Feb

-10

22-

Apr-

14

US8703467Inactivation of a pathogen in a sample by a treatment with formalin and UV lightBaxter Healthcare SA27-

May-

04

26-

May

-05

22-

Apr-

14

US8702958Electrochemistry and electrogenerated chemiluminescence with a single faradaic electrodeBoard of Regents of the University of Texas System3-

Jun-

05

31-

May

-12

22-

Apr-

14

US8697873Amide substituted imidazopyridines, imidazoquinolines, and imidazonaphthyridines3M Innovative Properties Company24-

Mar-

04

24-

Mar

-05

15-

Apr-

14

US8697853TAL effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

10-

Jan

-13

15-

Apr-

14

US8697659Analogues of glycolipids useful as immunoadjuvantsLuigi Panza12-

Oct-

07

10-

Oct

-08

15-

Apr-

14

US8697140Virucidal disinfectantB. Braun Medical AG28-

Jan-

05

28-

May

-09

15-

Apr-

14

US8697088VLPs derived from cells that do not express a viral matrix or core proteinNovavax, Inc.25-

May-

07

27-

May

-08

15-

Apr-

14

US8697087Influenza vaccines including combinations of particulate adjuvants and immunopotentiatorsNovartis AG4-

Nov-

05

6-

Nov

-06

15-

Apr-

14

US8691837Substituted imidazo ring systems and methods3M Innovative Properties Company25-

Nov-

03

24-

Nov

-04

8-

Apr-

14

US8691826CompoundsChiesi Farmaceutici S.p.A.14-

Sep-

11

13-

Sep

-12

8-

Apr-

14

US8691781Compositions for treating respiratory viral infections and their useSirnaomics, Inc.5-

Nov-

04

4-

Nov

-05

8-

Apr-

14

 

US8691777Combination therapyEmory University27-

Jan-

11

25-

Jan

-12

8-

Apr-

14

US86861524,4-disubstituted piperidine derivatives useful as inhibitors of dipeptidyl peptidase-1 (DPP-1)Janssen Pharmaceutica NV10-

Mar-

10

9-

Mar

-11

1-

Apr-

14

US8682619Device including altered microorganisms, and methods and systems of useThe Invention Science Fund I, LLC14-

Dec-

05

28-

May

-10

25-

Mar

-14

US8679839Cell line from rousettus as host cell for pathogen amplificationProbiogen AG4-

Mar-

08

4-

Mar

-09

25-

Mar

-14

US8678184Methods for producing vaccine adjuvantsNovartis AG3-

Dec-

09

3-

Dec

-10

25-

Mar

-14

US8678002Devices and methods for decreasing human pathogen transmissionFilligent Limited26-

Jun-

07

25-

Jun

-08

25-

Mar

-14

US8673983Melanins synthesized chemically or via enzyme catalysisLoyola University Chicago21-

Dec-

07

22-

Dec

-08

18-

Mar

-14

US8673932Oxime substituted imidazo-containing compounds3M Innovative Properties Company12-

Aug-

03

12-

Aug

-04

18-

Mar

-14

US8673907Pharmaceutically acceptable salts of methyl (3-{ [[3-(6-amino- 2- butoxy-8-oxo-7,8-dihydro-9H-purin-9-yl) propyl] (3-morpholin-4- ylpropyl) amino] methyl }phenyl) acetate and their use in therapyAstraZeneca AB17-

Dec-

07

16-

Dec

-08

18-

Mar

-14

US8673904Epoxide inhibitors of cysteine proteasesThe Board of Trustees of the Leland Stanford Junior University13-

Jun-

06

13-

Jun

-07

18-

Mar

-14

US8673558Luciferase biosensorPromega Corporation10-

Oct-

03

24-

Apr

-12

18-

Mar

-14

US8673331Composition with sterilizing activity against bacteria, fungus and viruses, application thereof and method for preparation thereofGP&E18-

Nov-

11

18-

Nov

-11

18-

Mar

-14

US8669263Use of TAM receptor inhibitors as antimicrobialsSalk Institute for Biological Studies9-

Nov-

07

8-

Mar

-13

11-

Mar

-14

US86692623,5-diamino-6-chloro-N-(N-(4-(4-(2-(hexyl(2,3,4,5,6-

pentahydroxyhexyl)amino)ethoxy)phenyl)butyl)carbamimidoyl)pyra

zine-2-carboxamide

Parion Sciences, Inc.27-

Jun-

11

26-

Jun

-12

11-

Mar

-14

US8669240Biological specimen collection and transport system and method of useLonghorn Vaccines & Diagnostics, LLC1-

Oct-

07

19-

Mar

-13

11-

Mar

-14

US8664274Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena virusesSiga Technologies, Inc.6-

Dec-

04

6-

Jul-

11

4-

Mar

-14

US8664218Pharmaceutical compoundsAstex Therapeutics Ltd.11-

Apr-

08

30-

Jan

-13

4-

Mar

-14

US8664188siRNA compositions and methods for potently inhibiting viral infectionXiangxue Group (Hong Kong) Company Limited11-

Dec-

08

11-

Dec

-09

4-

Mar

-14

US8663922Systems and methods for detecting multiple optical signalsGen-Probe Incorporated10-

Mar-

05

1-

Jun

-10

4-

Mar

-14

US8658767Lipidated polyepitope vaccinesNational Health Research Institutes15-

Nov-

10

15-

Nov

-11

25-

Feb

-14

US8658697Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenavirusesSiga Technologies, Inc.6-

Dec-

04

26-

Oct

-10

25-

Feb

-14

US8658666Substituted imidazoquinolines and imidazonaphthyridines3M Innovative Properties Company11-

Feb-

05

10-

Feb

-06

25-

Feb

-14

US8658178Carbon nanotube compositions and methods of use thereofYale University19-

Mar-

08

19-

Mar

-09

25-

Feb

-14

US8653252Short interfering RNA (siRNA) analoguesSantaris Pharma A/S21-

Mar-

03

22-

Mar

-04

18-

Feb

-14

US8653084Hydrobenzamide derivatives as inhibitors of Hsp90Astex Therapeutics Ltd.12-

Oct-

06

12-

Oct

-07

18-

Feb

-14

US8653034Compositions and methods comprising phosphatidylethanolamine­binding peptide derivativesBoard of Regents, The University of Texas System15-

Jul-02

8-

May

-08

18-

Feb

-14

US8652836Defective ribosomal products in blebs (DRibbles) and methods of use to stimulate an immune responseProvidence Health System29-

Jul-05

27-

Jul-

06

18-

Feb

-14

 

US8652782Compositions and methods for detecting, identifying and quantitating mycobacterial-specific nucleic acidsLonghorn Vaccines & Diagnostics, LLC12-

Sep-

06

26-

Apr

-11

18-

Feb

-14

US8652533Durable biocides and disinfectantsMitsui Norin Co., Ltd.7-Jul-

04

5-

Jul-

05

18-

Feb

-14

US8648076Cysteine protease inhibitors and their therapeutic applicationsHybrigenics SA5-

Aug-

05

26-

Jul-

06

11-

Feb

-14

US8647676Antimicrobial composition from copepodsNofima Ingrediens28-

Oct-

08

28-

Oct

-09

11-

Feb

-14

US8642596Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arena virusesSiga Technologies, Inc.6-

Dec-

04

6-

Dec

-05

4-

Feb

-14

US8642260Single quantum-dot based aptameric nanosensorsThe Research Foundation of the City University of New York21-

Oct-

08

21-

Oct

-09

4-

Feb

-14

US8633322Alkynyl derivatives useful as DPP-1 inhibitorsJanssen Pharmaceutica NV29-

Oct-

09

28-

Oct

-10

21-

Jan-

14

US8633308Compounds for preventing or treating viral infections and methods of use thereofThe Governors of The University of Alberta28-

Feb-

07

27-

Feb

-08

21-

Jan-

14

US8632764Directed evolution and in vivo panning of virus vectorsUniversity of North Carolina at Chapel Hill30-

Apr-

08

29-

Apr

-09

21-

Jan-

14

US8629283Compounds that modulate negative-sense, single-stranded RNA virus replication and uses thereofIcahn School of Medicine at Mount Sinai6-

Mar-

08

6-

Mar

-09

14-

Jan-

14

US8629271CompoundsAstraZeneca AB6-

Feb-

08

2-

Apr

-12

14-

Jan-

14

US8629098Compositions and methods for adoptive and active immunotherapyYale University15-

Jan-

08

14-

Jan

-09

14-

Jan-

14

US8628786Polychlorinated biphenyls and squalene-containing adjuvantsNovartis AG28-

Dec-

07

2-

Dec

-11

14-

Jan-

14

US8624011Vaccines and immunotherapeutics comprising IL-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the sameThe Trustees of the University of Pennsylvania14-

Sep-

09

14-

Sep

-10

7-

Jan-

14

US8623419Technology for preparation of macromolecular microspheresAnsun Biopharma, Inc.24-

Jan-

06

4-

Nov

-11

7-

Jan-

14

US8623382Immunogenic compositions for inducing an immune response to HIVWyeth LLC17-

Jun-

04

18-

Jan

-11

7-

Jan-

14

US8623364Antigenic GM-CSF peptides and antibodies to GM-CSFMorphotek, Inc.8-

Feb-

06

24-

Oct

-12

7-

Jan-

14

US8617838Fluorescent proteins and related methods and compoundsUniversity of Massachusetts20-

Sep-

04

20-

Sep

-05

31-

Dec

-13

US8615368Method for determining the amount of an analyte in a sampleGen-Probe Incorporated10-

Mar-

05

10-

Mar

-06

24-

Dec

-13

US8609370Highly active glycoproteins-process conditions and an efficient method for their productionGlycotope GmbH13-

Feb-

04

14-

Feb

-05

17-

Dec

-13

US8609101Granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralizing antibodiesTheraclone Sciences, Inc.23-

Apr-

09

23-

Apr

-10

17-

Dec

-13

US8604215Crystalline tripeptide epoxy ketone protease inhibitorsOnyx Therapeutics, Inc.20-

Mar-

09

22-

Mar

-10

10-

Dec

-13

US8603469Methods of treating cancer with human monoclonal antibodies against interleukin 8Genmab A/S16-

Dec-

02

27-

Dec

-11

10-

Dec

-13

US8599383Optical cytometryThe Regents of the University of California6-

May-

09

6-

May

-09

3-

Dec

-13

US8598192Hydroxylamine substituted imidazoquinolines3M Innovative Properties Company14-

Nov-

03

12-

Nov

-04

3-

Dec

-13

US8598134RNAi modulation of RSV, PIV and other respiratory viruses and uses thereofSouth Alabama Medical Science Foundation22-

Oct-

04

23-

Jul-

10

3-

Dec

-13

US8598116Treatment of influenza virus infectionEducational Fund and Autoimmune Technologies, LLC4-

Nov-

03

29-

May

-12

3-

Dec

-13

US8598106Anti-microbial composition exhibiting residual anti-microbial properties on a surfaceByotrol PLC17-

Sep-

07

5-

Jul-

11

3-

Dec

-13

US8597650Methods for treating rheumatoid arthritis with anti-bile salt- stimulated lipase (BSSL) antibodiesHERNELL OLLE8-

Apr-

09

6-

Apr

-10

3-

Dec

-13

 

US8592567Vaccines and immunotherapeutics using codon-optimized IL-15 and methods for using the sameThe Trustees of the University of Pennsylvania13-

Jan-

06

3-

May

-12

26-

Nov

-13

US8592391Method for therapeutic, clinical and veterinary use poly-ICLCSALAZAR ANDRES1-Jul-

03

17-

Oct

-08

26-

Nov

-13

US8586770Unsaturated steroid compoundsHarbor Therapeutics, Inc.29-

Sep-

04

18-

Feb

-11

19-

Nov

-13

US8586364Cells and methodology to generate non-segmented negative-strand RNA virusesInstitut Pasteur22-

Dec-

06

21-

Dec

-07

19-

Nov

-13

US8586363TAL effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

10-

Dec

-10

19-

Nov

-13

US8581584Membrane proteins, mechanisms of action and uses thereofFlorida State University Research Foundation26-

May-

10

26-

May

-11

12-

Nov

-13

US8580927Engineered antibody constant domain moleculesThe United States of America, as represented by the Secretary, Department of Health and Human Services31-

Jan-

08

30-

Jan

-09

12-

Nov

-13

US8580268CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activityColey Pharmaceutical GmbH27-

Sep-

06

27-

Sep

-07

12-

Nov

-13

US8569283Compounds and compositions as c-Kit kinase inhibitorsLIU XIAODONG1-

Sep-

11

29-

Aug

-12

29-

Oct-

13

US8562996RSV-specific binding molecules and means for producing themMedImmune Limited1-

Jun-

07

30-

May

-08

22-

Oct-

13

US8562943Quality control methods for oil-in-water emulsions containing squaleneNovartis AG8-

Nov-

06

6-

Nov

-07

22-

Oct-

13

US8560339System and method to predict the global spread of infectious agents via commercial air travelKamran Khan2-

Apr-

07

2-

Apr

-08

15-

Oct-

13

US8557767Synthetic apolipoprotein E mimicking polypeptides and methods of useUAB Research Foundation28-

Aug-

07

27-

Aug

-08

15-

Oct-

13

US8557248Methods and compositions for treating malariaCyvax, Inc.9-

Aug-

10

9-

Aug

-11

15-

Oct-

13

US8552051Use of pharmaceutical compositions containing mesembrenoneH. L. Hall & Sons Limited20-

Mar-

09

16-

Mar

-10

8-

Oct-

13

US8552032Bicyclic derivatives useful as inhibitors of DPP-1Janssen Pharmaceutica NV18-

Dec-

09

16-

Dec

-10

8-

Oct-

13

US8551968Methods for generation of antibodiesNational Jewish Health13-

Mar-

07

13-

Mar

-08

8-

Oct-

13

US8551756Avian influenza chimeric VLPSNovavax, Inc.11-

Jul-03

19-

Jan

-10

8-

Oct-

13

US8551750Device including bone cage and method for treatment of disease in a subjectThe Invention Science Fund I, LLC23-

Apr-

09

28-

Jul-

09

8-

Oct-

13

US8551749Device including bone cage and method for treatment of disease in a subjectThe Invention Science Fund I, LLC23-

Apr-

09

23-

Apr

-09

8-

Oct-

13

US8551738Systems and methods for rapid identification of nucleic acid variantsIbis Biosciences, Inc.21-

Jul-05

11-

Nov

-09

8-

Oct-

13

US8551469Treatment of tumors and viral diseases with recombinant interferon alphaSuperlab Far East Limited28-

Feb-

01

6-

Oct

-08

8-

Oct-

13

US8546432Tetrazolones as inhibitors of fatty acid synthaseInfinity Pharmaceuticals, Inc.5-

May-

10

5-

May

-11

1-

Oct-

13

US8546383Chiral fused [1,2]imidazo[4,5-c] ring compounds3M Innovative Properties Company30-

Dec-

04

25-

May

-12

1-

Oct-

13

US8546082Methods for identification of sepsis-causing bacteriaIbis Biosciences, Inc.11-

Sep-

03

25-

May

-07

1-

Oct-

13

US8541568Compositions and methods using siRNA molecules for treatment of gliomasBIGNER DARELL D24-

May-

08

26-

May

-09

24-

Sep

-13

US8541457Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitorsXenon Pharmaceuticals Inc.3-

Jun-

05

5-

Jun

-06

24-

Sep

-13

US8541438Substituted imidazoquinolines, imidazopyridines, and imidazonaphthyridines3M Innovative Properties Company18-

Jun-

04

21-

Dec

-10

24-

Sep

-13

US8541221Primate T-lymphotropic virusesJohns Hopkins University21-

Feb-

05

1-

Jul-

10

24-

Sep

-13

US8541003Vectors expressing SARS immunogens, compositions containing such vectors or expression products thereof, methods and assays for making and usingProtein Sciences Corporation20-

Jun-

03

21-

Jun

-04

24-

Sep

-13

 

US8529968Decontaminating composition having simultaneously bactericidal, fungicidal and virocidal properties, methods for obtaining and using said compositionHightech Bio-Activities Holding GmbH29-

Mar-

04

29-

Mar

-05

10-

Sep

-13

US8524715Phenoxyacetic acid derivatives useful for treating respiratory diseasesAstrazeneca AB23-

Nov-

04

22-

Nov

-05

3-

Sep

-13

US8524488Methods and devices for determining a cell characteristic, and applications employing the sameThe Regents of the University of California10-

Sep-

02

9-

Mar

-05

3-

Sep

-13

US8524241Fusion proteins comprising a fragment of Vibrio cholerae exotoxin AThe General Hospital Corporation20-

Jul-07

18-

Jul-

08

3-

Sep

-13

US8519106Monoclonal human tumor-specific antibodyUniversity of Zurich13-

Mar-

07

13-

Mar

-08

27-

Aug

-13

US8507545Cytotoxic T cell activator comprising EP4 agonistNational University Corporation, Hamamatsu University School of Medicine8-

May-

07

7-

May

-08

13-

Aug

-13

US8507544Bi-aryl amide compounds as CRTh2 receptor modulatorsAstrazeneca AB5-Jul-

07

3-

Jul-

08

13-

Aug

-13

US8507455Folate conjugatesAlnylam Pharmaceuticals, Inc.4-

Dec-

07

4-

Dec

-08

13-

Aug

-13

US8506968SARS vaccine compositions and methods of making and using themEli Lilly and Company29-

Jun-

00

28-

Dec

-09

13-

Aug

-13

US8506966Adjuvanted influenza vaccines for pediatric useNovartis AG22-

Feb-

08

20-

Feb

-09

13-

Aug

-13

US8501746Organic compoundsNovartis AG5-

Jun-

06

4-

Jun

-07

6-

Aug

-13

US8501699Bicyclic nucleosides and nucleotides as therapeutic agentsBiota Scientific Management Pty Ltd3-Jul-

08

7-

Sep

-12

6-

Aug

-13

US8501461System for performing multi-formatted assaysGen-Probe Incorporated10-

Mar-

05

3-

Dec

-09

6-

Aug

-13

US8497405Process for dispersing vaporous hydrogen peroxideSTERIS Inc.6-

Mar-

07

28-

Feb

-13

30-

Jul-

13

US8497112Method for producing viral vaccinesBaxter Healthcare SA28-

Aug-

07

28-

Aug

-08

30-

Jul-

13

US8494781Systems and methods for identifying replikin scaffolds and uses of said replikin scaffoldsBOGOCH ELENORE S6-

Jun-

03

10-

Dec

-10

23-

Jul-

13

US8492329Bioactive peptides and methods of using sameCompugen Ltd.12-

Jul-07

11-

Jul-

08

23-

Jul-

13

US8486959Dibenzo[f,h]isoquinoline derivativesNational Health Research Institutes14-

Jan-

10

14-

Jan

-11

16-

Jul-

13

US8486678Pharmaceutical compositions for the treatment of virus infectionKineta Two, LLC23-

Nov-

05

1-

Feb

-12

16-

Jul-

13

US8486619Arrayed imaging reflectometry (air) sensor chip comprising influenza hemagglutinin (HA) polypeptides suitable for the detection of antiviral immune responsesUniversity of Rochester2-

May-

08

1-

May

-09

16-

Jul-

13

US8486420Live virus vaccinesChildren’s Hospital, Inc.15-

Feb-

05

15-

Feb

-06

16-

Jul-

13

US8481547Substituted benzothiazole and benzoxazole derivatives useful as inhibitors of DPP-1Janssen Pharmaceutica NV18-

Dec-

09

16-

Dec

-10

9-

Jul-

13

US8481270Method for chromogenic detection of two or more target molecules in a single sampleVentana Medical Systems, Inc.22-

Aug-

08

21-

Aug

-09

9-

Jul-

13

US8481255Scytovirin domain 1 related polypeptidesThe United States of America, as represented by the Secretary, Department of Health and Human Services25-

May-

05

30-

Sep

-11

9-

Jul-

13

US8476292Amide and carbamate derivatives of N-{2-[4-amino-2- (ethoxymethyl)-1H-imidazo[4,5-c] quinolin-1-Yl]-1,1-

dimethylethyl}methanesulfonamide and methods

3M Innovative Properties Company9-

Sep-

05

8-

Sep

-06

2-

Jul-

13

US8476288Salts 756AstraZeneca AB21-

May-

09

20-

May

-10

2-

Jul-

13

US8476265Compounds-801AstraZeneca AB30-

Jul-10

14-

Sep

-12

2-

Jul-

13

US8470771Method and medicament for inhibiting the infection of influenza virusInstitute of Microbiology, Chinese Academy of Sciences14-

Nov-

07

18-

Dec

-07

25-

Jun-

13

US8470769Method of treatment of bacterial infection by administration of poly­lysineNovabiotics, Ltd.18-

Aug-

04

30-

Nov

-11

25-

Jun-

13

 

US8470346Anti-viral pharmaceutical compositionsMast Therapeutics, Inc.10-

Dec-

03

19-

May

-11

25-

Jun-

13

US8470335Recombinant SARS-CoV nsp12 and the use of thereof and the method for producing itIndustry-Academic Cooperation Foundation, Yonsei University Kookmin University Industry Academy Cooperation Foundation13-

Jun-

08

13-

Jun

-08

25-

Jun-

13

US8466284Some 2-pyrazinone derivatives and their use as inhibitors of neutrophile elastaseAstra Zeneca AB6-

Nov-

07

5-

Nov

-08

18-

Jun-

13

US8466167Compounds and compositions as TLR activity modulatorsIRM LLC3-

Mar-

08

27-

Feb

-09

18-

Jun-

13

US8466124RNA sequence motifs in the context of defined internucleotide linkages inducing specific immune modulatory profilesColey Pharmaceutical GmbH13-

Aug-

07

12-

Jun

-12

18-

Jun-

13

US8465751Cna—B domain antigens in vaccines against gram positive bacteriaNovartis AG12-

Jan-

09

12-

Jan

-10

18-

Jun-

13

US8461125Compositions and methods to treat asthmaThe Children’s Hospital of Philadelphia14-

Feb-

08

13-

Aug

-10

11-

Jun-

13

US8460914Decreasing potential iatrogenic risks associated with vaccines and vaccine antigensNovartis AG9-

Sep-

04

10-

Jan

-13

11-

Jun-

13

US8460605Decontaminant dispenser suitable for use as a projectileSTERIS Inc.6-

Mar-

07

20-

Feb

-08

11-

Jun-

13

US8455483Compounds—801AstraZeneca AB31-

Jul-09

30-

Jul-

10

4-

Jun-

13

US8450471TAL effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

22-

Mar

-12

28-

May

-13

US8450467Carbohydrate conjugates as delivery agents for oligonucleotidesAlnylam Pharmaceuticals, Inc.4-

Dec-

07

14-

Dec

-11

28-

May

-13

US8450350Triazoles as inhibitors of fatty acid synthaseInfinity Pharmaceuticals, Inc.5-

May-

10

5-

May

-11

28-

May

-13

US8450284Coiled-coil lipopeptide helical bundles and synthetic virus-like particlesUniversitaet Zuerich9-

Dec-

06

6-

Dec

-07

28-

May

-13

US8450055Malaria antigen screening methodThe United States of America as Represented by the Secretary of the Navy31-

Aug-

05

25-

Aug

-06

28-

May

-13

US8445650Mutant botulinum neurotoxin serotype A polypeptide and uses thereofThomas Jefferson University25-

Sep-

07

25-

Sep

-08

21-

May

-13

US8445447B7-DC variants immunogenic compositions and methods of use thereofThe Johns Hopkins University13-

Jul-07

7-

Mar

-12

21-

May

-13

US8444961RNA virus infection inhibitor, method for inhibition of infection by RNA virus, RNA virus infection-inhibiting product, and use as RNA virus infection inhibitorSekisui Chemical Co., Ltd.16-

Jun-

09

16-

Jun

-10

21-

May

-13

US8440704Quercetin-containing compositionsQuercegen Pharmaceuticals LLC17-

Jul-06

16-

Dec

-09

14-

May

-13

US8440649Phenanthroindolizidine analoguesNational Health Research Institutes24-

Feb-

09

11-

Feb

-10

14-

May

-13

US8440642Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

1-

Sep

-11

14-

May

-13

US8440432Tal effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

22-

Mar

-12

14-

May

-13

US8440431TAL effector-mediated DNA modificationIowa State University Research Foundation, Inc.10-

Dec-

09

22-

Mar

-12

14-

May

-13

US8440408Animal protein-free media for cultivation of cellsBaxter Healthcare S.A.29-

Oct-

04

10-

Dec

-10

14-

May

-13

US8436178Imidazoquinolines with immuno-modulating propertiesAstraZeneca AB8-

May-

07

6-

May

-08

7-

May

-13

US84360242-pyridone compoundsAstrazeneca AB2-

Oct-

09

1-

Oct

-10

7-

May

-13

US8431160Microparticles containing biodegradable polymer and cationic polysaccharide for use in immunogenic compositionsNovartis AG24-

Feb-

06

24-

Feb

-07

30-

Apr-

13

US8431134Use of a pneumococcal P4 peptide for enhancing opsonophagocytosis in response to a pathogenThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention31-

Jul-08

31-

Jul-

09

30-

Apr-

13

US8426565Dendritic cell marker and uses thereofWalter and Eliza Hall Institute of Medical Research30-

Aug-

07

29-

Aug

-08

23-

Apr-

13

US8420798Method for producing nucleic acid probesVentana Medical Systems, Inc.1-

Sep-

06

31-

Aug

-07

16-

Apr-

13

 

US8420784Interleukin 10 receptor, (IL-10R) antibodiesKyowa Hakko Kirin Co., Ltd.27-

May-

08

27-

May

-09

16-

Apr-

13

US8420096Cell-penetrating SOCS polypeptides that inhibit cytokine-induced signalingVanderbilt University4-

Mar-

04

4-

Mar

-05

16-

Apr-

13

US8420094Fusion proteins comprising a fragment of Vibrio cholerae exotoxin AThe General Hospital Corporation20-

Jul-07

18-

Jul-

08

16-

Apr-

13

US8415394Biphenyloxyacetic acid derivatives for the treatment of respiratory diseaseAstrazeneca AB6-

Oct-

05

21-

Dec

-11

9-

Apr-

13

US8415361Use of TAM receptor inhibitors as antimicrobialsThe Salk Institute for Biological Studies9-

Nov-

07

7-

Nov

-08

9-

Apr-

13

US8415330Biological specimen collection and transport system and method of useLonghorn Vaccines & Diagnostics, LLC1-

Oct-

07

1-

Oct

-12

9-

Apr-

13

US8415309Bicyclic nucleosides and nucleotides as therapeutic agentsBiota Scientific Managment Pty Ltd1-Jul-

09

11-

Jan

-12

9-

Apr-

13

US8415118Porcine DC-SIGN, ICAM-3 and LSECtin and uses thereofVirginia Tech Intellectual Properties, Inc.29-

Oct-

07

29-

Oct

-08

9-

Apr-

13

US8415102Methods and computer systems for identifying target-specific sequences for use in nanoreportersNanoString Technologies, Inc.10-

Apr-

07

10-

Apr

-08

9-

Apr-

13

US8410149Sulfonyl semicarbazides, semicarbazides and ureas, pharmaceutical compositions thereof, and methods for treating hemorrhagic fever viruses, including infections associated with arenavirusesSiga Technologies Inc.6-

Dec-

04

28-

Oct

-10

2-

Apr-

13

US84101142-pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficialAstraZeneca AB8-

May-

06

6-

Jan

-12

2-

Apr-

13

US8409589Mutant forms of streptolysin ONovartis AG21-

Dec-

07

14-

Sep

-11

2-

Apr-

13

US8399651Nucleic acids encoding GAS57 mutant antigensNovartis AG12-

Sep-

07

10-

Sep

-12

19-

Mar

-13

US8398992Methods and compositions for polytopic vaccinationPolytopos LLC29-

Apr-

05

22-

Dec

-11

19-

Mar

-13

US8394986Phenoxiacetic acid derivativesAstraZeneca AB21-

Aug-

03

26-

Jul-

11

12-

Mar

-13

US8394945Compositions for use in identification of bacteriaIbis Biosciences, Inc.11-

Sep-

03

7-

Mar

-07

12-

Mar

-13

US8394386Sequential delivery of immunogenic molecules via adenovirus and adeno-associated virus-mediated administrationsThe Trustees of the University of Pennsylvania28-

Apr-

04

27-

Apr

-05

12-

Mar

-13

US7829712Pyridazine derivatives for inhibiting human stearoyl-CoA-desaturaseXenon Pharmaceuticals Inc.20-

Sep-

04

20-

Sep

-05

9-

Nov

-10

US7829707Pyrrolo [3,2-d]pyrimidin-4-one derivatives and their use in therapyAstraZeneca AB6-

Dec-

04

5-

Dec

-05

9-

Nov

-10

US7829302Method for detecting the specificity of activated lymphocyteHU JUN8-

Dec-

03

7-

Dec

-04

9-

Nov

-10

US7820210Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancersInhalation, Inc.3-

Apr-

00

18-

Mar

-08

26-

Oct-

10

US7812135GITR-binding antibodiesTOLERRX, Inc.25-

Mar-

05

27-

Mar

-06

12-

Oct-

10

US7803918Coronavirus, nucleic acid, protein, and methods for the generation of vaccine, medicaments and diagnosticsAmsterdam Institute of Viral Genomics B.V.18-

Aug-

03

18-

Aug

-04

28-

Sep

-10

US7803796Homopiperazine compounds that inhibit ribosomal frameshifting by binding to RNA pseudoknot structure of SARS coronavirusSungkyunkwan University Foundation For Corporate Collaboration22-

Dec-

06

20-

Dec

-07

28-

Sep

-10

US7803765Methods of constructing biodiverse gene fragment libraries and biological modulators isolated therefromPhylogica Limited20-

Feb-

04

20-

Feb

-04

28-

Sep

-10

US7799800Lipid-modified immune response modifiers3M Innovative Properties Company30-

Oct-

03

12-

Aug

-04

21-

Sep

-10

US7794998Primate T-lymphotropic virusesJohns Hopkins University21-

Feb-

05

24-

Feb

-07

14-

Sep

-10

US7794659Signal measuring system having a movable signal measuring deviceGen-Probe Incorporated10-

Mar-

05

10-

Mar

-06

14-

Sep

-10

US7790878RNAi modulation of RSV, PIV and other respiratory viruses and uses thereofAlnylam Pharmaceuticals, Inc.22-

Oct-

04

25-

Jun

-09

7-

Sep

-10

 

US7790449Adeno-associated virus (AAV) serotype 8 sequences, vectors containing the same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

6-

Sep

-07

7-

Sep

-10

US7790159Methods, combinations and kits for treating viral infections using immunoconjugates and antibodies to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

7-

Sep

-10

US7786290Double-stranded ribonucleic acid with increased effectiveness in an organismAlnylam Pharmaceuticals, Inc.13-

Jun-

03

14-

Jun

-04

31-

Aug

-10

US7785775Human virus causing severe acute respiratory syndrome (SARS) and uses thereofVersitech Limited24-

Mar-

03

8-

Jun

-07

31-

Aug

-10

US7785612Polyamino acid for use as adjuvantMasanori Baba20-

Apr-

05

19-

Apr

-06

31-

Aug

-10

US7781226Particle on membrane assay systemThe Board of Regents of the University of Texas System27-

Feb-

04

22-

Dec

-04

24-

Aug

-10

US7781203Supports for assaying analytes and methods of making and using thereofCorning Incorporated29-

Dec-

05

7-

Jun

-06

24-

Aug

-10

US7777036Heterocyclic derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.20-

Sep-

04

20-

Sep

-05

17-

Aug

-10

US7777022Bioinformatically detectable group of novel regulatory viral and viral associated oligonucleotides and uses thereofRosetta Genomics, Ltd.26-

Nov-

02

26-

May

-04

17-

Aug

-10

US7776521Coronavirus isolated from humansThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention25-

Apr-

03

14-

May

-07

17-

Aug

-10

US7767817Water soluble boronic acid fluorescent reporter compounds and methods of use thereofFANG HAO5-

Sep-

03

7-

Sep

-04

3-

Aug

-10

US7767677Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitorsXenon Pharmaceuticals Inc.20-

Sep-

04

20-

Sep

-05

3-

Aug

-10

US7767658Vaccine compositionAventis Pasteur SA17-

Nov-

03

9-

Jan

-08

3-

Aug

-10

US7767657Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

16-

Aug

-06

3-

Aug

-10

US7767210RNA virus vaccines and methodsThe Board of Regents of the University of Oklahoma14-

Dec-

05

14-

Dec

-06

3-

Aug

-10

US7763618Pyridyl derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.29-

Jul-03

29-

Jul-

04

27-

Jul-

10

US7758868Modified polymerases and attenuated viruses and methods of use thereofThe Penn State Research Foundation22-

Dec-

06

24-

Dec

-07

20-

Jul-

10

US7754711Pyridazine derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.30-

Jul-03

9-

Feb

-05

13-

Jul-

10

US7750123Antibodies against SARS-CoV and methods of use thereofDana Farber Cancer Institute, Inc.25-

Nov-

03

24-

Nov

-04

6-

Jul-

10

US7749445Method and apparatus for analyzing bioprocess fluidsBioScale, Inc.2-

May-

05

19-

Dec

-06

6-

Jul-

10

US7745486Quercetin-containing compositionsQuercegen Pharma LLC17-

Jul-06

16-

Jul-

07

29-

Jun-

10

US7745442Methods of reducing risk of infection from pathogensParion Sciences, Inc.20-

Aug-

03

18-

Aug

-04

29-

Jun-

10

US7745147Methods and uses of antibodies in the purification of interferonViraNative AB12-

Feb-

05

13-

Feb

-06

29-

Jun-

10

US7745119System for detecting polynucleotidesInvestigen, Inc.20-

May-

03

21-

Nov

-05

29-

Jun-

10

US7745118Comparative genomic resequencingRoche Nimblegen, Inc.8-

Apr-

04

8-

Apr

-05

29-

Jun-

10

US7741450Antibodies to GM-CSFMorphotek Inc.8-

Feb-

06

8-

Feb

-07

22-

Jun-

10

US7741360Bi-aryl or aryl-heteroaryl substituted indolesAstraZeneca AB26-

May-

06

25-

May

-07

22-

Jun-

10

US7740858SARS-CoV-specific B-cell epitope and applications thereofNational Taiwan University21-

Sep-

04

21-

Sep

-04

22-

Jun-

10

US7737135Biphenyloxyacetic acid derivatives for the treatment of respiratory diseaseAstraZeneca AB24-

Aug-

04

22-

Aug

-05

15-

Jun-

10

US7736850Strain of SARS-associated coronavirus and applications thereofCentre National de la Recherche Scientifique2-

Dec-

03

2-

Dec

-04

15-

Jun-

10

 

US7732177Oligoadenylate Synthetase (OAS)Illumigen Biosciences, Inc.23-

Nov-

05

17-

Nov

-06

8-

Jun-

10

US7731978Mutant forms of streptolysin ONovartis AG21-

Dec-

07

19-

Dec

-08

8-

Jun-

10

US7728110Antibodies to SARS coronavirusAmgen, Inc.19-

May-

06

21-

May

-07

1-

Jun-

10

US7725565System and method for detecting, collecting, analyzing, and communicating event related informationGeorgetown University25-

Feb-

08

19-

Nov

-08

25-

May

-10

US7723570Edible vaccines expressed in soybeansSoyMeds, Inc.12-

Oct-

04

12-

Oct

-05

25-

May

-10

US7723041Assay for SARS coronavirus by amplification and detection of the replicase sequenceBecton, Dickinson and Company12-

Sep-

03

3-

Feb

-09

25-

May

-10

US7722886Compositions and methods for treatment of severe acute respiratory syndrome (SARS)Wyeth20-

May-

04

20-

May

-04

25-

May

-10

US7714109Combinations and kits for cancer treatment using selected antibodies to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

11-

May

-10

US7713515Methods and compositions for use in diagnosing and characterizing diseases involving abnormal apoptosisR.E.D. Laboratories N.V.27-

May-

03

26-

May

-04

11-

May

-10

US7709521Substituted indole derivatives for pharmaceutical compositions for treating respiratory diseasesAstraZeneca AB18-

Aug-

03

16-

Aug

-04

4-

May

-10

US7709511Benzothiazolone derivativesAstraZeneca AB9-

Aug-

05

3-

Aug

-06

4-

May

-10

US7709188Multi-allelic detection of SARS-associated coronavirusBirch Biomedical Research LLC22-

Aug-

03

13-

Aug

-04

4-

May

-10

US7700782Compounds 569AstraZeneca AB19-

Dec-

07

19-

Dec

-07

20-

Apr-

10

US7700728Use of chimeric receptors in a screening assay for identifying agonists and antagonists of cell receptorsSchering Corporation24-

Mar-

05

24-

Mar

-06

20-

Apr-

10

US7700727Compositions and kits for detecting pathogen infectionBiokit, S.A.23-

Dec-

03

27-

Apr

-05

20-

Apr-

10

US7700273Peptidomimetics that mimic a conformational-dependent neutralizing epitope of the human immunodeficiency virus (HIV) CCR5 coreceptorThe United States of America as represented by the Department of Health and Human Services9-

Apr-

04

11-

Apr

-05

20-

Apr-

10

US7700120Adjuvancy and immune potentiating properties of natural products of Onchocerca volvulusNew York Blood Center15-

Jun-

04

15-

Jun

-05

20-

Apr-

10

US7696406Expression of a recombinant transgeneBoard of Trustees Operating Michigan State University3-Jul-

03

2-

Jul-

04

13-

Apr-

10

US7696330Binding molecules against SARS-coronavirus and uses thereofCrucell Holland B.V.22-

Jul-03

20-

Jan

-06

13-

Apr-

10

US7691877PharmaceuticalsPfizer Inc.17-

Feb-

06

16-

Feb

-07

6-

Apr-

10

US7691646Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereofDaikin Industries, Ltd.28-

Mar-

03

21-

Nov

-08

6-

Apr-

10

US7691599Mammalian genes involved in viral infection and tumor suppressionZirus, Inc.2-

May-

02

2-

May

-03

6-

Apr-

10

US7691390Viral proteinCHANG MING-FU2-

Mar-

04

19-

Sep

-07

6-

Apr-

10

US7687535Substituted 3-sulfur indolesAstraZeneca AB27-

May-

03

25-

May

-04

30-

Mar

-10

US7687475RNA interference in respiratory epithelial cellsUniversity of Iowa Research Foundation9-Jul-

04

16-

Oct

-07

30-

Mar

-10

US7682688Microporous materials, methods, and articles for localizing and quantifying analytesUniversity of Utah Research Foundation26-

Nov-

02

20-

Nov

-03

23-

Mar

-10

US7678774Treating severe acute respiratory syndromeHemispherx Biopharma16-

May-

03

26-

Jan

-07

16-

Mar

-10

US7678386Liposomes coated with selected antibodies that bind to aminophospholipidsBoard of Regents the University of Texas15-

Jul-02

15-

Aug

-03

16-

Mar

-10

US7674795Fluorene derivatives, composition containing said derivatives and the use thereofAventis Pharma SA19-

May-

05

14-

Nov

-07

9-

Mar

-10

 

US7670807RNA-dependent DNA polymerase from Geobacillus stea rothermophilusEast Tennessee State Univ. Research Foundation10-

Mar-

04

10-

Mar

-04

2-

Mar

-10

US7670565Building decontamination with vaporous hydrogen peroxideSteris Inc31-

Jan-

03

3-

Mar

-08

2-

Mar

-10

US7666996Casein derived peptides and uses thereofPeptera Pharmaceuticals Ltd1-

Mar-

00

1-

Mar

-04

23-

Feb

-10

US7666592Methods for concurrent identification and quantification of an unknown bioagentIbis Biosciences, Inc.18-

Feb-

04

17-

Feb

-05

23-

Feb

-10

US76628603D-structure model of SARS coronavirus 3CL protease and anti- SARS drugsShanghai Institute of Materia Medica, Chinese Academy of Sciences4-

Jun-

03

2-

Dec

-05

16-

Feb

-10

US7648997Hydroxylamine substituted imidazoquinolinesColey Pharmaceutical Group, Inc.12-

Aug-

03

12-

Aug

-04

19-

Jan-

10

US7648844Method and apparatus for detection of analyte using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

19-

Jan-

10

US7645881Methods for treating hepatitis CPTC Therapeutics, Inc.22-

Jul-04

14-

Jul-

05

12-

Jan-

10

US7642350Purine derivativesPfizer Limited4-

May-

05

3-

May

-06

5-

Jan-

10

US7636637Variable length probe selectionRoche NimbleGen, Inc.18-

Jun-

04

20-

Jun

-05

22-

Dec

-09

US7635557Enzymatic diagnostic test for SARS and other viral diseasesMND Diagnostic Ltd.23-

Jun-

03

23-

Jun

-04

22-

Dec

-09

US7635485Method of accelerated vaccination against Ebola virusesThe United States of America as represented by the Department of Health and Human Services1-

Aug-

03

17-

Jan

-06

22-

Dec

-09

US7632638Methods and apparatus for detecting viruses using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

15-

Dec

-09

US7629443Neutralizing monoclonal antibodies against severe acute respiratory syndrome-associated coronavirusNew York Blood Center, Inc.2-

Jun-

04

8-

Feb

-06

8-

Dec

-09

US7629385Sphingolipid-derived pharmaceutical compositionsJado Technologies GmbH29-

Jun-

04

29-

Jun

-05

8-

Dec

-09

US7629137Methods and apparatus for detecting bacteria using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

8-

Dec

-09

US7629114Method of collecting nasopharyngeal cells and secretions for diagnosis of viral upper respiratory infections and screening for nasopharyngeal cancerWorld Sense Technology Limited26-

Aug-

03

20-

Aug

-04

8-

Dec

-09

US7625563Cancer treatment methods using selected immunoconjugates for binding to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

1-

Dec

-09

US7625492Charge-based water filtration systemsThe University of Wyoming Research Corporation28-

Jan-

03

28-

Jan

-04

1-

Dec

-09

US7625428Bioagent air filtration systemsThe University of Wyoming Research Corporation28-

Jan-

03

28-

Jan

-04

1-

Dec

-09

US7623997Computer-implemented biological sequence identifier system and methodThe United States of America as represented by the Secretary of the Navy2-Jul-

04

6-

Jun

-06

24-

Nov

-09

US7622559Human monoclonal antibodies against interleukin 8 (IL-8)Genmab A/S16-

Dec-

02

27-

Jun

-07

24-

Nov

-09

US7622125Polycistronic HIV vector constructsNovartis Vaccines and Diagnostics, Inc.5-

May-

04

5-

May

-05

24-

Nov

-09

US7622118Cancer treatment methods using selected antibodies to a minophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

24-

Nov

-09

US7622112Anti-SARS monoclonal antibodiesNot Available5-

Dec-

03

6-

Dec

-04

24-

Nov

-09

US7619067Evolved interferon-alpha polypeptidesMaxygen, Inc.18-

May-

05

17-

May

-06

17-

Nov

-09

US7618802Compositions of coronaviruses with a recombination-resistant genomeThe University of North Carolina at Chapel Hill21-

Jul-03

19-

Jan

-06

17-

Nov

-09

US7618788Proteome epitope tags and methods of use thereof in protein modification analysisMillipore Corporation10-

May-

02

5-

Feb

-04

17-

Nov

-09

US7618635Super-antigen fusion proteins and the use thereofHealthbanks Biotech Co., Ltd.21-

Jul-04

19-

Jul-

05

17-

Nov

-09

US7615381Method and apparatus for detecting estradiol and metabolites thereof using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

10-

Nov

-09

 

US7615223Selected immunoconjugates for binding to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

10-

Nov

-09

US7611908Method and apparatus for therapeutic drug monitoring using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

3-

Nov

-09

US7611704Compositions and methods for treating viral infections using antibodies and immunoconjugates to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

3-

Nov

-09

US7605161Pyridyl derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.30-

Jul-03

29-

Jul-

04

20-

Oct-

09

US7605135Baicalin as a treatment for SARS infectionThe University of Hong Kong10-

Nov-

03

8-

Nov

-04

20-

Oct-

09

US7604960Transient protein expression methodsCrucell Holland B.V.15-

Apr-

99

1-

Jun

-07

20-

Oct-

09

US7604801Methods for detecting parvovirus infectionsThe Research Foundation of State University of New York5-

May-

03

16-

Oct

-08

20-

Oct-

09

US7598382Aryl substituted imidazoquinolinesColey Pharmaceutical Group, Inc.20-

Dec-

02

13-

Jan

-06

6-

Oct-

09

US7598094Methods and apparatus for detecting cardiac injury markers using an acoustic deviceBioScale, Inc.2-

May-

05

2-

May

-06

6-

Oct-

09

US7598072Assay to detect viral uncoatingWisconsin Alumni Research Foundation9-

Dec-

03

8-

Dec

-04

6-

Oct-

09

US7597936Method of producing a pigmented composite microporous materialUniversity of Utah Research Foundation26-

Nov-

02

26-

May

-04

6-

Oct-

09

US7595381Method for detecting SARS coronavirusEiken Kagaku Kabushiki Kaisha27-

Jun-

03

10-

Jun

-08

29-

Sep

-09

US7595163Method for detecting SARS coronavirusEiken Kagaku Kabushiki Kaisha27-

Jun-

03

10-

Jun

-08

29-

Sep

-09

US7592343Pyridazine-piperazine compounds and their use as stearoyl-CoA desaturase inhibitorsXenon Pharmaceuticals Inc.20-

Sep-

04

20-

Sep

-05

22-

Sep

-09

US7592322RNAi modulation of RSV, PIV and other respiratory viruses and uses thereofAlnylam Pharmaceuticals, Inc.22-

Oct-

04

14-

Jun

-05

22-

Sep

-09

US7592008Membrane scaffold proteinsThe Board of Trustees of the University of Illinois, a body corporate and politic of the State of Illinois20-

Nov-

00

11-

Jan

-05

22-

Sep

-09

US7589092Prodrugs of heteroaryl compoundsKoronis Pharmaceuticals, Incorporated20-

Jun-

03

27-

Dec

-06

15-

Sep

-09

US7585647Nucleic acid encoding recombinant interferonWEI GUANGWEN28-

Aug-

03

26-

Aug

-04

8-

Sep

-09

US7582740Methods and kits for detecting SARS-associated coronavirusThe Trustees of Columbia University In the City of New York17-

Apr-

03

23-

Jan

-04

1-

Sep

-09

US7582621Boron-containing small moleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

16-

Feb

-06

1-

Sep

-09

US7579396Polymer compositeEastman Kodak Company31-

Jan-

07

31-

Jan

-07

25-

Aug

-09

US75793591-alkoxy lH-imidazo ring systems and methods3M Innovative Properties Company2-

Sep-

04

1-

Sep

-05

25-

Aug

-09

US7572621Detection, characterization and treatment of viral infection and methods thereofCanadian Blood Services9-

Apr-

03

11-

Oct

-05

11-

Aug

-09

US7572448Combined cancer treatment methods using selected antibodies to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

11-

Aug

-09

US7572442Selected antibody compositions for binding to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Jul-

03

11-

Aug

-09

US7569536Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activityMasatoshi Hagiwara26-

Dec-

03

24-

Dec

-04

4-

Aug

-09

US7569384Albumin fusion proteinsHuman Genome Sciences, Inc.9-

Feb-

04

8-

Aug

-06

4-

Aug

-09

US7550140Antibody to the human OX40 receptorCrucell Holland B.V.13-

Jun-

02

13-

Jun

-03

23-

Jun-

09

US7547698Bicyclic heterocyclic derivatives and their use as inhibitors of stearoyl-coadesaturase (SCD)Xenon Pharmaceuticals Inc.20-

Sep-

04

20-

Sep

-05

16-

Jun-

09

US7547516Method for reducing the presence of amplification inhibitors in a reaction receptacleGen-Probe Incorporated10-

Mar-

05

10-

Mar

-06

16-

Jun-

09

 

US7547512High-throughput diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)The University of Hong Kong24-

Mar-

03

24-

Mar

-04

16-

Jun-

09

US7544697Pyrazolopyridines and analogs thereofColey Pharmaceutical Group, Inc.3-

Oct-

03

1-

Apr

-05

9-

Jun-

09

US7541436Interferon-alpha polypeptides and conjugatesMaxygen, Inc.19-

May-

04

4-

May

-07

2-

Jun-

09

US7541163Interferon-alpha polypeptides and conjugatesMaxygen, Inc.19-

May-

04

14-

Aug

-07

2-

Jun-

09

US7531630Interferon-alpha polypeptides and conjugatesMaxygen, Inc.19-

May-

04

13-

Sep

-06

12-

May

-09

US7531324Interferon-alpha polypeptides and conjugatesMaxygen, Inc.19-

May-

04

13-

Sep

-06

12-

May

-09

US7521424Albumin fusion proteinsHuman Genome Sciences, Inc.22-

Jan-

03

7-

Jul-

05

21-

Apr-

09

US7521185Assay for SARS coronavirus by amplification and detection of the replicase sequenceBecton, Dickinson and Company12-

Sep-

03

13-

Sep

-04

21-

Apr-

09

US7514436Pyridazine derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.30-

Jul-03

29-

Jul-

04

7-

Apr-

09

US7511124Compositions comprising phosphatidylethanolamine-binding peptides linked to anti-viral agentsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

31-

Mar

-09

US7504384Use of lipid conjugates in the treatment of infectionYissum Research Development Company of the Hebrew University of Jerusalem10-

Jan-

00

8-

Sep

-05

17-

Mar

-09

US7504382Protease inhibitors for coronaviruses and SARS-CoV and the use thereofCytovia, Inc.6-

May-

03

6-

May

-04

17-

Mar

-09

US7504205Uncharacterized ORF3 in SARS-coronavirus is a cyclic-AMP- dependent kinase and a target for SARS therapyThe Burnham Institute17-

May-

04

17-

May

-05

17-

Mar

-09

US7504097Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

30-

Oct

-06

17-

Mar

-09

US7498409Screening assay for TLR7, TLR8 and TLR9 agonists and antagonistsSchering Corporation24-

Mar-

05

23-

Mar

-06

3-

Mar

-09

US7498152Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

30-

Oct

-06

3-

Mar

-09

US7495011Anti-coronavirus drugaRigen Pharmaceuticals, Inc.15-

Jul-03

14-

Jul-

04

24-

Feb

-09

US7491793Influenza virus inhibiting peptidesThe Administrators of the Tulane Educational Fund4-

Nov-

03

3-

Nov

-04

17-

Feb

-09

US7491706Artificial cpg single-stranded oligodeoxynucleotide and antiviral use thereofChangchun Huapu Biotechnology Co., Ltd.25-

Jul-03

26-

Jul-

04

17-

Feb

-09

US7491508Methods of generating chimeric adenoviruses and uses for such chimeric adenovirusesThe Trustees of the University of Pennsylvania20-

Jun-

03

15-

Jun

-04

17-

Feb

-09

US7491489Synthetic peptide targeting critical sites on the SARS-associated coronavirus spike protein responsible for viral infection and method of use thereofThe University of Hong Knog22-

Nov-

04

28-

Oct

-05

17-

Feb

-09

US7491397Receptor binding polypeptidesNational Health Research Institutes9-

Jan-

04

10-

Jan

-05

17-

Feb

-09

US7488801Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7488589Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7488473Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

30-

Oct

-06

10-

Feb

-09

US7485432Selective modulation of TLR-mediated biological activity3M Innovative Properties Company27-

Feb-

03

27-

Feb

-04

3-

Feb

-09

US7482334Therapeutic treatment methodsHollis-Eden Pharmaceuticals, Inc.28-

Aug-

02

12-

Feb

-07

27-

Jan-

09

US7482149Inhibition of SARS coronavirus infection with clinically approved antiviral drugsGenome Institute of Singapore9-

Jun-

03

9-

Jun

-04

27-

Jan-

09

US7479484Peptides and peptidomimetics having immune-modulating, anti­inflammatory, and anti-viral activityTakeda Pharmaceutical Company Limited25-

Jun-

03

25-

Jun

-04

20-

Jan-

09

US7470666Use of Ulinastatin and its pharmaceutical composition for treating severe acute respiratory syndromeGuangdong Techpool Biochem. Pharma. Co., Ltd.26-

May-

03

25-

May

-04

30-

Dec

-08

 

US7470548Hazardous substance removing method, hazardous substance removing material used therein such as air filter, mask, wipe sheet, and the like, and storage method thereofDaikin Industries, Ltd.28-

Mar-

03

26-

Mar

-04

30-

Dec

-08

US7468418Compositions for enhancing transport of molecules into cellsAVI BioPharma., Inc.29-

Apr-

03

29-

Apr

-04

23-

Dec

-08

US7465836Hydrolytically-resistant boron-containing therapeutics and methods of useAnacor Pharmaceuticals, Inc.16-

Jun-

03

15-

Jun

-04

16-

Dec

-08

US7462615Inhibitors of cysteine proteases, the pharmaceutical compositions thereof and their therapeutic applicationsHybrigenics SA8-

Dec-

05

8-

Dec

-05

9-

Dec

-08

US7460960Proteome epitope tags and methods of use thereof in protein modification analysisEpitome Biosystems, Inc.10-

May-

02

13-

Nov

-03

2-

Dec

-08

US7456180Piperazine derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.30-

Jul-03

29-

Jul-

04

25-

Nov

-08

US7455833Methods and compositions for treating viral infections using antibodies and immunoconjugates to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

25-

Nov

-08

US7452542Live attenuated coronavirus vaccinesVanderbilt University21-

May-

04

23-

May

-05

18-

Nov

-08

US7445889Methods for detecting parvovirus infectionsThe Research Foundation of State University of New York5-

May-

03

5-

May

-04

4-

Nov

-08

US7442761Replikin peptides and uses thereofBOGOCH ELENORE S6-

Jun-

03

4-

Jun

-04

28-

Oct-

08

US7442508Methods for detection and production of influenza virusesDiagnostic Hybrids, Inc.24-

Apr-

98

28-

Apr

-06

28-

Oct-

08

US7439349Method for preparation of large volume batches of poly-ICLC with increased biological potency; therapeutic, clinical and veterinary uses thereofNot Available3-Jul-

02

1-

Jul-

03

21-

Oct-

08

US7439052Method of making modified immunodeficiency virus particlesLipid Sciences29-

Jun-

00

10-

Apr

-06

21-

Oct-

08

US7435588Systems for detection and production of respiratory, herpes and enteric virusesDiagnostic Hybrids, Inc.20-

Sep-

05

28-

Apr

-06

14-

Oct-

08

US7435538High throughput screening method of drug for physiologically active proteinCellFree Sciences Co., Ltd.8-

Sep-

03

8-

Sep

-04

14-

Oct-

08

US7432045Method of inhibiting influenza infection with antiviral peptidesWisconsin Alumni Research Foundation1-

Dec-

03

1-

Dec

-04

7-

Oct-

08

US7429656Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interferenceThe University of Hong Kong19-

May-

03

14-

Jun

-06

30-

Sep

-08

US7427479Methods and kits for identifying target nucleotides in mixed populationsApplera Corporation30-

Apr-

04

29-

Apr

-05

23-

Sep

-08

US7424370Computational method for identifying adhesin and adhesin-like proteins of therapeutic potentialCouncil of Scientific and Industrial Research20-

Jul-04

7-

Feb

-05

9-

Sep

-08

US7407663Modified immunodeficiency virus particlesLipid Sciences, Inc.29-

Jun-

00

20-

Jun

-03

5-

Aug

-08

US7407662Modified viral particles with immunogenic properties and reduced lipid contentLipid Sciences, Inc.29-

Jun-

00

21-

Jun

-04

5-

Aug

-08

US7405207Nebulizer formulations of dehydroepiandrosterone and methods of treating asthma or chronic obstructive pulmonary disease using compositions thereofEpigenesis Pharmaceuticals, Inc.17-

Jun-

02

17-

Jun

-03

29-

Jul-

08

US7405046Compositions and methods for treatment of rhinovirusThe Quigley Corporation6-

Aug-

01

27-

Oct

-06

29-

Jul-

08

US7399588Method for detecting SARS coronavirusEiken Kagaku Kabushiki Kaisha27-

Jun-

03

15-

Jun

-04

15-

Jul-

08

US7396914SARS nucleic acids, proteins, antibodies, and uses thereofUniversity of Massachusetts4-

Aug-

03

4-

Aug

-04

8-

Jul-

08

US7393856Anti-viral uses of borinic acid complexesAnacor Pharmaceuticals, Inc.14-

Jun-

04

14-

Jun

-05

1-

Jul-

08

US7393638Assay system and methods for detecting SARS-CVAsiaGEN Corporation1-Jul-

03

1-

Jul-

03

1-

Jul-

08

US7387271Immunostimulatory combinations3M Innovative Properties Company30-

Dec-

02

30-

Dec

-03

17-

Jun-

08

 

US7384909Anti-viral treatment methods using phosphatidylethanolamine­binding peptides linked to anti-viral agentsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

10-

Jun-

08

US7378386Anti-viral treatment methods using phosphatidylethanolamine­binding peptide derivativesBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

27-

May

-08

US7375210PCR primer set for detecting severe acute respiratory syndrome (SARS)-Coronavirus, method and kit for detecting SARS- Coronavirus using the sameSamsung Electronics Co., Ltd.12-

Dec-

03

24-

Nov

-04

20-

May

-08

US7375202Human virus causing severe acute respiratory syndrome (SARS) and uses thereofThe University of Hong Kong24-

Mar-

03

24-

Mar

-04

20-

May

-08

US7375180Methods and compositions related to IRM compounds and Toll-like receptor 83M Innovative Properties Company13-

Feb-

03

12-

Feb

-04

20-

May

-08

US7374883Method and kit for the detection of a novel coronoavirus associated with the severe acute respiratory syndrome (SARS)QIAGEN Diagnostics GmbH30-

Apr-

03

30-

Apr

-04

20-

May

-08

US7371850Method and composition for reducing expression of ROCK-IIMyriad Genetics, Inc.20-

Aug-

03

20-

Aug

-04

13-

May

-08

US7371837Human virus causing respiratory tract infection and uses thereofThe University of Hong Kong21-

Jul-04

16-

May

-05

13-

May

-08

US7371525Compositions and methods for diagnosing and treating severe acute respiratory syndrome (SARS)The Chinese University of Hong Kong29-

Jul-03

28-

Jul-

04

13-

May

-08

US7361747Isolation and characterization of the precursor virus of human SARS virus: SARS-associated corona virus-like virusThe University of Hong Kong22-

May-

03

24-

May

-04

22-

Apr-

08

US7361304Building decontamination with vaporous hydrogen peroxideSteris Inc.31-

Jan-

03

29-

Jan

-04

22-

Apr-

08

US7358068Antiviral oligonucleotidesReplicor, Inc.13-

Sep-

02

12-

Sep

-03

15-

Apr-

08

US7354908Materials and methods for prevention and treatment of RNA viral diseasesUniversity of South Florida30-

Apr-

02

30-

Apr

-03

8-

Apr-

08

US7354551Room decontamination with hydrogen peroxide vaporSteris Inc8-Jul-

04

8-

Jul-

04

8-

Apr-

08

US7344740Methods and apparatus to prevent, treat, and cure the symptoms of nausea caused by chemotherapy treatments of human cancersInhalation, Inc.3-

Apr-

00

27-

Nov

-04

18-

Mar

-08

US7344720Vaccine compositionSanofi Pasteur SA17-

Nov-

03

15-

Nov

-04

18-

Mar

-08

US7339051Compositions and methods for the treatment of severe acute respiratory syndrome (SARS)Isis Pharmaceuticals, Inc.28-

Apr-

03

26-

Apr

-04

4-

Mar

-08

US7335658Pyridazine derivatives and their use as therapeutic agentsXenon Pharmaceuticals Inc.30-

Jul-03

29-

Jul-

04

26-

Feb

-08

US7332475Preventive or therapeutic composition for viral infectious diseaseKyowa Hakko Kogyo Co., Ltd.22-

Jul-03

22-

Jul-

04

19-

Feb

-08

US7332294CXCL10-based diagnosis and treatment of respiratory illnessesUniversity Health Network17-

Aug-

04

17-

Aug

-04

19-

Feb

-08

US7320857Characterization of the earliest stages of the severe acute respiratory syndrome (SARS) virus and uses thereofChinese National Human Genome Center at Shanghai9-Jul-

04

9-

Jul-

04

22-

Jan-

08

US7318918Interferon-alpha polypeptides and conjugatesMaxygen, Inc.19-

May-

04

18-

May

-05

15-

Jan-

08

US7314613Interferon-alpha polypeptides and conjugatesMaxygen, Inc.18-

Nov-

02

19-

May

-04

1-

Jan-

08

US7312036Compositions for use in identification of viral hemorrhagic fever virusesISIS Pharmaceuticals, Inc.22-

Mar-

04

21-

Mar

-05

25-

Dec

-07

US7297786RNA interference in respiratory epitheial cellsUniversity of Iowa Research Foundation9-Jul-

04

11-

Jul-

05

20-

Nov

-07

US7291498Methods of generating chimeric adenoviruses and uses for such chimeric adenovirusesThe Trustees of the University of Pennsylvania20-

Jun-

03

20-

Jun

-03

6-

Nov

-07

US7282568Human monoclonal antibodies against interleukin 8 (IL-8)Genmab A/S16-

Dec-

02

16-

Dec

-03

16-

Oct-

07

US7282199Adeno-associated virus (AAV) serotype 8 sequences, vectors containing same, and uses thereforThe Trustees of the University of Pennsylvania17-

Dec-

01

25-

Apr

-03

16-

Oct-

07

US7267942Diagnostic assay for the human virus causing severe acute respiratory syndrome (SARS)The University of Hong Kong24-

Mar-

03

24-

Mar

-04

11-

Sep

-07

 

US7261867Production of silver sulfate grains using organo-sulfate or organo- sulfonate additivesEastman Kodak Company7-

Apr-

06

7-

Apr

-06

28-

Aug

-07

US7247303Selected antibody CDRs for binding to aminophospholipidsBoard of Regents, The University of Texas System15-

Jul-02

15-

Aug

-03

24-

Jul-

07

US7244732Prodrugs of heteroaryl compoundsKoronis Pharmaceuticals, Incorporated20-

Jun-

03

31-

Mar

-04

17-

Jul-

07

US7223787Prenylation inhibitors reduce host cell permissiveness to viral replicationBoard of Regents, The University of Texas System21-

Oct-

03

21-

Oct

-03

29-

May

-07

US7220852Coronavirus isolated from humansThe United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention25-

Apr-

03

12-

Apr

-04

22-

May

-07

US7183300Inhibitors of HIV-1 capsid formation: substituted aryl aminomethyl thiazole ureas and analogues thereofAGARWAL ATUL11-

Nov-

04

10-

Nov

-05

27-

Feb

-07

US7166435Compositions and methods for reducing the transmissivity of illnessesThe Quigley Corporation6-

Aug-

01

14-

Dec

-04

23-

Jan-

07

US71639471-Amino lH-imidazoquinolines3M Innovative Properties Company7-

Mar-

03

3-

Sep

-04

16-

Jan-

07

US7151163Antiviral agents for the treatment, control and prevention of infections by coronavirusesSequoia Pharmaceuticals, Inc.28-

Apr-

03

28-

Apr

-04

19-

Dec

-06

US7151091Compositions and methods for preventing infectionLa Jolla Biosciences LLC20-

Sep-

02

22-

Sep

-03

19-

Dec

-06

US7148248Method of treating or inhibiting the development of brain inflammation and sepsisNOZAKI MASAKO29-

Nov-

02

26-

Nov

-03

12-

Dec

-06

US7129223Inhibition of SARS-associated coronavirus (SCoV) infection and replication by RNA interferenceThe University of HongKong19-

May-

03

19-

May

-04

31-

Oct-

06

US7129042Compositions and methods for detecting severe acute respiratory syndrome coronavirusDiagnostic Hybrids, Inc.3-

Nov-

03

3-

Nov

-03

31-

Oct-

06

US7115563Composition and its therapeutic useInsignion Holding Limited29-

May-

02

29-

May

-03

3-

Oct-

06

US7091214Aryl substituted Imidazoquinolines3M Innovative Properties Co.20-

Dec-

02

18-

Dec

-03

15-

Aug

-06

US7048953Methods and apparatus to prevent, treat and cure infections of the human respiratory system by pathogens causing severe acute respiratory syndrome (SARS)Inhalation, Inc.3-

Apr-

00

2-

May

-03

23-

May

-06

US7023593Apparatus for forming nano-grating deviceIndustrial Technology Research Institute28-

Nov-

03

17-

Mar

-04

4-

Apr-

06

US6946291Mixed cell diagnostic systemsDiagnostic Hybrids, Inc.24-

Apr-

98

30-

Mar

-04

20-

Sep

-05

US20200176

079

METHODS AND DEVICES FOR NUCLEIC ACID-BASED REAL-TIME DETERMINATION OF DISEASE STATESNot Available19-

Jul-17

18-

Jul-

18

4-

Jun-

20

US20200173

925

MICROSCOPIC BODY ENCLOSING METHOD, MICROSCOPIC BODY DETECTION METHOD, AND MICROSCOPIC BODY DETECTION DEVICEJAPAN SCIENCE AND TECHNOLOGY AGENCY29-

Mar-

17

28-

Mar

-18

4-

Jun-

20

US20200172

883

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODSNot Available19-

Nov-

09

13-

Sep

-19

4-

Jun-

20

US20200172

879

DHFR TUNABLE PROTEIN REGULATIONNot Available3-

Mar-

17

2-

Sep

-19

4-

Jun-

20

US20200172

600

RSV F PROTEIN COMPOSITIONS AND METHOD FOR MAKING SAMEGLAXOSMITHKLINE BIOLOGICALS, SA15-

Jul-09

16-

Aug

-17

4-

Jun-

20

US20200172

513

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDSHoffmann-La Roche Inc.12-

Jun-

16

5-

Feb

-20

4-

Jun-

20

US20200172

480

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTSHANGZHOU DAC BIOTECH CO., LTD.12-

Jul-12

5-

Feb

-20

4-

Jun-

20

US20200171

085

Method of Treating Respiratory Tract InfectionNot Available19-

May-

17

18-

May

-18

4-

Jun-

20

US20200171

060

FLEX-NUCLEOSIDE ANALOGUES, NOVEL THERAPEUTICS AGAINST FILOVIRUSES AND FLAVIVIRUSESNot Available31-

Jul-17

26-

Jan

-18

4-

Jun-

20

US20200166

505

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETSThe U.S.A., as represented by the Secretary, Department of Health and Human Services1-

Sep-

15

30-

Jan

-20

28-

May

-20

US20200165

632

ENHANCING AGENTS FOR IMPROVED CELL TRANSFECTION AND/OR rAAV VECTOR PRODUCTIONSpark Therapeutics, Inc.7-

Jun-

17

6-

Jun

-18

28-

May

-20

 

US20200165

630

COMPOSITIONS FOR THE TREATMENT OF DISEASENot Available29-

Apr-

16

28-

Apr

-17

28-

May

-20

US20200165

613

VIRUS LIKE PARTICLEThe University of Leeds1-

Jun-

17

31-

May

-18

28-

May

-20

US20200165

594

CRISPR SYSTEM BASED ANTIVIRAL THERAPYMASSACHUSETTS INSTITUTE OF TECHNOLOGY7-Jul-

17

6-

Jul-

18

28-

May

-20

US20200165

585

NEW CHIMERIC ENZYMES AND THEIR APPLICATIONSNot Available27-

Jul-17

27-

Jul-

18

28-

May

-20

US20200165

357

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOFNot Available2-

Dec-

05

21-

Oct

-19

28-

May

-20

US20200164

334

MICROSPOTTING DEVICENot Available18-

Apr-

12

11-

Oct

-19

28-

May

-20

US20200164

067

Methods and Compositions for Inhibiting Akt3Not Available15-

Jan-

16

5-

Feb

-20

28-

May

-20

US20200164

058

TRIMERIC S1-CD40L FUSION PROTEIN VACCINE AGAINST MIDDLE EAST RESPIRATORY SYNDROME-CORONAVIRUSKing Abdulaziz University27-

Nov-

18

27-

Nov

-18

28-

May

-20

US20200164

020

PUM 1 PROTEIN AS TARGET FOR VIRUS INHIBITIONNot Available12-

Apr-

17

12-

Apr

-17

28-

May

-20

US20200163

878

LIPID NANOPARTICLE MRNA VACCINESNot Available26-

Oct-

16

26-

Oct

-17

28-

May

-20

US20200157

600

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATIONNot Available19-

Nov-

18

19-

Nov

-18

21-

May

-20

US20200157

222

ANTI-PD-L1 ANTIBODIES AND USES THEREOFNot Available29-

Mar-

18

29-

Mar

-19

21-

May

-20

US20200157

221

ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDESNot Available30-

Jun-

16

28-

Jan

-20

21-

May

-20

US20200155

704

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

30-

Jan

-20

21-

May

-20

US20200155

699

MODIFIED VIRUS-LIKE PARTICLES OF CMVNot Available22-

Oct-

14

26-

Nov

-19

21-

May

-20

US20200155

667

VACCINE COMPOSITIONSNot Available27-

Jul-17

24-

Jan

-20

21-

May

-20

US20200155

664

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENENot Available10-

Feb-

09

26-

Jun

-19

21-

May

-20

US20200155

662

COMBINATION IMMUNOTHERAPIES COMPRISING IL-15 SUPERAGONISTSNot Available26-

May-

17

25-

May

-18

21-

May

-20

US20200155

660

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERYNot Available23-

Sep-

15

22-

Nov

-19

21-

May

-20

US20200155

646

EV576 For Use in the Treatment of Viral Infections of the Respiratory TractVolution Immuno Pharmaceuticals SA8-

Jan-

10

7-

Jun

-19

21-

May

-20

US20200149

062

ENGINEERED TSC2Not Available14-

Jul-17

13-

Jul-

18

14-

May

-20

US20200149

048

Transbiotic Regulation of Bacterial Gene ExpressionNot Available22-

May-

17

22-

May

-18

14-

May

-20

US20200148

749

ANTIBODIES AND PROCESSES FOR PREPARING THE SAMENot Available16-

May-

08

10-

Oct

-19

14-

May

-20

US20200147

203

VACCINATION OF IMMUNOCOMPROMISED SUBJECTSNot Available26-

Sep-

14

10-

Jan

-20

14-

May

-20

US20200147

193

COMPOSITIONS AND METHODS FOR TUMOR VACCINATION AND IMMUNOTHERAPY INVOLVING HER ANTIGENSNot Available2-

Jun-

17

2-

Jun

-18

14-

May

-20

US20200147

171

COMPOSITIONS OF CRACC FUSIONS AND METHODS FOR MODULATING AN IMMUNE RESPONSE AGAINST CANCERS, INFECTIONS DISEASES AND DISORDERSNot Available18-

Sep-

18

18-

Sep

-19

14-

May

-20

US20200140

547

MULTIFUNCTIONAL ANTIBODY-LIGAND TRAPS TO MODULATE IMMUNE TOLERANCENot Available26-

May-

17

25-

May

-18

7-

May

-20

US20200140

493

Engineering Virus-like Nanocarriers for Biomolecule DeliveryNot Available26-

Oct-

18

25-

Oct

-19

7-

May

-20

US20200140

398

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTSAZIENDA OSPEDALIERA UNIVERSITARIA SENESE13-

Feb-

15

6-

Jan

-20

7-

May

-20

 

US20200138

937

Genetically Attenuated Nucleic Acid VaccineNot Available2-

Jun-

17

1-

Jun

-18

7-

May

-20

US20200138

936

Phenotypically Wild-Type and Genetically Attenuated VirusesNot Available2-

Jun-

17

1-

Jun

-18

7-

May

-20

US20200138

818

METHODS OF TREATING PAIN AND/OR INFLAMMATORY DISORDERS USING LAPATINIBNot Available7-

Nov-

18

6-

Nov

-19

7-

May

-20

US20200138

780

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN CNot Available14-

Mar-

13

19-

Dec

-19

7-

May

-20

US20200131

518

CONTROL OF TOTAL AFUCOSYLATED GLYCOFORMS OF ANTIBODIES PRODUCED IN CELL CULTURENot Available14-

Mar-

17

14-

Mar

-18

30-

Apr-

20

US20200129

487

CHEMOTHERAPY FOR CANCER USING AZABICYCLO COMPOUNDTAIHO PHARMACEUTICAL CO., LTD.30-

Jun-

17

29-

Jun

-18

30-

Apr-

20

US20200127

954

RNA TARGETING METHODS AND COMPOSITIONSSalk Institute for Biological Studies22-

Aug-

17

31-

Dec

-18

23-

Apr-

20

US20200124

599

ACCURATE, RAPID AND CONVENIENT SINGLE-STEP DISEASE DIAGNOSTIC METHOD USING SELF-AMPLIFICATION PRINCIPLE OF DETECTION SIGNALCELLEMEDY CO., LTD13-

Apr-

17

13-

Apr

-18

23-

Apr-

20

US20200123

233

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASESAblynx N.V.5-

Jun-

08

1-

Aug

-19

23-

Apr-

20

US20200123

205

Inhibition Of TCR Signaling With Peptide VariantsNot Available22-

Oct-

18

18-

Dec

-19

23-

Apr-

20

US20200123

203

COMPOSITIONS COMPRISING CURONS AND USES THEREOFFLAGSHIP PIONEERING INNOVATIONS V, INC.13-

Jun-

17

13-

Jun

-18

23-

Apr-

20

US20200115

448

CELLS EXPRESSING CHIMERIC ACTIVATING RECEPTORS AND CHIMERIC STIMULATING RECEPTORS AND USES THEREOFNot Available26-

Apr-

17

22-

Oct

-19

16-

Apr-

20

US20200115

434

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOFNot Available23-

Oct-

15

29-

Oct

-19

16-

Apr-

20

US20200113

996

CHIMERIC VIRUS-LIKE PARTICLES AND USES THEREOF AS ANTIGEN-SPECIFIC REDIRECTORS OF IMMUNE RESPONSESNot Available23-

Jun-

17

21-

Jun

-18

16-

Apr-

20

US20200113

967

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTSNot Available26-

May-

17

26-

May

-17

16-

Apr-

20

US20200113

831

LIPOSOMES HAVING USEFUL N:P RATIO FOR DELIVERY OF RNA MOLECULESGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

11

16-

Dec

-19

16-

Apr-

20

US20200113

830

PEGYLATED LIPOSOMES FOR DELIVERY OF IMMUNOGEN-ENCODING RNAGLAXOSMITHKLINE BIOLOGICALS S.A.31-

Aug-

11

16-

Dec

-19

16-

Apr-

20

US20200109

403

IN VIVO DELIVERY OF OLIGONUCLEOTIDESNot Available12-

Dec-

11

18-

Dec

-19

9-

Apr-

20

US20200108

136

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSESNot Available6-

Apr-

07

22-

Nov

-19

9-

Apr-

20

US20200102

558

TRANSKINGDOM PLATFORM FOR THERAPEUTIC NUCLEIC ACID DELIVERYNot Available3-

Apr-

17

3-

Oct

-19

2-

Apr-

20

US20200102

550

TAL EFFECTOR-MEDIATED DNA MODIFICATIONNot Available10-

Dec-

09

28-

Aug

-19

2-

Apr-

20

US20200102

544

POXVIRUS-PLASMODIUM RECOMBINANTS, COMPOSITIONS CONTAINING SUCH RECOMBINANTS, USES THEREOF, AND METHODS OF MAKING AND USING THE SAMENot Available30-

Dec-

13

11-

Sep

-19

2-

Apr-

20

US20200102

362

TUMOR NECROSIS FACTOR RECEPTOR (TNFR) BINDING PROTEIN COMPLEX WITH IMPROVED BINDING AND BIOACTIVITYNot Available6-

Apr-

17

5-

Apr

-18

2-

Apr-

20

US20200102

292

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOFNot Available3-Jul-

13

10-

Jul-

19

2-

Apr-

20

US20200101

158

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFNot Available1-

Oct-

15

22-

Oct

-19

2-

Apr-

20

US20200101

153

MVA-BN AND AD26.ZEBOV OR AD26.FILO PRIME-BOOST REGIMENNot Available6-

Apr-

17

6-

Apr

-18

2-

Apr-

20

US20200101

142

PDE5 COMPOSITIONS AND METHODS FOR IMMUNOTHERAPYNot Available12-

Jun-

17

12-

Jun

-18

2-

Apr-

20

 

US20200101

119

METHODS OF TREATMENT OF INFECTIONS USING BACTERIANot Available27-

Sep-

18

26-

Sep

-19

2-

Apr-

20

US20200101

087

PHARMACEUTICAL COMPOSITIONS AND METHODSNot Available3-

Aug-

15

21-

Nov

-19

2-

Apr-

20

US20200100

480

TRAIT SELECTION IN AVIANSNot Available31-

May-

17

31-

May

-18

2-

Apr-

20

US20200095

324

ANTI-TIGIT ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFNot Available30-

Mar-

17

30-

Mar

-18

26-

Mar

-20

US20200093

919

MODIFIED PEDV SPIKE PROTEINNot Available20-

Sep-

18

18-

Sep

-19

26-

Mar

-20

US20200093

909

PLASMODIUM SPOROZOITE NPDP PEPTIDES AS VACCINE AND TARGET NOVEL MALARIA VACCINES AND ANTIBODIES BINDING TONot Available19-

Apr-

17

19-

Apr

-18

26-

Mar

-20

US20200093

855

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDENot Available11-

Sep-

17

3-

Jun

-19

26-

Mar

-20

US20200093

841

Broad Spectrum Antiviral and Methods of UseNot Available17-

Apr-

06

30-

Apr

-19

26-

Mar

-20

US20200087

655

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDESNot Available14-

Jul-15

22-

Nov

-19

19-

Mar

-20

US20200087

646

OPTIMIZED HUMAN CLOTTING FACTOR IX GENE EXPRESSION CASSETTES AND THEIR USENot Available31-

May-

17

31-

May

-18

19-

Mar

-20

US20200087

630

INFLUENZA VIRUS AND TYPE 1 DIABETESIstituto Zooprofilattico Sperimentale delle Venezie10-

Oct-

12

25-

Jul-

19

19-

Mar

-20

US20200087

359

GRIFFITHSIN MUTANTSThe United States of America,as represented by the Secretary,Department of Health and Human Services10-

Feb-

15

27-

Nov

-19

19-

Mar

-20

US20200087

313

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available29-

Jul-11

25-

Apr

-19

19-

Mar

-20

US20200087

298

Imidazo[4,5-c] Ring Compounds Containing Guanidine Substituted Benzamide GroupsNot Available1-

Mar-

17

27-

Feb

-18

19-

Mar

-20

US20200087

280

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

25-

Nov

-19

19-

Mar

-20

US20200086

324

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTIONNot Available30-

Jun-

16

27-

Dec

-18

19-

Mar

-20

US20200085

984

APPARATUS, METHOD AND SYSTEM FOR SELECTIVELY AFFECTING AND/OR KILLING A VIRUSTHE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK7-

Mar-

11

25-

Nov

-19

19-

Mar

-20

US20200085

947

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCERNot Available7-

Sep-

12

14-

May

-19

19-

Mar

-20

US20200085

943

PHARMACEUTICAL COMPOSITION COMPRISING A POLYMERIC CARRIER CARGO COMPLEX AND AT LEAST ONE PROTEIN OR PEPTIDE ANTIGENCureVac AG31-

Jan-

12

29-

Aug

-19

19-

Mar

-20

US20200085

872

IMMUNE CELLS EXPRESSING ENGINEERED ANTIGEN RECEPTORSNot Available19-

Apr-

17

19-

Apr

-18

19-

Mar

-20

US20200085

852

EPIDERMAL MRNA VACCINENot Available5-

Aug-

15

5-

Aug

-16

19-

Mar

-20

US20200085

756

NANOPARTICLE VACCINE ADJUVANT AND METHODS OF USE THEREOFNot Available14-

Sep-

18

12-

Jul-

19

19-

Mar

-20

US20200080

141

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTSNot Available11-

Dec-

13

19-

Nov

-19

12-

Mar

-20

US20200080

111

Methods for Autocatalytic Genome Editing and Neutralizing Autocatalytic Genome Editing and Compositions ThereofNot Available18-

Sep-

15

19-

Sep

-16

12-

Mar

-20

US20200079

820

DERIVATIVES OF AMANITA TOXINS AND THEIR CONJUGATION TO A CELL BINDING MOLECULEHangzhou DAC Biotech Co., Ltd.20-

Apr-

16

20-

Apr

-16

12-

Mar

-20

US20200079

781

Substituted 2,4 diamino-quinoline as new medicament for fibrosis, autophagy and cathepsins B (CTSB), L (CTSL) and D (CTSD) related diseasesNot Available5-

Sep-

18

1-

Aug

-19

12-

Mar

-20

US20200078

335

COMPOSITIONS AND METHODS TO REDUCE PATHOGENESISNot Available1-

May-

17

1-

May

-18

12-

Mar

-20

US20200072

836

MEDIA ELABORATED WITH NEWLY SYNTHESIZED ANTIBODIES (MENSA) AND USES THEREOFNot Available5-

May-

14

2-

Apr

-19

5-

Mar

-20

US20200071

723

RNA-BASED DELIVERY SYSTEMS WITH LEVELS OF CONTROLNot Available30-

Aug-

18

29-

Aug

-19

5-

Mar

-20

 

US20200071

421

BISPECIFIC ANTIBODYNot Available20-

Nov-

13

8-

Apr

-19

5-

Mar

-20

US20200069

814

CONJUGATION OF A CYTOTOXIC DRUG WITH BIS-LINKAGEHangzhou DAC Biotech Co., Ltd.6-

Apr-

17

6-

Apr

-17

5-

Mar

-20

US20200062

764

ALKYL PYRROLOPYRIMIDINE ANALOGS AND METHODS OF MAKING AND USING SAMENot Available17-

Nov-

16

17-

Nov

-17

27-

Feb

-20

US20200061

187

METHODS FOR PREPARING SQUALENENot Available12-

May-

10

4-

Nov

-19

27-

Feb

-20

US20200061

185

PREFUSION CORONAVIRUS SPIKE PROTEINS AND THEIR USEThe Scripps Research Institute25-

Oct-

16

25-

Oct

-17

27-

Feb

-20

US20200060

981

CATIONIC NANOPARTICLES FOR ENHANCING INFECTIOUS CAPACITY OF LIVE VIRUSESNot Available9-

Dec-

16

11-

Dec

-17

27-

Feb

-20

US20200056

221

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIANot Available8-

Nov-

13

25-

Oct

-19

20-

Feb

-20

US20200056

159

NOVEL ADENO-ASSOCIATED VIRUS (AAV) CLADE F VECTOR AND USES THEREFORNot Available28-

Feb-

17

27-

Feb

-18

20-

Feb

-20

US20200055

927

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTIONNot Available8-

Sep-

16

25-

Oct

-19

20-

Feb

-20

US20200055

926

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTIONNot Available8-

Sep-

16

25-

Oct

-19

20-

Feb

-20

US20200054

731

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOFNot Available7-

Jan-

14

15-

Jul-

19

20-

Feb

-20

US20200054

660

DNA METHYLATION PROFILING FOR T-CELL IMMUNOTHERAPYSt. Jude Children’s Research Hospital9-

Dec-

16

7-

Dec

-17

20-

Feb

-20

US20200054

259

HIGH DENSITY ANALOG MULTIPEXINGEnLiSense, LLC17-

Aug-

18

16-

Aug

-19

20-

Feb

-20

US20200048

722

METHODS FOR REAL-TIME MULTIPLEX ISOTHERMAL DETECTION AND IDENTIFICATION OF BACTERIAL, VIRAL, AND PROTOZOAN NUCLEIC ACIDSNot Available8-

May-

15

24-

Aug

-19

13-

Feb

-20

US20200048

649

VIRUS-LIKE PARTICLES AND USES THEREOFNot Available13-

Mar-

17

13-

Mar

-18

13-

Feb

-20

US20200048

636

IMMUNISATION OF LARGE MAMMALS WITH LOW DOSES OF RNAGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

10

18-

Oct

-19

13-

Feb

-20

US20200046

865

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATIONNot Available29-

Dec-

17

22-

Aug

-19

13-

Feb

-20

US20200046

826

METHODS AND COMPOSITIONS FOR IMMUNIZATION AGAINST VIRUSAcademia Sinica27-

Mar-

09

4-

Jun

-19

13-

Feb

-20

US20200046

692

SPECIFIC AKT3 INHIBITOR AND USES THEREOFNot Available15-

Jan-

16

2-

Oct

-19

13-

Feb

-20

US20200040

408

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATIONNot Available8-

Feb-

16

6-

May

-19

6-

Feb

-20

US20200040

042

CHIMERIC MOLECULES AND USES THEREOFNot Available30-

Mar-

17

29-

Mar

-18

6-

Feb

-20

US20200038

871

DEVICES, PROCESSES, AND SYSTEMS FOR DETERMINATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, COPY NUMBER, OR METHYLATION CHANGES USING COMBINED NUCLEASE, LIGASE, POLYMERASE, AND SEQUENCING REACTIONSNot Available29-

Mar-

17

29-

Mar

-18

6-

Feb

-20

US20200038

373

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available9-

May-

12

16-

May

-19

6-

Feb

-20

US20200033

343

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASESNot Available6-

Oct-

08

14-

Oct

-19

30-

Jan-

20

US20200032

255

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASESNot Available26-

Jan-

07

6-

Mar

-19

30-

Jan-

20

US20200031

871

NOVEL DEPSIPEPTIDES AND USES THEREOFNot Available4-

Apr-

17

30-

Mar

-18

30-

Jan-

20

US20200031

819

COMPOSITIONS AND METHODS FOR INHIBITING KINASESNot Available23-

Apr-

15

26-

Jun

-19

30-

Jan-

20

US20200030

441

Lipidated Immune Response Modifier Compound Compositions, Formulations, and MethodsNot Available17-

Aug-

10

8-

Jul-

19

30-

Jan-

20

 

US20200030

432

ZOONOTIC DISEASE RNA VACCINESModernaTX, Inc.17-

Mar-

17

16-

Mar

-18

30-

Jan-

20

US20200030

422

COMBINATION OF VACCINATION AND OX40 AGONISTSCureVac AG9-

Sep-

16

15-

Apr

-19

30-

Jan-

20

US20200024

616

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN PANCREATIC TROPISMNot Available30-

Mar-

18

29-

Mar

-19

23-

Jan-

20

US20200024

310

NOVEL DEPSIPEPTIDE AND USES THEREOFNot Available3-

Dec-

12

1-

Aug

-19

23-

Jan-

20

US20200020

420

Method for Establishing Machine Learning Model for Predicting Toxicity of siRNA to Certain Type of Cells and Application ThereofNot Available8-

Dec-

16

7-

Dec

-17

16-

Jan-

20

US20200017

926

CELL-FREE NUCLEIC ACIDS FOR THE ANALYSIS OF THE HUMAN MICROBIOME AND COMPONENTS THEREOFNot Available7-

Nov-

13

28-

Aug

-19

16-

Jan-

20

US20200017

832

COMPOSITIONS FOR REPROGRAMMING CELLS INTO DENDRITIC CELLS OR ANTIGEN PRESENTING CELLS, METHODS AND USES THEREOFNot Available5-

Apr-

17

5-

Apr

-18

16-

Jan-

20

US20200017

588

MODULAR TETRAVALENT BISPECIFIC ANTIBODY PLATFORMNot Available14-

Oct-

16

16-

Oct

-17

16-

Jan-

20

US20200017

554

SELF-ASSEMBLING PROTEIN NANOPARTICLES WITH BUILT-IN SIX- HELIX BUNDLE PROTEINSNot Available23-

Mar-

17

22-

Mar

-18

16-

Jan-

20

US20200017

514

ADAMANTANE DERIVATIVES FOR THE TREATMENT OF FILOVIRUS INFECTIONNot Available12-

Jul-18

12-

Jul-

18

16-

Jan-

20

US20200017

455

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSNot Available24-

Jan-

14

19-

Mar

-19

16-

Jan-

20

US20200016

589

LOADING VIALSNot Available10-

Nov-

11

24-

Sep

-19

16-

Jan-

20

US20200016

286

Production of Immune-Response-Stimulating Aerosols By Non­Thermal Plasma Treatment Of Airborne PathogensNot Available13-

Jul-18

12-

Jul-

19

16-

Jan-

20

US20200016

280

Compositions For Enhancing Transport Of Molecules Into CellsNot Available29-

Apr-

03

9-

Apr

-19

16-

Jan-

20

US20200016

161

METHODS FOR TREATING VIRAL DISORDERSTRUSTEES OF BOSTON UNIVERSITY24-

Sep-

09

22-

Jul-

19

16-

Jan-

20

US20200010

883

METHODS AND COMPOSITIONS FOR ENRICHMENT OF AMPLIFICATION PRODUCTSNot Available9-

Oct-

15

7-

Jun

-19

9-

Jan-

20

US20200010

519

NUCLEASE FUSIONS FOR ENHANCING GENOME EDITING BY HOMOLOGY-DIRECTED TRANSGENE INTEGRATIONNot Available10-

Mar-

17

9-

Mar

-18

9-

Jan-

20

US20200009

244

NANOPARTICLE VACCINES WITH NOVEL STRUCTURAL COMPONENTSNot Available13-

Jun-

18

13-

Jun

-19

9-

Jan-

20

US20200002

674

ERYTHROID CELLS COMPRISING PHENYLALANINE HYDROXYLASENot Available18-

Nov-

13

16-

Sep

-19

2-

Jan-

20

US20200000

931

SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDSNot Available15-

Jul-16

10-

Apr

-19

2-

Jan-

20

US20190391

150

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMESNot Available1-

May-

15

10-

Sep

-19

26-

Dec

-19

US20190390

249

BIOLOGICAL SPECIMEN COLLECTION AND TRANSPORT SYSTEMLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

19-

Jun

-17

26-

Dec

-19

US20190390

229

GENE EDITING REAGENTS WITH REDUCED TOXICITYNot Available21-

Apr-

16

20-

Apr

-17

26-

Dec

-19

US20190390

179

SYNTHETIC REVERSE TRANSCRIPTASES AND USES THEREOFNot Available12-

Apr-

16

12-

Apr

-17

26-

Dec

-19

US20190390

176

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS WITH ENHANCED HUMAN SKELETAL MUSCLE TROPISMNot Available2-

Dec-

15

3-

Jul-

19

26-

Dec

-19

US20190389

816

ANTIVIRAL COMPOUNDS AND METHODSBiotron Limited26-

Jun-

03

29-

Aug

-19

26-

Dec

-19

US20190388

473

METHODS AND COMPOSITIONS FOR IMMUNOMODULATIONNot Available1-

Apr-

14

30-

Aug

-19

26-

Dec

-19

US20190382

799

VIRAL METHODS OF MAKING GENETICALLY MODIFIED CELLSNot Available27-

Oct-

16

19-

Apr

-19

19-

Dec

-19

 

US20190382

433

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPYTHE UNIVERSITY OF NOTTINGHAM4-

Apr-

14

25-

Jul-

19

19-

Dec

-19

US20190381

180

HYBRID CARRIERS FOR NUCLEIC ACID CARGONot Available9-

Jun-

16

9-

Jun

-17

19-

Dec

-19

US20190381

162

PAN FILOVIRUS VACCINE COMPOSITIONS AND METHODS OF MAKINGNot Available28-

Mar-

16

27-

Mar

-17

19-

Dec

-19

US20190381

155

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAYCureVac AG22-

Feb-

13

29-

Aug

-19

19-

Dec

-19

US20190380

995

PREVENTION AND TREATMENT OF VIRAL INFECTIONSNot Available2-

Jun-

16

3-

Jul-

19

19-

Dec

-19

US20190380

891

MOBILE CLINICSBaylor College of Medicine12-

Nov-

14

28-

Aug

-19

19-

Dec

-19

US20190376

151

MODIFIED OLIGONUCLEOTIDES COMPRISING THIOL FUNCTIONS AND USE THEREOF FOR DETECTING NUCLEIC ACIDSNot Available4-

Apr-

12

8-

Feb

-19

12-

Dec

-19

US20190376

034

PLATELETS COMPRISING EXOGENOUS POLYPEPTIDES AND USES THEREOFNot Available18-

Nov-

13

23-

Aug

-19

12-

Dec

-19

US20190375

801

HSP FUSION PROTEIN WITH ANTI-CHEMOREPELLANT AGENT FOR TREATMENT OF INFECTIOUS DISEASENot Available9-

Sep-

16

8-

Sep

-17

12-

Dec

-19

US20190374

650

COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER/BIOMACROMOLECULE CONJUGATESNot Available22-

Feb-

17

21-

Feb

-18

12-

Dec

-19

US20190374

610

MEDICAL USE OF INTERFERON-LAMBDA FOR THE TREATMENT OF FIBROSISNot Available20-

Dec-

16

20-

Dec

-17

12-

Dec

-19

US20190374

576

VIRAL METHODS OF T CELL THERAPYNot Available27-

Oct-

16

19-

Apr

-19

12-

Dec

-19

US20190370

834

SYSTEM FOR DETERMINING PUBLIC SENTIMENT TOWARDS PATHOGENSNot Available1-

Jun-

18

1-

Jun

-18

5-

Dec

-19

US20190367

553

COMPOSITIONS AND METHODS OF MODULATING THE IMMUNE RESPONSE BY ACTIVATING ALPHA PROTEIN KINASE 1Not Available27-

Oct-

17

26-

Apr

-19

5-

Dec

-19

US20190367

525

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

19-

Jul-

19

5-

Dec

-19

US20190367

453

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTSHANGZHOU DAC BIOTECH CO., LTD.12-

Jul-12

13-

Aug

-19

5-

Dec

-19

US20190365

925

AAV VECTORS TARGETED TO THE CENTRAL NERVOUS SYSTEMNot Available21-

Nov-

14

13-

Jun

-19

5-

Dec

-19

US20190365

756

PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPSNot Available4-

Jun-

18

3-

Jun

-19

5-

Dec

-19

US20190359

990

VIRAL SYNTHETIC NUCLEIC ACID SEQUENCES AND USE THEREOFNot Available25-

Jan-

17

25-

Jan

-18

28-

Nov

-19

US20190359

635

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

18-

Jul-

19

28-

Nov

-19

US20190359

629

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

18-

Jul-

19

28-

Nov

-19

US20190358

335

STOMACH ACID-STABLE AND MUCIN-BINDING PROTEIN-POLYMER CONJUGATESNot Available12-

Jan-

17

12-

Jan

-18

28-

Nov

-19

US20190358

312

ANTIGEN-ADJUVANT COUPLING REAGENTS AND METHODS OF USENot Available19-

Dec-

17

19-

Dec

-18

28-

Nov

-19

US20190358

304

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7)-BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTESNIONS, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPOERIMENTALLY INDUCED OCULAR DISORDERSNot Available18-

Oct-

13

29-

May

-19

28-

Nov

-19

US20190358

170

Lipids and Lipid Compositions for the Delivery of Active AgentsNot Available19-

Dec-

13

12-

Aug

-19

28-

Nov

-19

US20190352

639

GENOME EDITING REAGENTS AND THEIR USENot Available10-

Feb-

17

12-

Feb

-18

21-

Nov

-19

US20190352

615

METHOD FOR PURIFYING VIRUSNot Available22-

Dec-

16

21-

Dec

-17

21-

Nov

-19

 

US20190352

608

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTIONNot Available16-

Sep-

13

30-

Jan

-19

21-

Nov

-19

US20190352

357

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONSColorado State University Research Foundation7-

Nov-

14

7-

Aug

-19

21-

Nov

-19

US20190346

443

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASESNot Available6-

Oct-

08

28-

Jun

-19

14-

Nov

-19

US20190345

504

ARTIFICIAL NUCLEIC ACID MOLECULESCureVac AG30-

Dec-

14

26-

Jul-

19

14-

Nov

-19

US20190345

503

CIRCULAR RNAS AND THEIR USE IN IMMUNOMODULATIONNot Available20-

Jun-

16

15-

Jun

-17

14-

Nov

-19

US20190345

481

PURIFICATION OF NUCLEIC ACIDS USING METAL-TITANIUM OXIDESNot Available14-

Jul-15

5-

Jul-

19

14-

Nov

-19

US20190345

221

BROAD SPECTRUM VACCINE, PREPARING METHOD AND APPLICATION THEREOFTianjin Dongya Biological Technology Co., Ltd.9-

May-

18

9-

May

-18

14-

Nov

-19

US20190345

166

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTSNot Available1-

May-

14

24-

Jul-

19

14-

Nov

-19

US20190343

862

DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSGLAXOSMITHKLINE BIOLOGICALS, SA6-Jul-

10

16-

Jul-

19

14-

Nov

-19

US20190337

990

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPYNot Available13-

Feb-

15

5-

Jun

-19

7-

Nov

-19

US20190336

969

PARALLELIZED SAMPLE HANDLINGNot Available19-

Apr-

13

27-

Mar

-19

7-

Nov

-19

US20190336

611

HYBRID CARRIERS FOR NUCLEIC ACID CARGOCureVac AG9-

Jun-

16

9-

Jun

-17

7-

Nov

-19

US20190336

608

CATIONIC CARRIERS FOR NUCLEIC ACID DELIVERYCureVac AG9-

Jun-

16

9-

Jun

-17

7-

Nov

-19

US20190336

597

METHODS OF GENERATING ROBUST PASSIVE AND ACTIVE IMMUNE RESPONSESNot Available8-

Jan-

13

17-

May

-19

7-

Nov

-19

US20190336

456

USE OF XIBORNOL AS ACTIVE AGENT IN THE TREATMENT OF VIRAL INFECTIONSABIOGEN PHARMA S.P.A.15-

Jul-16

13-

Jul-

17

7-

Nov

-19

US20190330

618

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIESNot Available1-

Dec-

05

22-

Jan

-19

31-

Oct-

19

US20190330

572

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFNot Available8-

Sep-

16

21-

Jun

-19

31-

Oct-

19

US20190330

245

Boron-Containing Small MoleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

12-

Jul-

19

31-

Oct-

19

US20190330

187

Chemical CompoundsNot Available18-

Mar-

14

10-

May

-19

31-

Oct-

19

US20190330

164

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available29-

Jul-11

28-

Nov

-18

31-

Oct-

19

US20190330

149

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTSHANGZHOU DAC BIOTECH CO., LTD.12-

Jul-12

9-

May

-19

31-

Oct-

19

US20190328

869

IMMUNOTHERAPEUTIC PRODUCT AND MDSC MODULATOR COMBINATION THERAPYTransgene SA10-

Oct-

16

10-

Oct

-17

31-

Oct-

19

US20190328

865

IMMUNOGENIC COMPOSITION FOR MERS CORONAVIRUS INFECTIONNot Available28-

Jul-14

17-

Nov

-17

31-

Oct-

19

US20190328

804

AAV Vectors Targeted to OligodendrocytesNot Available28-

Sep-

12

15-

Jul-

19

31-

Oct-

19

US20190323

068

PCR Ready Compositions and Methods for Screening Biological SamplesLonghorn Vaccines and Diagnostics, LLC12-

Sep-

06

28-

Jun

-19

24-

Oct-

19

US20190322

989

PRODUCTION OF VIRUSES IN CELL CULTURENot Available24-

Nov-

15

25-

Jan

-19

24-

Oct-

19

US20190322

725

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOFNot Available13-

May-

14

2-

Jul-

19

24-

Oct-

19

US20190321

481

IMMUNOMODULATORY COMPOSITIONS, PROCESSES FOR MAKING THE SAME, AND METHODS FOR INHIBITING CYTOKINE STORMSNantBio, Inc.11-

Nov-

16

9-

Nov

-17

24-

Oct-

19

US20190321

403

ENGINEERED B CELLS AND RELATED COMPOSITIONS AND METHODSJuno Therapeutics, Inc.2-

Dec-

16

30-

Nov

-17

24-

Oct-

19

 

US20190316

109

COMPOSITION COMPRISING A GENE VECTOR THAT SELECTIVELY DEPLETES P16 POSITIVE SENESCENT CELLSNot Available17-

Apr-

12

10-

Jun

-19

17-

Oct-

19

US20190316

091

ERYTHROID CELLS COMPRISING ARGINASENot Available18-

Nov-

13

30-

May

-19

17-

Oct-

19

US20190316

090

ERYTHROID CELLS COMPRISING ARGININE DEIMINASERUBIUS THERAPEUTICS, INC.18-

Nov-

13

30-

May

-19

17-

Oct-

19

US20190316

089

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

10-

May

-19

17-

Oct-

19

US20190315

840

ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USENot Available16-

Sep-

16

10-

Jun

-19

17-

Oct-

19

US20190315

807

VIRUS-LIKE PARTICLES WITH HIGH-DENSITY COATING FOR INDUCING THE EXPRESSION OF ANTIBODIESNot Available27-

Jul-16

26-

Jul-

17

17-

Oct-

19

US20190314

496

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANTCureVac AG1-

Apr-

14

18-

Jun

-19

17-

Oct-

19

US20190314

483

Vaccines Including Antigen From Four Strains of Influenza VirusNot Available6-

Dec-

06

30-

Nov

-18

17-

Oct-

19

US20190314

482

VACCINES AGAINST INFECTIOUS DISEASES CAUSED BY POSITIVE STRANDED RNA VIRUSESMedigen, Inc.28-

Nov-

16

21-

Nov

-17

17-

Oct-

19

US20190314

480

IMMUNOGENIC COMPOSITIONS AND USES THEREOFNot Available25-

Mar-

15

23-

Apr

-19

17-

Oct-

19

US20190314

471

MOLECULAR VACCINES FOR INFECTIOUS DISEASENot Available2-

Oct-

08

27-

Jun

-19

17-

Oct-

19

US20190314

455

CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASESNot Available3-

Aug-

17

7-

Jun

-19

17-

Oct-

19

US20190314

372

PYRIMIDINE COMPOUNDS CONTAINING ACIDIC GROUPSNot Available5-

Dec-

16

25-

Mar

-19

17-

Oct-

19

US20190310

168

AIRBORNE AGENT COLLECTORS, METHODS, SYSTEMS AND DEVICES FOR MONITORING AIRBORNE AGENTSNot Available22-

Jul-14

4-

Mar

-19

10-

Oct-

19

US20190309

357

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICSMASSACHUSETTS INSTITUTE OF TECHNOLOGY9-

Dec-

16

25-

Feb

-19

10-

Oct-

19

US20190309

262

ERYTHROID CELLS COMPRISING SERINE DEHYDRATASENot Available18-

Nov-

13

4-

Jun

-19

10-

Oct-

19

US20190309

261

ERYTHROID CELLS COMPRISING LYSINE OXIDASENot Available18-

Nov-

13

4-

Jun

-19

10-

Oct-

19

US20190309

048

Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their UseNot Available6-

Feb-

15

20-

May

-19

10-

Oct-

19

US20190309

039

CRYPTIC POLYPEPTIDES AND USES THEREOFNot Available29-

Jan-

15

22-

Apr

-19

10-

Oct-

19

US20190308

980

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

24-

Jun

-19

10-

Oct-

19

US20190308

969

HETEROCYCLIC MODULATORS OF LIPID SYNTHESISNot Available11-

Nov-

16

13-

Nov

-17

10-

Oct-

19

US20190308

943

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDSParion Sciences, Inc.17-

Dec-

12

13-

Mar

-19

10-

Oct-

19

US20190307

878

IMMUNE COMPLEXThe Rockefeller University20-

Mar-

15

10-

May

-19

10-

Oct-

19

US20190307

722

ANTIVIRAL COMPOSITIONS FOR THE TREATMENT OF INFECTIONS LINKED TO CORONAVIRUSESNot Available21-

Oct-

16

20-

Oct

-17

10-

Oct-

19

US20190298

824

ALBUMIN-BINDING IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOFTHE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv4-

May-

16

4-

May

-17

3-

Oct-

19

US20190298

752

METHODS FOR THE USE OF 5′-ADENOSINE DIPHOSPHATE RIBOSE (ADPR)Invirsa, Inc.27-

Mar-

18

26-

Mar

-19

3-

Oct-

19

US20190298

750

Nucleotide and Nucleoside Therapeutic Compositions and Uses Related TheretoNot Available11-

Sep-

13

21-

Nov

-18

3-

Oct-

19

US20190293

656

NON-RADIOACTIVE CYTOTOXICITY ASSAYSNot Available19-

Sep-

16

19-

Sep

-17

26-

Sep

-19

US20190292

580

DNA LOGIC-GATED PROXIMITY ASSEMBLY CIRCUIT FOR BIOCHEMICAL SENSINGRutgers, The State University of New Jersey23-

Mar-

18

22-

Mar

-19

26-

Sep

-19

 

US20190292

563

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORThe Trustees of the University of Pennsylvania17-

Dec-

01

8-

Apr

-19

26-

Sep

-19

US20190292

561

SCALABLE METHODS FOR PRODUCING RECOMBINANT ADENO- ASSOCIATED VIRAL (AAV) VECTOR IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEM SUITABLE FOR CLINICAL USESPARK THERAPEUTICS, INC.1-

Dec-

15

1-

Dec

-16

26-

Sep

-19

US20190292

236

MODULATION OF IFI16 AND STING ACTIVITYNot Available9-

Aug-

16

9-

Aug

-17

26-

Sep

-19

US20190292

216

Cyclic Di-Nucleotide Induction of Type I InterferonNot Available3-

May-

13

19-

Feb

-19

26-

Sep

-19

US20190292

178

HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSESDana-Farber Cancer Institute, Inc.11-

Apr-

12

26-

Jan

-18

26-

Sep

-19

US20190290

674

Composition for Promoting Production of Immunostimulatory FactorKyoto University2-

Aug-

16

31-

Jul-

17

26-

Sep

-19

US20190285

632

METABALOMICS AND VIRAL DIAGNOSTICS SUITEExcision Biotherapeutics, Inc.24-

May-

16

24-

May

-17

19-

Sep

-19

US20190284

575

REVERSE GENETICS USING NON-ENDOGENOUS POL I PROMOTERSNot Available21-

May-

09

30-

Jan

-19

19-

Sep

-19

US20190284

531

DETECTION OF T CELL EXHAUSTION OR LACK OF T CELL COSTIMULATION AND USES THEREOFNot Available15-

May-

15

24-

May

-19

19-

Sep

-19

US20190284

230

ASSEMBLED GLYCOPROTEINSNot Available29-

Sep-

16

22-

Sep

-17

19-

Sep

-19

US20190282

694

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODSAUTOIMMUNE TECHNOLOGIES, LLC14-

Mar-

13

30-

May

-19

19-

Sep

-19

US20190282

608

Method Of Treating InflammationNot Available1-

Apr-

10

29-

May

-19

19-

Sep

-19

US20190276

523

COMPOSITION AND METHODS OF TREATING B CELL DISORDERSNot Available2-

Sep-

16

5-

Sep

-17

12-

Sep

-19

US20190275

519

SYSTEM FOR THE PRODUCTION OF CELLS AND/OR CELL PRODUCTSNot Available8-

Nov-

16

8-

Nov

-17

12-

Sep

-19

US20190275

101

STRUCTURE OF GII.4 NOROVIRUS PROTEASE – DESIGN OF BROAD- SPECTRUM PROTEASE INHIBITORSNot Available5-

Oct-

16

5-

Oct

-17

12-

Sep

-19

US20190269

694

HETEROCYCLIC MODULATORS OF LIPID SYNTHESISNot Available8-

Mar-

11

11-

Oct

-18

5-

Sep

-19

US20190269

672

Specific Akt3 Inhibitor and Uses ThereofNot Available15-

Jan-

16

20-

May

-19

5-

Sep

-19

US20190264

267

PHASINGWave Life Sciences Ltd.25-

Jul-16

24-

Jul-

17

29-

Aug

-19

US20190264

177

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

10-

May

-19

29-

Aug

-19

US20190263

934

FC VARIANTS WITH ENHANCED BINDING TO FCRN AND PROLONGED HALF-LIFENot Available26-

Jan-

18

25-

Jan

-19

29-

Aug

-19

US20190262

448

Cationic Oil-In-Water EmulsionsGLAXOSMITHKLINE BIOLOGICALS, SA18-

Sep-

11

7-

Mar

-19

29-

Aug

-19

US20190262

371

METHODS AND COMPOSITION FOR THE TREATMENT OF RNA VIRAL INFECTIONSNot Available20-

Oct-

16

20-

Oct

-17

29-

Aug

-19

US20190256

585

ANTIBODY SPECIFICALLY BINDING TO AN ISOLATED PEPTIDE DERIVED FROM VIMENTIN OR A FRAGMENT BINDING TO THE PEPTIDENot Available10-

Jun-

15

10-

Jun

-16

22-

Aug

-19

US20190256

579

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USEThe U.S.A., as represented by the Secretary, Department of Health and Human Services24-

Feb-

15

3-

May

-19

22-

Aug

-19

US20190255

085

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONSNot Available16-

Sep-

15

1-

Feb

-19

22-

Aug

-19

US20190254

968

OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDSGLAXOSMITHKLINE BIOLOGICALS S.A.6-Jul-

11

2-

May

-19

22-

Aug

-19

US20190250

153

MULTI-CONFIGURABLE SENSING ARRAY AND METHODS OF USING SAMEBoard of Regents, The University of Texas System20-

Oct-

16

19-

Oct

-17

15-

Aug

-19

US20190248

883

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)Not Available16-

Dec-

02

20-

Feb

-19

15-

Aug

-19

US20190248

866

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONNot Available30-

Jun-

11

30-

Apr

-18

15-

Aug

-19

 

US20190248

865

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOFNot Available23-

Oct-

15

21-

Oct

-16

15-

Aug

-19

US20190247

529

METHOD AND SYSTEM FOR DECONTAMINATING SMALL ENCLOSURESNot Available29-

Dec-

17

23-

Apr

-19

15-

Aug

-19

US20190247

489

ADJUVANTED INFLUENZA B VIRUS VACCINES FOR PEDIATRIC PRIMINGNot Available20-

Oct-

11

16-

Nov

-18

15-

Aug

-19

US20190247

485

Dimethyl Fumarate and Vaccination RegimensBiogen MA Inc.14-

Mar-

14

23-

Apr

-19

15-

Aug

-19

US20190247

440

METHODS AND COMPOSITIONS FOR IMMUNOMODULATIONNot Available1-

Apr-

14

12-

Apr

-19

15-

Aug

-19

US20190247

367

TREATMENT OF INFECTIOUS DISEASESCHILDREN’S MEDICAL CENTER CORPORATION26-

Jan-

15

23-

Apr

-19

15-

Aug

-19

US20190241

646

ANTI-PNEUMOCOCCAL HYPERIMMUNE GLOBULIN FOR THE TREATMENT AND PREVENTION OF PNEUMOCOCCAL INFECTIONNot Available15-

Mar-

17

15-

Apr

-19

8-

Aug

-19

US20190241

618

INHIBITION OF TCR SIGNALING WITH PEPTIDE VARIANTSNot Available30-

Sep-

09

22-

Oct

-18

8-

Aug

-19

US20190240

317

HPIV3 RNA VACCINESModernaTX, Inc.22-

Oct-

15

28-

Mar

-19

8-

Aug

-19

US20190233

447

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PARAFFIN EMBEDDED TISSUE USING CAGED HAPTENSNot Available28-

Aug-

15

25-

Feb

-19

1-

Aug

-19

US20190232

282

METHODS AND COMPOSITIONS FOR DETECTING ANALYTESNot Available23-

Sep-

16

20-

Sep

-17

1-

Aug

-19

US20190231

004

MASKNBC MESHTEC INC.17-

Oct-

16

13-

Oct

-17

1-

Aug

-19

US20190225

986

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

Not Available28-

Oct-

05

30-

Nov

-18

25-

Jul-

19

US20190225

971

METHOD OF INCREASING THE REPLICATION OF A CIRCULAR DNA MOLECULENot Available10-

Aug-

15

4-

Aug

-16

25-

Jul-

19

US20190224

339

COMPOSITIONS FOR THE TREATMENT OF DISEASENot Available29-

Apr-

16

28-

Apr

-17

25-

Jul-

19

US20190223

445

ANTIMICROBIAL GEOPOLYMER COMPOSITIONSNot Available14-

Jul-16

13-

Jul-

17

25-

Jul-

19

US20190220

524

DETERMINING EXPLANATIONS FOR PREDICTED LINKS IN KNOWLEDGE GRAPHSNot Available16-

Jan-

18

29-

Mar

-18

18-

Jul-

19

US20190219

563

Assay for Detecting TH1 and TH2 Cell PopulationsNot Available16-

May-

14

17-

Dec

-18

18-

Jul-

19

US20190218

574

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORThe Trustees of the University of Pennsylvania2-

Oct-

07

28-

Mar

-19

18-

Jul-

19

US20190218

277

ANTI-DENGUE VIRUS ANTIBODIES, POLYPEPTIDES CONTAINING VARIANT FC REGIONS, AND METHODS OF USENot Available16-

Sep-

16

15-

Sep

-17

18-

Jul-

19

US20190218

207

3-(Pyridin-3-yl)-Acrylamide and N-(Pyridin-3-yl)-Acrylamide Derivatives and Their Use as PAK or NaMPT ModulatorsNot Available17-

Aug-

15

17-

Aug

-16

18-

Jul-

19

US20190216

951

METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINSCureVac AG21-

Aug-

13

1-

Apr

-19

18-

Jul-

19

US20190216

917

HMPV RNA VACCINESModernaTX, Inc.22-

Oct-

15

28-

Mar

-19

18-

Jul-

19

US20190216

915

TRANSGENIC VERO-CD4/CCR5 CELL LINENot Available2-

Oct-

15

15-

Feb

-19

18-

Jul-

19

US20190216

841

Regimens and Compositions for AAV-Mediated Passive Immunization of Airborne PathogensNot Available20-

Apr-

11

20-

Mar

-19

18-

Jul-

19

US20190211

361

COMPOSITIONS COMPRISING CURONS AND USES THEREOFNot Available13-

Jun-

17

27-

Mar

-19

11-

Jul-

19

US20190211

355

DNA MOLECULES PRODUCING CUSTOM DESIGNED REPLICATING AND NON-REPLICATING NEGATIVE STRANDED RNA VIRUSES AND USES THERE OFNot Available5-

Jan-

15

4-

Jan

-16

11-

Jul-

19

US20190211

024

SMALL MOLECULES HAVING ANTIVIRAL PROPERTIESGeneral Research Laboratory19-

Aug-

16

19-

Aug

-17

11-

Jul-

19

 

US20190209

678

MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONS WITH ENHANCED STABILITYNot Available2-

Dec-

14

12-

Mar

-19

11-

Jul-

19

US20190209

604

OLIGONUCLEOTIDES, COMPOSITIONS AND METHODS THEREOFWAVE LIFE SCIENCES LTD.3-

Jun-

16

2-

Jun

-17

11-

Jul-

19

US20190207

890

RNA TARGETING METHODS AND COMPOSITIONSSalk Institute for Biological Studies22-

Aug-

17

31-

Dec

-18

4-

Jul-

19

US20190204

330

APPLICATION OF CLICK CHEMISTRY FOR SIGNAL AMPLIFICATION IN IHC AND ISH ASSAYSNot Available28-

Jun-

16

19-

Dec

-18

4-

Jul-

19

US20190203

268

LOOP-MEDIATED ISOTHERMAL AMPLIFICATION (LAMP) BASED ASSAY FOR DETECTING MICROBESNot Available2-

Jan-

18

31-

Dec

-18

4-

Jul-

19

US20190203

186

PRODUCTION OF VIRUSES IN AVIAN EGGSNot Available24-

Nov-

15

25-

Jan

-19

4-

Jul-

19

US20190203

170

Avian Cells for Improved Virus ProductionNot Available5-

Jun-

13

21-

Dec

-18

4-

Jul-

19

US20190202

929

COMPOSITIONS AND METHODS FOR IDENTIFICATION, ASSESSMENT, PREVENTION, AND TREATMENT OF AML USING USP10 BIOMARKERS AND MODULATORSNot Available20-

Sep-

16

20-

Sep

-17

4-

Jul-

19

US20190202

868

CORONAVIRUS PROTEINS AND ANTIGENSPhibro Animal Health Corporation7-

Feb-

14

15-

Mar

-19

4-

Jul-

19

US20190202

854

ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN ANot Available4-

Aug-

14

8-

Mar

-19

4-

Jul-

19

US20190201

565

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATIONNot Available29-

Dec-

17

11-

Sep

-18

4-

Jul-

19

US20190201

564

DECONTAMINATION DEVICE AND METHOD USING ULTRASONIC CAVITATIONNot Available29-

Dec-

17

29-

Dec

-17

4-

Jul-

19

US20190201

552

Aptamer Compositions and Methods of Use ThereofNot Available28-

Dec-

17

28-

Dec

-18

4-

Jul-

19

US20190201

433

2′-SUBSTITUTED-N6-SUBSTITUTED PURINE NUCLEOTIDES FOR RNA VIRUS TREATMENTAtea Pharmaceuticals, Inc.7-

Sep-

16

5-

Mar

-19

4-

Jul-

19

US20190201

352

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITYNot Available30-

Jan-

15

12-

Mar

-19

4-

Jul-

19

US20190201

337

HYDROPHILIC FILTRATION DURING MANUFACTURE OF VACCINE ADJUVANTSNot Available3-

Dec-

09

3-

Jan

-19

4-

Jul-

19

US20190194

728

Systemic inflammatory and pathogen biomarkers and uses thereforNot Available24-

Aug-

16

24-

Aug

-17

27-

Jun-

19

US20190194

717

METHOD AND KIT FOR DETECTING PATHOGENIC MICROORGANISMJAPAN SCIENCE AND TECHNOLOGY AGENCY5-

Sep-

16

4-

Sep

-17

27-

Jun-

19

US20190194

628

METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTIONTakeda Pharmaceutical Company Limited1-

Sep-

16

1-

Sep

-17

27-

Jun-

19

US20190194

322

IDENTIFICATION OF VSIG3/VISTA AS A NOVEL IMMUNE CHECKPOINT AND USE THEREOF FOR IMMUNOTHERAPYBIO-TECHNE CORPORATION3-

Aug-

16

3-

Aug

-17

27-

Jun-

19

US20190194

299

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOFNot Available25-

Apr-

14

19-

Nov

-18

27-

Jun-

19

US20190194

226

FUSED [1,2]IMIDAZO[4,5-C] RING COMPOUNDS SUBSTITUTED WITH GUANIDINO GROUPSNot Available26-

Aug-

16

1-

Aug

-17

27-

Jun-

19

US20190194

150

COMPOUNDS AND METHODS FOR MODULATING RNA FUNCTIONArrakis Therapeutics, Inc.1-Jul-

16

30-

Jun

-17

27-

Jun-

19

US20190192

691

REGULATED BIOCIRCUIT SYSTEMSNot Available11-

Apr-

16

11-

Apr

-17

27-

Jun-

19

US20190192

581

Methods of Populating a Gastrointestinal TractNot Available4-

Feb-

13

1-

Aug

-18

27-

Jun-

19

US20190187

151

ASSAY FOR QUANTITATION OF PROTEINS AND PEPTIDES USING STABLE ISOTOPE STANDARDSUVic Industry Partnerships Inc.6-

Jun-

16

7-

Apr

-17

20-

Jun-

19

US20190187

130

COLORS FOR CHROMOGENIC IHC AND ISH STAINING WITH MULTI­DYE QUINONE METHIDE AND TYRAMIDE CONJUGATESNot Available28-

Jun-

16

19-

Dec

-18

20-

Jun-

19

US20190185

922

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYSCapitalBio Corporation5-

Dec-

13

20-

Nov

-18

20-

Jun-

19

 

US20190185

832

DIET CONTROLLED EXPRESSION OF A NUCLEIC ACID ENCODING CAS9 NUCLEASE AND USES THEREOFNot Available3-

Jun-

16

2-

Jun

-17

20-

Jun-

19

US20190184

067

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONSNot Available1-

Nov-

15

28-

Feb

-19

20-

Jun-

19

US20190184

018

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDESNot Available4-

Dec-

07

20-

Nov

-18

20-

Jun-

19

US20190183

968

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLSNot Available13-

Jan-

11

27-

Feb

-19

20-

Jun-

19

US20190183

918

SYSTEMIC IN VIVO DELIVERY OF OLIGONUCLEOTIDESNot Available12-

Jun-

13

29-

Oct

-18

20-

Jun-

19

US20190177

739

RECOMBINANT INFLUENZA VIRUS-LIKE PARTICLES (VLPS) PRODUCED IN TRANSGENIC PLANTSNot Available21-

Jan-

08

13-

Dec

-18

13-

Jun-

19

US20190175

716

Adenoviral VectorNot Available23-

Jun-

16

23-

Jun

-17

13-

Jun-

19

US20190175

528

INHIBITION OF BIOFILM ORGANISMSNot Available31-

Mar-

09

13-

Feb

-19

13-

Jun-

19

US20190169

677

PORTABLE MOLECULAR DIAGNOSTIC DEVICE AND METHODS FOR THE DETECTION OF TARGET VIRUSESClick Diagnostics, Inc.9-

Nov-

17

9-

Nov

-18

6-

Jun-

19

US20190169

639

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASEDITAS MEDICINE, INC.7-

Nov-

13

24-

Jan

-19

6-

Jun-

19

US20190169

595

RNA TARGETING METHODS AND COMPOSITIONSSalk Institute for Biological Studies22-

Aug-

17

25-

Jan

-19

6-

Jun-

19

US20190167

787

Methods and Compositions for Inhibiting Akt3Not Available15-

Jan-

16

6-

Feb

-19

6-

Jun-

19

US20190167

786

EMULSIONS WITH FREE AQUEOUS-PHASE SURFACTANT FOR ADJUVANTING SPLIT INFLUENZA VACCINESNot Available4-

Nov-

05

9-

Jul-

18

6-

Jun-

19

US20190167

636

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN CNot Available14-

Mar-

13

8-

Feb

-19

6-

Jun-

19

US20190166

866

METHOD FOR PRODUCING A PROTEIN PHOSPHOLIPID COMPLEX FROM A CRUSTACEAN CATCHNot Available4-

Dec-

17

30-

Nov

-18

6-

Jun-

19

US20190160

129

Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating AgentsNot Available1-

Oct-

15

1-

Feb

-19

30-

May

-19

US20190160

063

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available31-

Dec-

15

30-

Dec

-16

30-

May

-19

US20190154

687

DETECTION DEVICE AND DETECTION METHODKabushiki Kaisha Toshiba17-

Nov-

17

7-

Mar

-18

23-

May

-19

US20190154

550

BIOAEROSOL DETECTION SYSTEMS AND METHODS OF USENot Available6-

Apr-

16

6-

Apr

-17

23-

May

-19

US20190153

471

COMPOSITIONS FOR THE TREATMENT OF DISEASENot Available29-

Apr-

16

28-

Apr

-17

23-

May

-19

US20190153

086

Heterodimeric ImmunoglobulinsNot Available21-

Nov-

12

5-

Feb

-19

23-

May

-19

US20190151

844

DEVICES AND METHODS FOR THE DETECTION OF MOLECULES USING A FLOW CELLClick Diagnostics, Inc.29-

Jun-

16

21-

Dec

-18

23-

May

-19

US20190151

474

RNA-BASED LOGIC CIRCUITS WITH RNA BINDING PROTEINS, APTAMERS AND SMALL MOLECULESKyoto University8-

Sep-

14

8-

Sep

-15

23-

May

-19

US20190144

930

ENHANCED METHODS OF RIBONUCLEIC ACID HYBRIDIZATIONNot Available6-

Dec-

13

9-

Jan

-19

16-

May

-19

US20190144

929

DEVICES FOR CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICSNot Available15-

Mar-

17

15-

Mar

-18

16-

May

-19

US20190144

827

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESRUBIUS THERAPEUTICS, INC.18-

Nov-

13

19-

Nov

-18

16-

May

-19

US20190144

556

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIESNot Available13-

May-

16

12-

May

-17

16-

May

-19

US20190144

484

ALKYNE CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETONot Available28-

Apr-

16

28-

Apr

-17

16-

May

-19

 

US20190142

929

INFLUENZA VACCINE REGIMENS FOR PANDEMIC ASSOCIATED STRAINSNot Available10-

Feb-

09

15-

Oct

-18

16-

May

-19

US20190142

927

LOW-ADDITIVE INFLUENZA VACCINESNot Available27-

Jun-

07

26-

Jun

-18

16-

May

-19

US20190136

226

DEVICES AND METHODS FOR NUCLEIC ACID EXTRACTIONNot Available11-

May-

16

9-

Nov

-18

9-

May

-19

US20190136

215

Replication Conditional Virus that Specifically Kills Senescent CellsNot Available17-

Apr-

12

6-

Jul-

18

9-

May

-19

US20190135

875

TRI-SEGMENTED PICHINDE VIRUSES AS VACCINE VECTORSNot Available18-

May-

16

17-

May

-17

9-

May

-19

US20190135

873

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASENot Available19-

Dec-

16

19-

Dec

-18

9-

May

-19

US20190135

788

DIHYDROPYRIMIDINYL BENZAZEPINE CARBOXAMIDE COMPOUNDSHoffmann-La Roche Inc.12-

Jun-

16

7-

Dec

-18

9-

May

-19

US20190134

214

GLP-1 Receptor Ligand Moiety Conjugated Oligonucleotides and Uses ThereofNot Available6-

May-

16

4-

May

-17

9-

May

-19

US20190134

193

USE OF TAM RECEPTOR INHIBITORS AS IMMUNOENHANCERS AND TAM ACTIVATORS AS IMMUNOSUPPRESSORSSALK INSTITUTE FOR BIOLOGICAL STUDIES9-

Nov-

07

9-

Aug

-18

9-

May

-19

US20190134

186

INFLUENZA VACCINES WITH REDUCED AMOUNT OF EMULSION ADJUVANTNot Available4-

Nov-

05

10-

Jul-

18

9-

May

-19

US20190134

062

PHARMACEUTICAL COMPOSITIONS AND METHODSNot Available3-

Aug-

15

8-

Jan

-19

9-

May

-19

US20190128

893

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATIONNot Available24-

Feb-

14

7-

Nov

-18

2-

May

-19

US20190128

810

SYSTEM FOR MEASURING OPTICAL SIGNAL DETECTOR PERFORMANCENot Available31-

Dec-

15

13-

Dec

-18

2-

May

-19

US20190127

441

METHODS AND COMPOSITIONS FOR REDUCING VIRUS INFECTIVITYUniversity of Vermont and State Agricultural College13-

Apr-

16

13-

Apr

-17

2-

May

-19

US20190127

405

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATIONNot Available(Ml)

LL

7-

Nov

-18

2-

May

-19

US20190127

401

CHARGED LINKERS AND THEIR USES FOR CONJUGATIONHANGZHOU DAC BIOTECH CO., LTD.12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190127

400

CHARGED LINKERS AND THEIR USES FOR CONJUGATIONHANGZHOU DAC BIOTECH CO., LTD.12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190127

399

CHARGED LINKERS AND THEIR USES FOR CONJUGATIONHANGZHOU DAC BIOTECH CO., LTD.12-

Aug-

16

20-

Dec

-18

2-

May

-19

US20190125

858

COLD ADAPTED AND VIRULENCE FACTOR DELETED LIVE

ATTENUATED VACCINE SUITABLE FOR MUCOSAL DELIVERY

Not Available18-

Apr-

16

18-

Apr

-17

2-

May

-19

US20190125

806

Antimicrobial and Antiviral Agent, Antimicrobial and Antiviral Member, and Method for Producing Antimicrobial and Antiviral AgentMurata Manufacturing Co., Ltd.13-

Jun-

16

13-

Dec

-18

2-

May

-19

US20190125

724

PREVENTION AND TREATMENT OF VIRAL INFECTIONSNot Available2-

Jun-

16

27-

Nov

-18

2-

May

-19

US20190119

744

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTSNot Available31-

Jul-09

5-

Nov

-18

25-

Apr-

19

US20190119

743

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTSNot Available15-

Aug-

16

26-

Oct

-18

25-

Apr-

19

US20190119

701

METHODS FOR IMPROVED HOMOLOGOUS RECOMBINATION AND COMPOSITIONS THEREOFNot Available8-

Sep-

17

7-

Sep

-18

25-

Apr-

19

US20190119

266

COMPOSITIONS AND METHODS FOR INHIBITING KINASESNot Available23-

Apr-

15

24-

Oct

-18

25-

Apr-

19

US20190119

220

CARBOXYLIC ACID COMPOUNDSSumitomo Dainippon Pharma Co., Ltd.18-

May-

12

23-

Oct

-18

25-

Apr-

19

US20190117

793

MODULAR NANODEVICES FOR SMART ADAPTABLE VACCINESNot Available15-

Feb-

07

1-

Oct

-18

25-

Apr-

19

US20190117

702

USE OF ASC AND ASC-CM TO TREAT ARDS, SARS, AND MERSIndiana University Research and Technology Corporation6-

May-

14

31-

Oct

-18

25-

Apr-

19

US20190112

596

TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYSNot Available4-

Apr-

12

12-

Apr

-18

18-

Apr-

19

US20190112

394

USING SORTASES TO INSTALL CLICK CHEMISTRY HANDLES FOR PROTEIN LIGATIONWhitehead Institute for Biomedical Research28-

Jun-

11

24-

Sep

-18

18-

Apr-

19

 

US20190111

141

A PEPTIDE WITH ABILITY TO PENETRATE CELL MEMBRANEEwha University – Industry Collaboration Foundation6-

Apr-

16

6-

Apr

-17

18-

Apr-

19

US20190105

653

PORTABLE PATHOGEN ANALYSIS SYSTEM FOR DETECTING WATERBORNE PATHOGENSNot Available5-

Oct-

17

5-

Oct

-18

11-

Apr-

19

US20190105

381

METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR TREATING CANCERNot Available16-

Mar-

16

16-

Mar

-16

11-

Apr-

19

US20190105

334

Anti-Viral Azide Containing CompoundsNot Available28-

Jul-10

3-

Dec

-18

11-

Apr-

19

US20190100

586

Humanized Anti-Claudin-1 Antibodies and Uses ThereofChu Strasbourg, Les HA’pitaux Universitaires de Strasbourg22-

Mar-

16

21-

Mar

-17

4-

Apr-

19

US20190099

493

Targeting LipidsArbutus Biopharma Corporation4-

Dec-

07

10-

Oct

-17

4-

Apr-

19

US20190099

479

RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOFNot Available14-

May-

10

27-

Apr

-18

4-

Apr-

19

US20190094

224

METHODS AND COMPOSITIONS FOR DETECTING SINGLE T CELL RECEPTOR AFFINITY AND SEQUENCENot Available11-

Apr-

16

6-

Apr

-17

28-

Mar

-19

US20190091

329

CATIONIC OIL-IN-WATER EMULSIONSGLAXOSMITHKLINE BIOLOGICALS, SA6-Jul-

11

6-

Dec

-18

28-

Mar

-19

US20190091

221

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONSTRUSTEES OF BOSTON UNIVERSITY11-

Mar-

10

23-

Apr

-18

28-

Mar

-19

US20190085

057

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTIONNot Available8-

Sep-

16

15-

Nov

-18

21-

Mar

-19

US20190085

024

Alpha-Ketoamide Inhibitors Of Cysteine ProteasesNot Available15-

Sep-

17

17-

Sep

-18

21-

Mar

-19

US20190085

013

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETONot Available7-

Mar-

16

7-

Mar

-17

21-

Mar

-19

US20190084

943

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL

SODIUM CHANNEL BLOCKING ACTIVITY

Parion Sciences, Inc.17-

Dec-

12

23-

Aug

-18

21-

Mar

-19

US20190083

602

METHOD FOR PRODUCING RNA MOLECULE COMPOSITIONSNot Available22-

Dec-

15

22-

Dec

-16

21-

Mar

-19

US20190083

592

IMMUNOSTIMULATORY COMBINATIONSNot Available30-

Dec-

02

22-

Oct

-18

21-

Mar

-19

US20190083

569

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSNot Available11-

Jun-

15

24-

Jul-

18

21-

Mar

-19

US20190083

525

COMPOSITIONS COMPRISING AN RNA POLYMERASE INHIBITOR AND CYCLODEXTRIN FOR TREATING VIRAL INFECTIONSNot Available11-

Jul-17

10-

Jul-

18

21-

Mar

-19

US20190083

520

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related TheretoNot Available10-

Mar-

16

10-

Mar

-17

21-

Mar

-19

US20190083

408

CONTROLLED-RELEASE PEPTIDE COMPOSITIONS AND USES THEREOFNot Available2-

Dec-

11

4-

Dec

-18

21-

Mar

-19

US20190083

397

OIL-IN-WATER EMULSIONS INCLUDING RETINOIC ACIDNOVARTIS AG23-

Dec-

15

21-

Dec

-16

21-

Mar

-19

US20190078

060

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINESNovartis AG9-

Sep-

04

8-

Nov

-18

14-

Mar

-19

US20190078

051

Animal Protein-Free Media for Cultivation of CellsBaxalta GmbH29-

Oct-

04

29-

Oct

-18

14-

Mar

-19

US20190077

847

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASESAblynx N.V.5-

Jun-

08

17-

Oct

-17

14-

Mar

-19

US20190077

764

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH SECONDARY AMIDE FUNCTIONHoffmann-La Roche Inc.23-

May-

16

13-

Nov

-18

14-

Mar

-19

US20190077

763

BENZAZEPINE DICARBOXAMIDE COMPOUNDS WITH TERTIARY AMIDE FUNCTIONHoffmann-La Roche Inc.23-

May-

16

13-

Nov

-18

14-

Mar

-19

US20190076

520

VACCINES AND IMMUNOTHERAPEUTICS USING IL-28 AND COMPOSITIONS AND METHODS OF USINGNot Available4-

Apr-

08

11-

Sep

-18

14-

Mar

-19

US20190076

468

ENHANCED IMMUNE RESPONSE UPON TREATMENT WITH NITRIC OXIDENot Available11-

Sep-

17

11-

Sep

-17

14-

Mar

-19

 

US20190071

423

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

422

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

421

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

420

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

419

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190071

418

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

2-

Nov

-18

7-

Mar

-19

US20190062

785

MULTIVALENT VACCINES FOR RABIES VIRUS AND CORONOVIRUSESNot Available4-

Apr-

16

31-

Mar

-17

28-

Feb

-19

US20190062

724

RNA TARGETING METHODS AND COMPOSITIONSSalk Institute for Biological Studies22-

Aug-

17

27-

Mar

-18

28-

Feb

-19

US20190062

713

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINSNot Available11-

Jul-03

22-

Mar

-18

28-

Feb

-19

US20190062

408

CONSERVED HEMAGGLUTININ EPITOPE, ANTIBODIES TO THE EPITOPE, AND METHODS OF USENot Available25-

Aug-

08

20-

Jun

-18

28-

Feb

-19

US20190062

380

FUSION PROTEINS FOR PROMOTING AN IMMUNE RESPONSE, NUCLEIC ACIDS ENCODING SAME, AND METHODS OF MAKING AND USE THEREOFNot Available7-

Sep-

12

28-

Aug

-18

28-

Feb

-19

US20190062

326

2-PHENYL-3-(PIPERAZINOMETHYL)IMIDAZO[1,2-A] PYRIDINE DERIVATIVES AS BLOCKERS OF TASK-1 AND TASK-2 CHANNELS, FOR THE TREATMENT OF SLEEP-RELATED BREATHING DISORDERSBAYER PHARMA AKTIENGESELLSCHAFT10-

Dec-

15

7-

Dec

-16

28-

Feb

-19

US20190062

323

PI-Kinase Inhibitors with Anti-Infective ActivityNot Available26-

Feb-

16

24-

Feb

-17

28-

Feb

-19

US20190060

435

PEPTIDE VACCINE FORMULATIONS AND USE THEREOF FOR INDUCING AN IMMUNE RESPONSEThe United States of America, as represented by the Secretary, Dept of Health and Human Service27-

Feb-

16

27-

Feb

-17

28-

Feb

-19

US20190060

364

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPYNot Available31-

Jul-15

6-

Nov

-18

28-

Feb

-19

US20190060

363

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPYNot Available31-

Jul-15

6-

Nov

-18

28-

Feb

-19

US20190060

262

ENHANCED EXPRESSION OF RNA VECTORSUNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH25-

Mar-

13

5-

Sep

-18

28-

Feb

-19

US20190060

239

Technology for the Preparation of MicroparticlesNot Available24-

Jul-07

17-

Oct

-18

28-

Feb

-19

US20190056

122

Clean Rooms Having Dilute Hydrogen Peroxide (DHP) Gas and Methods of Use ThereofSynexis LLC20-

Apr-

15

20-

Apr

-16

21-

Feb

-19

US20190055

256

ANTI-VIRAL DRUGDORING INTERNATIONAL GMBH24-

Feb-

16

24-

Feb

-17

21-

Feb

-19

US20190055

241

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDSNot Available31-

Aug-

15

22-

Oct

-18

21-

Feb

-19

US20190055

234

COMPOSITIONS AND METHODS FOR INHIBITING KINASESNot Available23-

Apr-

15

24-

Oct

-18

21-

Feb

-19

US20190054

188

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

2-

Oct

-18

21-

Feb

-19

US20190054

127

ANTIVIRAL AGENT AND ANTIVIRAL FOODEDUCATIONAL CORPORATION MUKOGAWA GAKUIN4-

Mar-

16

22-

Nov

-16

21-

Feb

-19

US20190054

122

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPYNot Available31-

Jul-15

5-

Nov

-18

21-

Feb

-19

US20190049

378

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYSNot Available10-

Mar-

05

21-

Jun

-18

14-

Feb

-19

US20190048

344

CHEMICAL MODIFICATIONS OF MONOMERS AND OLIGONUCLEOTIDES WITH CYCLOADDITIONNot Available23-

Sep-

08

16-

Aug

-18

14-

Feb

-19

US20190048

082

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDESNot Available30-

Jun-

16

25-

Oct

-18

14-

Feb

-19

 

US20190048

049

CARGOMERSCERENIS THERAPEUTICS HOLDING SA10-

Aug-

17

10-

Aug

-18

14-

Feb

-19

US20190048

026

Boron-Containing Small MoleculesAnacor Pharmaceuticals, Inc.16-

Feb-

05

18-

Oct

-18

14-

Feb

-19

US20190046

690

MATERIALS WITH IMPROVED PROPERTIESNot Available1-

Nov-

15

2-

Nov

-16

14-

Feb

-19

US20190046

654

ALBUMIN BINDING PEPTIDE CONJUGATES AND METHODS THEREOFNot Available9-

Aug-

17

9-

Aug

-18

14-

Feb

-19

US20190046

635

COMPOSITION FOR IMMUNITY INDUCTION PROMOTION AND VACCINE PHARMACEUTICAL COMPOSITIONNITTO DENKO CORPORATION2-

Feb-

16

1-

Feb

-17

14-

Feb

-19

US20190040

451

FULLY INTEGRATED HAND-HELD DEVICE TO DETECT SPECIFIC NUCLEIC ACID SEQUENCESNot Available8-

Jan-

16

9-

Jan

-17

7-

Feb

-19

US20190040

378

NOVEL NUCLEIC ACID MOLECULESNot Available4-Jul-

17

3-

Jul-

18

7-

Feb

-19

US20190040

370

TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9Not Available23-

Nov-

15

3-

Aug

-18

7-

Feb

-19

US20190040

105

Method for Preventing and Treating HyperpermeabilityNot Available5-

Mar-

09

19-

Oct

-18

7-

Feb

-19

US20190038

742

MESENCHYMAL STEM CELLS AS VACCINE ADJUVANTS AND METHODS FOR USING THE SAMELongeveron LLC4-

Feb-

16

2-

Feb

-17

7-

Feb

-19

US20190032

077

ARTIFICIAL NUCLEIC ACID MOLECULESCureVac AG30-

Dec-

13

9-

Jul-

18

31-

Jan-

19

US20190032

041

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENSNot Available21-

Feb-

06

12-

Feb

-18

31-

Jan-

19

US20190031

740

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOFNot Available13-

May-

14

15-

Oct

-18

31-

Jan-

19

US20190031

679

NOVEL MONOTHIOL MUCOLYTIC AGENTSNot Available30-

Jan-

15

5-

Sep

-18

31-

Jan-

19

US20190031

605

TETRAHYDRONAPHTHALENE DERIVATIVEONO PHARMACEUTICAL CO., LTD.29-

Jan-

16

27-

Jan

-17

31-

Jan-

19

US20190030

187

sirna/Nanoparticle Formulations for Treatment of Middle-East Respiratory Syndrome Coronaviral InfectionSirnaomics, Inc.8-

Sep-

15

7-

Sep

-16

31-

Jan-

19

US20190030

094

BACTERIAL STRAIN AS AGENTS FOR PREVENTING AND/OR TREATING RESPIRATORY DISORDERSNot Available27-

Jan-

16

27-

Jan

-17

31-

Jan-

19

US20190025

292

ANTIGEN PRESENTING CELL ASSAYUniversity of Pittsburgh – Of the Com monwealth System of Higher Education8-

Apr-

10

25-

Sep

-18

24-

Jan-

19

US20190024

096

PROCESS FOR THE IN VIVO PRODUCTION OF RNA IN A HOST CELLNot Available7-

Aug-

15

7-

Aug

-15

24-

Jan-

19

US20190023

799

GITR Antibodies And Methods Of Inducing Or Enhancing An Immune ResponseNot Available25-

Mar-

05

28-

Jun

-18

24-

Jan-

19

US20190023

779

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITYNot Available28-

Dec-

11

5-

Oct

-18

24-

Jan-

19

US20190023

769

COMPOSITIONS AND METHODS FOR INHIBITING PATHOGEN INFECTIONNot Available29-

Oct-

12

21-

Sep

-18

24-

Jan-

19

US20190022

249

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

2-

Oct

-18

24-

Jan-

19

US20190022

216

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOFNot Available23-

Oct-

15

4-

Sep

-18

24-

Jan-

19

US20190022

214

Attenuated Infectious Bronchitis VirusNot Available27-

Jan-

16

26-

Jan

-17

24-

Jan-

19

US20190022

213

MERS-CoV VaccineNot Available29-

Nov-

13

29-

Jun

-18

24-

Jan-

19

US20190022

116

N4-Hydroxycytidine and Derivatives and Anti-Viral Uses Related TheretoNot Available26-

Dec-

14

16-

Dec

-15

24-

Jan-

19

US20190017

112

METHOD OF DIRECT TARGET SEQUENCING USING NUCLEASE PROTECTIONHTG Molecular Diagnostics, Inc.11-

Feb-

16

10-

Feb

-17

17-

Jan-

19

US20190017

068

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available17-

Dec-

01

26-

Sep

-18

17-

Jan-

19

 

US20190017

000

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFNot Available8-

Sep-

16

19-

Sep

-18

17-

Jan-

19

US20190016

785

ANTIBODIES THAT POTENTLY NEUTRALIZE HEPATITIS B VIRUS

AND USES THEREOF

Not Available7-

Oct-

15

7-

Oct

-16

17-

Jan-

19

US20190016

772

GM-CSF and IL-4 Conjugates, Compositions, and Methods Related TheretoNot Available23-

Oct-

12

2-

Oct

-18

17-

Jan-

19

US20190016

710

MULTICYCLIC COMPOUNDS AND USES THEREOFNot Available31-

Dec-

15

29-

Dec

-16

17-

Jan-

19

US20190016

690

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available31-

Dec-

15

30-

Dec

-16

17-

Jan-

19

US20190015

527

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

25-

Jul-

18

17-

Jan-

19

US20190015

522

IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOFNot Available5-

Apr-

12

19-

Jul-

18

17-

Jan-

19

US20190015

501

NUCLEIC ACID VACCINESModernaTX, Inc.23-

Apr-

14

27-

Sep

-18

17-

Jan-

19

US20190015

432

Lipid Disulfide Prodrugs and Uses Related TheretoNot Available13-

Jul-17

13-

Jul-

18

17-

Jan-

19

US20190010

469

ATTENUATED VIRUSES USEFUL FOR VACCINESNot Available30-

Mar-

07

16-

Jul-

18

10-

Jan-

19

US20190010

240

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGANDNot Available15-

Mar-

13

2-

Aug

-18

10-

Jan-

19

US20190010

132

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDSParion Sciences, Inc.13-

Dec-

13

4-

Apr

-18

10-

Jan-

19

US20190008

954

NEGATIVELY CHARGED NUCLEIC ACID COMPRISING COMPLEXES FOR IMMUNOSTIMULATIONCureVac AG31-

Jan-

12

11-

Jun

-18

10-

Jan-

19

US20190008

948

NUCLEIC ACID VACCINESModernaTX, Inc.23-

Apr-

14

16-

Jul-

18

10-

Jan-

19

US20190008

833

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available9-

May-

12

17-

Jul-

18

10-

Jan-

19

US20190004

061

DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRYNot Available2-Jul-

10

4-

Aug

-18

3-

Jan-

19

US20190002

477

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOFKineta, Inc.9-

May-

14

31-

Jan

-18

3-

Jan-

19

US20190002

448

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOFNot Available31-

Dec-

15

29-

Dec

-16

3-

Jan-

19

US20190002

393

Lipids and Lipid Compositions for the Delivery of Active AgentsNot Available5-

Sep-

14

19-

Sep

-18

3-

Jan-

19

US20190001

010

ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOFNot Available8-

Dec-

14

13-

Jul-

18

3-

Jan-

19

US20190000

959

NUCLEIC ACID VACCINESModernaTX, Inc.23-

Apr-

14

27-

Jul-

18

3-

Jan-

19

US20190000

745

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOFeXion labs Inc.28-

Jul-16

4-

Sep

-18

3-

Jan-

19

US20180372

747

METHODS OF IDENTIFYING IMMUNE CELLS IN PD-L1 POSITIVE TUMOR TISSUENot Available22-

Nov-

15

21-

May

-18

27-

Dec

-18

US20180372

733

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATESNot Available27-

Apr-

10

21-

Jun

-18

27-

Dec

-18

US20180371

536

METHODS FOR RNA QUANTIFICATIONNot Available1-

Jun-

15

26-

May

-16

27-

Dec

-18

US20180371

461

APTAMERS, NUCLEIC ACID MOLECULES, POLYNUCLEOTIDES, SYNTHETIC ANTIBODIES COMPOSITIONS FOR DETECTING PRRS VIRUSES AND TREATING PRRS VIRUS INFECTIONNot Available10-

Dec-

15

1-

Dec

-16

27-

Dec

-18

US20180371

410

MEANS AND METHODS FOR INFLUENCING THE STABILITY OF CELLSNot Available4-

Dec-

09

28-

Aug

-18

27-

Dec

-18

US20180369

386

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTSNot Available8-

Mar-

13

29-

Aug

-18

27-

Dec

-18

US20180369

364

RECOMBINANT VIRUS LIKE PARTICLES USING BOVINE IMMUNODEFICIENCY VIRUS GAG PROTEINNot Available2-Jul-

15

1-

Jul-

16

27-

Dec

-18

 

US20180368

417

ANTIMICROBIAL COMPOSITIONS AND METHODSNot Available23-

Sep-

14

19-

Jun

-18

27-

Dec

-18

US20180365

375

METHODS AND SYSTEMS FOR MULTIPLE TAXONOMIC CLASSIFICATIONNot Available24-

Apr-

15

4-

Oct

-17

20-

Dec

-18

US20180363

027

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACIDNot Available6-

Oct-

06

15-

May

-18

20-

Dec

-18

US20180362

625

REGULATION OF CYTOKINE PRODUCTIONNot Available4-

Dec-

15

2-

Dec

-16

20-

Dec

-18

US20180360

877

METHODS FOR EXPANDING A POPULATION OF ALVEOLAR MACROPHAGES IN A LONG TERM CULTURENot Available8-

Dec-

15

8-

Dec

-16

20-

Dec

-18

US20180360

736

FILM DOSAGE FORM WITH EXTENDED RELEASE MUCOADHESIVE PARTICLESIntelgenx Corp.2-

Dec-

13

23-

Aug

-18

20-

Dec

-18

US20180355

017

COMPOSITIONS AND METHODS FOR INTERNALIZING ENZYMESNot Available7-

Jun-

17

6-

Jun

-18

13-

Dec

-18

US20180353

594

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMSNot Available26-

Jul-13

21-

Aug

-18

13-

Dec

-18

US20180346

574

ANTI-PD-L1 ANTIBODIES AND USES THEREOFNot Available13-

Jun-

16

9-

Aug

-18

6-

Dec

-18

US20180346

573

ANTI-PD-L1 ANTIBODIES AND USES THEREOFNot Available13-

Jun-

16

9-

Aug

-18

6-

Dec

-18

US20180346

522

HUMAN RESPIRATORY SYNCYTIAL VIRUS CONSENSUS ANTIGENS, NUCLEIC ACID CONSTRUCTS AND VACCINES MADE THEREFROM, AND METHODS OF USING THE SAMENot Available10-

Apr-

12

6-

Aug

-18

6-

Dec

-18

US20180346

516

PEPTIDES AND USES THEREFOR AS ANTIVIRAL AGENTSNot Available27-

Nov-

15

28-

Nov

-16

6-

Dec

-18

US20180346

485

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

27-

Feb

-18

6-

Dec

-18

US20180346

480

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

1-

Mar

-18

6-

Dec

-18

US20180344

877

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOFChildren’s Healthcare of Atlanta, Inc.16-

Apr-

15

8-

Aug

-18

6-

Dec

-18

US20180344

832

METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPYNot Available20-

Apr-

15

20-

Apr

-16

6-

Dec

-18

US20180344

751

Broad Spectrum Antiviral and Methods of UseNot Available17-

Apr-

06

26-

Dec

-17

6-

Dec

-18

US20180340

219

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICSMASSACHUSETTS INSTITUTE OF TECHNOLOGY9-

Dec-

16

9-

Mar

-18

29-

Nov

-18

US20180340

218

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICSMASSACHUSETTS INSTITUTE OF TECHNOLOGY9-

Dec-

16

9-

Mar

-18

29-

Nov

-18

US20180340

215

SAMPLE ANALYSIS, PRESENCE DETERMINATION OF A TARGET SEQUENCENot Available28-

Aug-

15

26-

Aug

-16

29-

Nov

-18

US20180340

154

PRODUCTION OF VIRUSES IN AVIAN EGGSNot Available24-

Nov-

15

23-

Nov

-16

29-

Nov

-18

US20180340

153

PRODUCTION OF VIRUSES IN CELL CULTURENot Available24-

Nov-

15

23-

Nov

-16

29-

Nov

-18

US20180339

991

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

24-

May

-18

29-

Nov

-18

US20180339

988

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

18-

Jan

-18

29-

Nov

-18

US20180339

014

PEPTIDOMIMETIC MACROCYCLESNot Available14-

Jan-

09

7-

Jun

-18

29-

Nov

-18

US20180334

480

CORONAVIRUSES EPITOPE-BASED VACCINESRAMOT AT TEL-AVIV UNIVERSITY LTD.17-

Sep-

15

15-

Sep

-16

22-

Nov

-18

US20180333

485

Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The SameNot Available12-

Dec-

11

9-

May

-18

22-

Nov

-18

US20180327

800

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLSNot Available26-

Feb-

03

21-

May

-18

15-

Nov

-18

 

US20180327

738

STABILIZED REAGENTS FOR GENOME MODIFICATIONNot Available20-

Nov-

15

18-

Nov

-16

15-

Nov

-18

US20180327

697

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFNot Available8-

Sep-

16

12-

Jun

-18

15-

Nov

-18

US20180327

484

RSV-SPECIFIC BINDING MOLECULES AND MEANS FOR PRODUCING THEMNot Available1-

Jun-

07

23-

Jul-

18

15-

Nov

-18

US20180326

070

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDESNot Available4-

Dec-

07

20-

Nov

-17

15-

Nov

-18

US20180326

051

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODSNot Available17-

Aug-

10

24-

Jul-

18

15-

Nov

-18

US20180326

045

COMBINATION PIV3/HMPV RNA VACCINESModernaTX, Inc.22-

Oct-

15

20-

Jul-

18

15-

Nov

-18

US20180326

044

NSP10 SELF-ASSEMBLING FUSION PROTEINS FOR VACCINES, THERAPEUTICS, DIAGNOSTICS AND OTHER NANOMATERIAL APPLICATIONSNot Available13-

Oct-

15

13-

Oct

-16

15-

Nov

-18

US20180326

039

VACCINE COMPOSITIONSNot Available16-

Sep-

15

16-

Sep

-16

15-

Nov

-18

US20180325

076

ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEMOXISCIENCE, LLC28-

Aug-

14

24-

Jul-

18

15-

Nov

-18

US20180321

242

VIRAL BIOMARKERS AND USES THEREFORNot Available6-

Nov-

15

4-

Nov

-16

8-

Nov

-18

US20180319

811

DERIVATIVES OF PORPHYRINS, THEIR PROCESS OF PREPARATION AND THEIR USE FOR TREATING VIRAL INFECTIONSNot Available30-

Oct-

15

28-

Oct

-16

8-

Nov

-18

US20180319

779

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOFNot Available3-Jul-

13

4-

Dec

-17

8-

Nov

-18

US20180318

447

COMPOSITIONS AND METHODS FOR IMPROVING VIRAL VECTOR EFFICIENCYNot Available3-

Dec-

15

30-

Nov

-16

8-

Nov

-18

US20180318

366

METHOD OF TREATMENT USING ONCOLYTIC VIRUSESNot Available15-

Jun-

15

15-

Jun

-16

8-

Nov

-18

US20180318

350

Immune Cells with DNMT3A Gene Modifications and Methods Related TheretoNot Available4-

Nov-

15

4-

Nov

-16

8-

Nov

-18

US20180312

575

ANTIBODIES AGAINST INFLUENZA VIRUS AND METHODS OF USE THEREOFNot Available6-

Dec-

07

20-

Mar

-18

1-

Nov

-18

US20180312

545

OPTIMIZED NUCLEIC ACID MOLECULESNot Available9-

Nov-

15

9-

Nov

-16

1-

Nov

-18

US20180312

544

RECOMBINANT HUMAN/BOVINE PARAINFLUENZA VIRUS 3 (B/HPIV3) EXPRESSING A CHIMERIC RSV/BPIV3 F PROTEIN AND USES THEREOFThe United States of America, as represented by the Secretary, Dept. of Health and Human Services20-

Jan-

15

20-

Jan

-16

1-

Nov

-18

US20180311

338

MICRONEEDLE COMPOSITIONS AND METHODS OF USING SAMENot Available11-

Jan-

16

11-

Jul-

18

1-

Nov

-18

US20180311

273

Method of Treating InflammationNot Available1-

Apr-

10

26-

Jun

-18

1-

Nov

-18

US20180305

773

CRISPR EFFECTOR SYSTEM BASED DIAGNOSTICS FOR MALARIA DETECTIONNot Available12-

Apr-

17

12-

Apr

-18

25-

Oct-

18

US20180305

760

Pathogen biomarkers and uses thereforNot Available30-

Sep-

15

30-

Sep

-16

25-

Oct-

18

US20180305

451

HIDE1 COMPOSITIONS AND METHODSNot Available13-

Jul-15

13-

Jul-

16

25-

Oct-

18

US20180305

412

COMPOSITIONS AND METHODS FOR TREATING DISEASES BY INHIBITING EXOSOME RELEASENot Available19-

Dec-

16

9-

Jul-

18

25-

Oct-

18

US20180305

357

IMMUNE RESPONSE MODIFIER COMPOSITIONS AND METHDOSNot Available22-

Dec-

06

25-

Jun

-18

25-

Oct-

18

US20180305

356

NOVEL KINASE INHIBITORSNot Available19-

Oct-

12

18-

May

-18

25-

Oct-

18

US20180303

874

Compositions and Methods for the Prevention of Microbial InfectionsNot Available10-

Nov-

11

30-

Nov

-17

25-

Oct-

18

US20180303

768

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITYNot Available30-

Jan-

15

2-

Jul-

18

25-

Oct-

18

US20180303

090

TREATMENT COMPOSITIONS PROVIDING AN ANTIMICROBIAL BENEFITNot Available30-

Oct-

15

17-

Oct

-16

25-

Oct-

18

 

US20180267

031

METHOD AND DEVICE FOR DETECTING ANTIGEN-SPECIFIC ANTIBODIES IN A BIOLOGICAL FLUID SAMPLE BY USING NEODYMIUM MAGNETSThe U.S.A., as represented by the Secretary, Department of Health and Human Services1-

Sep-

15

8-

Aug

-16

20-

Sep

-18

US20180265

847

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

29-

Mar

-18

20-

Sep

-18

US20180265

822

LIQUID LOADING COMPOSITION, METHOD OF MAKING AND USE THEREOFNot Available8-

Sep-

16

21-

May

-18

20-

Sep

-18

US20180265

574

Anti-pneumococcal hyperimmune globulin for the treatment and prevention of pneumococcal infectionNot Available15-

Mar-

17

15-

Mar

-17

20-

Sep

-18

US20180265

507

HOST TARGETED INHIBITORS OF DENGUE VIRUS AND OTHER VIRUSESDana-Farber Cancer Institute, Inc.11-

Apr-

12

26-

Jan

-18

20-

Sep

-18

US20180264

098

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONSThe Government of the USA as represented by the Secretary of the Dept. of Health and Human Service8-

Oct-

04

31-

May

-18

20-

Sep

-18

US20180258

162

Methods Of Treating Inflammation Associated Airway Diseases And Viral InfectionsNot Available2-

Jan-

15

22-

May

-18

13-

Sep

-18

US20180258

160

Optimized Crosslinkers for Trapping a Target on a SubstrateNot Available13-

Nov-

15

11-

May

-18

13-

Sep

-18

US20180258

159

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYNot Available28-

Oct-

14

14-

May

-18

13-

Sep

-18

US20180258

151

RECOMBINANT SUPER-COMPOUND INTERFERON AND USES THEREOFNot Available28-

Feb-

01

2-

Mar

-18

13-

Sep

-18

US20180251

737

COMPOSITIONS, METHODS AND USES FOR INDUCING VIRAL GROWTHNot Available5-

Dec-

08

28-

Dec

-17

6-

Sep

-18

US20180251

540

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)Not Available16-

Dec-

02

30-

Apr

-18

6-

Sep

-18

US20180251

436

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSNot Available24-

Jan-

14

19-

Sep

-17

6-

Sep

-18

US20180250

602

PAPAYA MOSAIC VIRUS COMPOSITIONS AND USES THEREOF FOR STIMULATION OF THE INNATE IMMUNE RESPONSENot Available11-

Feb-

14

1-

May

-18

6-

Sep

-18

US20180250

381

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINESNot Available20-

Aug-

10

12-

Oct

-17

6-

Sep

-18

US20180245

056

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODSNot Available19-

Nov-

09

9-

Oct

-17

30-

Aug

-18

US20180245

053

VIRAL VACCINES AND METHODS OF FORMING THE SAMENot Available27-

Feb-

17

27-

Feb

-18

30-

Aug

-18

US20180244

759

NOVEL METHODS OF GENERATING ANTIBODIESRutgers, The State University of New Jersey19-

Aug-

15

18-

Aug

-16

30-

Aug

-18

US20180244

756

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS IMMUNOGENS, ANTIBODIES, AND THEIR USEThe United States of America, as Represented by the Secretary, Dept. of Health and Human Services24-

Feb-

15

24-

Feb

-16

30-

Aug

-18

US20180244

669

IMIDAZO[4,5-c] RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPSNot Available31-

Aug-

15

26-

Aug

-16

30-

Aug

-18

US20180244

660

CYCLOPROPYLDERIVATIVES AND THEIR USE AS KINASE INHIBITORSNot Available17-

Aug-

15

17-

Aug

-16

30-

Aug

-18

US20180243

347

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOFNot Available25-

Aug-

15

22-

Aug

-16

30-

Aug

-18

US20180237

835

METHODS OF ANALYZING VIRUS-DERIVED THERAPEUTICSAmerican International Biotechnology, LLC31-

Jul-15

29-

Jul-

16

23-

Aug

-18

US20180237

788

IMPROVEMENTS IN OR RELATING TO DNA RECOMBINATIONThe Regents of the University of California8-

Aug-

15

5-

Aug

-16

23-

Aug

-18

US20180237

786

ARTIFICIAL NUCLEIC ACID MOLECULESCUREVAC AG28-

Aug-

15

22-

Aug

-16

23-

Aug

-18

US20180237

502

PAN-EBOLA AND PAN-FILOVIRUS PROTECTIVE EPITOPES, ANTIBODIES, AND ANTIBODY COCKTAILSIntegrated BioTherapeutics, Inc.11-

Mar-

15

11-

Mar

-16

23-

Aug

-18

US20180237

435

GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDSNot Available31-

Aug-

15

26-

Aug

-16

23-

Aug

-18

US20180236

058

REVERSE GENETICS SYSTEMSNot Available31-

Jul-09

16-

Oct

-17

23-

Aug

-18

US20180236

054

Tetanus Toxoid and CCL3 Improve DC VaccinesDuke University14-

Nov-

13

19-

Apr

-18

23-

Aug

-18

 

US20180235

948

(S,E)-3-(6-AMINOPYRIDIN-3-YL)-N-((5-(4-(3-FLUORO-3- METHYLPYRROLIDINE-1-CARBONYL)PHENYL)-7-(4- FLUOROPHENYL)BENZOFURAN-2-YL)METHYL)ACRYLAMIDE FOR THE TREATMENT OF CANCERNot Available18-

Aug-

15

18-

Aug

-16

23-

Aug

-18

US20180230

521

BIOAGENT DETECTION OLIGONUCLEOTIDESNot Available27-

Dec-

11

13-

Apr

-18

16-

Aug

-18

US20180230

447

ACTIVE LOW MOLECULAR WEIGHT VARIANTS OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2)Northwestern University24-

Jan-

17

24-

Jan

-18

16-

Aug

-18

US20180228

695

DEVICES, SYSTEM AND METHOD TO CONTROL THE DELIVERY OF ORAL MEDICATIONS TO ENSURE THEY ARE EFFICACIOUS , TAKEN AS PRESCRIBED, AND TO AVOID UNWANTED SIDE EFFECTSNot Available11-

Aug-

15

11-

Aug

-16

16-

Aug

-18

US20180223

290

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTSGenVec, Inc.10-

Nov-

05

7-

Sep

-17

9-

Aug

-18

US20180222

906

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINES3M Innovative Properties Company18-

Jun-

04

9-

Apr

-18

9-

Aug

-18

US20180221

464

IMMUNOGENIC COMPOSITIONS, ANTIGEN SCREENING METHODS, AND METHODS OF GENERATING IMMUNE RESPONSESNot Available3-

Aug-

15

3-

Aug

-16

9-

Aug

-18

US20180216

164

HIGH DENSITY SELF-CONTAINED BIOLOGICAL ANALYSISNot Available15-

Nov-

06

19-

Mar

-18

2-

Aug

-18

US20180216

067

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

29-

Mar

-18

2-

Aug

-18

US20180215

831

Antibody Derivatives with Conditionally Enabled Effector FunctionNot Available27-

Jul-15

27-

Jul-

16

2-

Aug

-18

US20180215

801

CRYPTIC POLYPEPTIDES AND USES THEREOFNot Available29-

Jan-

15

29-

Jan

-16

2-

Aug

-18

US20180215

794

TREATING CANCER WITH VIRAL NUCLEIC ACIDMayo Foundation for Medical Education and Research20-

Feb-

07

27-

Mar

-18

2-

Aug

-18

US20180214

430

Selective Inhibitors Of i-NOS For Use Against Viral InfectionUCL Business PLC17-

Jul-15

15-

Jul-

16

2-

Aug

-18

US20180209

960

Method of Determining, Identifying or Isolating Cell-Penetrating PeptidesNot Available23-

May-

11

11-

Dec

-17

26-

Jul-

18

US20180208

897

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

19-

Mar

-18

26-

Jul-

18

US20180208

659

ANTI-PD-L1 ANTIBODIES AND USES THEREOFNot Available13-

Jun-

16

13-

Jun

-17

26-

Jul-

18

US20180208

653

METHODS FOR ENHANCING AN IMMUNE RESPONSENot Available20-

Jan-

17

19-

Jan

-18

26-

Jul-

18

US20180207

258

ADJUVANTED INFLUENZA VACCINES FOR PEDIATRIC USENot Available22-

Feb-

08

5-

Mar

-18

26-

Jul-

18

US20180207

145

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASESGlaxoSmithKline Intellectual Property (No. 2) Limited12-

May-

14

19-

Mar

-18

26-

Jul-

18

US20180201

998

COMPOSITIONS AND METHODS FOR DETECTION OF GENETIC DEAFNESS GENE MUTATIONCapitalBio Corporation14-

Jul-15

14-

Jul-

15

19-

Jul-

18

US20180201

907

METHODS FOR INCREASING THE INFECTIVITY OF VIRUSESNot Available26-

Jan-

12

13-

Mar

-18

19-

Jul-

18

US20180201

687

ANTIBODIES HAVING SPECIFICITY TO MYOSIN 18A AND USES THEREOFNot Available7-Jul-

15

7-

Jul-

16

19-

Jul-

18

US20180200

365

Methods and Compositions for Inhibiting Akt3Not Available17-

Jan-

17

20-

Feb

-18

19-

Jul-

18

US20180200

364

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS3M Innovative Properties Company17-

Aug-

10

27-

Nov

-17

19-

Jul-

18

US20180200

224

Antiviral Activity from Medicinal Mushrooms and Their Active ConstituentsNot Available31-

Mar-

15

12-

Mar

-18

19-

Jul-

18

US20180200

196

Modular Particulars for ImmunotherapyNot Available1-

Nov-

13

3-

Jan

-18

19-

Jul-

18

US20180196

061

INFLUENZA POTENCY ASSAYSNot Available7-Jul-

15

7-

Jul-

16

12-

Jul-

18

US20180195

048

METHODS FOR PRODUCING VIRUS FOR VACCINE PRODUCTIONTakeda Vaccines, Inc.13-

Feb-

15

12-

Feb

-16

12-

Jul-

18

 

US20180194

850

ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY ANTIBODIESNot Available15-

May-

15

13-

May

-16

12-

Jul-

18

US20180194

829

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCERNot Available15-

Apr-

11

13-

Nov

-17

12-

Jul-

18

US20180194

735

Sulfinylphenyl or Sulfonimidoylphenyl BenzazepinesHoffmann La-Roche Inc.17-

Sep-

15

8-

Mar

-18

12-

Jul-

18

US20180193

477

DRUG-CONJUGATED BI-SPECIFIC ANTIGEN-BINDING CONSTRUCTSNot Available15-

Jul-15

15-

Jul-

16

12-

Jul-

18

US20180187

213

Variant AAV and Compositions, Methods and Uses for Gene Transfer to Cells, Organs and TissuesThe Children’s Hospital of Philadelphia22-

Jul-13

6-

Dec

-17

5-

Jul-

18

US20180187

211

METHODS AND COMPOSITIONS FOR COMBINATION IMMUNOTHERAPYNot Available9-

Jan-

15

7-

Jan

-16

5-

Jul-

18

US20180187

165

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOFTakeda Vaccines, Inc.7-

Nov-

14

27-

Oct

-17

5-

Jul-

18

US20180187

154

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

20-

Feb

-18

5-

Jul-

18

US20180187

153

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

20-

Feb

-18

5-

Jul-

18

US20180187

131

DISINFECTING AQUEOUS FOAM, PROCESS FOR PREPARING SAME AND USE THEREOFCOMMISSARIAT A L’ENERGIE ATOMIQUE ET AUX ENERGIES ALTERNATIVES16-

Jun-

15

15-

Jun

-16

5-

Jul-

18

US20180186

897

NOVEL VACCINES IN PREVENTION AND TREATMENT OF MALARIANot Available26-

Jun-

15

24-

Jun

-16

5-

Jul-

18

US20180186

821

PROTEIN PROXIMITY ASSAY IN FORMALIN FIXED PAFFAFIN EMBEDDED TISSUE USING CAGED HAPTENSNot Available28-

Aug-

15

28-

Feb

-18

5-

Jul-

18

US20180186

802

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTSNot Available1-

May-

14

27-

Feb

-18

5-

Jul-

18

US20180186

792

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM3M Innovative Properties Company3-

Jun-

11

26-

Feb

-18

5-

Jul-

18

US20180186

534

Powdered Pouch And Method Of Making SameMONOSOL, LLC16-

Apr-

12

29-

Dec

-17

5-

Jul-

18

US20180185

469

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROMENot Available24-

Apr-

12

14-

Dec

-17

5-

Jul-

18

US20180185

392

Pharmaceutical Compositions and MethodsNot Available3-

Aug-

15

29-

Nov

-17

5-

Jul-

18

US20180185

345

METHODS AND COMPOSITIONS FOR TREATING HERPESVIRUS INDUCED CONDITIONSNot Available19-

Jun-

15

17-

Jun

-16

5-

Jul-

18

US20180180

544

USE OF A FLUORESCENT MATERIAL TO DETECT FAILURE OR DETERIORATED PERFORMANCE OF A FLUOROMETERNot Available14-

Jun-

12

22-

Feb

-18

28-

Jun-

18

US20180179

300

GENERATION OF BINDING MOLECULESMerus N.V.26-

Sep-

11

22-

Nov

-17

28-

Jun-

18

US20180179

274

PROTEINS COMPRISING A MUTATED LAIR-1 FRAGMENT AND USES THEREOFNot Available26-

Jun-

15

24-

Jun

-16

28-

Jun-

18

US20180177

863

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSESNot Available23-

Sep-

15

31-

Oct

-17

28-

Jun-

18

US20180177

862

ANTIGENICALLY MATCHED INFLUENZA VACCINESNot Available26-

Jun-

15

24-

Jun

-16

28-

Jun-

18

US20180177

860

VACCINE CONTAINING VIRUS INACTIVATED BY GREEN TEA EXTRACT, AND PREPARATION METHOD THEREFORNot Available11-

Jun-

15

7-

Jun

-16

28-

Jun-

18

US20180163

182

PROCESSES FOR PRODUCTION AND PURIFICATION OF NUCLEIC ACID-CONTAINING COMPOSITIONSHuman Services10-

Jun-

15

10-

Jun

-16

14-

Jun-

18

US20180162

838

Chemical CompoundsNot Available18-

Mar-

14

13-

Dec

-17

14-

Jun-

18

US20180162

835

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

11-

Dec

-17

14-

Jun-

18

US20180161

425

NOVEL PROTEIN STRUCTURE USED FOR EFFICIENT ANTIBODY PRODUCTION IN IMMUNIZATIONNot Available10-

Dec-

14

10-

Dec

-15

14-

Jun-

18

 

US20180161

422

NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM- LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED PATHOGENIC ANTIGENCureVac AG15-

Feb-

12

8-

Feb

-18

14-

Jun-

18

US20180161

279

GASTRO-RETENTIVE MODIFIED RELEASE DOSAGE FORMS FOR OPROZOMIB AND PROCESS TO MAKE THEREOFNot Available14-

Dec-

16

13-

Dec

-17

14-

Jun-

18

US20180160

662

Transgenic Immunodeficient Mouse Expressing Human SIRP-alphaInstitut Pasteur26-

Mar-

12

25-

Jan

-18

14-

Jun-

18

US20180149

659

DIAGNOSIS AND TREATMENT OF MERS-RELATED RENAL DISEASENot Available4-

Jun-

15

3-

Jun

-16

31-

May

-18

US20180148

727

ARTIFICIAL NUCLEIC ACID MOLECULESNot Available30-

Dec-

14

29-

Dec

-15

31-

May

-18

US20180142

239

METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER OR OTHER DISEASESNot Available26-

Jan-

07

14-

Jun

-17

24-

May

-18

US20180142

198

DELIVERY OF BIOMOLECULES TO IMMUNE CELLSNot Available31-

Oct-

14

30-

Oct

-15

24-

May

-18

US20180142

006

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

12-

Jan

-18

24-

May

-18

US20180142

005

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

12-

Jan

-18

24-

May

-18

US20180142

004

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

11-

Jan

-18

24-

May

-18

US20180142

003

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

9-

Jan

-18

24-

May

-18

US20180142

002

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

5-

Jan

-18

24-

May

-18

US20180140

659

ANALOGS OF C5a AND METHODS OF USING SAMENot Available29-

Jun-

10

12-

Jan

-18

24-

May

-18

US20180140

625

PRODUCTION OF STABLE NON-POLYADENYLATED RNASMassachusetts Institute of Technology16-

Oct-

12

31-

Jul-

17

24-

May

-18

US20180140

580

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSISNot Available29-

Nov-

02

23-

Oct

-17

24-

May

-18

US20180135

099

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOFNot Available23-

Dec-

05

2-

Jan

-18

17-

May

-18

US20180135

012

MEMBRANE-RECEIVER COMPLEX THERAPEUTICSNot Available13-

May-

15

13-

May

-16

17-

May

-18

US20180134

783

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)Not Available16-

Dec-

02

26-

Apr

-16

17-

May

-18

US20180134

770

ANTIBODY PRODUCING NON-HUMAN ANIMALSMerus N.V.27-

Jun-

08

12-

Jan

-18

17-

May

-18

US20180133

246

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASESNot Available7-

Mar-

12

1-

Nov

-17

17-

May

-18

US20180127

836

IMPROVED COMPOSITIONS AND METHODS FOR DETECTION OF VIRUSESNot Available7-

May-

15

6-

May

-16

10-

May

-18

US20180127

783

CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNASEDITAS MEDICINE, INC.7-

Nov-

13

29-

Nov

-17

10-

May

-18

US20180127

384

HYDRAZIDE CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available29-

Jul-11

21-

Jun

-17

10-

May

-18

US20180125

965

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOFTakeda Vaccines, Inc.7-

Nov-

14

6-

Nov

-15

10-

May

-18

US20180125

952

PRIME-BOOST REGIMENS INVOLVING ADMINISTRATION OF AT LEAST ONE mRNA CONSTRUCTNot Available15-

May-

15

13-

May

-16

10-

May

-18

US20180125

883

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASESNot Available7-

Mar-

12

20-

Sep

-17

10-

May

-18

US20180112

270

C-CBL MUTATIONS AND USES THEREOFNot Available4-

Jun-

10

22-

Mar

-16

26-

Apr-

18

US20180111

991

MODULATORS OF ACTIVIN AND METHODS FOR MODULATING IMMUNE RESPONSES AND T FOLLICULAR HELPER CELLSNot Available2-

Dec-

14

2-

Jun

-17

26-

Apr-

18

 

US20180U1

907

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER

MUCOSAL DISEASES

Not Available29-

May-

12

20-

Dec

-17

26-

Apr-

18

US20180110

845

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERSNot Available31-

Aug-

07

18-

Dec

-17

26-

Apr-

18

US20180105

815

Bivalent siRNA Chimeras and Methods of Use ThereofNot Available18-

Oct-

16

6-

Oct

-17

19-

Apr-

18

US20180105

596

ANTI-TYRO3 ANTIBODIES AND USES THEREOFNot Available17-

Apr-

15

15-

Apr

-16

19-

Apr-

18

US20180105

514

HETEROCYCLIC AMIDES USEFUL AS PROTEIN MODULATORSNot Available7-

Apr-

16

3-

Jan

-18

19-

Apr-

18

US20180104

241

CHEMICALLY AND METABOLICALLY STABLE DIPEPTIDE POSSESSING POTENT SODIUM CHANNEL BLOCKER ACTIVITYPARION SCIENCES, INC.27-

Jun-

11

15-

Dec

-17

19-

Apr-

18

US20180100

181

METHODS FOR DETECTING AGGLUTINATION AND COMPOSITIONS FOR USE IN PRACTICING THE SAMENot Available17-

Apr-

15

15-

Apr

-16

12-

Apr-

18

US20180099

999

FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIANot Available17-

Sep-

14

14-

Dec

-17

12-

Apr-

18

US20180098

972

TREATMENT OF INFECTIOUS DISEASESCHILDREN’S MEDICAL CENTER CORPORATION26-

Jan-

15

26-

Jan

-16

12-

Apr-

18

US20180092

932

Anti-Viral Azide Containing CompoundsNot Available28-

Jul-10

7-

Dec

-17

5-

Apr-

18

US20180087

049

MAXIMIZING DNA YIELD OF BLOOD SPECIMENS COLLECTED IN RAPID CLOT TUBESNot Available27-

Sep-

16

7-

Sep

-17

29-

Mar

-18

US20180086

818

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYNot Available28-

Oct-

14

13-

Nov

-17

29-

Mar

-18

US20180085

457

ANTIBODY/T-CELL RECEPTOR CHIMERIC CONSTRUCTS AND USES THEREOFNot Available23-

Oct-

15

1-

Dec

-17

29-

Mar

-18

US20180085

432

STING (Stimulator of Interferon Genes), A Regulator of Innate Immune ResponsesNot Available4-

Aug-

08

15-

Sep

-17

29-

Mar

-18

US20180085

388

DELIVERY OF RNA TO TRIGGER MULTIPLE IMMUNE PATHWAYSGLAXOSMITHKLINE BIOLOGICALS, SA6-Jul-

10

5-

Oct

-17

29-

Mar

-18

US20180079

746

HETEROCYCLIC MODULATORS OF LIPID SYNTHESISNot Available19-

Mar-

15

15-

Mar

-16

22-

Mar

-18

US20180078

625

COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTSNot Available25-

Mar-

15

25-

Mar

-16

22-

Mar

-18

US20180078

532

IMMEDIATE RELEASE FORMULATIONS FOR OPROZOMIBAMGEN INC.21-

Sep-

16

18-

Sep

-17

22-

Mar

-18

US20180078

507

BIODEGRADABLE POLYMERIC PARTICLES ENCAPSULATING AN ACTIVE AGENT, PHARMACEUTICAL COMPOSITIONS AND USES THEREOFNot Available16-

Sep-

16

15-

Sep

-17

22-

Mar

-18

US20180073

073

METHODS AND COMPOSITIONS FOR LABELING TARGETS AND HAPLOTYPE PHASINGNot Available18-

Mar-

15

16-

Mar

-16

15-

Mar

-18

US20180072

813

CARBONIC ANHYDRASE IX (G250) ANTIBODIES AND METHODS OF USE THEREOFNot Available2-

Dec-

05

9-

May

-17

15-

Mar

-18

US20180072

796

MAST CELL STABILIZERS FOR TREATMENT OF HYPERCYTOKINEMIA AND VIRAL INFECTIONNot Available8-

Sep-

16

17-

Nov

-17

15-

Mar

-18

US20180072

752

COUMARIN DERIVATIVE AS ANTIVIRAL AGENT, PHARMACEUTICAL COMPOSITION THEREOF, ITS PREPARATION AND USENot Available30-

Mar-

15

2-

Feb

-16

15-

Mar

-18

US20180071

219

Technology for Preparation of Macromolecular MicrospheresNot Available24-

Jan-

06

25-

Sep

-17

15-

Mar

-18

US20180067

299

ENDOSCOPIC APPARATUS FOR THERMAL DISTRIBUTION MONITORINGELECTRONICS AND TELECOMMUNICATIONS RESEARCH INSTITUTE7-

Sep-

16

31-

May

-17

8-

Mar

-18

US20180066

228

Detection of T Cell Exhaustion or Lack of T Cell Costimulation and Uses ThereofNot Available15-

May-

15

15-

Nov

-17

8-

Mar

-18

US20180066

216

CLEANING COMPOSITION, METHOD OF MAKING AND USE THEREOFNot Available8-

Sep-

16

6-

Sep

-17

8-

Mar

-18

US20180065

981

HETEROCYCLYLMETHYL-THIENOURACILE AS ANTAGONISTS OF THE ADENOSINE-A2B-RECEPTORNot Available26-

Mar-

15

21-

Mar

-16

8-

Mar

-18

 

US20180064

790

Composition for Treatment or Prevention of Infectious Inflammatory Diseases, or Composition for Immune Enhancement, Comprising Tryptophanyl-tRNA Synthetase as an Active IngredientNot Available26-

Feb-

15

25-

Aug

-17

8-

Mar

-18

US20180064

752

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVENot Available29-

Jul-14

25-

Oct

-17

8-

Mar

-18

US20180058

988

SAMPLE FIXATION AND STABILISATIONNot Available1-

Mar-

13

14-

Aug

-17

1-

Mar

-18

US20180057

871

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTSNot Available15-

Aug-

16

1-

Nov

-17

1-

Mar

-18

US20180057

841

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORNot Available7-

Apr-

05

27-

Oct

-17

1-

Mar

-18

US20180057

817

Particle-Nucleic Acid Conjugates and Therapeutic Uses Related TheretoNot Available25-

Jun-

12

9-

Oct

-17

1-

Mar

-18

US20180057

594

PSEUDOTYPED ONCOLYTIC VIRAL DELIVERY OF THERAPEUTIC POLYPEPTIDESNot Available30-

Jun-

16

29-

Sep

-17

1-

Mar

-18

US20180057

509

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINESNot Available9-

Feb-

05

2-

Nov

-17

1-

Mar

-18

US20180057

488

COMPOSITIONS AND METHODS FOR INHIBITING KINASESNot Available23-

Apr-

15

7-

Nov

-17

1-

Mar

-18

US20180055

925

DISPLAY PLATFORM FROM BACTERIAL SPORE COAT PROTEINSThe United States of America, as represented by the Secretary, Department of Health and Human Serv3-

Mar-

15

7-

Aug

-15

1-

Mar

-18

US20180055

769

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONSNot Available3-

Dec-

09

26-

Jun

-17

1-

Mar

-18

US20180051

267

TAL EFFECTOR-MEDIATED DNA MODIFICATIONNot Available10-

Dec-

09

5-

Oct

-17

22-

Feb

-18

US20180051

266

TAL EFFECTOR-MEDIATED DNA MODIFICATIONNot Available10-

Dec-

09

21-

Aug

-17

22-

Feb

-18

US20180050

059

DELIVERY OF RNA TO DIFFERENT CELL TYPESGLAXOSMITHKLINE BIOLOGICALS, SA6-Jul-

10

30-

Aug

-17

22-

Feb

-18

US20180044

687

ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSIONNot Available12-

Dec-

14

11-

Dec

-15

15-

Feb

-18

US20180044

328

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORSProzymex A/S5-

Mar-

15

4-

Mar

-16

15-

Feb

-18

US20180043

007

INFLUENZA VIRUS VECTORS AND USES THEREFORNot Available17-

Mar-

14

21-

Aug

-17

15-

Feb

-18

US20180037

952

SYSTEM AND METHOD FOR DNA SEQUENCING AND BLOOD CHEMISTRY ANALYSISNanomedical Diagnostics, Inc.28-

Apr-

14

21-

Aug

-17

8-

Feb

-18

US20180037

942

ENZYME-INDEPENDENT MOLECULAR INDEXINGNot Available3-

Aug-

16

1-

Aug

-17

8-

Feb

-18

US20180037

871

CANCER INITIATING CELL AND USE THEREOFNot Available8-

Aug-

16

8-

Aug

-16

8-

Feb

-18

US20180037

636

STRUCTURED VIRAL PEPTIDE COMPOSITIONS AND METHODS OF USEDANA-FARBER CANCER INSTITUTE, INC.18-

Jun-

09

21-

Sep

-17

8-

Feb

-18

US20180037

634

ENGINEERED POLYPEPTIDES AND USES THEREOFNot Available2-

Aug-

16

2-

Aug

-17

8-

Feb

-18

US20180037

617

METHODS AND COMPOSITIONS FOR TREATING AND/OR PREVENTING A DISEASE OR DISORDER ASSOCIATED WITH ABNORMAL LEVEL AND/OR ACTIVITY OF THE IFP35 FAMILY OF PROTEINSInstitute of Biophysics, Chinese Academy of Sciences22-

Aug-

14

21-

Aug

-15

8-

Feb

-18

US20180036

398

FLAVIVIRUS REPLICONSNot Available27-

Feb-

15

25-

Feb

-16

8-

Feb

-18

 

US20180036

237

OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATIONGLAXOSMITHKLINE BIOLOGICALS, SA23-

Feb-

15

23-

Feb

-16

8-

Feb

-18

US20180031

555

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIESMenus N.V.27-

Jun-

08

18-

Jul-

17

1-

Feb

-18

US20180030

429

Polypeptide Assemblies and Methods for the Production ThereofNot Available27-

Feb-

15

29-

Feb

-16

1-

Feb

-18

US20180030

411

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

13-

Oct

-17

1-

Feb

-18

US20180028

677

Peptides for Assisting Delivery Across the Blood Brain BarrierChildren’s Medical Center Corporation22-

May-

06

30-

Jun

-17

1-

Feb

-18

US20180028

626

IMMUNOTHERAPEUTIC VACCINE AND ANTIBODY COMBINATION THERAPYTnansgene SA13-

Feb-

15

12-

Feb

-16

1-

Feb

-18

US20180028

562

METHODS OF TREATING OR PREVENTING INFLAMMATION AND HYPERSENSITIVITY WITH OXIDATIVE REDUCTIVE POTENTIAL

WATER SOLUTION

SONOMA PHARMACEUTICALS, INC.20-

Jan-

06

10-

Oct

-17

1-

Feb

-18

US20180028

449

Technology for the Preparation of MicroparticlesNot Available24-

Jul-07

27-

Jun

-17

1-

Feb

-18

US20180028

431

POLYMER-BASED ANTIMICROBIAL COMPOSITIONS AND METHODS OF USE THEREOFeXion labs Inc.28-

Jul-16

27-

Jul-

17

1-

Feb

-18

US20180023

048

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLSNot Available29-

Oct-

04

22-

Sep

-17

25-

Jan-

18

US20180022

781

POLYPEPTIDES FOR ENGINEERING INTEGRASE CHIMERIC PROTEINS AND THEIR USE IN GENE THERAPYCENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)13-

Feb-

15

12-

Feb

-16

25-

Jan-

18

US20180021

448

Conjugates of Cell Binding Molecules with Cytotoxic AgentsHangzhou DAC Biotech Co., Ltd.12-

Jul-12

16-

Apr

-14

25-

Jan-

18

US20180016

307

GRIFFITHSIN MUTANTSThe United States of America, as represented by the Secretary, Department of Health and Human Serv10-

Feb-

15

10-

Feb

-16

18-

Jan-

18

US20180016

285

Boron-Containing Small MoleculesNot Available20-

Jun-

07

28-

Sep

-17

18-

Jan-

18

US20180016

243

HUMAN HELICASE DDX3 INHIBITORS AS THERAPEUTIC AGENTSNot Available13-

Feb-

15

12-

Feb

-16

18-

Jan-

18

US20180015

174

SYNTHETIC NANOPARTICLES FOR DELIVERY OF IMMUNOMODULATORY COMPOUNDSNot Available15-

Jul-16

14-

Jul-

17

18-

Jan-

18

US20180015

052

DESIGN, SYNTHESIS AND METHODS OF USE OF ACYCLIC FLEXMIER NUCLEOSIDE ANALOGUES HAVING ANTI-CORONAVIRUS ACTIVITYNot Available30-

Jan-

15

28-

Jan

-16

18-

Jan-

18

US20180010

167

ORGANISM IDENTIFICATION PANELNot Available2-

Apr-

07

26-

Jul-

17

11-

Jan-

18

US20180010

125

DOUBLE-STRANDED OLIGONUCLEOTIDE MOLECULES TO DDIT4 AND METHODS OF USE THEREOFQuark Pharmaceuticals Inc.12-

Sep-

12

15-

Feb

-17

11-

Jan-

18

US20180009

787

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.P.A.31-

May-

16

22-

Sep

-17

11-

Jan-

18

US20180008

689

RNA VIRUS ATTENUATION BY ALTERATION OF MUTATIONAL ROBUSTNESS AND SEQUENCE SPACENot Available28-

Jan-

15

28-

Jan

-16

11-

Jan-

18

US20180002

743

FLUOROGENIC PROBES AND THEIR USE IN QUANTITATIVE DETECTION OF TARGET RNA SEQUENCESNot Available18-

Jun-

16

16-

Jun

-17

4-

Jan-

18

US20180002

406

NEUTRALIZING GP41 ANTIBODIES AND THEIR USEThe United States of America, as represented by the Secretary, Department of Health and Human7-

Nov-

11

8-

Sep

-17

4-

Jan-

18

US20180000

929

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOFNot Available30-

Nov-

12

14-

Sep

-17

4-

Jan-

18

US20180000

926

METHODS OF INDUCING AN IMMUNE RESPONSE TO HEPATITIS C VIRUSNot Available15-

Jan-

15

15-

Jan

-16

4-

Jan-

18

US20180000

868

Induced Hepatocytes and Uses ThereofNot Available26-

Nov-

14

15-

Sep

-17

4-

Jan-

18

US20180000

724

METHODS FOR INDUCING AN IMMUNE RESPONSE VIA BUCCAL AND/OR SUBLINGUAL ADMINISTRATION OF A VACCINENot Available26-

Jul-10

10-

May

-17

4-

Jan-

18

US20170369

843

SYNTHETIC MEMBRANE-RECEIVER COMPLEXESNot Available18-

Nov-

13

29-

Mar

-17

28-

Dec

-17

US20170369

470

Cyclic Compounds and Uses ThereofNot Available16-

Dec-

14

16-

Dec

-15

28-

Dec

-17

 

US20170368

203

Compositions For Enhancing Transport Of Molecules Into CellsNot Available29-

Apr-

03

10-

Jan

-17

28-

Dec

-17

US20170368

201

SCALABLE MANUFACTURING PROCESS TO PRODUCE RECOMBINANT LENTIVIRAL VECTORS IN SERUM-FREE SUSPENSION CELL CULTURE SYSTEMThe Children’s Hospital of Philadelphia15-

Mar-

13

8-

Sep

-17

28-

Dec

-17

US20170368

167

COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERSNot Available21-

Aug-

12

6-

Jun

-16

28-

Dec

-17

US20170362

300

OLIGOPEPTIDE-FREE CELL CULTURE MEDIANot Available4-

Jan-

06

7-

Aug

-17

21-

Dec

-17

US20170362

297

CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USE THEREOFNot Available19-

Dec-

14

21-

Dec

-15

21-

Dec

-17

US20170362

187

3,5-DIAMINO-6-CHLORO-N-(N-(4-PHENYLBUTYL)CARBAMIMIDOYL) PYRAZINE-2- CARBOXAMIDE COMPOUNDSParion Sciences, Inc.17-

Dec-

12

29-

Jun

-17

21-

Dec

-17

US20170362

170

HEPATITIS C ANTIVIRAL COMPOSITIONS AND METHODSNot Available3-

Aug-

07

29-

Jun

-17

21-

Dec

-17

US20170360

962

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIESNot Available16-

Feb-

16

18-

Aug

-17

21-

Dec

-17

US20170360

960

AAV Vectors Targeted to the Central Nervous SystemNot Available21-

Nov-

14

20-

Nov

-15

21-

Dec

-17

US20170360

908

VACCINE PHARMACEUTICAL COMPOSITION FOR CELL-MEDIATED IMMUNITY CONTAINING BISPHOSPHONATESNITTO DENKO CORPORATION3-

Sep-

14

2-

Sep

-15

21-

Dec

-17

US20170360

881

PEPTIDOMIMETIC MACROCYCLES AND USES THEREOFNot Available17-

Jun-

16

16-

Jun

-17

21-

Dec

-17

US20170360

875

METHODS FOR TREATING IMMUNE-MEDIATED VIRAL INFECTIONSMIDDLE TENNESSEE STATE UNIVERSITY22-

Dec-

14

22-

Dec

-15

21-

Dec

-17

US20170358

082

STAIN-FREE HISTOPATHOLOGY BY CHEMICAL IMAGINGNot Available15-

Mar-

13

2-

Aug

-17

14-

Dec

-17

US20170354

727

MODULATION OF REPLICATIVE FITNESS BY DEOPTIMIZATION OF SYNONYMOUS CODONSNot Available8-

Oct-

04

23-

Aug

-17

14-

Dec

-17

US20170348

433

NOVEL RECOMBINANT ADENO-ASSOCIATED VIRUS CAPSIDS RESISTANT TO PRE-EXISTING HUMAN NEUTRALIZING ANTIBODIESThe Board of Trustees of the Leland Stanford Junior University16-

Feb-

16

16-

Feb

-17

7-

Dec

-17

US20170348

402

SYSTEM AND METHOD FOR DELIVERING GENETIC MATERIAL OR PROTEIN TO CELLSNot Available30-

Jul-14

30-

Jul-

15

7-

Dec

-17

US20170348

369

Plant Extract and Its Therapeutic UseNot Available16-

May-

08

18-

Jul-

17

7-

Dec

-17

US20170342

442

RECOMBINANT SELF-REPLICATING POLYCISTRONIC RNA MOLECULESGLAXOSMITHKLINE BIOLOGICALS, SA11-

Oct-

11

15-

Aug

-17

30-

Nov

-17

US20170342

405

MOLECULAR INDEXING OF INTERNAL SEQUENCESNot Available31-

May-

16

16-

May

-17

30-

Nov

-17

US20170342

056

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.P.A.31-

May-

16

26-

May

-17

30-

Nov

-17

US20170340

735

Anti-TIGIT Antigen-Binding Proteins and Methods of Use ThereofNot Available1-

Oct-

15

19-

Jun

-17

30-

Nov

-17

US20170340

725

COMBINATION PIV3/HMPV RNA VACCINESModernaTX, Inc.22-

Oct-

15

11-

Aug

-17

30-

Nov

-17

US20170340

721

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSESNot Available3-

Sep-

14

3-

Sep

-15

30-

Nov

-17

US20170340

611

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.P.A.31-

May-

16

26-

May

-17

30-

Nov

-17

US20170337

459

SPATIALLY ADDRESSABLE MOLECULAR BARCODINGNot Available27-

Feb-

15

2-

Aug

-17

23-

Nov

-17

US20170336

412

Multiplex Immuno Screening AssayInstitut Pasteur4-

May-

12

19-

Jul-

17

23-

Nov

-17

US20170336

411

B-CELL ANTIGEN PRESENTING CELL ASSAYThe University of Pittsburgh – Of the Commonwealth System of Higher Education8-

Apr-

10

9-

Aug

-17

23-

Nov

-17

US20170335

408

Methods and Systems of Multi-Assay Processing and AnalysisNot Available15-

Mar-

16

15-

Mar

-17

23-

Nov

-17

 

US20170335

374

METHODS AND COMPOSITIONS FOR IDENTIFICATION OF SOURCE OF MICROBIAL CONTAMINATION IN A SAMPLENot Available6-

Mar-

12

6-

Jul-

17

23-

Nov

-17

US20170334

984

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)Not Available16-

Dec-

02

26-

Apr

-16

23-

Nov

-17

US20170334

973

NON-HUMAN PRIMATE-DERIVED PAN-EBOLA AND PAN-FILOVIRUS MONOCLONAL ANTIBODIES DIRECTED AGAINST ENVELOPE GLYCOPROTEINSNot Available28-

Oct-

14

27-

Oct

-15

23-

Nov

-17

US20170334

941

2′,2′-DIHALO NUCLEOSIDE ANALOGS FOR TREATMENT OF THE FLAVIVIRIDAE FAMILY OF VIRUSES AND CANCERNot Available31-

Oct-

14

30-

Oct

-15

23-

Nov

-17

US20170334

919

2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H- PYRAZOLO[3,4-D]PYRIMIDIN-1 -YL)METHYL)-3-(2-(TRIFLUORO-MET HYL)BENZYL)QUINAZOLIN-4(3H)-ONE DERIVATIVES AND THEIR USE AS PHOSPHOINOSITIDE 3-KINASE INHIBITORSRESPIVERT LTD.15-

Mar-

13

27-

Jul-

17

23-

Nov

-17

US20170334

864

3,5-DIAMINO-6-CHLORO-N-(N-(4-(4-(2-(HEXYL(2,3,4,5,6-

PENTAHYDROXYHEXYL)AMINO)ETHOXY)PHENYL)BUTYL)

CARBAMIMIDOYL)PYRAZINE-2-CARBOXAMIDE

Parion Sciences, Inc.27-

Jun-

11

1-

Mar

-17

23-

Nov

-17

US20170333

586

ADDITIVE COMPOSITIONS FOR PIGMENTED DISINFECTION AND METHODS THEREOFNot Available8-

Dec-

14

23-

May

-15

23-

Nov

-17

US20170333

553

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODSNot Available21-

May-

13

1-

Aug

-17

23-

Nov

-17

US20170333

494

PROBIOTIC THERAPEUTIC APPLICATIONSNot Available10-

Nov-

14

9-

Nov

-15

23-

Nov

-17

US20170333

457

Anti-Viral Azide Containing CompoundsNot Available28-

Jul-10

8-

Aug

-17

23-

Nov

-17

US20170333

267

MOBILE CLINICSBaylor College of Medicine12-

Nov-

14

11-

Nov

-15

23-

Nov

-17

US20170328

819

SAMPLE FIXATION AND STABILISATIONNot Available1-

Mar-

13

30-

May

-17

16-

Nov

-17

US20170327

543

POLYIONIC PAPILLOMA VIRUS-LIKE PARTICLE (VLP) VACCINESNot Available8-

Sep-

10

31-

Jan

-17

16-

Nov

-17

US20170327

472

CHLORO-PYRAZINE CARBOXAMIDE DERIVATIVES WITH EPITHELIAL

SODIUM CHANNEL BLOCKING ACTIVITY

Parion Sciences, Inc.17-

Dec-

12

7-

Mar

-17

16-

Nov

-17

US20170327

439

DIHYDRONAPHTHALENE DERIVATIVEONO PHARMACEUTICAL CO., LTD.3-

Dec-

14

3-

Dec

-14

16-

Nov

-17

US20170326

256

RECOMBINANT PROMOTERS AND VECTORS FOR PROTEIN EXPRESSION IN LIVER AND USE THEREOFChildren’s Healthcare of Atlanta, Inc.16-

Apr-

15

15-

Apr

-16

16-

Nov

-17

US20170326

123

Throat solution for treatment of cold, flu and sore throatNot Available12-

May-

16

12-

May

-16

16-

Nov

-17

US20170322

682

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT-RELATED INFORMATIONGeorgetown University25-

Feb-

08

27-

Jul-

17

9-

Nov

-17

US20170322

201

ANTIGEN PRESENTING CELL ASSAYUniversity of Pittsburgh – Of the Com monwealth System of Higher Education8-

Apr-

10

20-

Jul-

17

9-

Nov

-17

US20170321

192

Recombinant RNA Viruses and Uses ThereofIcahn School of Medicine at Mount Sinai6-

Jun-

10

6-

Apr

-17

9-

Nov

-17

US20170319

712

METHODS AND COMPOSITIONS FOR ENHANCING IMMUNE RESPONSE3M INNOVATIVE PROPERTIES COMPANY10-

Apr-

03

27-

Jul-

17

9-

Nov

-17

US20170319

673

TRI-SEGMENTED ARENAVIRUSES AS VACCINE VECTORSNot Available13-

Nov-

14

12-

Nov

-15

9-

Nov

-17

US20170319

551

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available9-

May-

12

24-

Jan

-17

9-

Nov

-17

US20170313

765

DIRECT EXPRESSION OF ANTIBODIESNot Available29-

Oct-

14

28-

Oct

-15

2-

Nov

-17

US20170313

685

BROAD-SPECTRUM NON-COVALENT CORONAVIRUS PROTEASE INHIBITORSPurdue Research Foundation28-

Apr-

16

28-

Apr

-17

2-

Nov

-17

US20170312

371

MODIFIED VIRUS-LIKE PARTICLES OF CMVSAIBA GMBH22-

Oct-

14

20-

Oct

-15

2-

Nov

-17

 

US20170312

357

MANUFACTURE OF SURFACTANT-CONTAINING COMPOSITIONSNot Available2-

Dec-

14

2-

Dec

-15

2-

Nov

-17

US20170308

679

BIOSECURITY SCREENING SYSTEM AND METHODNot Available16-

Oct-

14

12-

Oct

-15

26-

Oct-

17

US20170307

562

CHEMICALLY DIFFERENTIATED SENSOR ARRAYNanomedical Diagnostics, Inc.28-

Apr-

14

8-

May

-17

26-

Oct-

17

US20170306

354

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available17-

Dec-

01

1-

May

-17

26-

Oct-

17

US20170306

293

MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLSNot Available9-

Dec-

05

2-

Jun

-17

26-

Oct-

17

US20170306

001

CHIMERIZATION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY WITH POTENT NEUTRALIZING ACTIVITY ACROSS MULTIPLE INFLUENZA A H5N1 CLADESNATIONAL UNIVERSITY OF SINGAPORE27-

Mar-

14

27-

Mar

-15

26-

Oct-

17

US20170305

868

ARYLALKYL-AND ARYLOXYALKYL-SUBSTITUTED EPITHELIAL SODIUM CHANNEL BLOCKING COMPOUNDSParion Sciences, Inc.13-

Dec-

13

1-

Mar

-17

26-

Oct-

17

US20170304

829

PRINTED CIRCUIT BOARD HEATER FOR AN AMPLIFICATION MODULEClick Diagnostics, Inc.22-

Apr-

16

21-

Apr

-17

26-

Oct-

17

US20170304

466

AAV-Based Gene TherapyNot Available6-

Oct-

14

6-

Oct

-15

26-

Oct-

17

US20170304

459

METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDENot Available10-

Oct-

14

7-

Oct

-15

26-

Oct-

17

US20170304

429

VACCINATION OF IMMUNOCOMPROMISED SUBJECTSNot Available26-

Sep-

14

25-

Sep

-15

26-

Oct-

17

US20170304

420

POLYMER ADJUVANTOxford University Innovation Limited10-

Oct-

14

9-

Oct

-15

26-

Oct-

17

US20170304

354

TREATMENT OF DISEASE WITH POLY-N-ACETYLGLUCOSAMINE NANOFIBERSMarine Polymer Technologies, Inc.15-

Apr-

11

13-

Mar

-17

26-

Oct-

17

US20170299

591

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASESNot Available6-

Oct-

08

13-

Dec

-16

19-

Oct-

17

US20170298

100

ANTI-VIRAL PEPTIDESNot Available1-

Oct-

14

30-

Sep

-15

19-

Oct-

17

US20170296

663

Conjugates of Cell Binding Molecules with Cytotoxic AgentsHangzhou DAC Biotech Co., Ltd.16-

Apr-

14

16-

Apr

-14

19-

Oct-

17

US20170296

574

Method of Treating InflammationNot Available1-

Apr-

10

28-

Jun

-17

19-

Oct-

17

US20170292

132

TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOFNot Available29-

Apr-

13

20-

Jun

-17

12-

Oct-

17

US20170290

909

METHODS AND COMPOSITIONS FOR INTRA-NASAL IMMUNIZATION WITH RECOMBINANT MVA ENCODING FLAGELLINBavarian Nordic A/S26-

Sep-

14

25-

Sep

-15

12-

Oct-

17

US20170281

966

Device to Kill Micro-Organisms Inside the Respiratory TractNot Available1-

Apr-

16

28-

Mar

-17

5-

Oct-

17

US20170281

759

BISPHOSPHONATE-CONTAINING VACCINE PHARMACEUTICAL COMPOSITION FOR HUMORAL IMMUNITYNITTO DENKO CORPORATION3-

Sep-

14

2-

Sep

-15

5-

Oct-

17

US20170275

621

CHIRAL CONTROLNot Available13-

Jul-12

17-

Mar

-17

28-

Sep

-17

US20170275

592

CULTURE MEDIUMKoninklijke Nederlandse Akademie Van Wetenschappen27-

Nov-

14

27-

Nov

-15

28-

Sep

-17

US20170275

323

GLYCOLIPIDS AND PHARMACEUTICAL COMPOSITIONS THEREOF FOR USE IN THERAPYTHE UNIVERSITY OF NOTTINGHAM4-

Apr-

14

7-

Apr

-15

28-

Sep

-17

US20170275

253

BENZAZEPINE SULFONAMIDE COMPOUNDSHoffmann-La Roche Inc.18-

Dec-

14

14-

Jun

-17

28-

Sep

-17

US20170275

243

Lipids and Lipid Compositions for the Delivery of Active AgentsNovartis AG5-

Sep-

14

4-

Sep

-15

28-

Sep

-17

US20170274

064

MODIFIED BAT INFLUENZA VIRUSES AND THEIR USESNot Available5-

Sep-

14

4-

Sep

-15

28-

Sep

-17

US20170274

024

AAV Vectors Targeted to OligodendrocytesNot Available28-

Sep-

12

17-

Apr

-17

28-

Sep

-17

 

US20170267

969

Animal Protein-Free Media for Cultivation of CellsBaxalta GmbH29-

Oct-

04

18-

May

-17

21-

Sep

-17

US20170267

722

INHIBITORY PEPTIDES OF VIRAL INFECTIONNot Available17-

Jul-14

25-

May

-17

21-

Sep

-17

US20170267

649

STABLE SODIUM CHANNEL BLOCKERSPARION SCIENCES, INC.30-

Jun-

14

30-

Jan

-17

21-

Sep

-17

US20170266

272

TRANSGENIC VERO-CD4/CCR5 CELL LINENot Available2-

Oct-

15

6-

Apr

-17

21-

Sep

-17

US20170266

190

DRUG COMBINATIONNot Available15-

Mar-

13

5-

Jun

-17

21-

Sep

-17

US20170266

160

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN CNot Available14-

Mar-

13

6-

Jun

-17

21-

Sep

-17

US20170261

431

CONTINUOUS PROCESS FOR PERFORMING MULTIPLE NUCLEIC ACID AMPLIFICATION ASSAYSNot Available10-

Mar-

05

19-

May

-17

14-

Sep

-17

US20170260

223

ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN ANot Available4-

Aug-

14

17-

May

-17

14-

Sep

-17

US20170260

147

ANTIVIRAL COMPOUNDS AND METHODSBiotron Limited26-

Jun-

03

23-

May

-17

14-

Sep

-17

US20170259

976

DEGRADABLE MATERIALS AND PACKAGING MADE FROM SAMEMONOSOL, LLC3-

Oct-

14

2-

Oct

-15

14-

Sep

-17

US20170258

904

Antagonism of the VIP Signaling PathwayNot Available2-

Feb-

11

22-

May

-17

14-

Sep

-17

US20170258

893

MERS-CoV VaccineNot Available29-

Nov-

13

26-

Nov

-14

14-

Sep

-17

US20170253

861

HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINSNot Available11-

Jul-03

6-

Oct

-16

7-

Sep

-17

US20170252

430

POLYMERIC CARRIER CARGO COMPLEX FOR USE AS AN IMMUNOSTIMULATING AGENT OR AS AN ADJUVANTNot Available1-

Apr-

14

1-

Apr

-15

7-

Sep

-17

US20170252

417

PROTEIN-CHAPERONED T-CELL VACCINESNot Available7-

Mar-

16

7-

Mar

-17

7-

Sep

-17

US20170247

688

ENZYMATIC ENCODING METHODS FOR EFFICIENT SYNTHESIS OF LARGE LIBRARIESNUEVOLUTION A/S1-

Dec-

05

12-

Dec

-16

31-

Aug

-17

US20170247

453

SOLUBLE ENGINEERED MONOMERIC FCThe United States of America, as represented by the Secretary, Department of Health and Human Serv16-

Mar-

12

9-

May

-17

31-

Aug

-17

US20170247

423

STAPLED INTRACELLULAR-TARGETING ANTIMICROBIAL PEPTIDES TO TREAT INFECTIONNot Available29-

Feb-

16

28-

Feb

-17

31-

Aug

-17

US20170246

347

MATERIALS WITH IMPROVED PROPERTIESNot Available1-

Nov-

15

5-

May

-17

31-

Aug

-17

US20170241

998

METHOD FOR THE IMMOBILIZATION OF BIOMOLECULESNot Available22-

Feb-

16

17-

Feb

-17

24-

Aug

-17

US20170240

639

ACTRII ANTAGONISTS FOR USE IN INCREASING IMMUNE ACTIVITYNot Available22-

Feb-

16

22-

Feb

-17

24-

Aug

-17

US20170239

397

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONSNot Available1-

Nov-

15

5-

May

-17

24-

Aug

-17

US20170239

364

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRYNot Available28-

Mar-

11

2-

Mar

-17

24-

Aug

-17

US20170239

349

COMPOSITIONS AND METHODS RELATED TO NEUROLOGICAL DISORDERSNot Available20-

Feb-

15

6-

Jun

-16

24-

Aug

-17

US20170239

291

METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTIONSONOMA PHARMACEUTICALS, INC.30-

Dec-

03

9-

May

-17

24-

Aug

-17

US20170234

781

MEMBRANE-ASSISTED PURIFICATIONAccelerate Diagnostics, Inc.7-

Mar-

11

3-

May

-17

17-

Aug

-17

US20170226

593

HANDHELD NUCLEIC ACID-BASED ASSAY FOR RAPID IDENTIFICATIONNot Available8-

Feb-

16

8-

Feb

-16

10-

Aug

-17

US20170226

511

APTAMERS FOR BINDING FLAVIVIRUS PROTEINSNational University of Singapore13-

Nov-

13

13-

Nov

-14

10-

Aug

-17

US20170226

232

MODIFIED ALGINATES FOR ANTI-FIBROTIC MATERIALS AND APPLICATIONSNot Available1-

Nov-

15

2-

Nov

-16

10-

Aug

-17

 

US20170226

222

BISPECIFIC ANTIBODYNot Available20-

Nov-

13

18-

Jan

-17

10-

Aug

-17

US20170226

173

GM-CSF and IL-4 Conjugates, Compositions, and Methods Related TheretoNot Available23-

Oct-

12

19-

Apr

-17

10-

Aug

-17

US20170224

813

VACCINE PHARMACEUTICAL COMPOSITION FOR SUPPRESSING APOPTOSIS OF CTL OR INHIBITING SUPPRESSION OF INDUCTION OF CTLNITTO DENKO CORPORATION4-

Aug-

14

4-

Aug

-15

10-

Aug

-17

US20170224

812

LIQUID IMMUNITY INDUCTION-PROMOTING COMPOSITION AND VACCINE PHARMACEUTICAL COMPOSITION THAT INCLUDE THROMBOSIS TREATMENT DRUGNITTO DENKO CORPORATION4-

Aug-

14

4-

Aug

-15

10-

Aug

-17

US20170224

616

OIL-IN-WATER EMULSIONS THAT CONTAIN NUCLEIC ACIDSGLAXOSMITHKLINE BIOLOGICALS SA6-Jul-

11

24-

Apr

-17

10-

Aug

-17

US20170219

560

MALARIA ANTIGEN SCREENING METHODUnited States of America as Represented by the Secretary of the Navy31-

Aug-

05

10-

Apr

-17

3-

Aug

-17

US20170216

431

VACCINE PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATIONNITTO DENKO CORPORATION2-

Oct-

14

1-

Oct

-15

3-

Aug

-17

US20170216

430

IMMUNE-INDUCTION-PROMOTING COMPOSITION INCLUDING NUCLEAR RECEPTOR LIGAND, AND VACCINE PHARMACEUTICAL COMPOSITIONNITTO DENKO CORPORATION4-

Aug-

14

4-

Aug

-15

3-

Aug

-17

US20170216

429

COMPOSITION FOR ENHANCING INDUCTION OF HUMORAL IMMUNITY, AND VACCINE PHARMACEUTICAL COMPOSITIONNITTO DENKO CORPORATION4-

Aug-

14

4-

Aug

-15

3-

Aug

-17

US20170216

427

CoronavirusNot Available23-

Jul-14

23-

Jul-

15

3-

Aug

-17

US20170216

348

METAL NANOCLUSTERS AND USES THEREOFNot Available7-

Aug-

14

7-

Aug

-15

3-

Aug

-17

US20170216

347

ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE, USE OF ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVE AS MEDICINE, PARTICULARLY FOR PROPYLAXIS AND TREATMENT OF INFECTIONS OF RESPIRATORY TRACT CAUSED BY HUMAN METAPNEUMOVIRUS (HMPV), HUMAN RHINOVIRUSES (HRV), AND INFECTION BY INFLUENZA VIRUS TYPE A (IAV) AND PHARMACEUTICAL COMPOSITION COMPRISING THE ANIONICALLY MODIFIED POLYALLYLAMINE DERIVATIVEUNIWERSYTET JAGIELLONSKI29-

Jul-14

29-

Jul-

15

3-

Aug

-17

US20170212

116

BIOSENSORS FOR THE DETECTION OF INFECTION AND ASSOCIATED MALADIESULISSE BIOMED SRL31-

Jan-

14

26-

Jan

-15

27-

Jul-

17

US20170212

019

POLYMER STABILIZATION OF CHROMOGEN SOLUTIONSNot Available23-

Jan-

12

10-

Apr

-17

27-

Jul-

17

US20170211

096

LCMV-GP-VSV-Pseudotyped Vectors and Tumor-Infiltrating Virus- Producing Cells for the Therapy of TumorsNot Available29-

Jun-

11

7-

Apr

-17

27-

Jul-

17

US20170211

069

USE OF THE CHROMOSOME 19 MICRORNA CLUSTER (C19MC) FOR TREATING MICROBIAL DISEASE AND PROMOTING AUTHOPHAGYUniversity of Pittsburgh – Of the Com monwealth System of Higher Education7-

Mar-

12

27-

Jan

-17

27-

Jul-

17

US20170211

058

METHOD AND APPARATUS FOR AUTOMATED PROCESSING OF POOLED SAMPLESNot Available6-

Aug-

14

5-

Aug

-15

27-

Jul-

17

US20170209

844

MICROSPOTTING DEVICENot Available18-

Apr-

12

5-

Jan

-17

27-

Jul-

17

US20170209

595

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULESuzhou M-Conj Biotech Co., Ltd.15-

Jul-15

5-

Apr

-17

27-

Jul-

17

US20170209

590

METHODS AND REAGENTS FOR EFFICIENT AND TARGETED DELIVERY OF THERAPEUTIC MOLECULES TO CXCR4 CELLSNot Available13-

Jan-

11

10-

Jan

-17

27-

Jul-

17

US20170209

570

Carbon Nanotube Compositions and Methods of Use ThereofNot Available19-

Mar-

08

17-

Mar

-17

27-

Jul-

17

US20170209

376

COMPOSITIONS WITH MODIFIED NUCLEASES TARGETED TO VIRAL NUCLEIC ACIDS AND METHODS OF USE FOR PREVENTION AND TREATMENT OF VIRAL DISEASESNot Available14-

Apr-

04

10-

Mar

-17

27-

Jul-

17

US20170205

399

POLYMERS AND CONJUGATES COMPRISING THE SAMENot Available2-

Oct-

14

31-

Mar

-17

20-

Jul-

17

 

US20170204

143

Constrained proteins and uses thereforNot Available21-

Jul-14

21-

Jul-

15

20-

Jul-

17

US20170204

083

THERAPEUTIC HYDROXYPYRIDINONES, HYDROXYPYRIMIDINONES AND HYDROXYPYRIDAZINONESRUTGERS, THE STATE UNIVERSITY OF NEW JERSEY11-

Sep-

12

13-

Jan

-17

20-

Jul-

17

US20170202

975

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULESuzhou M-Conj Biotech Co., Ltd.15-

Jul-15

5-

Apr

-17

20-

Jul-

17

US20170202

960

CATIONIC OIL-IN-WATER EMULSIONSGLAXOSMITHKLINE BIOLOGICALS, SA6-Jul-

11

23-

Mar

-17

20-

Jul-

17

US20170202

959

ADJUVANT COMPOSITIONS AND RELATED METHODSNot Available24-

Mar-

15

23-

Mar

-17

20-

Jul-

17

US20170202

956

Methods and Compositions for Inhibiting Akt3Not Available15-

Jan-

16

17-

Jan

-17

20-

Jul-

17

US20170202

955

Adjuvanted Influenza Vaccines for Pediatric UseNot Available22-

Feb-

08

30-

Dec

-16

20-

Jul-

17

US20170202

949

DEFECTIVE RIBOSOMAL PRODUCTS IN BLEBS (DRIBBLES) AND METHODS OF USE TO STIMULATE AN IMMUNE RESPONSEProvidence Health & Services – Oregon29-

Jul-05

29-

Dec

-16

20-

Jul-

17

US20170202

829

Specific Akt3 Inhibitor and Uses Thereof Cross-Reference to Related ApplicationsNot Available15-

Jan-

16

17-

Jan

-17

20-

Jul-

17

US20170196

979

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTSNovartis AG8-

Mar-

13

27-

Sep

-16

13-

Jul-

17

US20170196

954

PRIME-BOOST REGIMENS WITH A TLR4 AGONIST ADJUVANT AND A LENTIVIRAL VECTORNot Available15-

Jul-14

14-

Jul-

15

13-

Jul-

17

US20170191

933

Systems and Methods for Analyzing a Sample and for Monitoring the Performance of an Optical Signal DetectorNot Available31-

Dec-

15

23-

Dec

-16

6-

Jul-

17

US20170191

079

METHOD OF INCREASING THE FUNCTION OF AN AAV VECTORNot Available7-

Apr-

05

18-

Jan

-17

6-

Jul-

17

US20170190

770

HUMAN MONOCLONAL ANTIBODIES AGAINST INTERLEUKIN 8 (IL-8)CORMORANT PHARMACEUTICALS AB16-

Dec-

02

26-

Apr

-16

6-

Jul-

17

US20170189

521

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODS3M Innovative Properties Company17-

Aug-

10

19-

Aug

-16

6-

Jul-

17

US20170175

140

METHODS FOR USING A 5′-EXONUCLEASE TO INCREASE HOMOLOGOUS RECOMBINATION IN EUKARYOTIC CELLSNot Available16-

Dec-

15

14-

Dec

-16

22-

Jun-

17

US20170173

585

POINT OF CARE POLYMERASE CHAIN REACTION DEVICE FOR DISEASE DETECTIONNot Available11-

Jul-14

10-

Jul-

15

22-

Jun-

17

US20170173

176

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULESUZHOU M-CONJ BIOTECH CO., LTD.15-

Jul-15

3-

Mar

-17

22-

Jun-

17

US20170173

168

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULESUZHOU M-CONJ BIOTECH CO., LTD.15-

Jul-15

3-

Mar

-17

22-

Jun-

17

US20170173

164

HYDRAZINO 1H-IMIDAZOQUINOLIN-4-AMINES AND CONJUGATES MADE THEREFROMNot Available3-

Jun-

11

6-

Mar

-17

22-

Jun-

17

US20170168

052

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASESNot Available6-

Oct-

08

13-

Dec

-16

15-

Jun-

17

US20170168

044

QUANTITATIVE ANALYSIS METHOD BASED ON AIR PRESSURE MEASURINGXIAMEN UNIVERSITY9-

Jun-

14

24-

Sep

-14

15-

Jun-

17

US20170166

574

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.P.A.14-

Dec-

15

12-

Dec

-16

15-

Jun-

17

US20170165

366

Anti-TIGIT Antigen-Binding Proteins and Methods of Use ThereofNot Available1-

Oct-

15

13-

Feb

-17

15-

Jun-

17

US20170165

359

IMMUNOSTIMULATORY COMBINATIONS OF TLR LIGANDS AND METHODS OF USENot Available11-

Aug-

10

23-

Aug

-16

15-

Jun-

17

US20170165

341

REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATIONNot Available24-

Aug-

12

15-

Feb

-17

15-

Jun-

17

US20170165

230

USE OF GSK-3 INHIBITORS OR ACTIVATORS WHICH MODULATE PD-1 OR T-BET EXPRESSION TO MODULATE T CELL IMMUNITYNot Available9-

Apr-

14

9-

Apr

-15

15-

Jun-

17

US20170160

218

APPARATUS AND SYSTEM FOR PERFORMING THERMAL MELT ANALYSES AND AMPLIFICATIONSNot Available31-

Jul-12

23-

Feb

-17

8-

Jun-

17

 

US20170159

027

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

15-

Feb

-17

8-

Jun-

17

US20170159

026

Novel Recombinant Adeno-Associated Virus Capsids with Enhanced Human Skeletal Muscle TropismNot Available2-

Dec-

15

2-

Dec

-16

8-

Jun-

17

US20170158

752

MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS NEUTRALIZING ANTIBODIES AND METHODS OF USE THEREOFNot Available25-

Apr-

14

27-

Apr

-15

8-

Jun-

17

US20170157

262

CONJUGATES OF CELL BINDING MOLECULES WITH CYTOTOXIC AGENTSNot Available12-

Jul-12

12-

Jul-

12

8-

Jun-

17

US20170157

151

Broad Spectrum Antiviral and Methods of UseNot Available17-

Apr-

06

16-

Feb

-17

8-

Jun-

17

US20170152

274

CHARGED LINKERS AND THEIR USES FOR CONJUGATIONHangzhou DAC Biotech Co., Ltd.28-

Feb-

14

28-

Feb

-14

1-

Jun-

17

US20170152

271

GAK MODULATORS AS ANTIVIRALSKatholieke Universiteit Leuven23-

Jul-14

23-

Jul-

15

1-

Jun-

17

US20170151

346

DISULFUR BRIDGE LINKERS FOR CONJUGATION OF A CELL­BINDING MOLECULESUZHOU M-CONJ BIOTECH CO., LTD.15-

Jul-15

13-

Feb

-17

1-

Jun-

17

US20170151

291

SYNERGISTIC BACTERIAL COMPOSITIONS AND METHODS OF PRODUCTION AND USE THEREOFNot Available25-

Nov-

13

25-

Nov

-14

1-

Jun-

17

US20170145

394

TRACKING AND MANIPULATING CELLULAR RNA VIA NUCLEAR DELIVERY OF CRISPR/CAS9Not Available23-

Nov-

15

22-

Nov

-16

25-

May

-17

US20170144

984

MODULATORS OF THE RELAXIN RECEPTOR 1Not Available4-

May-

12

25-

Aug

-16

25-

May

-17

US20170143

845

ACETYLENEDICARBOXYL LINKERS AND THEIR USES IN SPECIFIC CONJUGATION OF A CELL-BINDING MOLECULESUZHOU M-CONJ BIOTECH CO., LTD15-

Jul-15

3-

Feb

-17

25-

May

-17

US20170143

820

IMMUNOGENIC COMBINATIONSGLAXOSMITHKLINE SA13-

Jun-

14

12-

Jun

-15

25-

May

-17

US20170143

758

INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASESAdvanced Inhalation Therapies (AIT) Ltd.11-

Sep-

13

4-

Jan

-17

25-

May

-17

US20170143

749

SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOFNot Available24-

Jun-

14

2-

Feb

-17

25-

May

-17

US20170137

527

GITR ANTIBODIES AND METHODS OF INDUCING OR ENHANCING AN IMMUNE RESPONSENot Available25-

Mar-

05

7-

Nov

-16

18-

May

-17

US20170137

430

Nuclear Transport Modulators And Uses ThereofNot Available29-

Jul-11

22-

Jul-

16

18-

May

-17

US20170136

118

NEUTRALIZING MOLECULES TO VIRAL ANTIGENSNot Available28-

Mar-

08

8-

Jun

-16

18-

May

-17

US20170136

043

THERAPEUTIC USES OF SELECTED PYRROLOPYRIMIDINE COMPOUNDS WITH ANTI-MER TYROSINE KINASE ACTIVITYThe University of North Carolina at Chapel Hill11-

Apr-

14

30-

Jan

-17

18-

May

-17

US20170131

271

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATESNot Available27-

Apr-

10

12-

Sep

-16

11-

May

-17

US20170130

200

INTRACELLULAR GENOMIC TRANSPLANT AND METHODS OF THERAPYNot Available31-

Jul-15

29-

Jul-

16

11-

May

-17

US20170129

947

REGULATING THE INTERACTION BETWEEN TAM LIGANDS AND LIPID MEMBRANES WITH EXPOSED PHOSPHATIDYL SERINEKolltan Pharmaceuticals, Inc.25-

Jul-12

20-

Sep

-16

11-

May

-17

US20170129

891

SUBSTITUTED IMIDAZOQUINOLINES, IMIDAZOPYRIDINES, AND IMIDAZONAPHTHYRIDINESNot Available18-

Jun-

04

23-

Jan

-17

11-

May

-17

US20170128

465

Pharmaceutical Compositions and MethodsNot Available3-

Aug-

15

6-

Dec

-16

11-

May

-17

US20170122

853

PHOTO-CONTROLLED REMOVAL OF TARGETS IN VITRO AND IN VIVOTHE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERV8-

Aug-

14

7-

Aug

-15

4-

May

-17

US20170121

372

NOVEL DEPSIPEPTIDE AND USES THEREOFNot Available3-

Dec-

12

15-

Jun

-16

4-

May

-17

US20170119

872

SOLUBLE NEEDLE ARRAYS FOR DELIVERY OF INFLUENZA VACCINESNot Available20-

Aug-

10

11-

Oct

-16

4-

May

-17

US20170119

871

LOW-ADDITIVE INFLUENZA VACCINESNot Available27-

Jun-

07

24-

Jun

-16

4-

May

-17

US20170119

820

MODIFIED CELLS AND METHODS OF THERAPYNot Available31-

Jul-15

29-

Jul-

16

4-

May

-17

 

US20170119

786

HETEROCYCLIC MODULATORS OF LIPID SYNTHESISNot Available8-

Mar-

11

11-

Nov

-16

4-

May

-17

US20170119

734

TETRAZOLONES AS INHIBITORS OF FATTY ACID SYNTHASENot Available5-

May-

10

22-

Apr

-16

4-

May

-17

US20170118

995

MINERAL FUNCTIONAL WATER, METHOD FOR PRODUCING THE SAME, AND METHOD FOR CONTROLLING UNICELLULAR ORGANISMS AND/OR VIRUSESRiken Techno System Co., Ltd.17-

Sep-

14

6-

Dec

-16

4-

May

-17

US20170114

053

HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOFThe United States of America, as represented by the Secretary, Department of Health and Human Serv12-

Jun-

14

12-

Jun

-15

27-

Apr-

17

US20170112

929

VISTA MODULATORS FOR DIAGNOSIS AND TREATMENT OF CANCERNot Available7-

Sep-

12

6-

Jun

-16

27-

Apr-

17

US20170107

254

Modified Antimicrobial PeptidesNot Available2-

Apr-

14

2-

Apr

-15

20-

Apr-

17

US20170107

195

Chemical CompoundsAstraZeneca AB18-

Mar-

14

17-

Mar

-15

20-

Apr-

17

US20170106

077

INFLUENZA VIRUS VECTORS AND USES THEREFORNot Available17-

Mar-

14

13-

Mar

-15

20-

Apr-

17

US20170101

459

CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDESNot Available6-

Jun-

14

5-

Jun

-15

13-

Apr-

17

US20170101

413

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.p.A.12-

Jun-

14

12-

Jun

-14

13-

Apr-

17

US20170100

474

METHODS AND COMPOSITIONS FOR LIVE ATTENUATED VIRUSESNot Available6-

Apr-

07

22-

Jul-

16

13-

Apr-

17

US20170100

385

PHARMACEUTICAL COMPOSITIONS COMPRISING DANIRIXIN FOR TREATING INFECTIOUS DISEASESGLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED12-

May-

14

8-

May

-15

13-

Apr-

17

US20170096

646

Modified Adenovirus Hexon Protein and Uses ThereofNot Available28-

Apr-

06

20-

Dec

-16

6-

Apr-

17

US20170096

455

METHODS AND COMPOSITIONS FOR CHIMERIC CORONAVIRUS SPIKE PROTEINSThe University of North Carolina at Chapel Hill20-

Mar-

14

20-

Mar

-15

6-

Apr-

17

US20170096

441

PHOSPHONATES WITH REDUCED TOXICITY FOR TREATMENT OF VIRAL INFECTIONSNot Available14-

Apr-

10

9-

Sep

-16

6-

Apr-

17

US20170096

417

Multicyclic Compounds And Methods Of Using SameKaryopharm Therapeutics Inc.20-

Sep-

13

19-

Sep

-14

6-

Apr-

17

US20170095

818

INTEGRATED MICROFLUIDIC DEVICE FOR TARGET AMPLIFICATION AND MICROARRAY DETECTIONCapitalBio Corporation31-

Mar-

14

31-

Mar

-15

6-

Apr-

17

US20170095

521

Novel Polygonum Cuspidatum Extracts and Their Use as Photodynamic Inactivating AgentsNot Available1-

Oct-

15

30-

Sep

-16

6-

Apr-

17

US20170089

911

QUINONE METHIDE ANALOG SIGNAL AMPLIFICATIONNot Available24-

Feb-

14

24-

Aug

-16

30-

Mar

-17

US20170088

858

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available17-

Dec-

01

20-

Oct

-16

30-

Mar

-17

US20170088

848

Recombinant Influenza Virus-Like Particles (VLPs) Produced in Transgenic Plants Expressing HemagglutininMedicago Inc.21-

Jan-

08

2-

Sep

-16

30-

Mar

-17

US20170088

559

ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINESNot Available9-

Feb-

05

12-

Dec

-16

30-

Mar

-17

US20170086

463

ANTIVIRAL AGENTNot Available3-

Sep-

08

12-

Dec

-16

30-

Mar

-17

US20170082

608

Assay for Detecting TH1 and TH2 Cell PopulationsNot Available16-

May-

14

15-

May

-15

23-

Mar

-17

US20170082

607

MALARIA ANTIGEN SCREENING METHODNot Available31-

Aug-

05

19-

Apr

-13

23-

Mar

-17

US20170081

655

PURIFICATION OF NUCLEIC ACIDS USING COPPER-TITANIUM OXIDESNot Available14-

Jul-15

13-

Jul-

16

23-

Mar

-17

US20170081

393

ENGINEERED ANTIBODY CONSTANT DOMAIN MOLECULESThe U.S.A., as represented by the Secretary, Department of Health and Human Services31-

Jan-

08

2-

Dec

-16

23-

Mar

-17

US20170081

392

COMPOSITIONS COMPRISING AAV EXPRESSING DUAL ANTIBODY CONSTRUCTS AND USES THEREOFNot Available13-

May-

14

13-

May

-15

23-

Mar

-17

 

US20170080

084

OIL/SURFACTANT MIXTURES FOR SELF-EMULSIFICATIONNot Available17-

Mar-

14

17-

Mar

-15

23-

Mar

-17

US20170080

079

METHODS OF MAKING AND USING LIVE ATTENUATED VIRUSESNot Available23-

Sep-

15

23-

Sep

-16

23-

Mar

-17

US20170080

078

COMPOSITIONS AND METHODS FOR TREATING AND PREVENTING PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROMENot Available24-

Apr-

12

3-

Oct

-16

23-

Mar

-17

US20170079

920

Technology for the Preparation of MicroparticlesNot Available24-

Jul-07

5-

Dec

-16

23-

Mar

-17

US20170079

916

COMPOSITIONS AND METHODS FOR MODIFIED DENDRIMER NANOPARTICLE DELIVERYNot Available23-

Sep-

15

23-

Sep

-16

23-

Mar

-17

US20170079

253

TRANSGENIC MICE HAVING A HUMAN MAJOR HISTOCOMPATIBILITY COMPLEX (MHC) PHENOTYPE, EXPERIMENTAL USES AND APPLICATIONSINSTITUT PASTEUR30-

Jul-03

17-

Jul-

12

23-

Mar

-17

US20170073

738

Compositions and Methods for Detecting and Quantifying Nucleic Acid Sequences in Blood SamplesLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

25-

Nov

-16

16-

Mar

-17

US20170073

730

METHODS AND COMPOSITIONS FOR LIBRARY NORMALIZATIONNot Available11-

Sep-

15

8-

Sep

-16

16-

Mar

-17

US20170073

727

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIANot Available8-

Nov-

13

2-

Nov

-16

16-

Mar

-17

US20170073

390

Method for Identifying and Validating Dominant T Helper Cell Epitopes Using an HLA-DM-Assisted Class II Binding AssayNot Available6-

Jan-

06

5-

Dec

-14

16-

Mar

-17

US20170073

352

NOVEL SUBSTITUTED SPIROCYCLESNot Available12-

Sep-

14

29-

Nov

-16

16-

Mar

-17

US20170072

053

METHODS FOR PREPARING SQUALENENot Available12-

May-

10

22-

Nov

-16

16-

Mar

-17

US20170071

980

METHOD OF USING OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTION IN DENTAL APPLICATIONSOCULUS INNOVATIVE SCIENCES, INC.2-

May-

05

22-

Nov

-16

16-

Mar

-17

US20170071

964

METHODS FOR TREATING ARENAVIRIDAE AND CORONAVIRIDAE VIRUS INFECTIONSNot Available16-

Sep-

15

16-

Sep

-16

16-

Mar

-17

US20170071

867

NOVEL NANOPARTICLE COMPOSITIONSNot Available3-

Apr-

13

28-

Nov

-16

16-

Mar

-17

US20170067

030

ATTENUATED VIRUSES USEFUL FOR VACCINESNot Available30-

Mar-

07

7-

Sep

-16

9-

Mar

-17

US20170067

021

MODIFIED CELLS AND METHODS OF THERAPYNot Available31-

Jul-15

2-

Sep

-16

9-

Mar

-17

US20170066

788

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

18-

Nov

-16

9-

Mar

-17

US20170066

787

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

18-

Nov

-16

9-

Mar

-17

US20170066

731

SMALL MOLECULE FATTY ACID SYNTHASE INHIBITORSNot Available7-

Mar-

14

5-

Mar

-15

9-

Mar

-17

US20170065

706

METHODS AND COMPOSITIONS FOR PRODUCING AN ADENOVIRUS VECTOR FOR USE WITH MULTIPLE VACCINATIONSNot Available2-Jul-

07

14-

Sep

-16

9-

Mar

-17

US20170065

693

Sequential administration of a replication defective adenovirus vector in vaccination protocolsNot Available2-Jul-

07

14-

Sep

-16

9-

Mar

-17

US20170065

677

EV576 FOR USE IN THE TREATMENT OF VIRAL INFECTIONS OF THE RESPIRATORY TRACTVolution Immuno Pharmaceuticals SA8-

Jan-

10

22-

Jul-

16

9-

Mar

-17

US20170065

636

MODIFIED CELLS AND METHODS OF THERAPYNot Available31-

Jul-15

29-

Aug

-16

9-

Mar

-17

US20170058

430

BACTERIAL IDENTIFICATION IN CLINICAL INFECTIONSNot Available18-

Feb-

14

18-

Feb

-15

2-

Mar

-17

US20170058

365

SYSTEMS AND METHODS FOR ANALYZING VIRAL NUCLEIC ACIDSNot Available1-

Sep-

15

3-

Feb

-16

2-

Mar

-17

US20170057

978

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOFKineta, Inc.9-

May-

14

8-

May

-15

2-

Mar

-17

US20170057

968

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTSNOVARTIS AG1-

May-

14

29-

Apr

-15

2-

Mar

-17

US20170057

938

CERTAIN (2S)-N-[(1S)-1-CYANO-2-PHENYLETHYL]-1,4- OXAZEPANE-2-CARBOXAMIDES AS DIPEPTIDYL PEPTIDASE 1 INHIBITORSNot Available24-

Jan-

14

8-

Nov

-16

2-

Mar

-17

 

US20170052

190

Covalently Linked Thermostable Kinase for Decontamination Process ValidationNot Available20-

Feb-

08

8-

Jul-

16

23-

Feb

-17

US20170051

053

METHOD OF PROVIDING MONOCLONAL AUTO-ANTIBODIES WITH DESIRED SPECIFICITYNot Available28-

Dec-

11

7-

Sep

-16

23-

Feb

-17

US20170051

046

H1N1 FLU VIRUS NEUTRALIZING ANTIBODIESMEDIGEN BIOTECHNOLOGY CORPORATION20-

Aug-

15

20-

Aug

-15

23-

Feb

-17

US20170051

022

ADENOVIRUS COMPRISING AN ALBUMIN-BINDING MOIETYNot Available30-

Apr-

14

30-

Apr

-15

23-

Feb

-17

US20170051

007

PHARMACEUTICAL COMPOSITIONS AND METHODSNot Available3-

Aug-

15

28-

Jul-

16

23-

Feb

-17

US20170049

813

ANTIMICROBIAL SOLUTIONS CONTAINING DICHLORINE MONOXIDE AND METHODS OF MAKING AND USING THE SAMEOCULUS INNOVATIVE SCIENCES, INC.13-

Mar-

07

8-

Nov

-16

23-

Feb

-17

US20170044

603

CAPTURE PRIMERS AND CAPTURE SEQUENCE LINKED SOLID SUPPORTS FOR MOLECULAR DIAGNOSTIC TESTSNot Available31-

Jul-09

15-

Aug

-16

16-

Feb

-17

US20170044

595

PCR Ready Compositions and Methods for Detecting and Identifying Nucleic Acid SequencesLonghorn Vaccines and Diagnostics, LLC24-

Aug-

07

26-

Oct

-16

16-

Feb

-17

US20170044

237

ANTIBODIES AND PROCESSES FOR PREPARING THE SAMENot Available16-

May-

08

23-

Aug

-16

16-

Feb

-17

US20170044

168

COMPOUNDS AND COMPOSITIONS AS TOLL-LIKE RECEPTOR 7 AGONISTSNOVARTIS AG1-

May-

14

29-

Apr

-15

16-

Feb

-17

US20170042

994

COMPOSITIONS HAVING MEANS FOR TARGETING AT LEAST ONE ANTIGEN TO DENDRITIC CELLSASSISTANCE PUBLIQUE – HOPITAUX DE PARIS22-

Jul-11

29-

Jul-

16

16-

Feb

-17

US20170042

898

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONSHEMAQUEST PHARMACEUTICALS, INC.11-

Mar-

10

27-

Oct

-16

16-

Feb

-17

US20170039

316

Compositions, processes and algorithms for microbial detectionNot Available12-

Nov-

03

25-

Oct

-04

9-

Feb

-17

US20170039

314

BIOINFORMATIC PROCESSES FOR DETERMINATION OF PEPTIDE BINDINGIOGENETICS, LLC23-

Mar-

10

13-

Sep

-12

9-

Feb

-17

US20170038

085

AIR CURTAIN DEVICENot Available7-

Aug-

15

19-

Nov

-15

9-

Feb

-17

US20170037

457

NUCLEIC ACID DETECTION OR QUANTIFICATION METHOD USING MASK OLIGONUCLEOTIDE, AND DEVICE FOR SAMENot Available5-

Feb-

14

29-

Jan

-15

9-

Feb

-17

US20170037

379

CHIMERIC VIRUSES PRESENTING NON-NATIVE SURFACE PROTEINS AND USES THEREOFIcahn School of Medicine at Mount Sinai2-

Dec-

05

3-

Mar

-16

9-

Feb

-17

US20170037

376

METHOD FOR PREPARING INDUCED PLURIPOTENT STEM CELL, COMPOSITION USED IN METHOD, AND USES THEREOFGUANGZHOU INSTITUTES OF BIOMEDICINE AND HEALTH, CHINESE ACADEMY OF SCIENCES15-

Nov-

13

12-

Nov

-14

9-

Feb

-17

US20170037

090

RECOMBINANT EXPRESSION OF MULTIPROTEIN COMPLEXES USING POLYGENESNot Available8-

Nov-

05

26-

Oct

-16

9-

Feb

-17

US20170037

045

HETEROBIFUNCTIONAL LINKERS WITH POLYETHYLENE GLYCOL SEGMENTS AND IMMUNE RESPONSE MODIFIER CONJUGATES MADE THEREFROM3M Innovative Properties Company3-

Jun-

11

24-

Oct

-16

9-

Feb

-17

US20170035

878

Multi-Functional Mucosal Vaccine PlatformNot Available11-

Feb-

14

11-

Feb

-15

9-

Feb

-17

US20170035

845

Compositions and Methods for Inhibiting Pro-Inflammatory Cytokine Gene ExpressionNot Available7-

Aug-

15

5-

Aug

-16

9-

Feb

-17

US20170029

877

POLYTAG PROBESNot Available26-

Feb-

10

31-

Mar

-16

2-

Feb

-17

US20170029

847

ARTIFICIAL NUCLEIC ACID MOLECULESCureVac AG30-

Dec-

13

28-

Jun

-16

2-

Feb

-17

US20170029

489

HUMAN MONOCLONAL ANTIBODY WITH SPECIFICITY FOR DENGUE VIRUS SEROTYPE 1 E PROTEIN AND USES THEREOFNot Available14-

Dec-

10

1-

Jun

-16

2-

Feb

-17

US20170028

082

ADENO-ASSOCIATED VIRUS (AAV) CLADES, SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available30-

Sep-

03

3-

Aug

-16

2-

Feb

-17

US20170028

054

VACCINE COMPOSITIONNITTO DENKO CORPORATION4-

Apr-

12

11-

Oct

-16

2-

Feb

-17

US20170027

975

Methods of Treating Coronavirus InfectionUnited States Government as represented by the Secretary, Department of Health and Human Services7-

Apr-

14

7-

Apr

-15

2-

Feb

-17

 

US20170027

944

METHODS FOR TREATING VIRAL DISORDERSNot Available24-

Sep-

09

18-

Feb

-15

2-

Feb

-17

US20170022

577

METHODS OF TESTING FOR INTRACELLULAR PATHOGENSNovartis AG8-

Mar-

10

23-

Sep

-16

26-

Jan-

17

US20170022

242

NOVEL ANTIVIRAL AND ANTITUMORAL COMPOUNDSKATHOLIEKE UNIVERSITEIT LEUVEN, KU LEUVEN R&D17-

Apr-

14

17-

Apr

-15

26-

Jan-

17

US20170021

013

D-AMINO ACID DERIVATIVE-MODIFIED PEPTIDOGLYCAN AND METHODS OF USE THEREOFNot Available30-

Nov-

12

31-

Mar

-16

26-

Jan-

17

US20170020

926

METHODS AND COMPOSITIONS FOR IMMUNOMODULATIONNot Available1-

Apr-

14

13-

Mar

-15

26-

Jan-

17

US20170016

048

COMPOSITIONS AND METHODS FOR ENRICHING POPULATIONS OF NUCLEIC ACIDSNot Available18-

May-

15

17-

May

-16

19-

Jan-

17

US20170015

716

STABILIZED ANTI-MICROBIAL PEPTIDESNot Available2-Jul-

15

1-

Jul-

16

19-

Jan-

17

US20170014

496

COMBINATION OF VACCINATION AND OX40 AGONISTSNot Available12-

Mar-

14

12-

Mar

-14

19-

Jan-

17

US20170014

423

Benzazepine Dicarboxamide CompoundsHoffmann-La Roche Inc.6-

Mar-

15

28-

Sep

-16

19-

Jan-

17

US20170011

131

SYSTEM AND METHOD FOR DETECTING, COLLECTING, ANALYZING, AND COMMUNICATING EVENT RELATED INFORMATIONGeorgetown University25-

Feb-

08

23-

Sep

-16

12-

Jan-

17

US20170010

264

EXOSOME-MEDIATED DIAGNOSIS OF HEPATITIS VIRUS INFECTIONS AND DISEASESNot Available6-

Oct-

08

20-

Sep

-16

12-

Jan-

17

US20170009

237

Short Interfering RNA (siRNA) AnaloguesNot Available21-

Mar-

03

28-

Mar

-16

12-

Jan-

17

US20170007

577

METHOD OF TREATING OR INHIBITING THE DEVELOPMENT OF BRAIN INFLAMMATION AND SEPSISNot Available29-

Nov-

02

19-

Sep

-16

12-

Jan-

17

US20170002

042

PEPTIDOMIMETIC MACROCYCLESNot Available1-Jul-

15

1-

Jul-

16

5-

Jan-

17

US20170000

878

CONSTRAINED IMMUNOGENIC COMPOSITIONS AND USES THEREFORNot Available23-

Jun-

10

9-

Aug

-16

5-

Jan-

17

US20170000

873

Dimethyl Fumarate and Vaccination RegimensNot Available14-

Mar-

14

13-

Mar

-15

5-

Jan-

17

US20160376

596

COMPOSITIONS AND METHODS FOR INDUCING AN ENHANCED IMMUNE RESPONSE USING POXVIRUS VECTORSBavarian Nordic A/S28-

Nov-

13

25-

Nov

-14

29-

Dec

-16

US20160376

321

A NOVEL SARS IMMUNOGENIC COMPOSITIONBAYLOR COLLEGE OF MEDICINE26-

Nov-

13

21-

Nov

-14

29-

Dec

-16

US20160375

137

TARGETING LIPIDSTekmira Pharmaceuticals Corporation4-

Dec-

07

22-

Oct

-13

29-

Dec

-16

US20160375

132

HOMOGENOUS SUSPENSION OF IMMUNOPOTENTIATING COMPOUNDS AND USES THEREOFNot Available15-

Dec-

09

5-

Jul-

16

29-

Dec

-16

US20160369

268

TRANSCRIPTION ACTIVATOR-LIKE EFFECTOR (TALE) LIBRARIES AND METHODS OF SYNTHESIS AND USEThe Board of Regents of the University of Texas System1-Jul-

13

25-

Jun

-14

22-

Dec

-16

US20160368

956

METHOD OF PREVENTIVELY TREATING A SUBJECT AT THE RISK OF DEVELOPING INFECTIONS OF A RESPIRATORY VIRUSNot Available9-

May-

13

23-

Aug

-16

22-

Dec

-16

US20160368

904

SUBSTITUTED BENZOFURANYL AND BENZOXAZOLYL COMPOUNDS AND USES THEREOFNot Available3-Jul-

13

3-

Jul-

14

22-

Dec

-16

US20160367

587

Systemic In Vivo Delivery of OligonucleotidesOncoImmunin, Inc.12-

Jun-

13

12-

Jun

-14

22-

Dec

-16

US20160367

188

ORAL SENSOR ALERTING AND COMMUNICATION SYSTEM AND DEVELOPERS’ TOOL KITNot Available17-

Jun-

15

10-

Sep

-15

22-

Dec

-16

US20160363

557

AMPEROMETRIC GAS SENSORNot Available25-

Jun-

12

25-

Aug

-16

15-

Dec

-16

US20160362

730

PHOTO-SELECTIVE METHOD FOR BIOLOGICAL SAMPLE ANALYSISNot Available26-

Feb-

14

26-

Aug

-16

15-

Dec

-16

US20160362

454

Identification and Attenuation of the Immunosuppressive Domains in Fusion Proteins of Enveloped RNA VirusesNot Available7-

Oct-

11

10-

Jun

-16

15-

Dec

-16

US20160361

382

MICROBICIDAL COMPOSITIONS AND METHODS FOR TREATMENT OF VIRAL INFECTIONSNot Available11-

Jun-

15

13-

Jun

-16

15-

Dec

-16

 

US20160361

259

Methods for the Preparation of LiposomesNot Available23-

Sep-

09

2-

Aug

-16

15-

Dec

-16

US20160354

451

METHOD OF PROVIDING PATIENT SPECIFIC IMMUNE RESPONSE IN AMYLOIDOSES AND PROTEIN AGGREGATION DISORDERSNot Available31-

Aug-

07

9-

Jun

-16

8-

Dec

-16

US20160354

428

METHODS AND COMPOSITIONS RELATED TO INHIBITION OF VIRAL ENTRYNot Available8-

Feb-

07

2-

Jun

-16

8-

Dec

-16

US20160354

347

Nuclear Transport Modulators and Uses ThereofNot Available9-

May-

12

6-

Jan

-16

8-

Dec

-16

US20160348

153

EXTRACTION AND PRESERVATION OF NUCLEIC ACID MOLECULES FROM PATHOGENSTHE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Serv29-

May-

15

31-

May

-16

1-

Dec

-16

US20160348

132

TC-83-DERIVED ALPHAVIRUS VECTORS, PARTICLES AND METHODSNot Available18-

May-

04

11-

Aug

-16

1-

Dec

-16

US20160348

115

CpG Oligonucleotide Analogs Containing Hydrophobic T Analogs with Enhanced Immunostimulatory ActivityNot Available27-

Sep-

06

26-

May

-16

1-

Dec

-16

US20160348

110

NUCLEIC ACID CHEMICAL MODIFICATIONSNot Available2-

Mar-

09

11-

Aug

-16

1-

Dec

-16

US20160347

816

POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF FOR TREATMENT OF IMMUNE RELATED DISORDERS AND CANCERNot Available15-

Apr-

11

29-

Feb

-16

1-

Dec

-16

US20160347

814

VSTM5 POLYPEPTIDES AND USES THEREOF AS A DRUG FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASESNot Available11-

Sep-

13

10-

Mar

-16

1-

Dec

-16

US20160347

784

NOVEL NUCLEIC ACID PRODRUGS AND METHODS OF USE THEREOFNot Available6-Jul-

09

27-

May

-16

1-

Dec

-16

US20160346

309

TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYSNot Available1-

Jun-

07

21-

Dec

-15

1-

Dec

-16

US20160340

713

STABILIZING COMPOSITIONS AND METHODS FOR EXTRACTION OF RIBONUCLEIC ACIDNot Available6-

Oct-

06

20-

May

-16

24-

Nov

-16

US20160340

319

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITYNot Available6-

Feb-

13

5-

Aug

-16

24-

Nov

-16

US20160339

097

CORONAVIRUS PROTEINS AND ANTIGENSMJ Biologics, Inc.7-

Feb-

14

4-

Aug

-16

24-

Nov

-16

US20160338

998

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS AND COMBINATIONS THEREOF3-V Biosciences, Inc.20-

Dec-

13

19-

Dec

-14

24-

Nov

-16

US20160333

356

OLIGONUCLEOTIDE MODULATORS OF THE TOLL-LIKE RECEPTOR PATHWAYNot Available3-

Mar-

11

28-

Jul-

16

17-

Nov

-16

US20160333

089

Antigenic GM-CSF Peptides and Antibodies to GM-CSFNot Available8-

Feb-

06

18-

Jul-

16

17-

Nov

-16

US20160333

076

NEUTRALIZING GP41 ANTIBODIES AND THEIR USEThe United States of America, as represented by the Secretary, Department of Health and Human Serv7-

Nov-

11

2-

Aug

-16

17-

Nov

-16

US20160331

828

NUCLEIC ACID VACCINESModerna Therapeutics, Inc.23-

Apr-

14

5-

Apr

-16

17-

Nov

-16

US20160331

816

ORAL DELIVERY OF ANGIOTENSIN CONVERTING ENZYME 2 (ACE2) OR ANGIOTENSIN-(1-7) BIOENCAPSULATED IN PLANT CELLS ATTENUATES PULMONARY HYPERTENSION, CARDIAC DYSFUNCTION AND DEVELOPMENT OF AUTOIMMUNE AND EXPERIMENTALLY INDUCED OCULAR DISORDERSNot Available18-

Oct-

13

18-

Apr

-16

17-

Nov

-16

US20160331

758

TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USENot Available1-

Aug-

08

21-

Dec

-15

17-

Nov

-16

US20160327

506

CAPACITIVE LIQUID CRYSTAL BIOSENSORSNot Available6-

May-

15

5-

May

-16

10-

Nov

-16

US20160327

484

A METHOD OF PREDICTING A PERFORMANCE CHARACTERISTIC OF A PLANT OR YEAST HYDROLYSATE AND ITS USENot Available30-

Dec-

13

18-

Dec

-14

10-

Nov

-16

US20160326

598

METHODS AND COMPOSITIONS FOR PROSTATE CANCER METASTASISNot Available25-

Mar-

11

27-

May

-16

10-

Nov

-16

US20160326

325

POWDERED POUCH AND METHOD OF MAKING SAMENot Available16-

Apr-

12

19-

Jul-

16

10-

Nov

-16

 

US20160326

233

NEUTRALIZING HUMAN MONOCLONAL ANTIBODIES AGAINST HEPATITIS B VIRUS SURFACE ANTIGENNot Available16-

Jan-

14

15-

Jan

-15

10-

Nov

-16

US20160326

141

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS FOR USE AGAINST CANCER AND VIRAL INFECTIONSNot Available7-

Jan-

14

7-

Jan

-15

10-

Nov

-16

US20160325

283

BIOAGENT DETECTION SYSTEMS, DEVICES, AND METHODSNot Available30-

Mar-

09

18-

Jul-

16

10-

Nov

-16

US20160324

834

Use of mTOR Inhibitors to Enhance T Cell Immune ResponsesNot Available5-

Aug-

08

16-

May

-16

10-

Nov

-16

US20160320

390

COMPOSITIONS AND METHODS FOR CAPTURING EXOSOMESNot Available1-

May-

15

1-

May

-15

3-

Nov

-16

US20160318

985

Chimeric Virus-Like Particles Incorporating Fusion GPI Anchored GM-CSF and IL-4 ConjugatesNot Available29-

Apr-

15

29-

Apr

-16

3-

Nov

-16

US20160318

861

NOVEL PRODRUGS OF DITHIOL MUCOLYTIC AGENTSPARION SCIENCES, INC.30-

Apr-

15

2-

May

-16

3-

Nov

-16

US20160317

647

NUCLEIC ACID VACCINESModerna Therapeutics, Inc.23-

Apr-

14

1-

Apr

-16

3-

Nov

-16

US20160317

637

IMMUNOMODULATORY COMPOSITIONS AND METHODS OF USE THEREOFNot Available7-

Jan-

14

7-

Jan

-15

3-

Nov

-16

US20160317

496

METHODS OF TREATING CANCER AND OTHER DISORDERSNot Available12-

Nov-

10

27-

Jun

-16

3-

Nov

-16

US20160317

458

Lipids and Lipid Compositions for the Delivery of Active AgentsNot Available19-

Dec-

13

17-

Dec

-14

3-

Nov

-16

US20160312

276

METHODS AND COMPOSITIONS FOR WHOLE TRANSCRIPTOME AMPLIFICATIONNot Available23-

Apr-

15

21-

Apr

-16

27-

Oct-

16

US20160311

886

Constructs Binding to Phosphatidylserine and Their Use in Disease Treatment and ImagingNot Available24-

Jan-

05

12-

Jul-

16

27-

Oct-

16

US20160311

835

NOVEL ANTIBIOTICSNot Available26-

May-

11

30-

Nov

-15

27-

Oct-

16

US20160311

816

COMPOSITIONS AND METHODS FOR INHIBITING KINASESNot Available23-

Apr-

15

22-

Apr

-16

27-

Oct-

16

US20160311

759

Lipids and Lipid Compositions for the Delivery of Active AgentsNot Available19-

Dec-

13

17-

Dec

-14

27-

Oct-

16

US20160310

511

Myxovirus Therapeutics, Compounds, and Uses Related TheretoNot Available24-

Oct-

11

7-

Jul-

16

27-

Oct-

16

US20160305

936

DIRECT CLONE ANALYSIS AND SELECTION TECHNOLOGYNot Available13-

Jul-10

18-

Feb

-16

20-

Oct-

16

US20160304

954

COMPOSITIONS AND METHODS FOR DETECTING RARE SEQUENCE VARIANTSNot Available11-

Dec-

13

11-

Dec

-14

20-

Oct-

16

US20160304

942

Enhanced Methods of Ribonucleic Acid HybridizationNot Available6-

Dec-

13

5-

Dec

-14

20-

Oct-

16

US20160304

904

Directed Evolution and In Vivo Panning of Virus VectorsNot AvailableCO 1 128-

Jun

-16

20-

Oct-

16

US20160304

883

ARTIFICIAL NUCLEIC ACID MOLECULESCureVac AG30-

Dec-

13

28-

Jun

-16

20-

Oct-

16

US20160304

882

METHOD FOR PROPAGATING ADENOVIRAL VECTORS ENCODING INHIBITORY GENE PRODUCTSGenVec, Inc.10-

Nov-

05

27-

Jun

-16

20-

Oct-

16

US20160304

586

PROCESS FOR PREPARING INFLUENZA VACCINESCrucell Holland B.V.5-

Dec-

13

4-

Dec

-14

20-

Oct-

16

US20160304

579

POLYPEPTIDES AND USES THEREOF FOR TREATMENT OF AUTOIMMUNE DISORDERS AND INFECTIONNot Available30-

Jun-

11

29-

Feb

-16

20-

Oct-

16

US20160304

472

Hydrazide Containing Nuclear Transport Modulators and Uses ThereofNot Available29-

Jul-11

13-

Nov

-15

20-

Oct-

16

US20160303

194

Compositions And Method For Treatment Of Inflammatory Bowel DiseaseNot Available2-

Jun-

11

21-

Apr

-16

20-

Oct-

16

US20160303

052

MODULAR PARTICLES FOR IMMUNOTHERAPYNot Available1-

Nov-

13

31-

Oct

-14

20-

Oct-

16

US20160299

141

NAD ANALOGS AND METHODS OF USING SAID NAD ANALOGS IN DETERMINING RIBOSYLATION OF PROTEINS WITH PARP MUTANTSBiolog Life Science Institute Forschungslabor und Biochemica-Vertrieb GmbH8-

Apr-

15

1-

Apr

-16

13-

Oct-

16

US20160298

179

LUMINOPHORE-LABELED MOLECULES COUPLED WITH PARTICLES FOR MICROARRAY-BASED ASSAYSCapitalBio Corporation5-

Dec-

13

2-

Dec

-14

13-

Oct-

16

 

US20160296

617

Immunogenic Composition for MERS Coronavirus InfectionNot Available1-

Mar-

13

28-

Feb

-14

13-

Oct-

16

US20160296

616

IMMUNOGENIC COMPOSITIONS AND USES THEREOFNot Available25-

Mar-

15

25-

Mar

-16

13-

Oct-

16

US20160295

844

GENETICALLY MODIFIED NON-HUMAN ANIMALS AND METHODS OF USE THEREOFNot Available13-

Apr-

15

12-

Apr

-16

13-

Oct-

16

US20160292

393

SYSTEMS AND METHODS FOR ORDERING LABORATORY TESTS AND PROVIDING RESULTS THEREOFNot Available24-

Oct-

13

13-

Apr

-16

6-

Oct-

16

US20160289

740

METHODS AND COMPOSITIONS FOR COMBINATORIAL BARCODINGNot Available30-

Mar-

15

29-

Mar

-16

6-

Oct-

16

US20160289

191

ORGANIC COMPOUNDSNOVARTIS AG27-

Jun-

08

9-

Oct

-15

6-

Oct-

16

US20160288

121

Slip Chip Device and MethodsNot Available24-

Mar-

09

25-

May

-16

6-

Oct-

16

US20160287

697

INJECTABLE VACCINE COMPOSITIONNITTO DENKO CORPORATION3-

Oct-

13

2-

Oct

-14

6-

Oct-

16

US20160287

622

COMPOSITIONS AND METHODS FOR TREATING IMMUNE AND VIRAL DISORDERS AND MODULATING PROTEIN-RNA INTERACTIONMassachusetts Institute of Technology18-

Nov-

13

7-

Nov

-14

6-

Oct-

16

US20160281

109

GENE TRANSFER INTO AIRWAY EPITHELIAL STEM CELL BY USING LENTIVIRAL VECTOR PSEUDOTYPED WITH RNA VIRUS OR DNA

VIRUS SPIKE PROTEIN

Not Available28-

Oct-

05

10-

Jun

-16

29-

Sep

-16

US20160280

707

ALKOXY SUBSTITUTED IMIDAZOQUINOLINESNot Available3-

Oct-

03

13-

Jun

-16

29-

Sep

-16

US20160279

237

ADJUVANT COMPOSITIONS AND RELATED METHODSNot Available24-

Mar-

15

24-

Mar

-16

29-

Sep

-16

US20160279

193

IMMUNOSUPPRESSIVE AGENTS AND THEIR USE IN THERAPYNot Available6-

Nov-

13

6-

Nov

-14

29-

Sep

-16

US20160279

165

PULSE INHALATION OF NITRIC OXIDE FOR TREATING RESPIRATORY DISEASESNot Available24-

Mar-

15

24-

Mar

-16

29-

Sep

-16

US20160279

163

Method of Treating InflammationNot Available1-

Apr-

10

3-

Jun

-16

29-

Sep

-16

US20160278

349

Immunocompromised UngulatesNot Available27-

Oct-

08

23-

Mar

-15

29-

Sep

-16

US20160272

707

VSTM5 ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER, INFECTIOUS DISEASES AND IMMUNE RELATED DISEASESNot Available11-

Sep-

13

11-

Sep

-14

22-

Sep

-16

US20160271

241

BUNYAVIRUSES WITH SEGMENTED GLYCOPROTEIN PRECURSOR GENES AND METHODS FOR GENERATING THESE VIRUSESStichting Dienst Landbouwkundig Onderzoek21-

May-

13

21-

May

-14

22-

Sep

-16

US20160271

240

Tetanus Toxoid and CCL3 Improve DC VaccinesDuke University14-

Nov-

13

14-

Nov

-15

22-

Sep

-16

US20160271

137

INHIBITORS OF LONG AND VERY LONG CHAIN FATTY ACID METABOLISM AS BROAD SPECTRUM ANTI-VIRALSNot Available18-

Feb-

10

27-

Oct

-15

22-

Sep

-16

US20160267

244

METHODS OF PREDICTING CANCER LETHALITY USING REPLIKIN COUNTSNot Available8-

Aug-

08

19-

May

-16

15-

Sep

-16

US20160265

025

NANOREPORTERS AND METHODS OF MANUFACTURING AND USE THEREOFNot Available23-

Dec-

05

20-

May

-16

15-

Sep

-16

US20160264

971

COMPOSITIONS AND METHODS FOR SILENCING EBOLA VIRUS GENE EXPRESSIONNot Available20-

Jul-09

9-

Oct

-15

15-

Sep

-16

US20160264

962

TAL-EFFECTOR ASSEMBLY PLATFORM, CUSTOMIZED SERVICES, KITS AND ASSAYSNot Available4-

Apr-

12

28-

Jul-

15

15-

Sep

-16

US20160263

156

RED BLOOD CELL MEMBRANE-DERIVED MICROPARTICLES AND THEIR USE FOR THE TREATMENT OF LUNG DISEASEUniversity of Pittsburgh – Of the Com monwealth System of Higher Education7-

Nov-

13

6-

Nov

-14

15-

Sep

-16

US20160258

949

CHIPS, DETECTION SYSTEMS, AND METHODS FOR MULTIPLEX PNEUMOCOCCUS SEROLOGYNot Available9-

Oct-

13

9-

Oct

-14

8-

Sep

-16

US20160257

932

GENETICALLY ENGINEERED ENUCLEATED ERYTHROID CELLS COMPRISING A PHENYLALANINE AMMONIA LYASE RECEIVER POLYPEPTIDENot Available18-

Nov-

13

17-

May

-16

8-

Sep

-16

US20160257

653

Benzazepine Dicarboxamide CompoundsHoffmann-La Roche Inc.6-

Mar-

15

4-

Mar

-16

8-

Sep

-16

 

US20160256

870

Slip Chip Device and MethodsNot Available24-

Mar-

09

25-

May

-16

8-

Sep

-16

US20160256

541

Cationic Oil-In-Water EmulsionsNot Available6-Jul-

10

11-

Mar

-16

8-

Sep

-16

US20160253

584

SPATIALLY ADDRESSABLE MOLECULAR BARCODINGNot Available27-

Feb-

15

26-

Feb

-16

1-

Sep

-16

US20160251

637

COMPOSITIONS FOR INCREASING POLYPEPTIDE STABILITY AND ACTIVITY, AND RELATED METHODSNot Available19-

Nov-

09

11-

Mar

-16

1-

Sep

-16

US20160251

631

DECREASING POTENTIAL IATROGENIC RISKS ASSOCIATED WITH INFLUENZA VACCINESNovartis AG9-

Sep-

04

9-

May

-16

1-

Sep

-16

US20160251

399

PEPTIDOMIMETIC MACROCYCLESNot Available14-

Jan-

09

7-

Apr

-16

1-

Sep

-16

US20160251

362

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.P.A.18-

Dec-

12

10-

May

-16

1-

Sep

-16

US20160251

319

CARBOXYLIC ACID COMPOUNDSAstrazeneca Aktiebolag18-

May-

12

11-

May

-16

1-

Sep

-16

US20160250

326

Conjugates of GM-CSF and IL-7, and Compositions ThereofNot Available14-

Nov-

11

18-

May

-16

1-

Sep

-16

US20160250

278

PEPTIDOMIMETIC MACROCYCLESNot Available14-

Jan-

09

7-

Apr

-16

1-

Sep

-16

US20160250

168

ESTERS OF SHORT CHAINS FATTY ACIDS FOR USE IN THE TREATMENT OF IMMUNOGENIC DISORDERSNot Available3-

Oct-

12

3-

Mar

-16

1-

Sep

-16

US20160238

601

METHODS AND COMPOSITIONS FOR CORONAVIRUS DIAGNOSTICS AND THERAPEUTICSNot Available14-

Oct-

13

14-

Oct

-14

18-

Aug

-16

US20160238

600

METHOD FOR SELECTING A SINGLE CELL EXPRESSING A HETEROGENEOUS COMBINATION OF ANTIBODIESMerus B.V.30-

May-

03

27-

Apr

-16

18-

Aug

-16

US20160237

455

CRISPR-RELATED METHODS AND COMPOSITIONSEditas Medicine, Inc.27-

Sep-

13

26-

Sep

-14

18-

Aug

-16

US20160237

123

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONSNot Available23-

Jan-

08

4-

May

-16

18-

Aug

-16

US20160237

082

DEUBIQUITINASE INHIBITORS AND METHODS FOR USE OF THE SAMENot Available10-

Oct-

13

10-

Oct

-14

18-

Aug

-16

US20160235

840

Compositions, Comprising Improved Il-12 Genetic Constructs And Vaccines, Immunotherapeutics And Methods Of Using The SameNot Available12-

Dec-

11

26-

Feb

-16

18-

Aug

-16

US20160235

837

THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR MIDDLE EAST RESPIRATORY SYNDROME VIRUS (MERS CoV)Not Available16-

Oct-

13

16-

Oct

-14

18-

Aug

-16

US20160235

835

INFLUENZA VACCINES WITH REDUCED AMOUNTS OF SQUALENESeqirus UK Limited10-

Feb-

09

27-

Jan

-16

18-

Aug

-16

US20160235

675

Technology for the Preparation of MicroparticlesNot Available24-

Jul-07

24-

Mar

-16

18-

Aug

-16

US20160230

190

Lentiviral Vectors Having a Mutated Integrase Protein and uses ThereofNot Available17-

Sep-

13

17-

Sep

-14

11-

Aug

-16

US20160229

904

Optimized Human Clotting Factor VIII Gene Expression Cassettes and Their UseNot Available6-

Feb-

15

5-

Feb

-16

11-

Aug

-16

US20160229

872

ISOTHIAZOLOPYRIMIDINONES, PYRAZOLOPYRIMIDINONES, AND PYRROLOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160229

864

THIENOPYRIMIDINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160229

833

QUINAZOLINONES AND AZAQUINAZOLINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available5-

Feb-

15

4-

Feb

-16

11-

Aug

-16

US20160228

540

NASAL MUCOSAL VACCINE COMPOSITIONNITTO DENKO CORPORATION3-

Oct-

13

2-

Oct

-14

11-

Aug

-16

US20160228

533

Use of EGFR Pathway Inhibitors to Increase Immune Responses to AntigensEmory University23-

Sep-

13

23-

Sep

-14

11-

Aug

-16

US20160228

532

METHOD OF OBTAINING THERMOSTABLE DRIED VACCINE FORMULATIONSMerck Sharp & Dohme Corp.16-

Oct-

13

13-

Oct

-14

11-

Aug

-16

US20160228

463

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

20-

Apr

-16

11-

Aug

-16

 

US20160222

414

CONSTRUCTS AND METHODS FOR DELIVERING MOLECULES VIA VIRAL VECTORS WITH BLUNTED INNATE IMMUNE RESPONSESNot Available14-

Mar-

13

15-

Apr

-16

4-

Aug

-16

US20160222

072

Universal Protein Tag for Double Stranded Nucleic Acid DeliveryNot Available23-

Oct-

13

22-

Oct

-14

4-

Aug

-16

US20160222

023

NOVEL MONOTHIOL MUCOLYTIC AGENTSPARION SCIENCES, INC.30-

Jan-

15

29-

Jan

-16

4-

Aug

-16

US20160222

010

4-AMINO-IMIDAZOQUINOLINE COMPOUNDSHoffmann-La Roche Inc.22-

Apr-

14

7-

Apr

-16

4-

Aug

-16

US20160221

994

Substituted 2,3-Dihydrobenzofuranyl Compounds And Uses ThereofNot Available29-

Nov-

12

27-

Nov

-13

4-

Aug

-16

US20160220

664

ANTIGEN AND METHOD FOR PRODUCTION THEREOFNot Available13-

Sep-

13

12-

Sep

-14

4-

Aug

-16

US20160220

595

NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETONot Available11-

Sep-

13

10-

Sep

-14

4-

Aug

-16

US20160220

536

USE OF PHENYLMETHIMAZOLES, METHIMAZOLE DERIVATIVES, AND TAUTOMERIC CYCLIC THIONES FOR THE TREATMENT OF AUTOIMMUNE/INFLAMMATORY DISEASES ASSOCIATED WITH TOLL­LIKE RECEPTOR OVEREXPRESSIONNot Available16-

Mar-

04

19-

Feb

-16

4-

Aug

-16

US20160215

282

SYNTHETIC ANTISERUM FOR RAPID-TURNAROUND THERAPIESNot Available28-

Jan-

15

20-

Jan

-16

28-

Jul-

16

US20160215

262

CD137 ENRICHMENT FOR EFFICIENT TUMOR INFILTRATING LYMPHOCYTE SELECTIONNot Available16-

Sep-

13

16-

Sep

-14

28-

Jul-

16

US20160213

776

ADSORPTION OF IMMUNOPOTENTIATORS TO INSOLUBLE METAL SALTSGlaxoSmithKline Biologicals SA1-

Sep-

10

7-

Apr

-16

28-

Jul-

16

US20160213

773

MUCOSAL VACCINE COMPOSITIONNITTO DENKO CORPORATION3-

Oct-

13

2-

Oct

-14

28-

Jul-

16

US20160213

761

CARBON NANOTUBE COMPOSITIONS AND METHODS OF USE THEREOFNot Available19-

Mar-

08

5-

Apr

-16

28-

Jul-

16

US20160213

647

COMPOSITIONS AND METHODS FOR INHIBITING VIRAL INFECTIONNot Available28-

Jan-

15

27-

Jan

-16

28-

Jul-

16

US20160213

610

MODIFIED RELEASE FORMULATIONS FOR OPROZOMIBNot Available24-

Oct-

12

28-

Jan

-16

28-

Jul-

16

US20160207

980

FC-CONTAINING MOLECULES EXHIBITING PREDICTABLE, CONSISTENT, AND REPRODUCIBLE GLYCOFORM PROFILESAMGEN INC.5-

Sep-

13

5-

Sep

-14

21-

Jul-

16

US20160207

949

NOVEL CYTOTOXIC AGENTS FOR CONJUGATION TO A CELL BINDING MOLECULEHangzhou DAC Biotech Co., Ltd2-

Sep-

13

2-

Sep

-13

21-

Jul-

16

US20160207

900

PEPTIDYL NITRIL COMPOUNDS AS DIPEPTIDYL PEPTIDASE I INHIBITORSPROZYMEX A/S9-

Sep-

13

8-

Sep

-14

21-

Jul-

16

US20160206

729

IMMUNOGENIC MIDDLE EAST RESPIRATORY SYNDROME CORONAVIRUS (MERS-CoV) COMPOSITIONS AND METHODSNot Available19-

Sep-

13

19-

Sep

-14

21-

Jul-

16

US20160206

719

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAYCureVac AG22-

Feb-

13

5-

Apr

-16

21-

Jul-

16

US20160206

638

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

5-

Apr

-16

21-

Jul-

16

US20160206

575

Inhibition of Biofilm OrganismsNOVABIOTICS LIMITED31-

Mar-

09

28-

Mar

-16

21-

Jul-

16

US20160202

258

B-CELL ANTIGEN PRESENTING CELL ASSAYUniversity of Pittsburgh – Of the Com monwealth System of Higher Education8-

Apr-

10

21-

Mar

-16

14-

Jul-

16

US20160201

110

DIAGNOSIS AND TREATMENT OF INCIPIENT DIABETESNot Available9-

Jan-

15

17-

Nov

-15

14-

Jul-

16

US20160201

088

ADENO-ASSOCIATED VIRUS (AAV) SEROTYPE 8 SEQUENCES, VECTORS CONTAINING SAME, AND USES THEREFORNot Available17-

Dec-

01

30-

Mar

-16

14-

Jul-

16

US20160199

486

ARRANGING INTERACTION AND BACK PRESSURE CHAMBERS FOR MICROFLUIDIZATIONNot Available3-

Dec-

09

22-

Mar

-16

14-

Jul-

16

US20160199

449

METHOD OF REDUCING ANTIGENIC DRIFT OR REASSORTMENT OF VIRUSES IN A HOST ANIMAL USING ALPHA INTERFERONHemispherx Biopharma, Inc.21-

Aug-

13

21-

Aug

-14

14-

Jul-

16

 

US20160199

416

Induced Hepatocytes and Uses ThereofNot Available26-

Nov-

14

25-

Nov

-15

14-

Jul-

16

US20160199

407

HALIDES IN THE TREATMENT OF PATHOGENIC INFECTIONTHE UNIVERSITY OF IOWA RESEARCH FOUNDATION25-

Jan-

08

17-

Dec

-15

14-

Jul-

16

US20160194

387

Methods Of Treating Inflammation Associated Airway Diseases And Viral InfectionsNot Available2-

Jan-

15

31-

Dec

-15

7-

Jul-

16

US20160194

322

SUBSTITUTED IMIDAZO RING SYSTEMS AND METHODSNot Available25-

Nov-

03

14-

Mar

-16

7-

Jul-

16

US20160194

278

DITHIOL MUCOLYTIC AGENTSPARION SCIENCES, INC.23-

Aug-

13

11-

Mar

-16

7-

Jul-

16

US20160193

603

SAMPLE-TO-ANSWER MICROFLUIDIC CARTRIDGENot Available29-

Jan-

10

5-

Aug

-15

7-

Jul-

16

US20160193

327

MUCOSAL VACCINE COMPOSITIONNITTO DENKO CORPORATION3-

Oct-

13

2-

Oct

-14

7-

Jul-

16

US20160193

321

MAKING INFLUENZA VIRUS VACCINES WITHOUT USING EGGSNovartis AG11-

Sep-

06

5-

Nov

-15

7-

Jul-

16

US20160193

315

PEPTIDES SHARED AMONG LETHAL CANCERS AND THERAPEUTIC COMPOSITIONS COMPRISING SAID PEPTIDESNot Available7-

Aug-

09

17-

Mar

-16

7-

Jul-

16

US20160192

658

HYDROGEN-CONTAINING ANTIMICROBIAL AGENTNot Available13-

Aug-

13

5-

Aug

-14

7-

Jul-

16

US20160185

786

PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN- SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

29-

Dec

-15

30-

Jun-

16

US20160185

785

PYRROLO AND PYRAZOLOPYRIMIDINES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORSNot Available30-

Dec-

14

29-

Dec

-15

30-

Jun-

16

US20160184

424

INTRANASAL VACCINATION DOSAGE REGIMENNot Available17-

Dec-

12

17-

Dec

-13

30-

Jun-

16

US20160184

334

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

11-

Mar

-16

30-

Jun-

16

US20160177

337

METHOD FOR PRODUCTION OF REPROGRAMMED CELL USING CHROMOSOMALLY UNINTEGRATED VIRUS VECTORNot Available16-

Jul-08

8-

Mar

-16

23-

Jun-

16

US20160177

336

Expression Tools for Multiprotein ApplicationsNot Available9-

Mar-

04

11-

Dec

-15

23-

Jun-

16

US20160175

433

LIPIDATED IMMUNE RESPONSE MODIFIER COMPOUND COMPOSITIONS, FORMULATIONS, AND METHODSNot Available17-

Aug-

10

15-

Dec

-15

23-

Jun-

16

US20160175

394

Compositions and Uses of LectinsEmory University12-

Feb-

10

11-

Dec

-15

23-

Jun-

16

US20160175

387

Use of Immune Suppressive Domains as MedicamentsNot Available10-

Apr-

13

10-

Apr

-14

23-

Jun-

16

US20160174

631

PROTECTIVE MASKS WITH COATING COMPRISING DIFFERENT ELECTROSPUN FIBERS INTERWEAVED WITH EACH OTHER, FORMULATIONS FORMING THE SAME, AND METHOD OF PRODUCING THEREOFNot Available23-

Dec-

14

10-

Dec

-15

23-

Jun-

16

US20160168

203

Cyclic Antimicrobial PeptidesNOVABIOTICS LIMITED24-

Feb-

06

9-

Nov

-15

16-

Jun-

16

US20160168

101

NOVEL COMPOUNDSCHIESI FARMACEUTICI S.p.A.15-

Dec-

14

27-

Nov

-15

16-

Jun-

16

US20160166

710

METHOD FOR INCREASING EXPRESSION OF RNA-ENCODED PROTEINSCureVac AG21-

Aug-

13

19-

Feb

-16

16-

Jun-

16

US20160166

676

Use of Immune Suppressive Peptides as AdjuvantsNot Available10-

Apr-

13

10-

Apr

-14

16-

Jun-

16

US20160160

258

MONOCLONAL ANTIBODY PRODUCTION BY EBV TRANSFORMATION OF B CELLSNot Available26-

Feb-

03

8-

Feb

-16

9-

Jun-

16

US20160160

178

IMMUNOTHERAPY USING STEM CELLSNot Available9-

Dec-

14

2-

Dec

-15

9-

Jun-

16

US20160159

927

IDENTIFICATION OF VSIG8 AS THE PUTATIVE VISTA RECEPTOR (V- R) AND USE THEREOF TO PRODUCE VISTA/VSIG8 AGONISTS AND ANTAGONISTSNot Available5-

Dec-

14

7-

Dec

-15

9-

Jun-

16

US20160158

341

PREPARATION OF INFLUENZA VIRUS VACCINE ANTIGENSNovartis AG18-

Mar-

08

7-

Dec

-15

9-

Jun-

16

 

US20160158

340

INFLUENZA VACCINES CONTAINING HEMAGGLUTININ AND MATRIX PROTEINSNot Available27-

Jan-

06

4-

Dec

-15

9-

Jun-

16

US20160158

339

METHOD FOR INACTIVATING VIRUSES USING ELECTRON BEAMSNot Available26-

Jul-13

24-

Jul-

14

9-

Jun-

16

US20160158

308

TREATMENT OF MULTIPLE EVOLVING BACTERIAL RESISTANCE DISEASES WITH LIPOSOMALLY FORMULATED GLUTATHIONECHILDREN’S HEALTHCARE OF ATLANTA, INC.12-

Nov-

13

14-

Aug

-14

9-

Jun-

16

US20160158

294

Methods of Populating a Gastrointestinal TractNot Available4-

Feb-

13

4-

Feb

-14

9-

Jun-

16

US20160158

154

PROTEIN VESICLES AND METHODS OF MAKING AND USING THEREOFNot Available5-

Dec-

14

7-

Dec

-15

9-

Jun-

16

US20160153

034

Rapid Epidemiologic Typing of BacteriaNot Available19-

May-

08

11-

Nov

-15

2-

Jun-

16

US20160152

693

AMINO ACID SEQUENCES DIRECTED AGAINST ENVELOPE PROTEINS OF A VIRUS AND POLYPEPTIDES COMPRISING THE SAME FOR THE TREATMENT OF VIRAL DISEASESAblynx N.V.5-

Jun-

08

29-

Oct

-15

2-

Jun-

16

US20160152

676

HELIX-GRAFTED PROTEINS AS INHIBITORS OF DISEASE-RELEVANT PROTEIN-PROTEIN INTERACTIONSCOLORADO STATE UNIVERSITY RESEARCH FOUNDATION7-

Nov-

14

9-

Nov

-15

2-

Jun-

16

US20160152

667

COMPOSITIONS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONSNot Available23-

Jan-

08

9-

Feb

-16

2-

Jun-

16

US20160152

596

Nuclear Transport Modulators and Uses ThereofKaryopharm Therapeutics Inc.21-

Jun-

13

20-

Jun

-14

2-

Jun-

16

US20160151

399

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

17-

Feb

-16

2-

Jun-

16

US20160146

806

RECEPTORS FOR B7-H4Not Available17-

May-

13

19-

May

-14

26-

May

-16

US20160146

786

Method of monitoring cellular trafficking of peptidesNot Available26-

Jun-

13

26-

Jun

-14

26-

May

-16

US20160145

246

NUCLEAR TRANSPORT MODULATORS AND USES THEREOFNot Available9-

May-

12

23-

Jun

-15

26-

May

-16

US20160144

061

Compositions and Imaging Methods Comprising Detectably Labeled Phosphatidylethanolamine-Binding PeptidesNot Available15-

Jul-02

4-

Feb

-16

26-

May

-16

US20160139

143

DETECTING TARGETS USING MASS TAGS AND MASS SPECTROMETRYNot Available2-Jul-

10

28-

Dec

-15

19-

May

-16

US20160137

702

GAS57 MUTANT ANTIGENS AND GAS57 ANTIBODIESNot Available12-

Sep-

07

7-

Aug

-15

19-

May

-16

US20160137

649

PYRROLO-PYRROLE CARBAMATE AND RELATED ORGANIC COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOFNot Available3-Jul-

13

1-

Jul-

14

19-

May

-16

US20160135

453

SHELF STABLE, REDUCED CORROSION, READY TO USE PEROXYCARBOXYLIC ACID ANTIMICROBIAL COMPOSITIONSNot Available30-

Aug-

07

20-

Jan

-16

19-

May

-16

US20160130

367

GENERATION OF BINDING MOLECULESMerus B.V.26-

Sep-

11

16-

Sep

-15

12-

May

-16

US20160130

345

COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAYNot Available22-

Feb-

13

21-

Feb

-14

12-

May

-16

US20160130

265

SUBSTITUTED 4-PYRIDONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITYNot Available23-

Aug-

12

29-

Dec

-15

12-

May

-16

US20160129

110

IMMUNOPROTECTIVE PRIMARY MESENCHYMAL STEM CELLS AND METHODSAUTOIMMUNE TECHNOLOGIES, LLC14-

Mar-

13

17-

Jul-

15

12-

May

-16

US20160129

104

HAND, FOOT, AND MOUTH VACCINES AND METHODS OF MANUFACTURE AND USE THEREOFNot Available7-

Nov-

14

6-

Nov

-15

12-

May

-16

US20160129

095

Immunostimulatory CombinationsNot Available30-

Dec-

02

10-

Sep

-15

12-

May

-16

US20160128

937

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONSNovartis AG3-

Dec-

09

5-

Sep

-14

12-

May

-16

US20160122

412

COMPOSITION COMPRISED OF ANTIGEN LINKED TO A TNF SUPERFAMILY LIGANDNot Available15-

Mar-

13

16-

Mar

-14

5-

May

-16

 

US20160122

397

REPLIKIN-BASED COMPOUNDS FOR PREVENTION AND TREATMENT OF INFLUENZA AND METHODS OF DIFFERENTIATING INFECTIVITY AND LETHALITY IN INFLUENZANot Available23-

Apr-

09

2-

Dec

-15

5-

May

-16

US20160122

312

ANTI-VIRAL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF USE THEREOFNot Available16-

Jul-13

16-

Jul-

14

5-

May

-16

US20160122

306

DENDRIMER LIKE AMINO AMIDES POSSESSING SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF DRY EYE AND OTHER

MUCOSAL DISEASES

PARION SCIENCES, INC.29-

May-

12

5-

Jan

-16

5-

May

-16

US20160116

462

ANTIBODY-NANOPARTICLE CONJUGATES AND METHODS FOR MAKING AND USING SUCH CONJUGATESNot Available27-

Apr-

10

21-

Apr

-15

28-

Apr-

16

US20160115

522

MUTANT PROTEASE BIOSENSORS WITH ENHANCED DETECTION CHARACTERISTICSNot Available11-

May-

10

7-

Jan

-16

28-

Apr-

16

US20160115

221

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYNot Available28-

Oct-

14

2-

Jul-

15

28-

Apr-

16

US20160114

322

PARALLELIZED SAMPLE HANDLINGNot Available19-

Apr-

13

18-

Apr

-14

28-

Apr-

16

US20160114

037

COMPOSITIONS AND METHODS FOR THE TREATMENT OF IMMUNODEFICIENCYNot Available28-

Oct-

14

8-

Jan

-15

28-

Apr-

16

US20160114

027

RECOMBINANT HCMV AND RHCMV VECTORS AND USES THEREOFNot Available14-

May-

10

1-

Oct

-15

28-

Apr-

16

US20160114

022

THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR FILOVIRUSES INCLUDING EBOLAVIRUS AND MARBURG VIRUSNot Available11-

Oct-

14

10-

Oct

-15

28-

Apr-

16

US20160113

929

METHODS AND COMPOSITIONS FOR TREATING VIRAL OR VIRALLY- INDUCED CONDITIONSNot Available11-

Mar-

10

2-

Jun

-15

28-

Apr-

16

US20160113

920

COMPOSITIONS AND METHODS FOR INHIBITING BACTERIAL AND VIRAL PATHOGENSNot Available24-

Oct-

14

23-

Oct

-15

28-

Apr-

16

US20160113

881

NOVEL NANOPARTICLE COMPOSITIONSNot Available3-

Apr-

13

3-

Apr

-14

28-

Apr-

16

US20160113

870

CIRCULATION OF COMPONENTS DURING MICROFLUIDIZATION AND/OR HOMOGENIZATION OF EMULSIONSNovartis AG3-

Dec-

09

5-

Sep

-14

28-

Apr-

16

US20160108

463

Biological Specimen Collection and Transport SystemLonghorn Vaccines and Diagnostics, LLC1-

Oct-

07

15-

Dec

-15

21-

Apr-

16

US20160108

461

TARGETED WHOLE GENOME AMPLIFICATION METHOD FOR IDENTIFICATION OF PATHOGENSNot Available14-

Sep-

06

5-

Oct

-15

21-

Apr-

16

US20160108

359

AVIAN CELLS FOR IMPROVED VIRUS PRODUCTIONNot Available5-

Jun-

13

3-

Jun

-14

21-

Apr-

16

US20160108

097

MONOMERIC GRIFFITHSIN TANDEMERSThe United States of America, as represented by the Secretary, Department of Health and Human Serv5-

Jun-

13

5-

Jun

-14

21-

Apr-

16

US20160108

096

FUSION PROTEINS, RECOMBINANT BACTERIA, AND METHODS FOR USING RECOMBINANT BACTERIANot Available17-

Sep-

14

17-

Sep

-15

21-

Apr-

16

US20160108

063

BORON-CONTAINING SMALL MOLECULESNot Available16-

Feb-

05

21-

Dec

-15

21-

Apr-

16

US20160106

842

LIPIDS AND LIPID COMPOSITIONS FOR THE DELIVERY OF ACTIVE AGENTSNot Available8-

Mar-

13

6-

Mar

-14

21-

Apr-

16

US20160102

295

MODIFIED ADENOVIRUS HEXON PROTEIN AND USES THEREOFNot Available28-

Apr-

06

22-

May

-15

14-

Apr-

16

US20160102

091

HETEROCYCLIC MODULATORS OF LIPID SYNTHESIS3-V BIOSCIENCES, INC.8-

Mar-

11

5-

Oct

-15

14-

Apr-

16

US20160101

145

PEPTIDOMIMETIC MACROCYCLES AND FORMULATIONS THEREOFNot Available24-

Sep-

14

24-

Sep

-15

14-

Apr-

16

US20160096

899

METHODS FOR TREATING JUVENILE ARTHRITIS WITH ANTI-BILE SALT-STIMULATED LIPASE (BSSL) ANTIBODIESNot Available8-

Apr-

09

28-

Sep

-15

7-

Apr-

16

US20160096

895

BINDING MEMBERS-513Not Available7-

Nov-

08

23-

Oct

-15

7-

Apr-

16

US20160095

936

IMMUNOSTIMULATORY COMPOSITIONS AND METHODS OF USE THEREOFNot Available5-

Apr-

12

2-

Jul-

15

7-

Apr-

16

US20160090

589

COMPOSITIONS FOR AND METHODS OF IDENTIFYING ANTIGENSNot Available21-

Feb-

06

6-

May

-15

31-

Mar

-16

 

US20160090

389

Phosphoinositide 3-Kinase InhibitorsRespivert Ltd.15-

Mar-

13

4-

Dec

-15

31-

Mar

-16

US20160084

835

METHODS FOR DIAGNOSING INFECTIOUS DISEASES USING ADSORPTION MEDIAEXTHERA MEDICAL CORPORATION8-

Nov-

13

16-

Oct

-15

24-

Mar

-16

US20160083

748

TISSUE PREFERENTIAL CODON MODIFIED EXPRESSION CASSETTES, VECTORS CONTAINING SAME, AND USES THEREOFNot Available29-

Apr-

13

29-

Apr

-14

24-

Mar

-16

US20160083

689

ANIMAL PROTEIN-FREE MEDIA FOR CULTIVATION OF CELLSNot Available29-

Oct-

04

30-

Nov

-15

24-

Mar

-16

US20160082

074

COMPOSITIONS AND METHODS FOR TREATING CORONAVIRUS INFECTIONLUDWIG-MAXIMILIANS-UNIVERSITAET MUENCHEN11-

Mar-

14

8-

May

-15

24-

Mar

-16

US20160081

982

METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN CNot Available14-

Mar-

13

1-

Dec

-15

24-

Mar

-16

US20160081

346

ANTIMICROBIAL COMPOSITIONS AND METHODSNot Available23-

Sep-

14

22-

Sep

-15

24-

Mar

-16

US20160077

094

Media Elaborated with Newly Synthesized Antibodies (MENSA) and Uses ThereofNot Available5-

May-

14

5-

May

-15

17-

Mar

-16

US20160076

094

Efficient Deep Sequencing and Rapid Genomic Speciation of RNA Viruses (vRNAseq)Not Available8-

Sep-

14

1-

Sep

-15

17-

Mar

-16

US20160076

053

REPLICATION DEFECTIVE ADENOVIRUS VECTOR IN VACCINATIONNot Available24-

Aug-

12

15-

Mar

-13

17-

Mar

-16

US20160075

704

NOVEL SUBSTITUTED SPIROCYCLESNot Available12-

Sep-

14

10-

Sep

-15

17-

Mar

-16

US20160074

507

METHOD FOR PREPARING VIRAL PARTICLES WITH CYCLIC DINUCLEOTIDE AND USE OF SAID PARTICLES FOR INDUCING IMMUNE RESPONSENot Available16-

Sep-

14

16-

Sep

-15

17-

Mar

-16

US20160074

506

DELIVERY OF SELF-REPLICATING RNA USING BIODEGRADABLE POLYMER PARTICLESNot Available6-Jul-

10

23-

Nov

-15

17-

Mar

-16

US20160074

481

Clottable Concentrate Of Platelet Growth Factors And Preparation Method ThereofZheng Yang Biomedical Technology Co., LTD.7-

Jan-

08

30-

Nov

-15

17-

Mar

-16

US20160068

843

Compositions and Methods for “Resistance-Proof” SiRNA Therapeutics for InfluenzaSirnaomics, Inc.8-Jul-

12

7-

Jul-

13

10-

Mar

-16

US20160068

587

OLIGOPEPTIDE-FREE CELL CULTURE MEDIANot Available3-

Jan-

07

16-

Nov

-15

10-

Mar

-16

US20160068

573

PEPTIDOMIMETIC MACROCYCLESNot Available14-

Jan-

09

14-

Sep

-15

10-

Mar

-16

US20160067

333

GENERATING PEPTOID VACCINESThe Board of Regents of the University of Texas System3-

May-

13

2-

May

-14

10-

Mar

-16

US20160060

598

MEANS AND METHODS FOR INFLUENCING THE STABILITY OF ANTIBODY PRODUCING CELLSNot Available9-

Dec-

05

26-

Aug

-15

3-

Mar

-16

US20160060

231

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITYNot Available6-

Feb-

13

9-

Nov

-15

3-

Mar

-16

US20160060

230

SUBSTITUTED BICYCLIC DIHYDROPYRIMIDINONES AND THEIR USE AS INHIBITORS OF NEUTROPHIL ELASTASE ACTIVITYNot Available6-

Feb-

13

9-

Nov

-15

3-

Mar

-16

US20160060

224

N-MYRISTOYL TRANSFERASE INHIBITORSUNIVERSITY OF DUNDEE2-

Sep-

08

31-

Aug

-15

3-

Mar

-16

US20160058

814

PLANT EXTRACTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMSNot Available26-

Aug-

14

26-

Aug

-14

3-

Mar

-16

US20160058

012

WEAR RESISTANT ANTIMICROBIAL COMPOSITIONS AND METHODS OF USENot Available14-

Dec-

10

24-

Sep

-15

3-

Mar

-16

US20160058

008

ANTIMICROBIAL COMPOSITIONS AND METHODS WITH NOVEL POLYMERIC BINDING SYSTEMNot Available28-

Aug-

14

28-

Aug

-15

3-

Mar

-16

US20160054

312

CHEMICALLY DIFFERENTIATED SENSOR ARRAYNanomedical Diagnostics, Inc.28-

Apr-

14

15-

Oct

-15

25-

Feb

-16

US20160053

308

PROBE KIT FOR DETECTING A SINGLE STRAND TARGET NUCLEOTIDE SEQUENCEFondzione Istituto Italiano Di Tecnolgia27-

Dec-

12

27-

Dec

-13

25-

Feb

-16

US20160053

222

BACILLUS BASED DELIVERY SYSTEM AND METHODS OF USENot Available18-

Apr-

11

9-

Sep

-15

25-

Feb

-16

 

US20160052

959

RADIOLABELED CATIONIC STEROID ANTIMICROBIALS AND DIAGNOSTIC METHODSBRIGHAM YOUNG UNIVERSITY22-

Aug-

14

19-

Aug

-15

25-

Feb

-16

US20160051

691

CARBOHYDRATE CONJUGATES AS DELIVERY AGENTS FOR OLIGONUCLEOTIDESNot Available4-

Dec-

07

25-

Aug

-15

25-

Feb

-16

US20160051

670

METHODS FOR PREPARING SQUALENENot Available12-

May-

10

23-

Oct

-15

25-

Feb

-16

US20160051

669

COMPOSITIONS AND METHODS FOR SELECTIVELY MODULATING TREGSNot Available21-

Aug-

14

21-

Aug

-15

25-

Feb

-16

US20160046

705

HETERODIMERIC IMMUNOGLOBULINSNot Available21-

Nov-

12

21-

Nov

-13

18-

Feb

-16

US20160046

687

GM-CSF AND IL-4 CONJUGATES, COMPOSITIONS, AND METHODS RELATED THERETONot Available23-

Oct-

12

23-

Oct

-13

18-

Feb

-16

US20160045

547

METHOD OF PREVENTING OR TREATING SINUSITIS WITH OXIDATIVE REDUCTIVE POTENTIAL WATER SOLUTIONOCULUS INNOVATIVE SCIENCES, INC.30-

Dec-

03

27-

Oct

-15

18-

Feb

-16

US20160041

168

ARRAYED DETECTOR SYSTEM FOR MEASUREMENT OF INFLUENZA IMMUNE RESPONSENot Available2-

May-

08

23-

Oct

-15

11-

Feb

-16

US20160040

161

In Vivo Delivery of OligonucleotidesOncoImmunin Inc.12-

Dec-

11

12-

Dec

-12

11-

Feb

-16

US20160039

867

SINGLE-CHAIN ANTIPARALLEL COILED COIL PROTEINSComplix NV8-

Dec-

08

21-

Aug

-15

11-

Feb

-16

US20160039

860

ENANTIOMERS OF THE 1′,6′-ISOMER OF NEPLANOCIN ANot Available4-

Aug-

14

4-

Aug

-15

11-

Feb

-16

US20160039

826

2-((4-AMINO-3-(3-FLUORO-5-HYDROXYPHENYL)-1H- PYRAZOLO[3,4-D